bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, IL4 is a Protein, CD19 is a Protein, LMP1 is a Protein, L32 is a Protein, GAPDH is a Protein, LMP1 is a Protein, pStat6 is a Protein, CD19 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, IL4 is a Protein, LMP1 is a Protein	105_task0	Sentence: Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.	[ "Wild", "-", "Type", "and", "LMP1", "Transgenic", "Lymphoma", "Cells", "Survive", "Independently", "of", "IL4", "/", "Stat6", "Signaling", "in", "Culture", "\n", "(", "A", ")", "Rnase", "protection", "assay", "for", "IL4", "mRNA", "from", "purified", "B", "cells", "(", "CD19", "+", ")", "from", "WT", "and", "LMP1", "transgenic", "splenocytes", ".", "The", "L32", "and", "GAPDH", "housekeeping", "genes", "were", "used", "as", "a", "loading", "control", ".", "Arrow", "indicates", "the", "position", "of", "the", "protected", "probe", ".", "\n", "(", "B", "and", "C", ")", "Immunoblot", "analysis", "of", "WT", "and", "LMP1", "transgenic", "mice", "for", "activated", "pStat6", "in", "(", "B", ")", "purified", "B", "cells", "(", "CD19", "+", ")", "at", "the", "time", "of", "harvest", "or", "in", "(", "C", ")", "whole", "splenocytes", "cultured", "with", "or", "without", "IL4", ".", "(", "B", ")", "Actin", "was", "used", "as", "a", "loading", "control", ",", "and", "the", "white", "line", "indicates", "that", "intervening", "lanes", "have", "been", "spliced", "out", ".", "\n", "(", "D", "and", "E", ")", "MTS", "assay", "of", "(", "D", ")", "WT", "lymphocytes", "and", "(", "E", ")", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "IL4", ",", "a", "neutralizing", "antibody", "to", "IL4", ",", "or", "a", "rat", "IgG", "isotype", "control", "at", "the", "indicated", "concentrations", ".", "Shown", "are", "the", "results", "from", "LMP1", "transgenic", "lymphoma", "3", ".", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "from", "a", "single", "representative", "experiment", "that", "was", "repeated", "twice", "with", "similar", "results", "." ]	[ "Protein" ]
LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, IL4 is a Protein, CD19 is a Protein, LMP1 is a Protein, L32 is a Protein, GAPDH is a Protein, LMP1 is a Protein, pStat6 is a Protein, CD19 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, IL4 is a Protein, LMP1 is a Protein	105_task1	Sentence: Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results. Instructions: please typing these entity words according to sentence: LMP1, IL4, Stat6, IL4, CD19, LMP1, L32, GAPDH, LMP1, pStat6, CD19, IL4, LMP1, IL4, IL4, LMP1 Options: Protein	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.	[ "Wild", "-", "Type", "and", "LMP1", "Transgenic", "Lymphoma", "Cells", "Survive", "Independently", "of", "IL4", "/", "Stat6", "Signaling", "in", "Culture", "\n", "(", "A", ")", "Rnase", "protection", "assay", "for", "IL4", "mRNA", "from", "purified", "B", "cells", "(", "CD19", "+", ")", "from", "WT", "and", "LMP1", "transgenic", "splenocytes", ".", "The", "L32", "and", "GAPDH", "housekeeping", "genes", "were", "used", "as", "a", "loading", "control", ".", "Arrow", "indicates", "the", "position", "of", "the", "protected", "probe", ".", "\n", "(", "B", "and", "C", ")", "Immunoblot", "analysis", "of", "WT", "and", "LMP1", "transgenic", "mice", "for", "activated", "pStat6", "in", "(", "B", ")", "purified", "B", "cells", "(", "CD19", "+", ")", "at", "the", "time", "of", "harvest", "or", "in", "(", "C", ")", "whole", "splenocytes", "cultured", "with", "or", "without", "IL4", ".", "(", "B", ")", "Actin", "was", "used", "as", "a", "loading", "control", ",", "and", "the", "white", "line", "indicates", "that", "intervening", "lanes", "have", "been", "spliced", "out", ".", "\n", "(", "D", "and", "E", ")", "MTS", "assay", "of", "(", "D", ")", "WT", "lymphocytes", "and", "(", "E", ")", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "IL4", ",", "a", "neutralizing", "antibody", "to", "IL4", ",", "or", "a", "rat", "IgG", "isotype", "control", "at", "the", "indicated", "concentrations", ".", "Shown", "are", "the", "results", "from", "LMP1", "transgenic", "lymphoma", "3", ".", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "from", "a", "single", "representative", "experiment", "that", "was", "repeated", "twice", "with", "similar", "results", "." ]	[ "Protein" ]
LMP1, IL4, Stat6, IL4, CD19, LMP1, L32, GAPDH, LMP1, pStat6, CD19, IL4, LMP1, IL4, IL4, LMP1	105_task2	Sentence: Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.	[ "Wild", "-", "Type", "and", "LMP1", "Transgenic", "Lymphoma", "Cells", "Survive", "Independently", "of", "IL4", "/", "Stat6", "Signaling", "in", "Culture", "\n", "(", "A", ")", "Rnase", "protection", "assay", "for", "IL4", "mRNA", "from", "purified", "B", "cells", "(", "CD19", "+", ")", "from", "WT", "and", "LMP1", "transgenic", "splenocytes", ".", "The", "L32", "and", "GAPDH", "housekeeping", "genes", "were", "used", "as", "a", "loading", "control", ".", "Arrow", "indicates", "the", "position", "of", "the", "protected", "probe", ".", "\n", "(", "B", "and", "C", ")", "Immunoblot", "analysis", "of", "WT", "and", "LMP1", "transgenic", "mice", "for", "activated", "pStat6", "in", "(", "B", ")", "purified", "B", "cells", "(", "CD19", "+", ")", "at", "the", "time", "of", "harvest", "or", "in", "(", "C", ")", "whole", "splenocytes", "cultured", "with", "or", "without", "IL4", ".", "(", "B", ")", "Actin", "was", "used", "as", "a", "loading", "control", ",", "and", "the", "white", "line", "indicates", "that", "intervening", "lanes", "have", "been", "spliced", "out", ".", "\n", "(", "D", "and", "E", ")", "MTS", "assay", "of", "(", "D", ")", "WT", "lymphocytes", "and", "(", "E", ")", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "IL4", ",", "a", "neutralizing", "antibody", "to", "IL4", ",", "or", "a", "rat", "IgG", "isotype", "control", "at", "the", "indicated", "concentrations", ".", "Shown", "are", "the", "results", "from", "LMP1", "transgenic", "lymphoma", "3", ".", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "from", "a", "single", "representative", "experiment", "that", "was", "repeated", "twice", "with", "similar", "results", "." ]	[ "Protein" ]
squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, vaginal tumor is a DISEASE, vesicovaginal fistula is a ADVERSE, squamous cell carcinoma of the vagina is a DISEASE	example-224_task0	Sentence: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE, DISEASE	[ "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.	[ "Concurrent", "chemoradiation", "for", "locally", "advanced", "squamous", "cell", "carcinoma", "of", "the", "vagina", ":", "case", "series", "and", "literature", "review", ".", " ", "BACKGROUND", ":", "We", "reviewed", "our", "experience", "with", "patients", "with", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "received", "concurrent", "chemoradiation", "therapy", "(", "CCRT", ")", ".", "METHODS", ":", "We", "retrospectively", "analyzed", "six", "patients", "(", "median", "age", ",", "60", "years", ")", "with", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "underwent", "CCRT", "between", "2002", "and", "2005", "at", "the", "University", "of", "the", "Ryukyus", "Hospital", ".", "Two", "patients", "were", "in", "International", "Federation", "of", "Obstetricians", "and", "Gynecologists", "(", "FIGO", ")", "stage", "II", ",", "one", "in", "stage", "III", ",", "and", "three", "in", "stage", "IVA", ".", "All", "patients", "had", "an", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "performance", "status", "of", "2", "or", "less", ".", "Tumor", "size", "ranged", "from", "3.2", "to", "7.7", "cm", ".", "All", "patients", "were", "treated", "with", "true", "pelvic", "external", "-", "beam", "radiotherapy", "(", "EBRT", ")", "at", "50", "Gy", ".", "Then", "two", "of", "the", "six", "patients", "underwent", "intracavitary", "vaginal", "brachy", "-", "therapy", ".", "The", "remaining", "four", "patients", "received", "boost", "EBRT", "with", "shrinking", "fields", ".", "Total", "radiation", "dose", "to", "the", "vaginal", "tumor", "ranged", "from", "60", "to", "66", "Gy", ".", "All", "patients", "received", "two", "or", "three", "concomitant", "cycles", "of", "cisplatin", "during", "EBRT", ".", "RESULTS", ":", "All", "six", "patients", "completed", "their", "scheduled", "CCRT", ",", "and", "achieved", "a", "clinical", "complete", "response", ".", "One", "stage", "II", "patient", "died", "of", "disease", "24", "months", "after", "treatment", ",", "and", "the", "stage", "III", "patient", "had", "local", "failure", "at", "12", "months", ".", "The", "remaining", "four", "patients", "were", "free", "of", "their", "disease", "at", "18", ",", "23", ",", "33", ",", "and", "55", "months", ",", "respectively", ".", "One", "patient", "with", "stage", "IVA", "developed", "a", "vesicovaginal", "fistula", "during", "CCRT", ".", "Nevertheless", ",", "CCRT", "was", "well", "tolerated", "by", "all", "six", "patients", ",", "and", "no", "grade", "3", "or", "4", "late", "toxicity", "was", "observed", ",", "as", "evaluated", "by", "the", "Radiation", "Therapy", "Oncology", "Group", "(", "RTOG", ")", "scoring", "system", ".", "CONCLUSION", ":", "CCRT", "is", "effective", "for", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "and", "should", "be", "considered", "for", "treatment", "in", "patients", "with", "high", "-", "risk", "disease", "having", "good", "performance", "status", "." ]	[ "DISEASE", "ADVERSE" ]
squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, vaginal tumor is a DISEASE, vesicovaginal fistula is a ADVERSE, squamous cell carcinoma of the vagina is a DISEASE	example-224_task1	Sentence: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status. Instructions: please typing these entity words according to sentence: squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, vaginal tumor, vesicovaginal fistula, squamous cell carcinoma of the vagina Options: ADVERSE, DISEASE	[ "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.	[ "Concurrent", "chemoradiation", "for", "locally", "advanced", "squamous", "cell", "carcinoma", "of", "the", "vagina", ":", "case", "series", "and", "literature", "review", ".", " ", "BACKGROUND", ":", "We", "reviewed", "our", "experience", "with", "patients", "with", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "received", "concurrent", "chemoradiation", "therapy", "(", "CCRT", ")", ".", "METHODS", ":", "We", "retrospectively", "analyzed", "six", "patients", "(", "median", "age", ",", "60", "years", ")", "with", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "underwent", "CCRT", "between", "2002", "and", "2005", "at", "the", "University", "of", "the", "Ryukyus", "Hospital", ".", "Two", "patients", "were", "in", "International", "Federation", "of", "Obstetricians", "and", "Gynecologists", "(", "FIGO", ")", "stage", "II", ",", "one", "in", "stage", "III", ",", "and", "three", "in", "stage", "IVA", ".", "All", "patients", "had", "an", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "performance", "status", "of", "2", "or", "less", ".", "Tumor", "size", "ranged", "from", "3.2", "to", "7.7", "cm", ".", "All", "patients", "were", "treated", "with", "true", "pelvic", "external", "-", "beam", "radiotherapy", "(", "EBRT", ")", "at", "50", "Gy", ".", "Then", "two", "of", "the", "six", "patients", "underwent", "intracavitary", "vaginal", "brachy", "-", "therapy", ".", "The", "remaining", "four", "patients", "received", "boost", "EBRT", "with", "shrinking", "fields", ".", "Total", "radiation", "dose", "to", "the", "vaginal", "tumor", "ranged", "from", "60", "to", "66", "Gy", ".", "All", "patients", "received", "two", "or", "three", "concomitant", "cycles", "of", "cisplatin", "during", "EBRT", ".", "RESULTS", ":", "All", "six", "patients", "completed", "their", "scheduled", "CCRT", ",", "and", "achieved", "a", "clinical", "complete", "response", ".", "One", "stage", "II", "patient", "died", "of", "disease", "24", "months", "after", "treatment", ",", "and", "the", "stage", "III", "patient", "had", "local", "failure", "at", "12", "months", ".", "The", "remaining", "four", "patients", "were", "free", "of", "their", "disease", "at", "18", ",", "23", ",", "33", ",", "and", "55", "months", ",", "respectively", ".", "One", "patient", "with", "stage", "IVA", "developed", "a", "vesicovaginal", "fistula", "during", "CCRT", ".", "Nevertheless", ",", "CCRT", "was", "well", "tolerated", "by", "all", "six", "patients", ",", "and", "no", "grade", "3", "or", "4", "late", "toxicity", "was", "observed", ",", "as", "evaluated", "by", "the", "Radiation", "Therapy", "Oncology", "Group", "(", "RTOG", ")", "scoring", "system", ".", "CONCLUSION", ":", "CCRT", "is", "effective", "for", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "and", "should", "be", "considered", "for", "treatment", "in", "patients", "with", "high", "-", "risk", "disease", "having", "good", "performance", "status", "." ]	[ "DISEASE", "ADVERSE" ]
squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, vaginal tumor, vesicovaginal fistula, squamous cell carcinoma of the vagina	example-224_task2	Sentence: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.	[ "Concurrent", "chemoradiation", "for", "locally", "advanced", "squamous", "cell", "carcinoma", "of", "the", "vagina", ":", "case", "series", "and", "literature", "review", ".", " ", "BACKGROUND", ":", "We", "reviewed", "our", "experience", "with", "patients", "with", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "received", "concurrent", "chemoradiation", "therapy", "(", "CCRT", ")", ".", "METHODS", ":", "We", "retrospectively", "analyzed", "six", "patients", "(", "median", "age", ",", "60", "years", ")", "with", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "underwent", "CCRT", "between", "2002", "and", "2005", "at", "the", "University", "of", "the", "Ryukyus", "Hospital", ".", "Two", "patients", "were", "in", "International", "Federation", "of", "Obstetricians", "and", "Gynecologists", "(", "FIGO", ")", "stage", "II", ",", "one", "in", "stage", "III", ",", "and", "three", "in", "stage", "IVA", ".", "All", "patients", "had", "an", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "performance", "status", "of", "2", "or", "less", ".", "Tumor", "size", "ranged", "from", "3.2", "to", "7.7", "cm", ".", "All", "patients", "were", "treated", "with", "true", "pelvic", "external", "-", "beam", "radiotherapy", "(", "EBRT", ")", "at", "50", "Gy", ".", "Then", "two", "of", "the", "six", "patients", "underwent", "intracavitary", "vaginal", "brachy", "-", "therapy", ".", "The", "remaining", "four", "patients", "received", "boost", "EBRT", "with", "shrinking", "fields", ".", "Total", "radiation", "dose", "to", "the", "vaginal", "tumor", "ranged", "from", "60", "to", "66", "Gy", ".", "All", "patients", "received", "two", "or", "three", "concomitant", "cycles", "of", "cisplatin", "during", "EBRT", ".", "RESULTS", ":", "All", "six", "patients", "completed", "their", "scheduled", "CCRT", ",", "and", "achieved", "a", "clinical", "complete", "response", ".", "One", "stage", "II", "patient", "died", "of", "disease", "24", "months", "after", "treatment", ",", "and", "the", "stage", "III", "patient", "had", "local", "failure", "at", "12", "months", ".", "The", "remaining", "four", "patients", "were", "free", "of", "their", "disease", "at", "18", ",", "23", ",", "33", ",", "and", "55", "months", ",", "respectively", ".", "One", "patient", "with", "stage", "IVA", "developed", "a", "vesicovaginal", "fistula", "during", "CCRT", ".", "Nevertheless", ",", "CCRT", "was", "well", "tolerated", "by", "all", "six", "patients", ",", "and", "no", "grade", "3", "or", "4", "late", "toxicity", "was", "observed", ",", "as", "evaluated", "by", "the", "Radiation", "Therapy", "Oncology", "Group", "(", "RTOG", ")", "scoring", "system", ".", "CONCLUSION", ":", "CCRT", "is", "effective", "for", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "and", "should", "be", "considered", "for", "treatment", "in", "patients", "with", "high", "-", "risk", "disease", "having", "good", "performance", "status", "." ]	[ "DISEASE", "ADVERSE" ]
cochlear implant is an umlsterm, method is an umlsterm, rehabilitation is an umlsterm, deafness is an umlsterm, adults is an umlsterm, children is an umlsterm, speech is an umlsterm, use is an umlsterm, adults is an umlsterm, children is an umlsterm, cochlear implant is an umlsterm, software is an umlsterm, cochlear implants is an umlsterm, patients is an umlsterm, hearing is an umlsterm, evaluation is an umlsterm, deformities is an umlsterm, children is an umlsterm, implantations is an umlsterm, deafness is an umlsterm	HNO.80460012.eng.abstr_task0	Sentence: In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness .	[ "In", "recent", "years", "the", "cochlear", "implant", "has", "become", "an", "established", "method", "for", "rehabilitation", "of", "bilateral", "sensory", "deafness", "in", "adults", "and", "children", ".", "Intracochlear", "multichannel", "stimulation", "with", "sophisticated", "speech", "coding", "strategies", "has", "proved", "to", "be", "reliable", "and", "safe", "enough", "for", "use", "in", "adults", "as", "well", "as", "young", "children", ";", "thus", ",", "a", "few", "cochlear", "implant", "systems", "with", "different", "specifications", "are", "currently", "available", ".", "The", "differences", "in", "their", "hardware", "and", "software", "are", "discussed", ".", "Furthermore", ",", "the", "current", "indications", "for", "cochlear", "implants", "in", "patients", "whose", "hearing", "is", "severely", "impaired", "and", "important", "aspects", "of", "the", "preoperative", "evaluation", "are", "presented", "with", "special", "emphasis", "on", "dificult", "cases", "such", "as", "deformities", ",", "multihandicapped", "subjects", "and", "very", "young", "children", ".", "Our", "results", "after", "12", "years", "of", "experience", "and", "more", "than", "700", "implantations", "suggest", "that", "the", "most", "important", "prognostic", "factor", "is", "the", "duration", "of", "deafness", "." ]	[ "umlsterm" ]
cochlear implant is an umlsterm, method is an umlsterm, rehabilitation is an umlsterm, deafness is an umlsterm, adults is an umlsterm, children is an umlsterm, speech is an umlsterm, use is an umlsterm, adults is an umlsterm, children is an umlsterm, cochlear implant is an umlsterm, software is an umlsterm, cochlear implants is an umlsterm, patients is an umlsterm, hearing is an umlsterm, evaluation is an umlsterm, deformities is an umlsterm, children is an umlsterm, implantations is an umlsterm, deafness is an umlsterm	HNO.80460012.eng.abstr_task1	Sentence: In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness . Instructions: please typing these entity words according to sentence: cochlear implant, method, rehabilitation, deafness, adults, children, speech, use, adults, children, cochlear implant, software, cochlear implants, patients, hearing, evaluation, deformities, children, implantations, deafness Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness .	[ "In", "recent", "years", "the", "cochlear", "implant", "has", "become", "an", "established", "method", "for", "rehabilitation", "of", "bilateral", "sensory", "deafness", "in", "adults", "and", "children", ".", "Intracochlear", "multichannel", "stimulation", "with", "sophisticated", "speech", "coding", "strategies", "has", "proved", "to", "be", "reliable", "and", "safe", "enough", "for", "use", "in", "adults", "as", "well", "as", "young", "children", ";", "thus", ",", "a", "few", "cochlear", "implant", "systems", "with", "different", "specifications", "are", "currently", "available", ".", "The", "differences", "in", "their", "hardware", "and", "software", "are", "discussed", ".", "Furthermore", ",", "the", "current", "indications", "for", "cochlear", "implants", "in", "patients", "whose", "hearing", "is", "severely", "impaired", "and", "important", "aspects", "of", "the", "preoperative", "evaluation", "are", "presented", "with", "special", "emphasis", "on", "dificult", "cases", "such", "as", "deformities", ",", "multihandicapped", "subjects", "and", "very", "young", "children", ".", "Our", "results", "after", "12", "years", "of", "experience", "and", "more", "than", "700", "implantations", "suggest", "that", "the", "most", "important", "prognostic", "factor", "is", "the", "duration", "of", "deafness", "." ]	[ "umlsterm" ]
cochlear implant, method, rehabilitation, deafness, adults, children, speech, use, adults, children, cochlear implant, software, cochlear implants, patients, hearing, evaluation, deformities, children, implantations, deafness	HNO.80460012.eng.abstr_task2	Sentence: In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness .	[ "In", "recent", "years", "the", "cochlear", "implant", "has", "become", "an", "established", "method", "for", "rehabilitation", "of", "bilateral", "sensory", "deafness", "in", "adults", "and", "children", ".", "Intracochlear", "multichannel", "stimulation", "with", "sophisticated", "speech", "coding", "strategies", "has", "proved", "to", "be", "reliable", "and", "safe", "enough", "for", "use", "in", "adults", "as", "well", "as", "young", "children", ";", "thus", ",", "a", "few", "cochlear", "implant", "systems", "with", "different", "specifications", "are", "currently", "available", ".", "The", "differences", "in", "their", "hardware", "and", "software", "are", "discussed", ".", "Furthermore", ",", "the", "current", "indications", "for", "cochlear", "implants", "in", "patients", "whose", "hearing", "is", "severely", "impaired", "and", "important", "aspects", "of", "the", "preoperative", "evaluation", "are", "presented", "with", "special", "emphasis", "on", "dificult", "cases", "such", "as", "deformities", ",", "multihandicapped", "subjects", "and", "very", "young", "children", ".", "Our", "results", "after", "12", "years", "of", "experience", "and", "more", "than", "700", "implantations", "suggest", "that", "the", "most", "important", "prognostic", "factor", "is", "the", "duration", "of", "deafness", "." ]	[ "umlsterm" ]
Verwendung is an umlsterm, Kreuzbandchirurgie is an umlsterm, Transplantatentnahmemorbiditaet is an umlsterm, Zugfestigkeit is an umlsterm, Transplantatintegration is an umlsterm, Transplantatverankerung is an umlsterm, Gelenkspalt is an umlsterm, biologischen Faktoren is an umlsterm, Weichgewebe - Transplantaten is an umlsterm	DerChirurg.00711034.ger.abstr_task0	Sentence: Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation .	[ "Zusammenfassung", ".", "Die", "Verwendung", "von", "Hamstringsehnen", "-", "Transplantaten", "in", "der", "Kreuzbandchirurgie", "hat", "in", "den", "letzten", "Jahren", "wieder", "zunehmend", "an", "Bedeutung", "gewonnen", ".", "Der", "wesentliche", "Vorteil", "der", "Hamstringsehnen", "gegenueber", "dem", "mittleren", "Patellarsehnendrittel", "liegt", "in", "einer", "erheblich", "reduzierten", "Transplantatentnahmemorbiditaet", ",", "kombiniert", "mit", "einer", "sehr", "hohen", "Zugfestigkeit", ".", "Die", "ossaere", "Transplantatintegration", "unterliegt", "jedoch", "spezifischen", "biomechanischen", "und", "biologischen", "Rahmenbedingungen", ".", "Neue", "Entwicklungen", "auf", "dem", "Gebiet", "der", "Transplantatverankerung", "haben", "sich", "darauf", "konzentriert", "die", "initiale", "Verankerungsfestigkeit", "zu", "erhoehen", "und", "das", "Verankerungslevel", "weiter", "in", "Richtung", "Gelenkspalt", "zu", "verschieben", ".", "Es", "wird", "also", "eine", "anatomische", "Verankerung", ",", "moeglichst", "nahe", "dem", "original", "Kreuzbandansatz", "angestrebt", ".", "Ziel", "der", "vorliegenden", "Uebersichtsarbeit", "ist", "es", "neue", "Entwicklungen", "unter", "besonderer", "Beruecksichtigung", "von", "biomechanischen", "und", "biologischen", "Faktoren", "vorzustellen", "und", "zu", "diskutieren", ".", "Spezielles", "Augenmerk", "liegt", "hier", "auf", "der", "Interferenzschrauben", "-", "Verankerung", "von", "Weichgewebe", "-", "Transplantaten", ",", "femoralen", "Transfixationsystemen", "und", "dem", "sog", ".", "Konzept", "der", "Hybridfixation", "." ]	[ "umlsterm" ]
Verwendung is an umlsterm, Kreuzbandchirurgie is an umlsterm, Transplantatentnahmemorbiditaet is an umlsterm, Zugfestigkeit is an umlsterm, Transplantatintegration is an umlsterm, Transplantatverankerung is an umlsterm, Gelenkspalt is an umlsterm, biologischen Faktoren is an umlsterm, Weichgewebe - Transplantaten is an umlsterm	DerChirurg.00711034.ger.abstr_task1	Sentence: Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation . Instructions: please typing these entity words according to sentence: Verwendung, Kreuzbandchirurgie, Transplantatentnahmemorbiditaet, Zugfestigkeit, Transplantatintegration, Transplantatverankerung, Gelenkspalt, biologischen Faktoren, Weichgewebe - Transplantaten Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation .	[ "Zusammenfassung", ".", "Die", "Verwendung", "von", "Hamstringsehnen", "-", "Transplantaten", "in", "der", "Kreuzbandchirurgie", "hat", "in", "den", "letzten", "Jahren", "wieder", "zunehmend", "an", "Bedeutung", "gewonnen", ".", "Der", "wesentliche", "Vorteil", "der", "Hamstringsehnen", "gegenueber", "dem", "mittleren", "Patellarsehnendrittel", "liegt", "in", "einer", "erheblich", "reduzierten", "Transplantatentnahmemorbiditaet", ",", "kombiniert", "mit", "einer", "sehr", "hohen", "Zugfestigkeit", ".", "Die", "ossaere", "Transplantatintegration", "unterliegt", "jedoch", "spezifischen", "biomechanischen", "und", "biologischen", "Rahmenbedingungen", ".", "Neue", "Entwicklungen", "auf", "dem", "Gebiet", "der", "Transplantatverankerung", "haben", "sich", "darauf", "konzentriert", "die", "initiale", "Verankerungsfestigkeit", "zu", "erhoehen", "und", "das", "Verankerungslevel", "weiter", "in", "Richtung", "Gelenkspalt", "zu", "verschieben", ".", "Es", "wird", "also", "eine", "anatomische", "Verankerung", ",", "moeglichst", "nahe", "dem", "original", "Kreuzbandansatz", "angestrebt", ".", "Ziel", "der", "vorliegenden", "Uebersichtsarbeit", "ist", "es", "neue", "Entwicklungen", "unter", "besonderer", "Beruecksichtigung", "von", "biomechanischen", "und", "biologischen", "Faktoren", "vorzustellen", "und", "zu", "diskutieren", ".", "Spezielles", "Augenmerk", "liegt", "hier", "auf", "der", "Interferenzschrauben", "-", "Verankerung", "von", "Weichgewebe", "-", "Transplantaten", ",", "femoralen", "Transfixationsystemen", "und", "dem", "sog", ".", "Konzept", "der", "Hybridfixation", "." ]	[ "umlsterm" ]
Verwendung, Kreuzbandchirurgie, Transplantatentnahmemorbiditaet, Zugfestigkeit, Transplantatintegration, Transplantatverankerung, Gelenkspalt, biologischen Faktoren, Weichgewebe - Transplantaten	DerChirurg.00711034.ger.abstr_task2	Sentence: Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation .	[ "Zusammenfassung", ".", "Die", "Verwendung", "von", "Hamstringsehnen", "-", "Transplantaten", "in", "der", "Kreuzbandchirurgie", "hat", "in", "den", "letzten", "Jahren", "wieder", "zunehmend", "an", "Bedeutung", "gewonnen", ".", "Der", "wesentliche", "Vorteil", "der", "Hamstringsehnen", "gegenueber", "dem", "mittleren", "Patellarsehnendrittel", "liegt", "in", "einer", "erheblich", "reduzierten", "Transplantatentnahmemorbiditaet", ",", "kombiniert", "mit", "einer", "sehr", "hohen", "Zugfestigkeit", ".", "Die", "ossaere", "Transplantatintegration", "unterliegt", "jedoch", "spezifischen", "biomechanischen", "und", "biologischen", "Rahmenbedingungen", ".", "Neue", "Entwicklungen", "auf", "dem", "Gebiet", "der", "Transplantatverankerung", "haben", "sich", "darauf", "konzentriert", "die", "initiale", "Verankerungsfestigkeit", "zu", "erhoehen", "und", "das", "Verankerungslevel", "weiter", "in", "Richtung", "Gelenkspalt", "zu", "verschieben", ".", "Es", "wird", "also", "eine", "anatomische", "Verankerung", ",", "moeglichst", "nahe", "dem", "original", "Kreuzbandansatz", "angestrebt", ".", "Ziel", "der", "vorliegenden", "Uebersichtsarbeit", "ist", "es", "neue", "Entwicklungen", "unter", "besonderer", "Beruecksichtigung", "von", "biomechanischen", "und", "biologischen", "Faktoren", "vorzustellen", "und", "zu", "diskutieren", ".", "Spezielles", "Augenmerk", "liegt", "hier", "auf", "der", "Interferenzschrauben", "-", "Verankerung", "von", "Weichgewebe", "-", "Transplantaten", ",", "femoralen", "Transfixationsystemen", "und", "dem", "sog", ".", "Konzept", "der", "Hybridfixation", "." ]	[ "umlsterm" ]
H2O2 is a compound, IL-6 is a protein	DS.d1608_task0	Sentence: Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]	Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels.	[ "Muscular", "oxidative", "stress", "and", "inflammation", "induced", "by", "H2O2", "or", "MS", "were", "assessed", "by", "measurements", "of", "isoprostanes", "and", "IL-6", "levels", "." ]	[ "protein", "compound" ]
H2O2 is a compound, IL-6 is a protein	DS.d1608_task1	Sentence: Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels. Instructions: please typing these entity words according to sentence: H2O2, IL-6 Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]	Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels.	[ "Muscular", "oxidative", "stress", "and", "inflammation", "induced", "by", "H2O2", "or", "MS", "were", "assessed", "by", "measurements", "of", "isoprostanes", "and", "IL-6", "levels", "." ]	[ "protein", "compound" ]
H2O2, IL-6	DS.d1608_task2	Sentence: Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]	Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels.	[ "Muscular", "oxidative", "stress", "and", "inflammation", "induced", "by", "H2O2", "or", "MS", "were", "assessed", "by", "measurements", "of", "isoprostanes", "and", "IL-6", "levels", "." ]	[ "protein", "compound" ]
complication is an umlsterm, stent is an umlsterm, implantation is an umlsterm, arteries is an umlsterm, complications is an umlsterm, case report is an umlsterm, artery is an umlsterm, old is an umlsterm, graft is an umlsterm, stent - implantation is an umlsterm, vessel is an umlsterm, methods is an umlsterm, pericardial effusion is an umlsterm, patient is an umlsterm, surgical revision is an umlsterm	ZfuerKardiologie.80870233.eng.abstr_task0	Sentence: We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed .	[ "We", "describe", "a", "case", "-", "report", "on", "an", "perforation", "of", "an", "aorto", "-", "coronary", "venous", "bypass", "-", "graft", ",", "a", "complication", "induced", "by", "a", "stent", "implantation", ".", "Perforations", "of", "coronary", "arteries", "are", "rare", ",", "however", ",", "for", "interventional", "cardiologists", "well", "-", "known", "complications", ".", "This", "case", "report", "is", "of", "special", "interest", "(", "1", ")", "because", "the", "perforation", "did", "not", "occur", "in", "a", "coronary", "artery", "but", "rather", "in", "an", "eight", "year", "old", "venous", "bypass", "graft", "and", "(", "2", ")", "because", "the", "perforation", "was", "induced", "by", "a", "stent", "-", "implantation", ".", "In", "addition", ",", "this", "case", "-", "report", "describes", "in", "great", "detail", "the", "management", "of", "vessel", "perforation", ":", "several", "invasive", "methods", "contributed", "to", "minimize", "pericardial", "effusion", "and", "to", "stabilize", "the", "patient", "until", "surgical", "revision", "could", "be", "performed", "." ]	[ "umlsterm" ]
complication is an umlsterm, stent is an umlsterm, implantation is an umlsterm, arteries is an umlsterm, complications is an umlsterm, case report is an umlsterm, artery is an umlsterm, old is an umlsterm, graft is an umlsterm, stent - implantation is an umlsterm, vessel is an umlsterm, methods is an umlsterm, pericardial effusion is an umlsterm, patient is an umlsterm, surgical revision is an umlsterm	ZfuerKardiologie.80870233.eng.abstr_task1	Sentence: We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed . Instructions: please typing these entity words according to sentence: complication, stent, implantation, arteries, complications, case report, artery, old, graft, stent - implantation, vessel, methods, pericardial effusion, patient, surgical revision Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed .	[ "We", "describe", "a", "case", "-", "report", "on", "an", "perforation", "of", "an", "aorto", "-", "coronary", "venous", "bypass", "-", "graft", ",", "a", "complication", "induced", "by", "a", "stent", "implantation", ".", "Perforations", "of", "coronary", "arteries", "are", "rare", ",", "however", ",", "for", "interventional", "cardiologists", "well", "-", "known", "complications", ".", "This", "case", "report", "is", "of", "special", "interest", "(", "1", ")", "because", "the", "perforation", "did", "not", "occur", "in", "a", "coronary", "artery", "but", "rather", "in", "an", "eight", "year", "old", "venous", "bypass", "graft", "and", "(", "2", ")", "because", "the", "perforation", "was", "induced", "by", "a", "stent", "-", "implantation", ".", "In", "addition", ",", "this", "case", "-", "report", "describes", "in", "great", "detail", "the", "management", "of", "vessel", "perforation", ":", "several", "invasive", "methods", "contributed", "to", "minimize", "pericardial", "effusion", "and", "to", "stabilize", "the", "patient", "until", "surgical", "revision", "could", "be", "performed", "." ]	[ "umlsterm" ]
complication, stent, implantation, arteries, complications, case report, artery, old, graft, stent - implantation, vessel, methods, pericardial effusion, patient, surgical revision	ZfuerKardiologie.80870233.eng.abstr_task2	Sentence: We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed .	[ "We", "describe", "a", "case", "-", "report", "on", "an", "perforation", "of", "an", "aorto", "-", "coronary", "venous", "bypass", "-", "graft", ",", "a", "complication", "induced", "by", "a", "stent", "implantation", ".", "Perforations", "of", "coronary", "arteries", "are", "rare", ",", "however", ",", "for", "interventional", "cardiologists", "well", "-", "known", "complications", ".", "This", "case", "report", "is", "of", "special", "interest", "(", "1", ")", "because", "the", "perforation", "did", "not", "occur", "in", "a", "coronary", "artery", "but", "rather", "in", "an", "eight", "year", "old", "venous", "bypass", "graft", "and", "(", "2", ")", "because", "the", "perforation", "was", "induced", "by", "a", "stent", "-", "implantation", ".", "In", "addition", ",", "this", "case", "-", "report", "describes", "in", "great", "detail", "the", "management", "of", "vessel", "perforation", ":", "several", "invasive", "methods", "contributed", "to", "minimize", "pericardial", "effusion", "and", "to", "stabilize", "the", "patient", "until", "surgical", "revision", "could", "be", "performed", "." ]	[ "umlsterm" ]
Italian and US American context sensitivity and Fear of Isolation is a Participant_Condition, differences is a Outcome_Other, chronic is a Outcome_Physical, different Western cultures is a Participant_Condition, Testing Italian ( IT ) and US American ( US ) is a Participant_Condition, adults is a Participant_Age, information more holistically and had a higher chronic level of FOI is a Outcome_Physical, US participants is a Participant_Condition, FOI affected context sensitivity is a Outcome_Mental, this difference is due to different chronic levels of FOI . is a Outcome_Physical	48234_task0	Sentence: West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]	West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI .	[ "West", "vs", ".", "West", "like", "East", "vs", ".", "West", "?", "A", "comparison", "between", "Italian", "and", "US", "American", "context", "sensitivity", "and", "Fear", "of", "Isolation", ".", "Easterners", "tend", "to", "process", "information", "more", "holistically", "than", "Westerners", ".", "Kim", "and", "Markman", "(", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "suggest", "that", "these", "differences", "are", "rooted", "in", "higher", "chronic", "levels", "of", "Fear", "of", "Isolation", "(", "FOI", ")", "for", "those", "cultures", "that", "process", "information", "more", "holistically", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "if", "these", "differences", "and", "their", "suggested", "cause", "could", "be", "found", "with", "two", "different", "Western", "cultures", ".", "Testing", "Italian", "(", "IT", ")", "and", "US", "American", "(", "US", ")", "adults", ",", "we", "found", "that", "IT", "participants", "processed", "information", "more", "holistically", "and", "had", "a", "higher", "chronic", "level", "of", "FOI", "than", "US", "participants", ";", "furthermore", ",", "the", "manipulation", "of", "FOI", "affected", "context", "sensitivity", "more", "for", "IT", "than", "for", "US", "participants", ".", "The", "results", "demonstrate", "that", "IT", "participants", "were", "more", "similar", "to", "previous", "research", "with", "Eastern", "populations", "than", "with", "Western", "populations", "(", "Kim", "and", "Markman", "in", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "and", "indicate", "a", "within", "-", "Western", "culture", "difference", "for", "reasoning", "styles", "and", "support", "the", "hypothesis", "that", "this", "difference", "is", "due", "to", "different", "chronic", "levels", "of", "FOI", "." ]	[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Outcome_Other", "Participant_Age" ]
Italian and US American context sensitivity and Fear of Isolation is a Participant_Condition, differences is a Outcome_Other, chronic is a Outcome_Physical, different Western cultures is a Participant_Condition, Testing Italian ( IT ) and US American ( US ) is a Participant_Condition, adults is a Participant_Age, information more holistically and had a higher chronic level of FOI is a Outcome_Physical, US participants is a Participant_Condition, FOI affected context sensitivity is a Outcome_Mental, this difference is due to different chronic levels of FOI . is a Outcome_Physical	48234_task1	Sentence: West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI . Instructions: please typing these entity words according to sentence: Italian and US American context sensitivity and Fear of Isolation, differences, chronic, different Western cultures, Testing Italian ( IT ) and US American ( US ), adults, information more holistically and had a higher chronic level of FOI, US participants, FOI affected context sensitivity, this difference is due to different chronic levels of FOI . Options: Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]	West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI .	[ "West", "vs", ".", "West", "like", "East", "vs", ".", "West", "?", "A", "comparison", "between", "Italian", "and", "US", "American", "context", "sensitivity", "and", "Fear", "of", "Isolation", ".", "Easterners", "tend", "to", "process", "information", "more", "holistically", "than", "Westerners", ".", "Kim", "and", "Markman", "(", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "suggest", "that", "these", "differences", "are", "rooted", "in", "higher", "chronic", "levels", "of", "Fear", "of", "Isolation", "(", "FOI", ")", "for", "those", "cultures", "that", "process", "information", "more", "holistically", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "if", "these", "differences", "and", "their", "suggested", "cause", "could", "be", "found", "with", "two", "different", "Western", "cultures", ".", "Testing", "Italian", "(", "IT", ")", "and", "US", "American", "(", "US", ")", "adults", ",", "we", "found", "that", "IT", "participants", "processed", "information", "more", "holistically", "and", "had", "a", "higher", "chronic", "level", "of", "FOI", "than", "US", "participants", ";", "furthermore", ",", "the", "manipulation", "of", "FOI", "affected", "context", "sensitivity", "more", "for", "IT", "than", "for", "US", "participants", ".", "The", "results", "demonstrate", "that", "IT", "participants", "were", "more", "similar", "to", "previous", "research", "with", "Eastern", "populations", "than", "with", "Western", "populations", "(", "Kim", "and", "Markman", "in", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "and", "indicate", "a", "within", "-", "Western", "culture", "difference", "for", "reasoning", "styles", "and", "support", "the", "hypothesis", "that", "this", "difference", "is", "due", "to", "different", "chronic", "levels", "of", "FOI", "." ]	[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Outcome_Other", "Participant_Age" ]
Italian and US American context sensitivity and Fear of Isolation, differences, chronic, different Western cultures, Testing Italian ( IT ) and US American ( US ), adults, information more holistically and had a higher chronic level of FOI, US participants, FOI affected context sensitivity, this difference is due to different chronic levels of FOI .	48234_task2	Sentence: West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]	West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI .	[ "West", "vs", ".", "West", "like", "East", "vs", ".", "West", "?", "A", "comparison", "between", "Italian", "and", "US", "American", "context", "sensitivity", "and", "Fear", "of", "Isolation", ".", "Easterners", "tend", "to", "process", "information", "more", "holistically", "than", "Westerners", ".", "Kim", "and", "Markman", "(", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "suggest", "that", "these", "differences", "are", "rooted", "in", "higher", "chronic", "levels", "of", "Fear", "of", "Isolation", "(", "FOI", ")", "for", "those", "cultures", "that", "process", "information", "more", "holistically", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "if", "these", "differences", "and", "their", "suggested", "cause", "could", "be", "found", "with", "two", "different", "Western", "cultures", ".", "Testing", "Italian", "(", "IT", ")", "and", "US", "American", "(", "US", ")", "adults", ",", "we", "found", "that", "IT", "participants", "processed", "information", "more", "holistically", "and", "had", "a", "higher", "chronic", "level", "of", "FOI", "than", "US", "participants", ";", "furthermore", ",", "the", "manipulation", "of", "FOI", "affected", "context", "sensitivity", "more", "for", "IT", "than", "for", "US", "participants", ".", "The", "results", "demonstrate", "that", "IT", "participants", "were", "more", "similar", "to", "previous", "research", "with", "Eastern", "populations", "than", "with", "Western", "populations", "(", "Kim", "and", "Markman", "in", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "and", "indicate", "a", "within", "-", "Western", "culture", "difference", "for", "reasoning", "styles", "and", "support", "the", "hypothesis", "that", "this", "difference", "is", "due", "to", "different", "chronic", "levels", "of", "FOI", "." ]	[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Outcome_Other", "Participant_Age" ]
heparin ( dalteparin ) is a Intervention_Pharmacological, extended duration therapy is a Intervention_Pharmacological, venous thromboembolism is a Participant_Condition, cancer is a Participant_Condition, anti - Xa levels is a Outcome_Physical, acute venous thromboembolism is a Participant_Condition, active cancer is a Participant_Condition, oral anticoagulant therapy is a Intervention_Pharmacological, Anti - Xa levels is a Outcome_Physical, bleeding is a Outcome_Adverse-effects, recurrent venous thromboembolism is a Outcome_Physical, 24 patients is a Participant_Sample-size, died is a Outcome_Mortality, mean anti - Xa levels is a Outcome_Physical, accumulation of anti - Xa effect is a Outcome_Physical	22422_task0	Sentence: Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required .	[ "Anti", "-", "Xa", "effect", "of", "a", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "does", "not", "accumulate", "in", "extended", "duration", "therapy", "for", "venous", "thromboembolism", "in", "cancer", "patients", ".", "Many", "patients", "with", "venous", "thromboembolism", "are", "being", "treated", "with", "low", "molecular", "weight", "heparin", "for", "extended", "periods", "of", "time", ".", "It", "is", "not", "certain", "if", "it", "is", "necessary", "to", "assess", "anti", "-", "Xa", "levels", "for", "extended", "treatment", "periods", ".", "This", "study", "is", "a", "prospective", "assessment", "of", "anti", "-", "Xa", "levels", "in", "patients", "on", "long", "-", "term", "therapy", "for", "acute", "venous", "thromboembolism", "who", "have", "active", "cancer", ".", "Consecutive", "consenting", "patients", "from", "one", "center", "in", "a", "multicenter", "trial", "that", "compared", "6", "months", "of", "low", "molecular", "weight", "heparin", "with", "oral", "anticoagulant", "therapy", "were", "treated", "with", "therapeutic", "doses", "of", "dalteparin", "(", "200", "IU", "per", "kilogram", ")", "subcutaneously", "daily", ".", "Anti", "-", "Xa", "levels", "were", "assessed", "at", "the", "end", "of", "weeks", "1", "and", "4,4", "-", "6", "hours", "after", "injection", "of", "dalteparin", ".", "Patients", "were", "followed", "for", "bleeding", "and", "recurrent", "venous", "thromboembolism", ".", "There", "were", "24", "patients", "who", "had", "anti", "-", "Xa", "levels", "measured", "at", "weeks", "1", "and", "4", ".", "Two", "other", "patients", "had", "week", "1", "measurements", "performed", "but", "died", "before", "the", "week", "4", "sample", "was", "collected", "due", "to", "their", "underlying", "cancer", ".", "The", "mean", "anti", "-", "Xa", "levels", "at", "weeks", "1", "and", "4", "were", "1.11", "and", "1.03", "anti", "-", "Xa", "units", "/", "ml", "respectively", "(", "P=0.13", ")", ".", "These", "results", "suggest", "that", "for", "patients", "with", "active", "cancer", "receiving", "extended", "duration", "therapy", "with", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "there", "is", "no", "accumulation", "of", "anti", "-", "Xa", "effect", "over", "the", "first", "month", "of", "therapy", ".", "Monitoring", "of", "anti", "-", "Xa", "levels", "in", "this", "situation", "is", "usually", "not", "required", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Adverse-effects", "Outcome_Mortality" ]
heparin ( dalteparin ) is a Intervention_Pharmacological, extended duration therapy is a Intervention_Pharmacological, venous thromboembolism is a Participant_Condition, cancer is a Participant_Condition, anti - Xa levels is a Outcome_Physical, acute venous thromboembolism is a Participant_Condition, active cancer is a Participant_Condition, oral anticoagulant therapy is a Intervention_Pharmacological, Anti - Xa levels is a Outcome_Physical, bleeding is a Outcome_Adverse-effects, recurrent venous thromboembolism is a Outcome_Physical, 24 patients is a Participant_Sample-size, died is a Outcome_Mortality, mean anti - Xa levels is a Outcome_Physical, accumulation of anti - Xa effect is a Outcome_Physical	22422_task1	Sentence: Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required . Instructions: please typing these entity words according to sentence: heparin ( dalteparin ), extended duration therapy, venous thromboembolism, cancer, anti - Xa levels, acute venous thromboembolism, active cancer, oral anticoagulant therapy, Anti - Xa levels, bleeding, recurrent venous thromboembolism, 24 patients, died, mean anti - Xa levels, accumulation of anti - Xa effect Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required .	[ "Anti", "-", "Xa", "effect", "of", "a", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "does", "not", "accumulate", "in", "extended", "duration", "therapy", "for", "venous", "thromboembolism", "in", "cancer", "patients", ".", "Many", "patients", "with", "venous", "thromboembolism", "are", "being", "treated", "with", "low", "molecular", "weight", "heparin", "for", "extended", "periods", "of", "time", ".", "It", "is", "not", "certain", "if", "it", "is", "necessary", "to", "assess", "anti", "-", "Xa", "levels", "for", "extended", "treatment", "periods", ".", "This", "study", "is", "a", "prospective", "assessment", "of", "anti", "-", "Xa", "levels", "in", "patients", "on", "long", "-", "term", "therapy", "for", "acute", "venous", "thromboembolism", "who", "have", "active", "cancer", ".", "Consecutive", "consenting", "patients", "from", "one", "center", "in", "a", "multicenter", "trial", "that", "compared", "6", "months", "of", "low", "molecular", "weight", "heparin", "with", "oral", "anticoagulant", "therapy", "were", "treated", "with", "therapeutic", "doses", "of", "dalteparin", "(", "200", "IU", "per", "kilogram", ")", "subcutaneously", "daily", ".", "Anti", "-", "Xa", "levels", "were", "assessed", "at", "the", "end", "of", "weeks", "1", "and", "4,4", "-", "6", "hours", "after", "injection", "of", "dalteparin", ".", "Patients", "were", "followed", "for", "bleeding", "and", "recurrent", "venous", "thromboembolism", ".", "There", "were", "24", "patients", "who", "had", "anti", "-", "Xa", "levels", "measured", "at", "weeks", "1", "and", "4", ".", "Two", "other", "patients", "had", "week", "1", "measurements", "performed", "but", "died", "before", "the", "week", "4", "sample", "was", "collected", "due", "to", "their", "underlying", "cancer", ".", "The", "mean", "anti", "-", "Xa", "levels", "at", "weeks", "1", "and", "4", "were", "1.11", "and", "1.03", "anti", "-", "Xa", "units", "/", "ml", "respectively", "(", "P=0.13", ")", ".", "These", "results", "suggest", "that", "for", "patients", "with", "active", "cancer", "receiving", "extended", "duration", "therapy", "with", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "there", "is", "no", "accumulation", "of", "anti", "-", "Xa", "effect", "over", "the", "first", "month", "of", "therapy", ".", "Monitoring", "of", "anti", "-", "Xa", "levels", "in", "this", "situation", "is", "usually", "not", "required", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Adverse-effects", "Outcome_Mortality" ]
heparin ( dalteparin ), extended duration therapy, venous thromboembolism, cancer, anti - Xa levels, acute venous thromboembolism, active cancer, oral anticoagulant therapy, Anti - Xa levels, bleeding, recurrent venous thromboembolism, 24 patients, died, mean anti - Xa levels, accumulation of anti - Xa effect	22422_task2	Sentence: Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required .	[ "Anti", "-", "Xa", "effect", "of", "a", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "does", "not", "accumulate", "in", "extended", "duration", "therapy", "for", "venous", "thromboembolism", "in", "cancer", "patients", ".", "Many", "patients", "with", "venous", "thromboembolism", "are", "being", "treated", "with", "low", "molecular", "weight", "heparin", "for", "extended", "periods", "of", "time", ".", "It", "is", "not", "certain", "if", "it", "is", "necessary", "to", "assess", "anti", "-", "Xa", "levels", "for", "extended", "treatment", "periods", ".", "This", "study", "is", "a", "prospective", "assessment", "of", "anti", "-", "Xa", "levels", "in", "patients", "on", "long", "-", "term", "therapy", "for", "acute", "venous", "thromboembolism", "who", "have", "active", "cancer", ".", "Consecutive", "consenting", "patients", "from", "one", "center", "in", "a", "multicenter", "trial", "that", "compared", "6", "months", "of", "low", "molecular", "weight", "heparin", "with", "oral", "anticoagulant", "therapy", "were", "treated", "with", "therapeutic", "doses", "of", "dalteparin", "(", "200", "IU", "per", "kilogram", ")", "subcutaneously", "daily", ".", "Anti", "-", "Xa", "levels", "were", "assessed", "at", "the", "end", "of", "weeks", "1", "and", "4,4", "-", "6", "hours", "after", "injection", "of", "dalteparin", ".", "Patients", "were", "followed", "for", "bleeding", "and", "recurrent", "venous", "thromboembolism", ".", "There", "were", "24", "patients", "who", "had", "anti", "-", "Xa", "levels", "measured", "at", "weeks", "1", "and", "4", ".", "Two", "other", "patients", "had", "week", "1", "measurements", "performed", "but", "died", "before", "the", "week", "4", "sample", "was", "collected", "due", "to", "their", "underlying", "cancer", ".", "The", "mean", "anti", "-", "Xa", "levels", "at", "weeks", "1", "and", "4", "were", "1.11", "and", "1.03", "anti", "-", "Xa", "units", "/", "ml", "respectively", "(", "P=0.13", ")", ".", "These", "results", "suggest", "that", "for", "patients", "with", "active", "cancer", "receiving", "extended", "duration", "therapy", "with", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "there", "is", "no", "accumulation", "of", "anti", "-", "Xa", "effect", "over", "the", "first", "month", "of", "therapy", ".", "Monitoring", "of", "anti", "-", "Xa", "levels", "in", "this", "situation", "is", "usually", "not", "required", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Adverse-effects", "Outcome_Mortality" ]
paraganglioma is a Cancer, pheochromocytoma is a Cancer, succinate dehydrogenase is a Gene_or_gene_product, Mitochondrial is a Cellular_component, complex II is a Gene_or_gene_product, succinate dehydrogenase is a Gene_or_gene_product, tricarboxylic acid is a Simple_chemical, TCA is a Simple_chemical, mitochondrial is a Cellular_component, succinate dehydrogenase subunit A is a Gene_or_gene_product, SDHA is a Gene_or_gene_product, patients is a Organism, mitochondrial is a Cellular_component, succinate dehydrogenase is a Gene_or_gene_product, SDHB is a Gene_or_gene_product, SDHC is a Gene_or_gene_product, SDHD is a Gene_or_gene_product, patients is a Organism, paraganglioma is a Cancer, pheochromocytoma is a Cancer, cancer is a Cancer, patients is a Organism, paragangliomas is a Cancer, pheochromocytomas is a Cancer, fumarase is a Gene_or_gene_product, TCA is a Simple_chemical, renal is a Cancer, uterine is a Cancer, cutaneous tumors is a Cancer, TCA is a Simple_chemical, mitochondria is a Cellular_component, cancer is a Cancer	70_task0	Sentence: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product	[ "O", "B-Cancer", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "B-Cancer", "O", "O" ]	Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer.	[ "Hereditary", "paraganglioma", "/", "pheochromocytoma", "and", "inherited", "succinate", "dehydrogenase", "deficiency", ".", "\n", "Mitochondrial", "complex", "II", ",", "or", "succinate", "dehydrogenase", ",", "is", "a", "key", "enzymatic", "complex", "involved", "in", "both", "the", "tricarboxylic", "acid", "(", "TCA", ")", "cycle", "and", "oxidative", "phosphorylation", "as", "part", "of", "the", "mitochondrial", "respiratory", "chain", ".", "Germline", "succinate", "dehydrogenase", "subunit", "A", "(", "SDHA", ")", "mutations", "have", "been", "reported", "in", "a", "few", "patients", "with", "a", "classical", "mitochondrial", "neurodegenerative", "disease", ".", "Mutations", "in", "the", "genes", "encoding", "the", "three", "other", "succinate", "dehydrogenase", "subunits", "(", "SDHB", ",", "SDHC", "and", "SDHD", ")", "have", "been", "identified", "in", "patients", "affected", "by", "familial", "or", "'", "apparently", "sporadic", "'", "paraganglioma", "and", "/", "or", "pheochromocytoma", ",", "an", "autosomal", "inherited", "cancer", "-", "susceptibility", "syndrome", ".", "These", "discoveries", "have", "dramatically", "changed", "the", "work", "-", "up", "and", "genetic", "counseling", "of", "patients", "and", "families", "with", "paragangliomas", "and", "/", "or", "pheochromocytomas", ".", "The", "subsequent", "identification", "of", "germline", "mutations", "in", "the", "gene", "encoding", "fumarase", "--", "another", "TCA", "cycle", "enzyme", "--", "in", "a", "new", "hereditary", "form", "of", "susceptibility", "to", "renal", ",", "uterine", "and", "cutaneous", "tumors", "has", "highlighted", "the", "potential", "role", "of", "the", "TCA", "cycle", "and", ",", "more", "generally", ",", "of", "the", "mitochondria", "in", "cancer", ".", "\n" ]	[ "Gene_or_gene_product", "Simple_chemical", "Cancer", "Cellular_component", "Organism" ]
paraganglioma is a Cancer, pheochromocytoma is a Cancer, succinate dehydrogenase is a Gene_or_gene_product, Mitochondrial is a Cellular_component, complex II is a Gene_or_gene_product, succinate dehydrogenase is a Gene_or_gene_product, tricarboxylic acid is a Simple_chemical, TCA is a Simple_chemical, mitochondrial is a Cellular_component, succinate dehydrogenase subunit A is a Gene_or_gene_product, SDHA is a Gene_or_gene_product, patients is a Organism, mitochondrial is a Cellular_component, succinate dehydrogenase is a Gene_or_gene_product, SDHB is a Gene_or_gene_product, SDHC is a Gene_or_gene_product, SDHD is a Gene_or_gene_product, patients is a Organism, paraganglioma is a Cancer, pheochromocytoma is a Cancer, cancer is a Cancer, patients is a Organism, paragangliomas is a Cancer, pheochromocytomas is a Cancer, fumarase is a Gene_or_gene_product, TCA is a Simple_chemical, renal is a Cancer, uterine is a Cancer, cutaneous tumors is a Cancer, TCA is a Simple_chemical, mitochondria is a Cellular_component, cancer is a Cancer	70_task1	Sentence: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer. Instructions: please typing these entity words according to sentence: paraganglioma, pheochromocytoma, succinate dehydrogenase, Mitochondrial, complex II, succinate dehydrogenase, tricarboxylic acid, TCA, mitochondrial, succinate dehydrogenase subunit A, SDHA, patients, mitochondrial, succinate dehydrogenase, SDHB, SDHC, SDHD, patients, paraganglioma, pheochromocytoma, cancer, patients, paragangliomas, pheochromocytomas, fumarase, TCA, renal, uterine, cutaneous tumors, TCA, mitochondria, cancer Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product	[ "O", "B-Cancer", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "B-Cancer", "O", "O" ]	Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer.	[ "Hereditary", "paraganglioma", "/", "pheochromocytoma", "and", "inherited", "succinate", "dehydrogenase", "deficiency", ".", "\n", "Mitochondrial", "complex", "II", ",", "or", "succinate", "dehydrogenase", ",", "is", "a", "key", "enzymatic", "complex", "involved", "in", "both", "the", "tricarboxylic", "acid", "(", "TCA", ")", "cycle", "and", "oxidative", "phosphorylation", "as", "part", "of", "the", "mitochondrial", "respiratory", "chain", ".", "Germline", "succinate", "dehydrogenase", "subunit", "A", "(", "SDHA", ")", "mutations", "have", "been", "reported", "in", "a", "few", "patients", "with", "a", "classical", "mitochondrial", "neurodegenerative", "disease", ".", "Mutations", "in", "the", "genes", "encoding", "the", "three", "other", "succinate", "dehydrogenase", "subunits", "(", "SDHB", ",", "SDHC", "and", "SDHD", ")", "have", "been", "identified", "in", "patients", "affected", "by", "familial", "or", "'", "apparently", "sporadic", "'", "paraganglioma", "and", "/", "or", "pheochromocytoma", ",", "an", "autosomal", "inherited", "cancer", "-", "susceptibility", "syndrome", ".", "These", "discoveries", "have", "dramatically", "changed", "the", "work", "-", "up", "and", "genetic", "counseling", "of", "patients", "and", "families", "with", "paragangliomas", "and", "/", "or", "pheochromocytomas", ".", "The", "subsequent", "identification", "of", "germline", "mutations", "in", "the", "gene", "encoding", "fumarase", "--", "another", "TCA", "cycle", "enzyme", "--", "in", "a", "new", "hereditary", "form", "of", "susceptibility", "to", "renal", ",", "uterine", "and", "cutaneous", "tumors", "has", "highlighted", "the", "potential", "role", "of", "the", "TCA", "cycle", "and", ",", "more", "generally", ",", "of", "the", "mitochondria", "in", "cancer", ".", "\n" ]	[ "Gene_or_gene_product", "Simple_chemical", "Cancer", "Cellular_component", "Organism" ]
paraganglioma, pheochromocytoma, succinate dehydrogenase, Mitochondrial, complex II, succinate dehydrogenase, tricarboxylic acid, TCA, mitochondrial, succinate dehydrogenase subunit A, SDHA, patients, mitochondrial, succinate dehydrogenase, SDHB, SDHC, SDHD, patients, paraganglioma, pheochromocytoma, cancer, patients, paragangliomas, pheochromocytomas, fumarase, TCA, renal, uterine, cutaneous tumors, TCA, mitochondria, cancer	70_task2	Sentence: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer. Instructions: please extract entity words from the input sentence	[ "O", "B-Cancer", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "B-Cancer", "O", "O" ]	Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer.	[ "Hereditary", "paraganglioma", "/", "pheochromocytoma", "and", "inherited", "succinate", "dehydrogenase", "deficiency", ".", "\n", "Mitochondrial", "complex", "II", ",", "or", "succinate", "dehydrogenase", ",", "is", "a", "key", "enzymatic", "complex", "involved", "in", "both", "the", "tricarboxylic", "acid", "(", "TCA", ")", "cycle", "and", "oxidative", "phosphorylation", "as", "part", "of", "the", "mitochondrial", "respiratory", "chain", ".", "Germline", "succinate", "dehydrogenase", "subunit", "A", "(", "SDHA", ")", "mutations", "have", "been", "reported", "in", "a", "few", "patients", "with", "a", "classical", "mitochondrial", "neurodegenerative", "disease", ".", "Mutations", "in", "the", "genes", "encoding", "the", "three", "other", "succinate", "dehydrogenase", "subunits", "(", "SDHB", ",", "SDHC", "and", "SDHD", ")", "have", "been", "identified", "in", "patients", "affected", "by", "familial", "or", "'", "apparently", "sporadic", "'", "paraganglioma", "and", "/", "or", "pheochromocytoma", ",", "an", "autosomal", "inherited", "cancer", "-", "susceptibility", "syndrome", ".", "These", "discoveries", "have", "dramatically", "changed", "the", "work", "-", "up", "and", "genetic", "counseling", "of", "patients", "and", "families", "with", "paragangliomas", "and", "/", "or", "pheochromocytomas", ".", "The", "subsequent", "identification", "of", "germline", "mutations", "in", "the", "gene", "encoding", "fumarase", "--", "another", "TCA", "cycle", "enzyme", "--", "in", "a", "new", "hereditary", "form", "of", "susceptibility", "to", "renal", ",", "uterine", "and", "cutaneous", "tumors", "has", "highlighted", "the", "potential", "role", "of", "the", "TCA", "cycle", "and", ",", "more", "generally", ",", "of", "the", "mitochondria", "in", "cancer", ".", "\n" ]	[ "Gene_or_gene_product", "Simple_chemical", "Cancer", "Cellular_component", "Organism" ]
Cholinesterase is a GENE-N, carboxylesterase is a GENE-N, azinphos - methyl is a CHEMICAL, chlorpyrifos is a CHEMICAL	23291050_task0	Sentence: Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O" ]	Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.	[ "Cholinesterase", "and", "carboxylesterase", "inhibition", "in", "Planorbarius", "corneus", "exposed", "to", "binary", "mixtures", "of", "azinphos", "-", "methyl", "and", "chlorpyrifos", "." ]	[ "GENE-N", "CHEMICAL" ]
Cholinesterase is a GENE-N, carboxylesterase is a GENE-N, azinphos - methyl is a CHEMICAL, chlorpyrifos is a CHEMICAL	23291050_task1	Sentence: Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos. Instructions: please typing these entity words according to sentence: Cholinesterase, carboxylesterase, azinphos - methyl, chlorpyrifos Options: GENE-N, CHEMICAL	[ "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O" ]	Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.	[ "Cholinesterase", "and", "carboxylesterase", "inhibition", "in", "Planorbarius", "corneus", "exposed", "to", "binary", "mixtures", "of", "azinphos", "-", "methyl", "and", "chlorpyrifos", "." ]	[ "GENE-N", "CHEMICAL" ]
Cholinesterase, carboxylesterase, azinphos - methyl, chlorpyrifos	23291050_task2	Sentence: Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos. Instructions: please extract entity words from the input sentence	[ "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O" ]	Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.	[ "Cholinesterase", "and", "carboxylesterase", "inhibition", "in", "Planorbarius", "corneus", "exposed", "to", "binary", "mixtures", "of", "azinphos", "-", "methyl", "and", "chlorpyrifos", "." ]	[ "GENE-N", "CHEMICAL" ]
Angiopoietin-1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Tissue, Src is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Angiopoietin 1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, blood vessels is a Multi-tissue_structure, VEGF is a Gene_or_gene_product, plasma is a Organism_substance, Ang1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, endothelial is a Tissue, Ang1 is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, mDia is a Gene_or_gene_product, RhoA is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Cell	38_task0	Sentence: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Gene_or_gene_product, Organism_substance, Multi-tissue_structure, Cell	[ "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability.	[ "Angiopoietin-1", "prevents", "VEGF", "-", "induced", "endothelial", "permeability", "by", "sequestering", "Src", "through", "mDia", ".", "\n\n", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "and", "Angiopoietin", "1", "(", "Ang1", ")", "are", "both", "potent", "proangiogenic", "factors", ",", "but", ",", "whereas", "VEGF", "causes", "vascular", "permeability", ",", "Ang1", "stabilizes", "blood", "vessels", "and", "protects", "them", "from", "VEGF", "-", "induced", "plasma", "leakage", ".", "The", "antivascular", "permeability", "mechanisms", "deployed", "by", "Ang1", "are", "still", "undefined", ".", "Here", ",", "we", "demonstrate", "that", "Ang1", "halts", "the", "ability", "of", "VEGF", "to", "induce", "the", "phosphorylation", "-", "dependent", "redistribution", "of", "the", "adhesion", "molecule", "VE", "-", "cadherin", ",", "thereby", "rescuing", "the", "endothelial", "barrier", "function", ".", "Ang1", "inhibits", "the", "activation", "of", "Src", "by", "VEGF", ",", "the", "most", "upstream", "component", "of", "the", "pathway", "linking", "VEGF", "receptors", "to", "VE", "-", "cadherin", "internalization", ".", "Indeed", ",", "Ang1", "promotes", "the", "activation", "of", "mDia", "through", "RhoA", ",", "resulting", "in", "the", "association", "of", "mDia", "with", "Src", ".", "This", "ultimately", "deprives", "VEGF", "receptors", "of", "an", "essential", "molecule", "required", "for", "promoting", "the", "disruption", "of", "endothelial", "cell", "-", "cell", "contacts", "and", "paracellular", "permeability", ".", "\n" ]	[ "Gene_or_gene_product", "Multi-tissue_structure", "Cell", "Tissue", "Organism_substance" ]
Angiopoietin-1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Tissue, Src is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Angiopoietin 1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, blood vessels is a Multi-tissue_structure, VEGF is a Gene_or_gene_product, plasma is a Organism_substance, Ang1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, endothelial is a Tissue, Ang1 is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, mDia is a Gene_or_gene_product, RhoA is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Cell	38_task1	Sentence: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability. Instructions: please typing these entity words according to sentence: Angiopoietin-1, VEGF, endothelial, Src, mDia, Vascular endothelial growth factor, VEGF, Angiopoietin 1, Ang1, VEGF, Ang1, blood vessels, VEGF, plasma, Ang1, Ang1, VEGF, VE - cadherin, endothelial, Ang1, Src, VEGF, VEGF, VE - cadherin, Ang1, mDia, RhoA, mDia, Src, VEGF, endothelial Options: Tissue, Gene_or_gene_product, Organism_substance, Multi-tissue_structure, Cell	[ "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability.	[ "Angiopoietin-1", "prevents", "VEGF", "-", "induced", "endothelial", "permeability", "by", "sequestering", "Src", "through", "mDia", ".", "\n\n", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "and", "Angiopoietin", "1", "(", "Ang1", ")", "are", "both", "potent", "proangiogenic", "factors", ",", "but", ",", "whereas", "VEGF", "causes", "vascular", "permeability", ",", "Ang1", "stabilizes", "blood", "vessels", "and", "protects", "them", "from", "VEGF", "-", "induced", "plasma", "leakage", ".", "The", "antivascular", "permeability", "mechanisms", "deployed", "by", "Ang1", "are", "still", "undefined", ".", "Here", ",", "we", "demonstrate", "that", "Ang1", "halts", "the", "ability", "of", "VEGF", "to", "induce", "the", "phosphorylation", "-", "dependent", "redistribution", "of", "the", "adhesion", "molecule", "VE", "-", "cadherin", ",", "thereby", "rescuing", "the", "endothelial", "barrier", "function", ".", "Ang1", "inhibits", "the", "activation", "of", "Src", "by", "VEGF", ",", "the", "most", "upstream", "component", "of", "the", "pathway", "linking", "VEGF", "receptors", "to", "VE", "-", "cadherin", "internalization", ".", "Indeed", ",", "Ang1", "promotes", "the", "activation", "of", "mDia", "through", "RhoA", ",", "resulting", "in", "the", "association", "of", "mDia", "with", "Src", ".", "This", "ultimately", "deprives", "VEGF", "receptors", "of", "an", "essential", "molecule", "required", "for", "promoting", "the", "disruption", "of", "endothelial", "cell", "-", "cell", "contacts", "and", "paracellular", "permeability", ".", "\n" ]	[ "Gene_or_gene_product", "Multi-tissue_structure", "Cell", "Tissue", "Organism_substance" ]
Angiopoietin-1, VEGF, endothelial, Src, mDia, Vascular endothelial growth factor, VEGF, Angiopoietin 1, Ang1, VEGF, Ang1, blood vessels, VEGF, plasma, Ang1, Ang1, VEGF, VE - cadherin, endothelial, Ang1, Src, VEGF, VEGF, VE - cadherin, Ang1, mDia, RhoA, mDia, Src, VEGF, endothelial	38_task2	Sentence: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability. Instructions: please extract entity words from the input sentence	[ "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability.	[ "Angiopoietin-1", "prevents", "VEGF", "-", "induced", "endothelial", "permeability", "by", "sequestering", "Src", "through", "mDia", ".", "\n\n", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "and", "Angiopoietin", "1", "(", "Ang1", ")", "are", "both", "potent", "proangiogenic", "factors", ",", "but", ",", "whereas", "VEGF", "causes", "vascular", "permeability", ",", "Ang1", "stabilizes", "blood", "vessels", "and", "protects", "them", "from", "VEGF", "-", "induced", "plasma", "leakage", ".", "The", "antivascular", "permeability", "mechanisms", "deployed", "by", "Ang1", "are", "still", "undefined", ".", "Here", ",", "we", "demonstrate", "that", "Ang1", "halts", "the", "ability", "of", "VEGF", "to", "induce", "the", "phosphorylation", "-", "dependent", "redistribution", "of", "the", "adhesion", "molecule", "VE", "-", "cadherin", ",", "thereby", "rescuing", "the", "endothelial", "barrier", "function", ".", "Ang1", "inhibits", "the", "activation", "of", "Src", "by", "VEGF", ",", "the", "most", "upstream", "component", "of", "the", "pathway", "linking", "VEGF", "receptors", "to", "VE", "-", "cadherin", "internalization", ".", "Indeed", ",", "Ang1", "promotes", "the", "activation", "of", "mDia", "through", "RhoA", ",", "resulting", "in", "the", "association", "of", "mDia", "with", "Src", ".", "This", "ultimately", "deprives", "VEGF", "receptors", "of", "an", "essential", "molecule", "required", "for", "promoting", "the", "disruption", "of", "endothelial", "cell", "-", "cell", "contacts", "and", "paracellular", "permeability", ".", "\n" ]	[ "Gene_or_gene_product", "Multi-tissue_structure", "Cell", "Tissue", "Organism_substance" ]
chemotherapy is a Intervention_Physical, doxorubicin is a Intervention_Pharmacological, lomustine is a Intervention_Pharmacological, DC is a Intervention_Pharmacological, cyclophosphamide and 5-FU ( CF ) is a Intervention_Pharmacological, tolerated is a Outcome_Other, levels of myelosuppression is a Outcome_Physical, objective partial response rate is a Outcome_Other, Objective stabilization is a Outcome_Physical, subjective response rate ( partial plus complete ) is a Outcome_Other, response rates is a Outcome_Other, survival is a Outcome_Mortality	77043_task0	Sentence: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Outcome_Mortality, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .	[ "Randomized", "trial", "of", "combination", "chemotherapy", "in", "hormone", "-", "resistant", "metastatic", "prostate", "carcinoma", ".", "A", "prospective", "randomized", "study", "was", "conducted", "in", "51", "patients", "with", "stage", "D", "hormone", "-", "resistant", "prostatic", "carcinoma", ",", "comparing", "a", "combination", "of", "doxorubicin", "and", "lomustine", "(", "DC", ")", "with", "cyclophosphamide", "and", "5-FU", "(", "CF", ")", ".", "Patients", "were", "assessed", "objectively", "(", "employing", "National", "Prostate", "Cancer", "Project", "criteria", ")", "and", "subjectively", "(", "using", "a", "numerical", "scoring", "scheme", ")", ".", "Each", "regimen", "was", "well", "tolerated", "with", "acceptable", "levels", "of", "myelosuppression", ".", "The", "objective", "partial", "response", "rate", "was", "57", "%", "for", "DC", "and", "8", "%", "for", "CF", ".", "Objective", "stabilization", "occurred", ",", "respectively", ",", "in", "14", "%", "and", "44", "%", "of", "the", "patients", ".", "Similarly", ",", "DC", "demonstrated", "a", "significantly", "superior", "subjective", "response", "rate", "(", "partial", "plus", "complete", ")", "of", "82", "%", ",", "compared", "to", "48", "%", "for", "CF", ".", "Patients", "with", "poor", "initial", "performance", "status", "or", "liver", "involvement", "had", "significantly", "lower", "response", "rates", "and", "reduced", "survival", ".", "Overall", ",", "there", "was", "no", "significant", "difference", "in", "survival", "between", "the", "two", "arms", ",", "reflecting", "the", "similarity", "between", "DC", "and", "CF", "in", "total", "objective", "response", "rate", "(", "partial", "response", "plus", "stable", "disease", ")", ".", "DC", "provided", "superior", "palliation", "and", "was", "well", "tolerated", "by", "an", "essentially", "geriatric", "population", "." ]	[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Physical", "Outcome_Mortality" ]
chemotherapy is a Intervention_Physical, doxorubicin is a Intervention_Pharmacological, lomustine is a Intervention_Pharmacological, DC is a Intervention_Pharmacological, cyclophosphamide and 5-FU ( CF ) is a Intervention_Pharmacological, tolerated is a Outcome_Other, levels of myelosuppression is a Outcome_Physical, objective partial response rate is a Outcome_Other, Objective stabilization is a Outcome_Physical, subjective response rate ( partial plus complete ) is a Outcome_Other, response rates is a Outcome_Other, survival is a Outcome_Mortality	77043_task1	Sentence: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population . Instructions: please typing these entity words according to sentence: chemotherapy, doxorubicin, lomustine, DC, cyclophosphamide and 5-FU ( CF ), tolerated, levels of myelosuppression, objective partial response rate, Objective stabilization, subjective response rate ( partial plus complete ), response rates, survival Options: Intervention_Pharmacological, Intervention_Physical, Outcome_Mortality, Outcome_Physical, Outcome_Other	[ "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .	[ "Randomized", "trial", "of", "combination", "chemotherapy", "in", "hormone", "-", "resistant", "metastatic", "prostate", "carcinoma", ".", "A", "prospective", "randomized", "study", "was", "conducted", "in", "51", "patients", "with", "stage", "D", "hormone", "-", "resistant", "prostatic", "carcinoma", ",", "comparing", "a", "combination", "of", "doxorubicin", "and", "lomustine", "(", "DC", ")", "with", "cyclophosphamide", "and", "5-FU", "(", "CF", ")", ".", "Patients", "were", "assessed", "objectively", "(", "employing", "National", "Prostate", "Cancer", "Project", "criteria", ")", "and", "subjectively", "(", "using", "a", "numerical", "scoring", "scheme", ")", ".", "Each", "regimen", "was", "well", "tolerated", "with", "acceptable", "levels", "of", "myelosuppression", ".", "The", "objective", "partial", "response", "rate", "was", "57", "%", "for", "DC", "and", "8", "%", "for", "CF", ".", "Objective", "stabilization", "occurred", ",", "respectively", ",", "in", "14", "%", "and", "44", "%", "of", "the", "patients", ".", "Similarly", ",", "DC", "demonstrated", "a", "significantly", "superior", "subjective", "response", "rate", "(", "partial", "plus", "complete", ")", "of", "82", "%", ",", "compared", "to", "48", "%", "for", "CF", ".", "Patients", "with", "poor", "initial", "performance", "status", "or", "liver", "involvement", "had", "significantly", "lower", "response", "rates", "and", "reduced", "survival", ".", "Overall", ",", "there", "was", "no", "significant", "difference", "in", "survival", "between", "the", "two", "arms", ",", "reflecting", "the", "similarity", "between", "DC", "and", "CF", "in", "total", "objective", "response", "rate", "(", "partial", "response", "plus", "stable", "disease", ")", ".", "DC", "provided", "superior", "palliation", "and", "was", "well", "tolerated", "by", "an", "essentially", "geriatric", "population", "." ]	[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Physical", "Outcome_Mortality" ]
chemotherapy, doxorubicin, lomustine, DC, cyclophosphamide and 5-FU ( CF ), tolerated, levels of myelosuppression, objective partial response rate, Objective stabilization, subjective response rate ( partial plus complete ), response rates, survival	77043_task2	Sentence: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .	[ "Randomized", "trial", "of", "combination", "chemotherapy", "in", "hormone", "-", "resistant", "metastatic", "prostate", "carcinoma", ".", "A", "prospective", "randomized", "study", "was", "conducted", "in", "51", "patients", "with", "stage", "D", "hormone", "-", "resistant", "prostatic", "carcinoma", ",", "comparing", "a", "combination", "of", "doxorubicin", "and", "lomustine", "(", "DC", ")", "with", "cyclophosphamide", "and", "5-FU", "(", "CF", ")", ".", "Patients", "were", "assessed", "objectively", "(", "employing", "National", "Prostate", "Cancer", "Project", "criteria", ")", "and", "subjectively", "(", "using", "a", "numerical", "scoring", "scheme", ")", ".", "Each", "regimen", "was", "well", "tolerated", "with", "acceptable", "levels", "of", "myelosuppression", ".", "The", "objective", "partial", "response", "rate", "was", "57", "%", "for", "DC", "and", "8", "%", "for", "CF", ".", "Objective", "stabilization", "occurred", ",", "respectively", ",", "in", "14", "%", "and", "44", "%", "of", "the", "patients", ".", "Similarly", ",", "DC", "demonstrated", "a", "significantly", "superior", "subjective", "response", "rate", "(", "partial", "plus", "complete", ")", "of", "82", "%", ",", "compared", "to", "48", "%", "for", "CF", ".", "Patients", "with", "poor", "initial", "performance", "status", "or", "liver", "involvement", "had", "significantly", "lower", "response", "rates", "and", "reduced", "survival", ".", "Overall", ",", "there", "was", "no", "significant", "difference", "in", "survival", "between", "the", "two", "arms", ",", "reflecting", "the", "similarity", "between", "DC", "and", "CF", "in", "total", "objective", "response", "rate", "(", "partial", "response", "plus", "stable", "disease", ")", ".", "DC", "provided", "superior", "palliation", "and", "was", "well", "tolerated", "by", "an", "essentially", "geriatric", "population", "." ]	[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Physical", "Outcome_Mortality" ]
paper is an umlsterm, period is an umlsterm, turnover is an umlsterm, human is an umlsterm, cartilages is an umlsterm, in vitro is an umlsterm, method is an umlsterm, relative is an umlsterm, human is an umlsterm, cartilages is an umlsterm, osteoarthritis is an umlsterm, rheumatoid arthritis is an umlsterm, cartilages is an umlsterm, cartilages is an umlsterm, turnover is an umlsterm, cartilages is an umlsterm, cells is an umlsterm, proteolytic enzymes is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, collagen is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, in vitro is an umlsterm, extracellular matrix is an umlsterm, human is an umlsterm, cartilages is an umlsterm, Aceclofenac is an umlsterm, Tenidap is an umlsterm, Tolmetin is an umlsterm, Piroxicam is an umlsterm, Tiaprofenic Acid is an umlsterm, Aspirin is an umlsterm, Naproxen is an umlsterm, Ibuprofen is an umlsterm, Indomethacin is an umlsterm, NSAID is an umlsterm, inhibition is an umlsterm, IL1 is an umlsterm, growth factor is an umlsterm, NSAIDs is an umlsterm, IL1 is an umlsterm, release is an umlsterm, chondrocyte is an umlsterm, toxic effects is an umlsterm, cartilage is an umlsterm, metabolism is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, Aceclofenac is an umlsterm, long - term treatment is an umlsterm, in vitro is an umlsterm, human is an umlsterm, cartilage is an umlsterm	ZfuerRheumatologie.90580125.eng.abstr_task0	Sentence: The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo .	[ "The", "present", "paper", "presents", "data", "obtained", "over", "a", "12", "year", "period", ",", "on", "the", "matrix", "synthesis", "and", "turnover", "in", "some", "650", "arthritic", "and", "180", "non", "-", "arthritic", "(", "N", ")", "human", "cartilages", "using", "a", "standardised", "in", "vitro", "method", ".", "When", "the", "relative", "metabolic", "(", "synthetic", "/", "repair", "activity", ")", "of", "these", "human", "cartilages", "was", "compared", ",", "it", "was", "demonstrated", "that", "in", "osteoarthritis", "(", "OA", ")", "and", "rheumatoid", "arthritis", "(", "RA", ")", "cartilages", "synthetic", "activity", "was", "diminished", "by", "approximately", "50", "%", "as", "compared", "with", "N", "cartilages", ".", "However", ",", "the", "turnover", "rate", "of", "matrix", "was", "not", "significantly", "different", "between", "Non", "-", "arthritic", "and", "OA", ",", "but", "was", "very", "substantially", "increased", "in", "RA", "cartilages", "compatible", "with", "the", "activity", "of", "inflammatory", "cells", "and", "proteolytic", "enzymes", "released", "from", "pannus", ".", "The", "action", "of", "13", "NSAIDs", "was", "compared", "in", "terms", "of", "their", "effect", "on", "cartilage", "GAG", "synthesis", ".", "3", "of", "these", "NSAIDs", "were", "also", "studied", "in", "terms", "of", "their", "effect", "on", "cartilage", "collagen", "synthesis", ".", "Consideration", "of", "the", "results", "in", "this", "study", "and", "from", "published", "material", ",", "led", "to", "the", "suggestion", "that", "NSAIDs", "may", "be", "divided", "into", "3", "categories", "in", "respect", "of", "their", "in", "vitro", "action", "on", "the", "extracellular", "matrix", "of", "human", "arthritic", "cartilages", ":", "1", ".", "Those", "such", "as", "Aceclofenac", ",", "Tenidap", "and", "Tolmetin", "which", "can", "stimulate", "matrix", "synthesis", "2", ".", "Those", "such", "as", "Piroxicam", ",", "Tiaprofenic", "Acid", "and", "Aspirin", "which", "appear", "to", "be", "without", "significant", "effect", "on", "matrix", "synthesis", "and", ",", "3", ".", "Those", "like", "Naproxen", ",", "Ibuprofen", ",", "Indomethacin", ",", "Nimezulide", "which", "significantly", "inhibit", "matrix", "synthesis", ".", "It", "is", "suggested", "that", "the", "stimulatory", "action", "of", "group", "1", "NSAID", "is", "due", "to", "inhibition", "of", "locally", "produced", "IL1", "and", "consequent", "expression", "of", "growth", "factor", "activity", ".", "Other", "NSAIDs", "may", "also", "inhibit", "IL1", "synthesis", "or", "release", ",", "but", "probably", "do", "not", "have", "a", "beneficial", "effect", "on", "chondrocyte", "synthetic", "activity", "as", "they", "have", "toxic", "effects", "on", "cartilage", "metabolism", ".", "These", "experiments", "led", "to", "the", "suggestion", "that", "NSAIDs", "such", "as", "Aceclofenac", "would", "be", "appropriate", "for", "long", "-", "term", "treatment", "of", "arthritic", "conditions", "provided", "that", "one", "is", "prepared", "to", "extrapolate", "between", "in", "vitro", "experiments", "on", "human", "cartilage", "and", "what", "may", "be", "happening", "in", "vivo", "." ]	[ "umlsterm" ]
paper is an umlsterm, period is an umlsterm, turnover is an umlsterm, human is an umlsterm, cartilages is an umlsterm, in vitro is an umlsterm, method is an umlsterm, relative is an umlsterm, human is an umlsterm, cartilages is an umlsterm, osteoarthritis is an umlsterm, rheumatoid arthritis is an umlsterm, cartilages is an umlsterm, cartilages is an umlsterm, turnover is an umlsterm, cartilages is an umlsterm, cells is an umlsterm, proteolytic enzymes is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, collagen is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, in vitro is an umlsterm, extracellular matrix is an umlsterm, human is an umlsterm, cartilages is an umlsterm, Aceclofenac is an umlsterm, Tenidap is an umlsterm, Tolmetin is an umlsterm, Piroxicam is an umlsterm, Tiaprofenic Acid is an umlsterm, Aspirin is an umlsterm, Naproxen is an umlsterm, Ibuprofen is an umlsterm, Indomethacin is an umlsterm, NSAID is an umlsterm, inhibition is an umlsterm, IL1 is an umlsterm, growth factor is an umlsterm, NSAIDs is an umlsterm, IL1 is an umlsterm, release is an umlsterm, chondrocyte is an umlsterm, toxic effects is an umlsterm, cartilage is an umlsterm, metabolism is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, Aceclofenac is an umlsterm, long - term treatment is an umlsterm, in vitro is an umlsterm, human is an umlsterm, cartilage is an umlsterm	ZfuerRheumatologie.90580125.eng.abstr_task1	Sentence: The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo . Instructions: please typing these entity words according to sentence: paper, period, turnover, human, cartilages, in vitro, method, relative, human, cartilages, osteoarthritis, rheumatoid arthritis, cartilages, cartilages, turnover, cartilages, cells, proteolytic enzymes, NSAIDs, cartilage, NSAIDs, cartilage, collagen, suggestion, NSAIDs, in vitro, extracellular matrix, human, cartilages, Aceclofenac, Tenidap, Tolmetin, Piroxicam, Tiaprofenic Acid, Aspirin, Naproxen, Ibuprofen, Indomethacin, NSAID, inhibition, IL1, growth factor, NSAIDs, IL1, release, chondrocyte, toxic effects, cartilage, metabolism, suggestion, NSAIDs, Aceclofenac, long - term treatment, in vitro, human, cartilage Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo .	[ "The", "present", "paper", "presents", "data", "obtained", "over", "a", "12", "year", "period", ",", "on", "the", "matrix", "synthesis", "and", "turnover", "in", "some", "650", "arthritic", "and", "180", "non", "-", "arthritic", "(", "N", ")", "human", "cartilages", "using", "a", "standardised", "in", "vitro", "method", ".", "When", "the", "relative", "metabolic", "(", "synthetic", "/", "repair", "activity", ")", "of", "these", "human", "cartilages", "was", "compared", ",", "it", "was", "demonstrated", "that", "in", "osteoarthritis", "(", "OA", ")", "and", "rheumatoid", "arthritis", "(", "RA", ")", "cartilages", "synthetic", "activity", "was", "diminished", "by", "approximately", "50", "%", "as", "compared", "with", "N", "cartilages", ".", "However", ",", "the", "turnover", "rate", "of", "matrix", "was", "not", "significantly", "different", "between", "Non", "-", "arthritic", "and", "OA", ",", "but", "was", "very", "substantially", "increased", "in", "RA", "cartilages", "compatible", "with", "the", "activity", "of", "inflammatory", "cells", "and", "proteolytic", "enzymes", "released", "from", "pannus", ".", "The", "action", "of", "13", "NSAIDs", "was", "compared", "in", "terms", "of", "their", "effect", "on", "cartilage", "GAG", "synthesis", ".", "3", "of", "these", "NSAIDs", "were", "also", "studied", "in", "terms", "of", "their", "effect", "on", "cartilage", "collagen", "synthesis", ".", "Consideration", "of", "the", "results", "in", "this", "study", "and", "from", "published", "material", ",", "led", "to", "the", "suggestion", "that", "NSAIDs", "may", "be", "divided", "into", "3", "categories", "in", "respect", "of", "their", "in", "vitro", "action", "on", "the", "extracellular", "matrix", "of", "human", "arthritic", "cartilages", ":", "1", ".", "Those", "such", "as", "Aceclofenac", ",", "Tenidap", "and", "Tolmetin", "which", "can", "stimulate", "matrix", "synthesis", "2", ".", "Those", "such", "as", "Piroxicam", ",", "Tiaprofenic", "Acid", "and", "Aspirin", "which", "appear", "to", "be", "without", "significant", "effect", "on", "matrix", "synthesis", "and", ",", "3", ".", "Those", "like", "Naproxen", ",", "Ibuprofen", ",", "Indomethacin", ",", "Nimezulide", "which", "significantly", "inhibit", "matrix", "synthesis", ".", "It", "is", "suggested", "that", "the", "stimulatory", "action", "of", "group", "1", "NSAID", "is", "due", "to", "inhibition", "of", "locally", "produced", "IL1", "and", "consequent", "expression", "of", "growth", "factor", "activity", ".", "Other", "NSAIDs", "may", "also", "inhibit", "IL1", "synthesis", "or", "release", ",", "but", "probably", "do", "not", "have", "a", "beneficial", "effect", "on", "chondrocyte", "synthetic", "activity", "as", "they", "have", "toxic", "effects", "on", "cartilage", "metabolism", ".", "These", "experiments", "led", "to", "the", "suggestion", "that", "NSAIDs", "such", "as", "Aceclofenac", "would", "be", "appropriate", "for", "long", "-", "term", "treatment", "of", "arthritic", "conditions", "provided", "that", "one", "is", "prepared", "to", "extrapolate", "between", "in", "vitro", "experiments", "on", "human", "cartilage", "and", "what", "may", "be", "happening", "in", "vivo", "." ]	[ "umlsterm" ]
paper, period, turnover, human, cartilages, in vitro, method, relative, human, cartilages, osteoarthritis, rheumatoid arthritis, cartilages, cartilages, turnover, cartilages, cells, proteolytic enzymes, NSAIDs, cartilage, NSAIDs, cartilage, collagen, suggestion, NSAIDs, in vitro, extracellular matrix, human, cartilages, Aceclofenac, Tenidap, Tolmetin, Piroxicam, Tiaprofenic Acid, Aspirin, Naproxen, Ibuprofen, Indomethacin, NSAID, inhibition, IL1, growth factor, NSAIDs, IL1, release, chondrocyte, toxic effects, cartilage, metabolism, suggestion, NSAIDs, Aceclofenac, long - term treatment, in vitro, human, cartilage	ZfuerRheumatologie.90580125.eng.abstr_task2	Sentence: The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]	The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo .	[ "The", "present", "paper", "presents", "data", "obtained", "over", "a", "12", "year", "period", ",", "on", "the", "matrix", "synthesis", "and", "turnover", "in", "some", "650", "arthritic", "and", "180", "non", "-", "arthritic", "(", "N", ")", "human", "cartilages", "using", "a", "standardised", "in", "vitro", "method", ".", "When", "the", "relative", "metabolic", "(", "synthetic", "/", "repair", "activity", ")", "of", "these", "human", "cartilages", "was", "compared", ",", "it", "was", "demonstrated", "that", "in", "osteoarthritis", "(", "OA", ")", "and", "rheumatoid", "arthritis", "(", "RA", ")", "cartilages", "synthetic", "activity", "was", "diminished", "by", "approximately", "50", "%", "as", "compared", "with", "N", "cartilages", ".", "However", ",", "the", "turnover", "rate", "of", "matrix", "was", "not", "significantly", "different", "between", "Non", "-", "arthritic", "and", "OA", ",", "but", "was", "very", "substantially", "increased", "in", "RA", "cartilages", "compatible", "with", "the", "activity", "of", "inflammatory", "cells", "and", "proteolytic", "enzymes", "released", "from", "pannus", ".", "The", "action", "of", "13", "NSAIDs", "was", "compared", "in", "terms", "of", "their", "effect", "on", "cartilage", "GAG", "synthesis", ".", "3", "of", "these", "NSAIDs", "were", "also", "studied", "in", "terms", "of", "their", "effect", "on", "cartilage", "collagen", "synthesis", ".", "Consideration", "of", "the", "results", "in", "this", "study", "and", "from", "published", "material", ",", "led", "to", "the", "suggestion", "that", "NSAIDs", "may", "be", "divided", "into", "3", "categories", "in", "respect", "of", "their", "in", "vitro", "action", "on", "the", "extracellular", "matrix", "of", "human", "arthritic", "cartilages", ":", "1", ".", "Those", "such", "as", "Aceclofenac", ",", "Tenidap", "and", "Tolmetin", "which", "can", "stimulate", "matrix", "synthesis", "2", ".", "Those", "such", "as", "Piroxicam", ",", "Tiaprofenic", "Acid", "and", "Aspirin", "which", "appear", "to", "be", "without", "significant", "effect", "on", "matrix", "synthesis", "and", ",", "3", ".", "Those", "like", "Naproxen", ",", "Ibuprofen", ",", "Indomethacin", ",", "Nimezulide", "which", "significantly", "inhibit", "matrix", "synthesis", ".", "It", "is", "suggested", "that", "the", "stimulatory", "action", "of", "group", "1", "NSAID", "is", "due", "to", "inhibition", "of", "locally", "produced", "IL1", "and", "consequent", "expression", "of", "growth", "factor", "activity", ".", "Other", "NSAIDs", "may", "also", "inhibit", "IL1", "synthesis", "or", "release", ",", "but", "probably", "do", "not", "have", "a", "beneficial", "effect", "on", "chondrocyte", "synthetic", "activity", "as", "they", "have", "toxic", "effects", "on", "cartilage", "metabolism", ".", "These", "experiments", "led", "to", "the", "suggestion", "that", "NSAIDs", "such", "as", "Aceclofenac", "would", "be", "appropriate", "for", "long", "-", "term", "treatment", "of", "arthritic", "conditions", "provided", "that", "one", "is", "prepared", "to", "extrapolate", "between", "in", "vitro", "experiments", "on", "human", "cartilage", "and", "what", "may", "be", "happening", "in", "vivo", "." ]	[ "umlsterm" ]
CIITA is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, class II major histocompatibility complex gene is a Entity, N - terminal region is a Entity, reporter gene is a Entity, DNA binding domain is a Entity, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, CIITA is a Protein, TBP is a Protein, TBP is a Protein, TBP is a Protein, TAFII250 is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, acidic activation domains is a Entity, CIITA is a Protein, VP16 is a Protein, CIITA is a Protein, CIITA is a Protein, VP16 is a Protein	302_task0	Sentence: Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.	[ "Transactivation", "by", "CIITA", ",", "the", "type", "II", "bare", "lymphocyte", "syndrome", "-", "associated", "factor", ",", "requires", "participation", "of", "multiple", "regions", "of", "the", "TATA", "box", "binding", "protein", ".", "\n", "CIITA", "is", "a", "positive", "regulator", "of", "class", "II", "major", "histocompatibility", "complex", "gene", "transcription", "that", "has", "been", "found", "to", "be", "defective", "in", "one", "of", "the", "five", "complementation", "groups", "of", "class", "II", "major", "histocompatibility", "complex", "-", "negative", "cell", "lines", ".", "Its", "N", "-", "terminal", "region", "is", "capable", "of", "activating", "transcription", "from", "a", "reporter", "gene", "when", "fused", "to", "a", "DNA", "binding", "domain", ".", "We", "have", "investigated", "the", "mechanism", "of", "transactivation", "mediated", "by", "the", "CIITA", "activation", "domain", "by", "studying", "its", "role", "in", "the", "process", "of", "transcription", "initiation", "and", "elongation", ".", "Specifically", "the", "altered", "specificity", "TBP", "(", "TATA", "box", "binding", "protein", ")", "assay", "has", "been", "used", "to", "analyze", "the", "response", "of", "the", "CIITA", "activation", "domain", "to", "mutations", "in", "TBP", "known", "to", "disrupt", "its", "interaction", "with", "its", "associated", "general", "factors", ".", "Transactivation", "by", "CIITA", "was", "extremely", "sensitive", "to", "a", "mutation", "in", "TBP", "that", "in", "yeast", "is", "known", "to", "abolish", "VP16-mediated", "transcription", "but", "leaves", "basal", "transcription", "unaffected", ".", "A", "TBP", "mutant", "defective", "in", "interaction", "with", "TBP", "-", "associated", "factor", "TAFII250", "also", "failed", "to", "mediate", "transactivation", "through", "the", "CIITA", "activation", "domain", ".", "Certain", "interactions", "between", "TBP", "and", "general", "factors", "that", "are", "specifically", "required", "for", "acidic", "activation", "domains", "were", "also", "required", "for", "CIITA", "-", "mediated", "transactivation", "to", "reach", "its", "full", "potential", ".", "Finally", ",", "like", "VP16", ",", "CIITA", "was", "able", "to", "stimulate", "elongation", "of", "transcription", ".", "Overall", "the", "mechanism", "of", "transactivation", "by", "the", "human", "B", "-", "cell", "-", "specific", "CIITA", "is", "very", "similar", "to", "that", "mediated", "by", "the", "herpes", "virus", "transactivator", "VP16", "in", "the", "ways", "that", "have", "been", "tested", ".", "\n" ]	[ "Entity", "Protein" ]
CIITA is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, class II major histocompatibility complex gene is a Entity, N - terminal region is a Entity, reporter gene is a Entity, DNA binding domain is a Entity, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, CIITA is a Protein, TBP is a Protein, TBP is a Protein, TBP is a Protein, TAFII250 is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, acidic activation domains is a Entity, CIITA is a Protein, VP16 is a Protein, CIITA is a Protein, CIITA is a Protein, VP16 is a Protein	302_task1	Sentence: Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested. Instructions: please typing these entity words according to sentence: CIITA, TATA box binding protein, CIITA, class II major histocompatibility complex gene, N - terminal region, reporter gene, DNA binding domain, CIITA, activation domain, TBP, TATA box binding protein, CIITA, activation domain, TBP, CIITA, TBP, TBP, TBP, TAFII250, CIITA, activation domain, TBP, acidic activation domains, CIITA, VP16, CIITA, CIITA, VP16 Options: Entity, Protein	[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.	[ "Transactivation", "by", "CIITA", ",", "the", "type", "II", "bare", "lymphocyte", "syndrome", "-", "associated", "factor", ",", "requires", "participation", "of", "multiple", "regions", "of", "the", "TATA", "box", "binding", "protein", ".", "\n", "CIITA", "is", "a", "positive", "regulator", "of", "class", "II", "major", "histocompatibility", "complex", "gene", "transcription", "that", "has", "been", "found", "to", "be", "defective", "in", "one", "of", "the", "five", "complementation", "groups", "of", "class", "II", "major", "histocompatibility", "complex", "-", "negative", "cell", "lines", ".", "Its", "N", "-", "terminal", "region", "is", "capable", "of", "activating", "transcription", "from", "a", "reporter", "gene", "when", "fused", "to", "a", "DNA", "binding", "domain", ".", "We", "have", "investigated", "the", "mechanism", "of", "transactivation", "mediated", "by", "the", "CIITA", "activation", "domain", "by", "studying", "its", "role", "in", "the", "process", "of", "transcription", "initiation", "and", "elongation", ".", "Specifically", "the", "altered", "specificity", "TBP", "(", "TATA", "box", "binding", "protein", ")", "assay", "has", "been", "used", "to", "analyze", "the", "response", "of", "the", "CIITA", "activation", "domain", "to", "mutations", "in", "TBP", "known", "to", "disrupt", "its", "interaction", "with", "its", "associated", "general", "factors", ".", "Transactivation", "by", "CIITA", "was", "extremely", "sensitive", "to", "a", "mutation", "in", "TBP", "that", "in", "yeast", "is", "known", "to", "abolish", "VP16-mediated", "transcription", "but", "leaves", "basal", "transcription", "unaffected", ".", "A", "TBP", "mutant", "defective", "in", "interaction", "with", "TBP", "-", "associated", "factor", "TAFII250", "also", "failed", "to", "mediate", "transactivation", "through", "the", "CIITA", "activation", "domain", ".", "Certain", "interactions", "between", "TBP", "and", "general", "factors", "that", "are", "specifically", "required", "for", "acidic", "activation", "domains", "were", "also", "required", "for", "CIITA", "-", "mediated", "transactivation", "to", "reach", "its", "full", "potential", ".", "Finally", ",", "like", "VP16", ",", "CIITA", "was", "able", "to", "stimulate", "elongation", "of", "transcription", ".", "Overall", "the", "mechanism", "of", "transactivation", "by", "the", "human", "B", "-", "cell", "-", "specific", "CIITA", "is", "very", "similar", "to", "that", "mediated", "by", "the", "herpes", "virus", "transactivator", "VP16", "in", "the", "ways", "that", "have", "been", "tested", ".", "\n" ]	[ "Entity", "Protein" ]
CIITA, TATA box binding protein, CIITA, class II major histocompatibility complex gene, N - terminal region, reporter gene, DNA binding domain, CIITA, activation domain, TBP, TATA box binding protein, CIITA, activation domain, TBP, CIITA, TBP, TBP, TBP, TAFII250, CIITA, activation domain, TBP, acidic activation domains, CIITA, VP16, CIITA, CIITA, VP16	302_task2	Sentence: Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.	[ "Transactivation", "by", "CIITA", ",", "the", "type", "II", "bare", "lymphocyte", "syndrome", "-", "associated", "factor", ",", "requires", "participation", "of", "multiple", "regions", "of", "the", "TATA", "box", "binding", "protein", ".", "\n", "CIITA", "is", "a", "positive", "regulator", "of", "class", "II", "major", "histocompatibility", "complex", "gene", "transcription", "that", "has", "been", "found", "to", "be", "defective", "in", "one", "of", "the", "five", "complementation", "groups", "of", "class", "II", "major", "histocompatibility", "complex", "-", "negative", "cell", "lines", ".", "Its", "N", "-", "terminal", "region", "is", "capable", "of", "activating", "transcription", "from", "a", "reporter", "gene", "when", "fused", "to", "a", "DNA", "binding", "domain", ".", "We", "have", "investigated", "the", "mechanism", "of", "transactivation", "mediated", "by", "the", "CIITA", "activation", "domain", "by", "studying", "its", "role", "in", "the", "process", "of", "transcription", "initiation", "and", "elongation", ".", "Specifically", "the", "altered", "specificity", "TBP", "(", "TATA", "box", "binding", "protein", ")", "assay", "has", "been", "used", "to", "analyze", "the", "response", "of", "the", "CIITA", "activation", "domain", "to", "mutations", "in", "TBP", "known", "to", "disrupt", "its", "interaction", "with", "its", "associated", "general", "factors", ".", "Transactivation", "by", "CIITA", "was", "extremely", "sensitive", "to", "a", "mutation", "in", "TBP", "that", "in", "yeast", "is", "known", "to", "abolish", "VP16-mediated", "transcription", "but", "leaves", "basal", "transcription", "unaffected", ".", "A", "TBP", "mutant", "defective", "in", "interaction", "with", "TBP", "-", "associated", "factor", "TAFII250", "also", "failed", "to", "mediate", "transactivation", "through", "the", "CIITA", "activation", "domain", ".", "Certain", "interactions", "between", "TBP", "and", "general", "factors", "that", "are", "specifically", "required", "for", "acidic", "activation", "domains", "were", "also", "required", "for", "CIITA", "-", "mediated", "transactivation", "to", "reach", "its", "full", "potential", ".", "Finally", ",", "like", "VP16", ",", "CIITA", "was", "able", "to", "stimulate", "elongation", "of", "transcription", ".", "Overall", "the", "mechanism", "of", "transactivation", "by", "the", "human", "B", "-", "cell", "-", "specific", "CIITA", "is", "very", "similar", "to", "that", "mediated", "by", "the", "herpes", "virus", "transactivator", "VP16", "in", "the", "ways", "that", "have", "been", "tested", ".", "\n" ]	[ "Entity", "Protein" ]
V3 loop is a Entity, peptides is a Entity, V3 region is a Entity, V3-BH10 is a Entity, 42 amino acids is a Entity, loop structure is a Entity, CD4 is a Protein, V3 loop is a Entity, V3-BH10 is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, chromatin is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, V3-BH10 is a Entity, IL-2 is a Protein, IL-2 receptors is a Entity, tyrosyl is a Entity, p120 is a Protein, p98 is a Protein, p96 is a Protein, p54 is a Protein, p38 is a Protein, IL-2 is a Protein, V3-BH10 is a Entity, c - fos is a Protein, c - myc is a Protein, V3 loop is a Entity, gp120 is a Protein, IL-2 is a Protein	679_task0	Sentence: V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth.	[ "V3", "loop", "of", "human", "immunodeficiency", "virus", "type", "1", "suppresses", "interleukin", "2-induced", "T", "cell", "growth", "[", "published", "erratum", "appears", "in", "AIDS", "Res", "Hum", "Retroviruses", "1997", "May", "1;13(7):633", "]", "\n", "We", "tested", "the", "effect", "of", "three", "linear", "or", "two", "loop", "peptides", "derived", "from", "the", "V3", "region", "of", "the", "HTLV", "-", "III", "BH10", "clone", "or", "the", "SF2", "strain", "of", "human", "immunodeficiency", "virus", "type", "1", "on", "IL-2-driven", "T", "cell", "proliferation", ".", "V3-BH10", ",", "which", "consists", "of", "42", "amino", "acids", "and", "has", "a", "loop", "structure", ",", "suppressed", "IL-2-driven", "proliferation", "of", "all", "IL-2-dependent", "cells", "[", "Kit225", ",", "ED-40515(+", ")", ",", "KT-3", ",", "7-day", "PHA", "-", "blasts", ",", "and", "fresh", "peripheral", "blood", "mononuclear", "cells", "]", "tested", ",", "whereas", "it", "did", "not", "suppress", "the", "cell", "growth", "of", "IL-2-independent", "cell", "lines", "(", "Hut102", ",", "Molt-4", ",", "and", "Jurkat", ")", ".", "This", "suppressive", "effect", "was", "also", "seen", "in", "IL-2-driven", "cell", "growth", "of", "CD8-positive", "lymphocytes", "purified", "from", "7-day", "PHA", "-", "blasts", ",", "indicating", "that", "CD4", "molecules", "were", "not", "required", "for", "the", "suppression", ".", "The", "treatment", "with", "anti", "-", "V3", "loop", "monoclonal", "antibody", "(", "902", "antibody", ")", "completely", "abolished", "the", "suppressive", "effect", "of", "V3-BH10", ".", "In", "addition", ",", "V3-BH10", "generated", "the", "arrest", "of", "Kit225", "cells", "and", "also", "purified", "CD8-positive", "lymphocytes", "in", "G1", "phase", "in", "the", "presence", "of", "IL-2", ".", "Neither", "chromatin", "condensation", "nor", "DNA", "fragmentation", "was", "detected", "in", "Kit225", "cells", "cultured", "with", "V3-BH10", "and", "IL-2", ".", "V3-BH10", "neither", "blocked", "radiolabeled", "IL-2", "binding", "to", "IL-2", "receptors", "nor", "affected", "tyrosyl", "phosphorylation", "of", "several", "cellular", "proteins", "(", "p120", ",", "p98", ",", "p96", ",", "p54", ",", "and", "p38", ")", ",", "which", "is", "immediately", "induced", "by", "IL-2", "stimulation", ".", "However", ",", "V3-BH10", "enhanced", "IL-2-induced", "mRNA", "expression", "of", "c", "-", "fos", "but", "not", "c", "-", "myc", "or", "junB.", "Thus", ",", "the", "binding", "of", "V3", "loop", "of", "gp120", "to", "the", "cell", "surface", "molecule(s", ")", "appears", "to", "affect", "intracellular", "IL-2", "signaling", ",", "which", "leads", "to", "the", "suppression", "of", "IL-2-induced", "T", "cell", "growth", ".", "\n" ]	[ "Entity", "Protein" ]
V3 loop is a Entity, peptides is a Entity, V3 region is a Entity, V3-BH10 is a Entity, 42 amino acids is a Entity, loop structure is a Entity, CD4 is a Protein, V3 loop is a Entity, V3-BH10 is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, chromatin is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, V3-BH10 is a Entity, IL-2 is a Protein, IL-2 receptors is a Entity, tyrosyl is a Entity, p120 is a Protein, p98 is a Protein, p96 is a Protein, p54 is a Protein, p38 is a Protein, IL-2 is a Protein, V3-BH10 is a Entity, c - fos is a Protein, c - myc is a Protein, V3 loop is a Entity, gp120 is a Protein, IL-2 is a Protein	679_task1	Sentence: V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth. Instructions: please typing these entity words according to sentence: V3 loop, peptides, V3 region, V3-BH10, 42 amino acids, loop structure, CD4, V3 loop, V3-BH10, V3-BH10, IL-2, chromatin, V3-BH10, IL-2, V3-BH10, IL-2, IL-2 receptors, tyrosyl, p120, p98, p96, p54, p38, IL-2, V3-BH10, c - fos, c - myc, V3 loop, gp120, IL-2 Options: Entity, Protein	[ "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth.	[ "V3", "loop", "of", "human", "immunodeficiency", "virus", "type", "1", "suppresses", "interleukin", "2-induced", "T", "cell", "growth", "[", "published", "erratum", "appears", "in", "AIDS", "Res", "Hum", "Retroviruses", "1997", "May", "1;13(7):633", "]", "\n", "We", "tested", "the", "effect", "of", "three", "linear", "or", "two", "loop", "peptides", "derived", "from", "the", "V3", "region", "of", "the", "HTLV", "-", "III", "BH10", "clone", "or", "the", "SF2", "strain", "of", "human", "immunodeficiency", "virus", "type", "1", "on", "IL-2-driven", "T", "cell", "proliferation", ".", "V3-BH10", ",", "which", "consists", "of", "42", "amino", "acids", "and", "has", "a", "loop", "structure", ",", "suppressed", "IL-2-driven", "proliferation", "of", "all", "IL-2-dependent", "cells", "[", "Kit225", ",", "ED-40515(+", ")", ",", "KT-3", ",", "7-day", "PHA", "-", "blasts", ",", "and", "fresh", "peripheral", "blood", "mononuclear", "cells", "]", "tested", ",", "whereas", "it", "did", "not", "suppress", "the", "cell", "growth", "of", "IL-2-independent", "cell", "lines", "(", "Hut102", ",", "Molt-4", ",", "and", "Jurkat", ")", ".", "This", "suppressive", "effect", "was", "also", "seen", "in", "IL-2-driven", "cell", "growth", "of", "CD8-positive", "lymphocytes", "purified", "from", "7-day", "PHA", "-", "blasts", ",", "indicating", "that", "CD4", "molecules", "were", "not", "required", "for", "the", "suppression", ".", "The", "treatment", "with", "anti", "-", "V3", "loop", "monoclonal", "antibody", "(", "902", "antibody", ")", "completely", "abolished", "the", "suppressive", "effect", "of", "V3-BH10", ".", "In", "addition", ",", "V3-BH10", "generated", "the", "arrest", "of", "Kit225", "cells", "and", "also", "purified", "CD8-positive", "lymphocytes", "in", "G1", "phase", "in", "the", "presence", "of", "IL-2", ".", "Neither", "chromatin", "condensation", "nor", "DNA", "fragmentation", "was", "detected", "in", "Kit225", "cells", "cultured", "with", "V3-BH10", "and", "IL-2", ".", "V3-BH10", "neither", "blocked", "radiolabeled", "IL-2", "binding", "to", "IL-2", "receptors", "nor", "affected", "tyrosyl", "phosphorylation", "of", "several", "cellular", "proteins", "(", "p120", ",", "p98", ",", "p96", ",", "p54", ",", "and", "p38", ")", ",", "which", "is", "immediately", "induced", "by", "IL-2", "stimulation", ".", "However", ",", "V3-BH10", "enhanced", "IL-2-induced", "mRNA", "expression", "of", "c", "-", "fos", "but", "not", "c", "-", "myc", "or", "junB.", "Thus", ",", "the", "binding", "of", "V3", "loop", "of", "gp120", "to", "the", "cell", "surface", "molecule(s", ")", "appears", "to", "affect", "intracellular", "IL-2", "signaling", ",", "which", "leads", "to", "the", "suppression", "of", "IL-2-induced", "T", "cell", "growth", ".", "\n" ]	[ "Entity", "Protein" ]
V3 loop, peptides, V3 region, V3-BH10, 42 amino acids, loop structure, CD4, V3 loop, V3-BH10, V3-BH10, IL-2, chromatin, V3-BH10, IL-2, V3-BH10, IL-2, IL-2 receptors, tyrosyl, p120, p98, p96, p54, p38, IL-2, V3-BH10, c - fos, c - myc, V3 loop, gp120, IL-2	679_task2	Sentence: V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth. Instructions: please extract entity words from the input sentence	[ "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth.	[ "V3", "loop", "of", "human", "immunodeficiency", "virus", "type", "1", "suppresses", "interleukin", "2-induced", "T", "cell", "growth", "[", "published", "erratum", "appears", "in", "AIDS", "Res", "Hum", "Retroviruses", "1997", "May", "1;13(7):633", "]", "\n", "We", "tested", "the", "effect", "of", "three", "linear", "or", "two", "loop", "peptides", "derived", "from", "the", "V3", "region", "of", "the", "HTLV", "-", "III", "BH10", "clone", "or", "the", "SF2", "strain", "of", "human", "immunodeficiency", "virus", "type", "1", "on", "IL-2-driven", "T", "cell", "proliferation", ".", "V3-BH10", ",", "which", "consists", "of", "42", "amino", "acids", "and", "has", "a", "loop", "structure", ",", "suppressed", "IL-2-driven", "proliferation", "of", "all", "IL-2-dependent", "cells", "[", "Kit225", ",", "ED-40515(+", ")", ",", "KT-3", ",", "7-day", "PHA", "-", "blasts", ",", "and", "fresh", "peripheral", "blood", "mononuclear", "cells", "]", "tested", ",", "whereas", "it", "did", "not", "suppress", "the", "cell", "growth", "of", "IL-2-independent", "cell", "lines", "(", "Hut102", ",", "Molt-4", ",", "and", "Jurkat", ")", ".", "This", "suppressive", "effect", "was", "also", "seen", "in", "IL-2-driven", "cell", "growth", "of", "CD8-positive", "lymphocytes", "purified", "from", "7-day", "PHA", "-", "blasts", ",", "indicating", "that", "CD4", "molecules", "were", "not", "required", "for", "the", "suppression", ".", "The", "treatment", "with", "anti", "-", "V3", "loop", "monoclonal", "antibody", "(", "902", "antibody", ")", "completely", "abolished", "the", "suppressive", "effect", "of", "V3-BH10", ".", "In", "addition", ",", "V3-BH10", "generated", "the", "arrest", "of", "Kit225", "cells", "and", "also", "purified", "CD8-positive", "lymphocytes", "in", "G1", "phase", "in", "the", "presence", "of", "IL-2", ".", "Neither", "chromatin", "condensation", "nor", "DNA", "fragmentation", "was", "detected", "in", "Kit225", "cells", "cultured", "with", "V3-BH10", "and", "IL-2", ".", "V3-BH10", "neither", "blocked", "radiolabeled", "IL-2", "binding", "to", "IL-2", "receptors", "nor", "affected", "tyrosyl", "phosphorylation", "of", "several", "cellular", "proteins", "(", "p120", ",", "p98", ",", "p96", ",", "p54", ",", "and", "p38", ")", ",", "which", "is", "immediately", "induced", "by", "IL-2", "stimulation", ".", "However", ",", "V3-BH10", "enhanced", "IL-2-induced", "mRNA", "expression", "of", "c", "-", "fos", "but", "not", "c", "-", "myc", "or", "junB.", "Thus", ",", "the", "binding", "of", "V3", "loop", "of", "gp120", "to", "the", "cell", "surface", "molecule(s", ")", "appears", "to", "affect", "intracellular", "IL-2", "signaling", ",", "which", "leads", "to", "the", "suppression", "of", "IL-2-induced", "T", "cell", "growth", ".", "\n" ]	[ "Entity", "Protein" ]
urokinase is a Intervention_Pharmacological, A multicentre trial ( 10 centres ) of urokinase ( UK ) is a Intervention_Pharmacological, patients with acute severe pulmonary embolism ( PE ) . is a Participant_Condition, two doses of UK is a Intervention_Pharmacological, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin is a Intervention_Pharmacological, degree of early revascularization is a Outcome_Physical, thrombolytic treatment is a Intervention_Pharmacological, died is a Outcome_Mortality, Miller angiographic index is a Outcome_Physical, significant degree of resolution is a Outcome_Physical, Minor and major bleeding problems is a Outcome_Adverse-effects	76212_task0	Sentence: The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "The", "UKEP", "study", ":", "multicentre", "clinical", "trial", "on", "two", "local", "regimens", "of", "urokinase", "in", "massive", "pulmonary", "embolism", ".", "The", "UKEP", "Study", "Research", "Group", ".", "A", "multicentre", "trial", "(", "10", "centres", ")", "of", "urokinase", "(", "UK", ")", "was", "performed", "in", "patients", "with", "acute", "severe", "pulmonary", "embolism", "(", "PE", ")", ".", "The", "aim", "of", "this", "trial", "was", ",", "to", "compare", "the", "efficacy", "of", "two", "doses", "of", "UK", "administered", "via", "a", "catheter", "in", "the", "pulmonary", "artery", ":", "2000", "IU", "kg-1", "h-1", "for", "24", "hours", "(", "UK", "2000", ")", "in", "conjunction", "with", "heparin", "versus", "4400", "IU", "kg-1", "h-1", "UK", "alone", "for", "12", "hours", "(", "UK", "4400", ")", "followed", "by", "heparin", ".", "PE", "was", "less", "than", "5", "days", "old", "and", "the", "clinical", "diagnosis", "was", "confirmed", "by", "pulmonary", "angiograms", "demonstrating", "a", "vascular", "obstruction", "of", "more", "than", "30", "%", "(", "Miller", "'", "s", "index", "greater", "than", "11", ")", ".", "The", "efficacy", "of", "treatment", "was", "evaluated", "by", "the", "degree", "of", "early", "revascularization", "(", "pulmonary", "angiograms", "were", "performed", "30", "to", "48", "hours", "after", "initiation", "of", "thrombolytic", "treatment", "and", "analysed", "blindly", "by", "four", "independent", "vascular", "radiologists", ")", ".", "133", "patients", "were", "included", "in", "this", "trial", ":", "two", "patients", "died", "before", "treatment", "and", "two", "were", "excluded", "retrospectively", ",", "leaving", "129", "patients", "for", "final", "analysis", "(", "67", ":", "UK", "2000", "+", "heparin", ";", "62", ":", "UK", "4400", ")", ".", "The", "two", "groups", "had", "similar", "pretreatment", "clinical", ",", "haemodynamic", "and", "angiographic", "characteristics", ":", "the", "Miller", "angiographic", "index", "of", "severity", "averaged", "22.6", "+", "/-", "3.7", "for", "patients", "in", "the", "UK", "2000", "group", ",", "and", "22.6", "+", "/-", "3.4", "for", "patients", "in", "the", "UK", "4400", "group", "(", "average", "filling", "defect", "of", "66", "%", "on", "pulmonary", "angiograms", ")", ".", "There", "was", "a", "similar", "and", "significant", "degree", "of", "resolution", "in", "the", "two", "groups", ":", "26", "%", "and", "20", "%", ",", "respectively", ".", "Minor", "and", "major", "bleeding", "problems", "were", "observed", "with", "equal", "frequency", "in", "the", "two", "groups", "(", "24", "%", "and", "29", "%", ",", "respectively", ")", ".", "These", "bleeding", "complications", "were", "severe", "in", "only", "4.5", "%", "and", "3", "%", ",", "respectively", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Mortality" ]
urokinase is a Intervention_Pharmacological, A multicentre trial ( 10 centres ) of urokinase ( UK ) is a Intervention_Pharmacological, patients with acute severe pulmonary embolism ( PE ) . is a Participant_Condition, two doses of UK is a Intervention_Pharmacological, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin is a Intervention_Pharmacological, degree of early revascularization is a Outcome_Physical, thrombolytic treatment is a Intervention_Pharmacological, died is a Outcome_Mortality, Miller angiographic index is a Outcome_Physical, significant degree of resolution is a Outcome_Physical, Minor and major bleeding problems is a Outcome_Adverse-effects	76212_task1	Sentence: The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: urokinase, A multicentre trial ( 10 centres ) of urokinase ( UK ), patients with acute severe pulmonary embolism ( PE ) ., two doses of UK, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin, degree of early revascularization, thrombolytic treatment, died, Miller angiographic index, significant degree of resolution, Minor and major bleeding problems Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "The", "UKEP", "study", ":", "multicentre", "clinical", "trial", "on", "two", "local", "regimens", "of", "urokinase", "in", "massive", "pulmonary", "embolism", ".", "The", "UKEP", "Study", "Research", "Group", ".", "A", "multicentre", "trial", "(", "10", "centres", ")", "of", "urokinase", "(", "UK", ")", "was", "performed", "in", "patients", "with", "acute", "severe", "pulmonary", "embolism", "(", "PE", ")", ".", "The", "aim", "of", "this", "trial", "was", ",", "to", "compare", "the", "efficacy", "of", "two", "doses", "of", "UK", "administered", "via", "a", "catheter", "in", "the", "pulmonary", "artery", ":", "2000", "IU", "kg-1", "h-1", "for", "24", "hours", "(", "UK", "2000", ")", "in", "conjunction", "with", "heparin", "versus", "4400", "IU", "kg-1", "h-1", "UK", "alone", "for", "12", "hours", "(", "UK", "4400", ")", "followed", "by", "heparin", ".", "PE", "was", "less", "than", "5", "days", "old", "and", "the", "clinical", "diagnosis", "was", "confirmed", "by", "pulmonary", "angiograms", "demonstrating", "a", "vascular", "obstruction", "of", "more", "than", "30", "%", "(", "Miller", "'", "s", "index", "greater", "than", "11", ")", ".", "The", "efficacy", "of", "treatment", "was", "evaluated", "by", "the", "degree", "of", "early", "revascularization", "(", "pulmonary", "angiograms", "were", "performed", "30", "to", "48", "hours", "after", "initiation", "of", "thrombolytic", "treatment", "and", "analysed", "blindly", "by", "four", "independent", "vascular", "radiologists", ")", ".", "133", "patients", "were", "included", "in", "this", "trial", ":", "two", "patients", "died", "before", "treatment", "and", "two", "were", "excluded", "retrospectively", ",", "leaving", "129", "patients", "for", "final", "analysis", "(", "67", ":", "UK", "2000", "+", "heparin", ";", "62", ":", "UK", "4400", ")", ".", "The", "two", "groups", "had", "similar", "pretreatment", "clinical", ",", "haemodynamic", "and", "angiographic", "characteristics", ":", "the", "Miller", "angiographic", "index", "of", "severity", "averaged", "22.6", "+", "/-", "3.7", "for", "patients", "in", "the", "UK", "2000", "group", ",", "and", "22.6", "+", "/-", "3.4", "for", "patients", "in", "the", "UK", "4400", "group", "(", "average", "filling", "defect", "of", "66", "%", "on", "pulmonary", "angiograms", ")", ".", "There", "was", "a", "similar", "and", "significant", "degree", "of", "resolution", "in", "the", "two", "groups", ":", "26", "%", "and", "20", "%", ",", "respectively", ".", "Minor", "and", "major", "bleeding", "problems", "were", "observed", "with", "equal", "frequency", "in", "the", "two", "groups", "(", "24", "%", "and", "29", "%", ",", "respectively", ")", ".", "These", "bleeding", "complications", "were", "severe", "in", "only", "4.5", "%", "and", "3", "%", ",", "respectively", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Mortality" ]
urokinase, A multicentre trial ( 10 centres ) of urokinase ( UK ), patients with acute severe pulmonary embolism ( PE ) ., two doses of UK, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin, degree of early revascularization, thrombolytic treatment, died, Miller angiographic index, significant degree of resolution, Minor and major bleeding problems	76212_task2	Sentence: The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS )	[ "The", "UKEP", "study", ":", "multicentre", "clinical", "trial", "on", "two", "local", "regimens", "of", "urokinase", "in", "massive", "pulmonary", "embolism", ".", "The", "UKEP", "Study", "Research", "Group", ".", "A", "multicentre", "trial", "(", "10", "centres", ")", "of", "urokinase", "(", "UK", ")", "was", "performed", "in", "patients", "with", "acute", "severe", "pulmonary", "embolism", "(", "PE", ")", ".", "The", "aim", "of", "this", "trial", "was", ",", "to", "compare", "the", "efficacy", "of", "two", "doses", "of", "UK", "administered", "via", "a", "catheter", "in", "the", "pulmonary", "artery", ":", "2000", "IU", "kg-1", "h-1", "for", "24", "hours", "(", "UK", "2000", ")", "in", "conjunction", "with", "heparin", "versus", "4400", "IU", "kg-1", "h-1", "UK", "alone", "for", "12", "hours", "(", "UK", "4400", ")", "followed", "by", "heparin", ".", "PE", "was", "less", "than", "5", "days", "old", "and", "the", "clinical", "diagnosis", "was", "confirmed", "by", "pulmonary", "angiograms", "demonstrating", "a", "vascular", "obstruction", "of", "more", "than", "30", "%", "(", "Miller", "'", "s", "index", "greater", "than", "11", ")", ".", "The", "efficacy", "of", "treatment", "was", "evaluated", "by", "the", "degree", "of", "early", "revascularization", "(", "pulmonary", "angiograms", "were", "performed", "30", "to", "48", "hours", "after", "initiation", "of", "thrombolytic", "treatment", "and", "analysed", "blindly", "by", "four", "independent", "vascular", "radiologists", ")", ".", "133", "patients", "were", "included", "in", "this", "trial", ":", "two", "patients", "died", "before", "treatment", "and", "two", "were", "excluded", "retrospectively", ",", "leaving", "129", "patients", "for", "final", "analysis", "(", "67", ":", "UK", "2000", "+", "heparin", ";", "62", ":", "UK", "4400", ")", ".", "The", "two", "groups", "had", "similar", "pretreatment", "clinical", ",", "haemodynamic", "and", "angiographic", "characteristics", ":", "the", "Miller", "angiographic", "index", "of", "severity", "averaged", "22.6", "+", "/-", "3.7", "for", "patients", "in", "the", "UK", "2000", "group", ",", "and", "22.6", "+", "/-", "3.4", "for", "patients", "in", "the", "UK", "4400", "group", "(", "average", "filling", "defect", "of", "66", "%", "on", "pulmonary", "angiograms", ")", ".", "There", "was", "a", "similar", "and", "significant", "degree", "of", "resolution", "in", "the", "two", "groups", ":", "26", "%", "and", "20", "%", ",", "respectively", ".", "Minor", "and", "major", "bleeding", "problems", "were", "observed", "with", "equal", "frequency", "in", "the", "two", "groups", "(", "24", "%", "and", "29", "%", ",", "respectively", ")", ".", "These", "bleeding", "complications", "were", "severe", "in", "only", "4.5", "%", "and", "3", "%", ",", "respectively", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Mortality" ]
Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, CD4 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein	212_task0	Sentence: Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].	[ "Foxp3", "Suppresses", "HIV-1", "Gene", "Expression", "in", "Part", "through", "Blocking", "Activation", "of", "NF", "-", "kappaB", "\n", "If", "Foxp3", "functions", "as", "a", "repressor", "of", "NF", "-", "kappaB", "-", "dependent", "gene", "expression", ",", "then", "we", "hypothesized", "that", "Foxp3", "overexpression", "could", "selectively", "down", "-", "regulate", "transcription", "from", "promoters", "previously", "shown", "to", "be", "responsive", "to", "NF", "-", "kappaB.", "To", "address", "this", "question", ",", "we", "examined", "the", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", ",", "which", "contains", "two", "tandem", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", "located", "between", "positions", "-102", "and", "-81", "with", "respect", "to", "the", "transcription", "initiation", "site", "[", "21", "]", ".", "NF", "-", "kappaB", "plays", "a", "crucial", "role", "in", "regulating", "gene", "expression", "directed", "from", "the", "HIV-1", "LTR", "in", "CD4", "+", "T", "cells", "[", "21", "]", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "deltaFKH", ",", "in", "HEK", "293", "T", "cells", "was", "able", "to", "inhibit", "basal", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3A", ")", ",", "similar", "to", "what", "was", "previously", "demonstrated", "with", "the", "synthetic", "NF", "-", "kappaB", "reporter", "vector", "(", "Figure", "2B", ")", ".", "Furthermore", ",", "HIV-1", "LTR", "activation", "was", "suppressed", "by", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "3B", ")", ".", "To", "demonstrate", "that", "Foxp3-mediated", "HIV-1", "LTR", "repression", "was", "associated", "with", "interactions", "with", "NF", "-", "kappaB", "bound", "to", "the", "HIV-1", "LTR", ",", "we", "compared", "basal", "activation", "of", "the", "HIV-1", "LTR", "or", "an", "identical", "HIV-1", "LTR", "lacking", "the", "NF", "-", "kappaB", "sites", "located", "between", "-102", "and", "-81", "(", "HIV-1", "delta", "-", "kappaB", "LTR", ")", "(", "Figure", "3C", ")", ".", "This", "mutant", "HIV-1", "LTR", "construct", "exhibited", "reduced", "levels", "of", "transcription", "compared", "to", "the", "parental", "HIV-1", "LTR", "in", "purified", "healthy", "donor", "CD4", "+", "T", "cells", "(", "unpublished", "data", ")", ".", "However", ",", "directly", "comparing", "the", "effect", "of", "Foxp3", "overexpression", "on", "the", "activation", "of", "these", "two", "viral", "promoters", "demonstrated", "that", "Foxp3", "was", "more", "capable", "of", "suppressing", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3D", ")", "compared", "to", "the", "mutated", "HIV-1", "LTR", "(", "Figure", "3E", ")", ".", "These", "results", "suggest", "that", "Foxp3", "down", "-", "regulation", "of", "HIV-1", "LTR", "activation", "was", "mediated", "at", "least", "in", "part", "by", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", ".", "Residual", "levels", "of", "inhibition", "of", "the", "HIV-1", "delta", "-", "kappaB", "LTR", "by", "Foxp3", "may", "be", "due", "to", "NF", "-", "AT", "binding", "sites", "located", "upstream", "of", "the", "NF", "-", "kappaB", "sites", "within", "the", "HIV-1", "LTR", "[", "22,23", "]", "." ]	[ "Protein" ]
Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, CD4 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein	212_task1	Sentence: Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23]. Instructions: please typing these entity words according to sentence: Foxp3, Foxp3, Foxp3, CD4, Foxp3, deltaFKH, Foxp3, deltaFKH, CD4, Foxp3, Foxp3, Foxp3, Foxp3 Options: Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].	[ "Foxp3", "Suppresses", "HIV-1", "Gene", "Expression", "in", "Part", "through", "Blocking", "Activation", "of", "NF", "-", "kappaB", "\n", "If", "Foxp3", "functions", "as", "a", "repressor", "of", "NF", "-", "kappaB", "-", "dependent", "gene", "expression", ",", "then", "we", "hypothesized", "that", "Foxp3", "overexpression", "could", "selectively", "down", "-", "regulate", "transcription", "from", "promoters", "previously", "shown", "to", "be", "responsive", "to", "NF", "-", "kappaB.", "To", "address", "this", "question", ",", "we", "examined", "the", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", ",", "which", "contains", "two", "tandem", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", "located", "between", "positions", "-102", "and", "-81", "with", "respect", "to", "the", "transcription", "initiation", "site", "[", "21", "]", ".", "NF", "-", "kappaB", "plays", "a", "crucial", "role", "in", "regulating", "gene", "expression", "directed", "from", "the", "HIV-1", "LTR", "in", "CD4", "+", "T", "cells", "[", "21", "]", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "deltaFKH", ",", "in", "HEK", "293", "T", "cells", "was", "able", "to", "inhibit", "basal", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3A", ")", ",", "similar", "to", "what", "was", "previously", "demonstrated", "with", "the", "synthetic", "NF", "-", "kappaB", "reporter", "vector", "(", "Figure", "2B", ")", ".", "Furthermore", ",", "HIV-1", "LTR", "activation", "was", "suppressed", "by", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "3B", ")", ".", "To", "demonstrate", "that", "Foxp3-mediated", "HIV-1", "LTR", "repression", "was", "associated", "with", "interactions", "with", "NF", "-", "kappaB", "bound", "to", "the", "HIV-1", "LTR", ",", "we", "compared", "basal", "activation", "of", "the", "HIV-1", "LTR", "or", "an", "identical", "HIV-1", "LTR", "lacking", "the", "NF", "-", "kappaB", "sites", "located", "between", "-102", "and", "-81", "(", "HIV-1", "delta", "-", "kappaB", "LTR", ")", "(", "Figure", "3C", ")", ".", "This", "mutant", "HIV-1", "LTR", "construct", "exhibited", "reduced", "levels", "of", "transcription", "compared", "to", "the", "parental", "HIV-1", "LTR", "in", "purified", "healthy", "donor", "CD4", "+", "T", "cells", "(", "unpublished", "data", ")", ".", "However", ",", "directly", "comparing", "the", "effect", "of", "Foxp3", "overexpression", "on", "the", "activation", "of", "these", "two", "viral", "promoters", "demonstrated", "that", "Foxp3", "was", "more", "capable", "of", "suppressing", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3D", ")", "compared", "to", "the", "mutated", "HIV-1", "LTR", "(", "Figure", "3E", ")", ".", "These", "results", "suggest", "that", "Foxp3", "down", "-", "regulation", "of", "HIV-1", "LTR", "activation", "was", "mediated", "at", "least", "in", "part", "by", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", ".", "Residual", "levels", "of", "inhibition", "of", "the", "HIV-1", "delta", "-", "kappaB", "LTR", "by", "Foxp3", "may", "be", "due", "to", "NF", "-", "AT", "binding", "sites", "located", "upstream", "of", "the", "NF", "-", "kappaB", "sites", "within", "the", "HIV-1", "LTR", "[", "22,23", "]", "." ]	[ "Protein" ]
Foxp3, Foxp3, Foxp3, CD4, Foxp3, deltaFKH, Foxp3, deltaFKH, CD4, Foxp3, Foxp3, Foxp3, Foxp3	212_task2	Sentence: Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23]. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].	[ "Foxp3", "Suppresses", "HIV-1", "Gene", "Expression", "in", "Part", "through", "Blocking", "Activation", "of", "NF", "-", "kappaB", "\n", "If", "Foxp3", "functions", "as", "a", "repressor", "of", "NF", "-", "kappaB", "-", "dependent", "gene", "expression", ",", "then", "we", "hypothesized", "that", "Foxp3", "overexpression", "could", "selectively", "down", "-", "regulate", "transcription", "from", "promoters", "previously", "shown", "to", "be", "responsive", "to", "NF", "-", "kappaB.", "To", "address", "this", "question", ",", "we", "examined", "the", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", ",", "which", "contains", "two", "tandem", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", "located", "between", "positions", "-102", "and", "-81", "with", "respect", "to", "the", "transcription", "initiation", "site", "[", "21", "]", ".", "NF", "-", "kappaB", "plays", "a", "crucial", "role", "in", "regulating", "gene", "expression", "directed", "from", "the", "HIV-1", "LTR", "in", "CD4", "+", "T", "cells", "[", "21", "]", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "deltaFKH", ",", "in", "HEK", "293", "T", "cells", "was", "able", "to", "inhibit", "basal", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3A", ")", ",", "similar", "to", "what", "was", "previously", "demonstrated", "with", "the", "synthetic", "NF", "-", "kappaB", "reporter", "vector", "(", "Figure", "2B", ")", ".", "Furthermore", ",", "HIV-1", "LTR", "activation", "was", "suppressed", "by", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "3B", ")", ".", "To", "demonstrate", "that", "Foxp3-mediated", "HIV-1", "LTR", "repression", "was", "associated", "with", "interactions", "with", "NF", "-", "kappaB", "bound", "to", "the", "HIV-1", "LTR", ",", "we", "compared", "basal", "activation", "of", "the", "HIV-1", "LTR", "or", "an", "identical", "HIV-1", "LTR", "lacking", "the", "NF", "-", "kappaB", "sites", "located", "between", "-102", "and", "-81", "(", "HIV-1", "delta", "-", "kappaB", "LTR", ")", "(", "Figure", "3C", ")", ".", "This", "mutant", "HIV-1", "LTR", "construct", "exhibited", "reduced", "levels", "of", "transcription", "compared", "to", "the", "parental", "HIV-1", "LTR", "in", "purified", "healthy", "donor", "CD4", "+", "T", "cells", "(", "unpublished", "data", ")", ".", "However", ",", "directly", "comparing", "the", "effect", "of", "Foxp3", "overexpression", "on", "the", "activation", "of", "these", "two", "viral", "promoters", "demonstrated", "that", "Foxp3", "was", "more", "capable", "of", "suppressing", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3D", ")", "compared", "to", "the", "mutated", "HIV-1", "LTR", "(", "Figure", "3E", ")", ".", "These", "results", "suggest", "that", "Foxp3", "down", "-", "regulation", "of", "HIV-1", "LTR", "activation", "was", "mediated", "at", "least", "in", "part", "by", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", ".", "Residual", "levels", "of", "inhibition", "of", "the", "HIV-1", "delta", "-", "kappaB", "LTR", "by", "Foxp3", "may", "be", "due", "to", "NF", "-", "AT", "binding", "sites", "located", "upstream", "of", "the", "NF", "-", "kappaB", "sites", "within", "the", "HIV-1", "LTR", "[", "22,23", "]", "." ]	[ "Protein" ]
posterior is an umlsterm, orbit is an umlsterm, optic nerve is an umlsterm, artery is an umlsterm, vein is an umlsterm, ocular muscles is an umlsterm, nerves is an umlsterm, surgical is an umlsterm, transmaxillary is an umlsterm, procedures is an umlsterm, injury is an umlsterm, non - tumor is an umlsterm, case report is an umlsterm, hemangioma is an umlsterm, mobilization is an umlsterm, optic nerve is an umlsterm, sphenoid sinus is an umlsterm, lamina is an umlsterm, sphenoid sinus is an umlsterm, skull base is an umlsterm, rectus muscle is an umlsterm, tumor is an umlsterm, hemangioma is an umlsterm, toto is an umlsterm, control is an umlsterm, Surgery is an umlsterm, technique is an umlsterm, procedure is an umlsterm, minor is an umlsterm, risk is an umlsterm, hands is an umlsterm, treatment is an umlsterm	HNO.90470192.eng.abstr_task0	Sentence: The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions .	[ "The", "posterior", "orbit", "contain", "'s", "a", "number", "of", "important", "and", "vulnerable", "structures", ",", "including", "the", "optic", "nerve", ",", "the", "opthalmic", "artery", "and", "vein", ",", "the", "ocular", "muscles", "and", "their", "motor", "nerves", ".", "Because", "of", "their", "close", "relation", "to", "the", "ocular", "bult", ",", "surgical", "access", "to", "this", "region", "is", "very", "difficult", ".", "Transfrontal", ",", "transfrontalethmoidal", "and", "transmaxillary", "procedures", "have", "the", "disadvantage", "of", "possible", "injury", "to", "a", "number", "of", "non", "-", "tumor", "affected", "structures", ".", "The", "endonasal", "microsurgical", "transethmoid", "access", "is", "described", "here", "along", "with", "a", "case", "report", "of", "a", "2x1", "cm", "intraconal", "hemangioma", ".", "Ethmoidectomy", "was", "performed", "after", "septal", "mobilization", ".", "The", "optic", "nerve", "was", "identified", "in", "the", "wall", "of", "the", "sphenoid", "sinus", ".", "The", "lamina", "papyracea", "was", "resected", "between", "the", "sphenoid", "sinus", "wall", ",", "skull", "base", "and", "ethmoid", ".", "The", "medial", "rectus", "muscle", "was", "mobilized", "after", "slitting", "open", "the", "periorbita", "to", "expose", "tumor", ".", "The", "hemangioma", "was", "then", "removed", "in", "toto", "under", "microscopic", "control", ".", "Surgery", "in", "the", "retrobulbar", "region", "could", "be", "performed", "gently", "and", "under", "microscopic", "magnification", "with", "this", "technique", ".", "The", "procedure", "used", "has", "a", "minor", "risk", "in", "the", "hands", "of", "an", "experienced", "nasalsurgeon", "and", "opens", "up", "new", "possibilities", "for", "the", "treatment", "of", "retroorbital", "lesions", "." ]	[ "umlsterm" ]
posterior is an umlsterm, orbit is an umlsterm, optic nerve is an umlsterm, artery is an umlsterm, vein is an umlsterm, ocular muscles is an umlsterm, nerves is an umlsterm, surgical is an umlsterm, transmaxillary is an umlsterm, procedures is an umlsterm, injury is an umlsterm, non - tumor is an umlsterm, case report is an umlsterm, hemangioma is an umlsterm, mobilization is an umlsterm, optic nerve is an umlsterm, sphenoid sinus is an umlsterm, lamina is an umlsterm, sphenoid sinus is an umlsterm, skull base is an umlsterm, rectus muscle is an umlsterm, tumor is an umlsterm, hemangioma is an umlsterm, toto is an umlsterm, control is an umlsterm, Surgery is an umlsterm, technique is an umlsterm, procedure is an umlsterm, minor is an umlsterm, risk is an umlsterm, hands is an umlsterm, treatment is an umlsterm	HNO.90470192.eng.abstr_task1	Sentence: The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions . Instructions: please typing these entity words according to sentence: posterior, orbit, optic nerve, artery, vein, ocular muscles, nerves, surgical, transmaxillary, procedures, injury, non - tumor, case report, hemangioma, mobilization, optic nerve, sphenoid sinus, lamina, sphenoid sinus, skull base, rectus muscle, tumor, hemangioma, toto, control, Surgery, technique, procedure, minor, risk, hands, treatment Options: umlsterm	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions .	[ "The", "posterior", "orbit", "contain", "'s", "a", "number", "of", "important", "and", "vulnerable", "structures", ",", "including", "the", "optic", "nerve", ",", "the", "opthalmic", "artery", "and", "vein", ",", "the", "ocular", "muscles", "and", "their", "motor", "nerves", ".", "Because", "of", "their", "close", "relation", "to", "the", "ocular", "bult", ",", "surgical", "access", "to", "this", "region", "is", "very", "difficult", ".", "Transfrontal", ",", "transfrontalethmoidal", "and", "transmaxillary", "procedures", "have", "the", "disadvantage", "of", "possible", "injury", "to", "a", "number", "of", "non", "-", "tumor", "affected", "structures", ".", "The", "endonasal", "microsurgical", "transethmoid", "access", "is", "described", "here", "along", "with", "a", "case", "report", "of", "a", "2x1", "cm", "intraconal", "hemangioma", ".", "Ethmoidectomy", "was", "performed", "after", "septal", "mobilization", ".", "The", "optic", "nerve", "was", "identified", "in", "the", "wall", "of", "the", "sphenoid", "sinus", ".", "The", "lamina", "papyracea", "was", "resected", "between", "the", "sphenoid", "sinus", "wall", ",", "skull", "base", "and", "ethmoid", ".", "The", "medial", "rectus", "muscle", "was", "mobilized", "after", "slitting", "open", "the", "periorbita", "to", "expose", "tumor", ".", "The", "hemangioma", "was", "then", "removed", "in", "toto", "under", "microscopic", "control", ".", "Surgery", "in", "the", "retrobulbar", "region", "could", "be", "performed", "gently", "and", "under", "microscopic", "magnification", "with", "this", "technique", ".", "The", "procedure", "used", "has", "a", "minor", "risk", "in", "the", "hands", "of", "an", "experienced", "nasalsurgeon", "and", "opens", "up", "new", "possibilities", "for", "the", "treatment", "of", "retroorbital", "lesions", "." ]	[ "umlsterm" ]
posterior, orbit, optic nerve, artery, vein, ocular muscles, nerves, surgical, transmaxillary, procedures, injury, non - tumor, case report, hemangioma, mobilization, optic nerve, sphenoid sinus, lamina, sphenoid sinus, skull base, rectus muscle, tumor, hemangioma, toto, control, Surgery, technique, procedure, minor, risk, hands, treatment	HNO.90470192.eng.abstr_task2	Sentence: The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions .	[ "The", "posterior", "orbit", "contain", "'s", "a", "number", "of", "important", "and", "vulnerable", "structures", ",", "including", "the", "optic", "nerve", ",", "the", "opthalmic", "artery", "and", "vein", ",", "the", "ocular", "muscles", "and", "their", "motor", "nerves", ".", "Because", "of", "their", "close", "relation", "to", "the", "ocular", "bult", ",", "surgical", "access", "to", "this", "region", "is", "very", "difficult", ".", "Transfrontal", ",", "transfrontalethmoidal", "and", "transmaxillary", "procedures", "have", "the", "disadvantage", "of", "possible", "injury", "to", "a", "number", "of", "non", "-", "tumor", "affected", "structures", ".", "The", "endonasal", "microsurgical", "transethmoid", "access", "is", "described", "here", "along", "with", "a", "case", "report", "of", "a", "2x1", "cm", "intraconal", "hemangioma", ".", "Ethmoidectomy", "was", "performed", "after", "septal", "mobilization", ".", "The", "optic", "nerve", "was", "identified", "in", "the", "wall", "of", "the", "sphenoid", "sinus", ".", "The", "lamina", "papyracea", "was", "resected", "between", "the", "sphenoid", "sinus", "wall", ",", "skull", "base", "and", "ethmoid", ".", "The", "medial", "rectus", "muscle", "was", "mobilized", "after", "slitting", "open", "the", "periorbita", "to", "expose", "tumor", ".", "The", "hemangioma", "was", "then", "removed", "in", "toto", "under", "microscopic", "control", ".", "Surgery", "in", "the", "retrobulbar", "region", "could", "be", "performed", "gently", "and", "under", "microscopic", "magnification", "with", "this", "technique", ".", "The", "procedure", "used", "has", "a", "minor", "risk", "in", "the", "hands", "of", "an", "experienced", "nasalsurgeon", "and", "opens", "up", "new", "possibilities", "for", "the", "treatment", "of", "retroorbital", "lesions", "." ]	[ "umlsterm" ]
Dokumentation is an umlsterm, Femur is an umlsterm, zementfreien is an umlsterm, robotergestuetzte is an umlsterm, Verwendung is an umlsterm, artefaktunterdrueckenden is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Technologie is an umlsterm, Robotersystemen is an umlsterm, Technik is an umlsterm	DerChirurg.80690973.ger.abstr_task0	Sentence: Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen .	[ "Zusammenfassung", ".", "Von", "14", "humanen", "Femura", "wurden", "anhand", "von", "CT", "-", "Daten", "dreidimensionale", "Rekonstruktionen", "durchgefuehrt", ".", "An", "jedem", "Praeparat", "erfolgte", "die", "digitale", "Dokumentation", "des", "Centrum", "-", "Collum", "-", "Diaphysen", "(", "CCD", "und", "Antetorsionswinkels", "(", "AT", ")", ".", ")", "-", "Mit", "Hilfe", "eines", "speziellen", "Operationsplanungsprogramms", "wurde", "fuer", "jeden", "Femur", "eine", "virtuelle", "Operationsplanung", "fuer", "die", "Implantation", "einer", "zementfreien", "Hueftendoprothese", "durchgefuehrt", ".", "Die", "so", "ermittelten", "Endoprothesen", "wurden", "-", "nach", "randomisierter", "Zuweisung", "von", "je", "7", "Femura", "zu", "den", "Gruppen", "standardisiert", "manuelle", "bzw", ".", "robotergestuetzte", "Implantation", "-", "eingebracht", ".", "Anschliessend", "wurden", "alle", "Praeparate", "wiederum", "computertomographisch", "erfasst", "und", "unter", "Verwendung", "eines", "artefaktunterdrueckenden", "Algorithmus", "dreidimensional", "rekonstruiert", ".", "Die", "praeoperativ", "dokumentierten", "Parameter", "wurden", "anschliessend", "erneut", "ermittelt", ".", "Der", "Mittelwert", "der", "CCD", "-", "Winkel", "betrug", "praeoperativ", "in", "der", "manuellen", "Gruppe", "126,7", "Grad", "(", "SD", "=", "4,0", ")", "und", "in", "der", "Robotergruppe", "127,8", "Grad", "(", "SD", "=", "4,3", ")", ".", "Postoperativ", "aenderte", "er", "sich", "in", "der", "1", ".", "Gruppe", "im", "Mittel", "auf", "131,9", "Grad", "(", "SD", "=", "0,8", ")", "und", "in", "der", "2", ".", "Gruppe", "auf", "133,2", "Grad", "(", "SD", "=", "1,9", ")", ".", "Signifikante", "Unterschiede", "ergaben", "sich", "beim", "AT", "-", "Winkel", ".", "Dieser", "betrug", "in", "der", "manuellen", "Gruppe", "praeoperativ", "31,3", "Grad", "(", "SD", "=", "8,8", ")", "und", "lag", "postoperativ", "lediglich", "noch", "bei", "20,5", "Grad", "(", "SD", "=", "9,5", ")", ".", "In", "der", "Robotergruppe", "lag", "dieser", "Winkel", "vor", "der", "Implantation", "bei", "30,9", "Grad", "(", "SD", "=", "8,0", ")", "und", "nach", "der", "Implantation", "bei", "31,3", "Grad", "(", "SD", "=", "8,7", ")", ".", "Die", "Betragsdifferenz", "zwischen", "prae-", "und", "postoperativem", "AT", "-", "Winkel", "betrug", "in", "der", "manuellen", "Gruppe", "10,8", "Grad", "(", "SD", "=", "6,4", ")", "und", "in", "der", "Robotergruppe", "0,4", "Grad", "(", "SD", "=", "0,9", ";", "p", "=", "0,01", ")", ".", "Fazit", ":", "Mit", "der", "verwendeten", "Technologie", "ist", "eine", "weitaus", "exaktere", "Berechnung", "moeglich", "als", "mit", "den", "bisherigen", ",", "allein", "auf", "Roentgenbildern", "basierenden", "Operationsplanungen", ".", "Die", "virtuelle", "Operationsplanung", "laesst", "sich", "mit", "Hilfe", "von", "Robotersystemen", "mit", "hoher", "Praezision", "umsetzen", ".", "Die", "verwendete", "Technik", "scheint", "in", "der", "Lage", "zu", "sein", ",", "eine", "Verbesserung", "in", "der", "Prozess-", "und", "Ergebnisqualitaet", "mit", "sich", "zu", "bringen", "." ]	[ "umlsterm" ]
Dokumentation is an umlsterm, Femur is an umlsterm, zementfreien is an umlsterm, robotergestuetzte is an umlsterm, Verwendung is an umlsterm, artefaktunterdrueckenden is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Technologie is an umlsterm, Robotersystemen is an umlsterm, Technik is an umlsterm	DerChirurg.80690973.ger.abstr_task1	Sentence: Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen . Instructions: please typing these entity words according to sentence: Dokumentation, Femur, zementfreien, robotergestuetzte, Verwendung, artefaktunterdrueckenden, Robotergruppe, Robotergruppe, Robotergruppe, Technologie, Robotersystemen, Technik Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen .	[ "Zusammenfassung", ".", "Von", "14", "humanen", "Femura", "wurden", "anhand", "von", "CT", "-", "Daten", "dreidimensionale", "Rekonstruktionen", "durchgefuehrt", ".", "An", "jedem", "Praeparat", "erfolgte", "die", "digitale", "Dokumentation", "des", "Centrum", "-", "Collum", "-", "Diaphysen", "(", "CCD", "und", "Antetorsionswinkels", "(", "AT", ")", ".", ")", "-", "Mit", "Hilfe", "eines", "speziellen", "Operationsplanungsprogramms", "wurde", "fuer", "jeden", "Femur", "eine", "virtuelle", "Operationsplanung", "fuer", "die", "Implantation", "einer", "zementfreien", "Hueftendoprothese", "durchgefuehrt", ".", "Die", "so", "ermittelten", "Endoprothesen", "wurden", "-", "nach", "randomisierter", "Zuweisung", "von", "je", "7", "Femura", "zu", "den", "Gruppen", "standardisiert", "manuelle", "bzw", ".", "robotergestuetzte", "Implantation", "-", "eingebracht", ".", "Anschliessend", "wurden", "alle", "Praeparate", "wiederum", "computertomographisch", "erfasst", "und", "unter", "Verwendung", "eines", "artefaktunterdrueckenden", "Algorithmus", "dreidimensional", "rekonstruiert", ".", "Die", "praeoperativ", "dokumentierten", "Parameter", "wurden", "anschliessend", "erneut", "ermittelt", ".", "Der", "Mittelwert", "der", "CCD", "-", "Winkel", "betrug", "praeoperativ", "in", "der", "manuellen", "Gruppe", "126,7", "Grad", "(", "SD", "=", "4,0", ")", "und", "in", "der", "Robotergruppe", "127,8", "Grad", "(", "SD", "=", "4,3", ")", ".", "Postoperativ", "aenderte", "er", "sich", "in", "der", "1", ".", "Gruppe", "im", "Mittel", "auf", "131,9", "Grad", "(", "SD", "=", "0,8", ")", "und", "in", "der", "2", ".", "Gruppe", "auf", "133,2", "Grad", "(", "SD", "=", "1,9", ")", ".", "Signifikante", "Unterschiede", "ergaben", "sich", "beim", "AT", "-", "Winkel", ".", "Dieser", "betrug", "in", "der", "manuellen", "Gruppe", "praeoperativ", "31,3", "Grad", "(", "SD", "=", "8,8", ")", "und", "lag", "postoperativ", "lediglich", "noch", "bei", "20,5", "Grad", "(", "SD", "=", "9,5", ")", ".", "In", "der", "Robotergruppe", "lag", "dieser", "Winkel", "vor", "der", "Implantation", "bei", "30,9", "Grad", "(", "SD", "=", "8,0", ")", "und", "nach", "der", "Implantation", "bei", "31,3", "Grad", "(", "SD", "=", "8,7", ")", ".", "Die", "Betragsdifferenz", "zwischen", "prae-", "und", "postoperativem", "AT", "-", "Winkel", "betrug", "in", "der", "manuellen", "Gruppe", "10,8", "Grad", "(", "SD", "=", "6,4", ")", "und", "in", "der", "Robotergruppe", "0,4", "Grad", "(", "SD", "=", "0,9", ";", "p", "=", "0,01", ")", ".", "Fazit", ":", "Mit", "der", "verwendeten", "Technologie", "ist", "eine", "weitaus", "exaktere", "Berechnung", "moeglich", "als", "mit", "den", "bisherigen", ",", "allein", "auf", "Roentgenbildern", "basierenden", "Operationsplanungen", ".", "Die", "virtuelle", "Operationsplanung", "laesst", "sich", "mit", "Hilfe", "von", "Robotersystemen", "mit", "hoher", "Praezision", "umsetzen", ".", "Die", "verwendete", "Technik", "scheint", "in", "der", "Lage", "zu", "sein", ",", "eine", "Verbesserung", "in", "der", "Prozess-", "und", "Ergebnisqualitaet", "mit", "sich", "zu", "bringen", "." ]	[ "umlsterm" ]
Dokumentation, Femur, zementfreien, robotergestuetzte, Verwendung, artefaktunterdrueckenden, Robotergruppe, Robotergruppe, Robotergruppe, Technologie, Robotersystemen, Technik	DerChirurg.80690973.ger.abstr_task2	Sentence: Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen .	[ "Zusammenfassung", ".", "Von", "14", "humanen", "Femura", "wurden", "anhand", "von", "CT", "-", "Daten", "dreidimensionale", "Rekonstruktionen", "durchgefuehrt", ".", "An", "jedem", "Praeparat", "erfolgte", "die", "digitale", "Dokumentation", "des", "Centrum", "-", "Collum", "-", "Diaphysen", "(", "CCD", "und", "Antetorsionswinkels", "(", "AT", ")", ".", ")", "-", "Mit", "Hilfe", "eines", "speziellen", "Operationsplanungsprogramms", "wurde", "fuer", "jeden", "Femur", "eine", "virtuelle", "Operationsplanung", "fuer", "die", "Implantation", "einer", "zementfreien", "Hueftendoprothese", "durchgefuehrt", ".", "Die", "so", "ermittelten", "Endoprothesen", "wurden", "-", "nach", "randomisierter", "Zuweisung", "von", "je", "7", "Femura", "zu", "den", "Gruppen", "standardisiert", "manuelle", "bzw", ".", "robotergestuetzte", "Implantation", "-", "eingebracht", ".", "Anschliessend", "wurden", "alle", "Praeparate", "wiederum", "computertomographisch", "erfasst", "und", "unter", "Verwendung", "eines", "artefaktunterdrueckenden", "Algorithmus", "dreidimensional", "rekonstruiert", ".", "Die", "praeoperativ", "dokumentierten", "Parameter", "wurden", "anschliessend", "erneut", "ermittelt", ".", "Der", "Mittelwert", "der", "CCD", "-", "Winkel", "betrug", "praeoperativ", "in", "der", "manuellen", "Gruppe", "126,7", "Grad", "(", "SD", "=", "4,0", ")", "und", "in", "der", "Robotergruppe", "127,8", "Grad", "(", "SD", "=", "4,3", ")", ".", "Postoperativ", "aenderte", "er", "sich", "in", "der", "1", ".", "Gruppe", "im", "Mittel", "auf", "131,9", "Grad", "(", "SD", "=", "0,8", ")", "und", "in", "der", "2", ".", "Gruppe", "auf", "133,2", "Grad", "(", "SD", "=", "1,9", ")", ".", "Signifikante", "Unterschiede", "ergaben", "sich", "beim", "AT", "-", "Winkel", ".", "Dieser", "betrug", "in", "der", "manuellen", "Gruppe", "praeoperativ", "31,3", "Grad", "(", "SD", "=", "8,8", ")", "und", "lag", "postoperativ", "lediglich", "noch", "bei", "20,5", "Grad", "(", "SD", "=", "9,5", ")", ".", "In", "der", "Robotergruppe", "lag", "dieser", "Winkel", "vor", "der", "Implantation", "bei", "30,9", "Grad", "(", "SD", "=", "8,0", ")", "und", "nach", "der", "Implantation", "bei", "31,3", "Grad", "(", "SD", "=", "8,7", ")", ".", "Die", "Betragsdifferenz", "zwischen", "prae-", "und", "postoperativem", "AT", "-", "Winkel", "betrug", "in", "der", "manuellen", "Gruppe", "10,8", "Grad", "(", "SD", "=", "6,4", ")", "und", "in", "der", "Robotergruppe", "0,4", "Grad", "(", "SD", "=", "0,9", ";", "p", "=", "0,01", ")", ".", "Fazit", ":", "Mit", "der", "verwendeten", "Technologie", "ist", "eine", "weitaus", "exaktere", "Berechnung", "moeglich", "als", "mit", "den", "bisherigen", ",", "allein", "auf", "Roentgenbildern", "basierenden", "Operationsplanungen", ".", "Die", "virtuelle", "Operationsplanung", "laesst", "sich", "mit", "Hilfe", "von", "Robotersystemen", "mit", "hoher", "Praezision", "umsetzen", ".", "Die", "verwendete", "Technik", "scheint", "in", "der", "Lage", "zu", "sein", ",", "eine", "Verbesserung", "in", "der", "Prozess-", "und", "Ergebnisqualitaet", "mit", "sich", "zu", "bringen", "." ]	[ "umlsterm" ]
cigarrillos is a UNCLEAR, acero is a NORMALIZABLES, cobalto is a NORMALIZABLES, carburo de tungsteno is a NORMALIZABLES, mármol is a NO_NORMALIZABLES, granito is a NO_NORMALIZABLES, plata is a NORMALIZABLES, cadmio is a NORMALIZABLES, cobre is a NORMALIZABLES, zinc is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, colesterol is a NORMALIZABLES, transaminasas is a PROTEINAS, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, C3 is a PROTEINAS, IgA is a PROTEINAS, Ig A is a PROTEINAS, enalapril is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, beta2-globulina is a PROTEINAS, N - acetilglucosaminidasa is a PROTEINAS, NAG is a PROTEINAS, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES	411_task0	Sentence: Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: UNCLEAR, NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-PROTEINAS", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g).	[ "Varón", "de", "47", "años", ",", "que", "cesó", "el", "hábito", "tabáquico", "hace", "diez", "años", ",", "fumó", "entre", "10", "-", "20", "cigarrillos", "/", "día", "durante", "15", "años", "y", "fue", "diagnosticado", "hace", "8", "años", "de", "glomerulonefritis", "mesangial", "IgA.", "Había", "estado", "trabajando", "durante", "12", "años", "como", "soldador", "en", "una", "empresa", "de", "fabricación", "de", "discos", "de", "acero", "que", "llevaban", "insertados", "unos", "«", "dientes", "»", "de", "cobalto", "y", "carburo", "de", "tungsteno", "que", "se", "utilizan", "para", "cortar", "mármol", "y", "granito", ".", "El", "soldador", "utilizaba", "un", "sistema", "de", "soldadura", "autógena", "de", "la", "que", "utilizaban", ",", "como", "metal", "de", "aporte", ",", "unas", "varillas", "metálicas", "a", "base", "de", ":", "plata", "(", "39", "%", ")", ",", "cadmio", "(", "25", "%", ")", ",", "cobre", "(", "22", "%", ")", "y", "zinc", "(", "14", "%", ")", ".", "Consumía", "1", "Kg", "/", "semana", ";", "no", "utilizaba", "equipos", "de", "protección", "respiratoria", "y", "su", "lugar", "de", "trabajo", "no", "tenía", "un", "sistema", "de", "extracción", "localizada", "de", "humos", ".", "Las", "concentraciones", "de", "cadmio", "en", "su", "puesto", "de", "trabajo", "fueron", "de", "52", "μg", "/", "m3", "(", "Valor", "Límite", "Ambiental", "(", "VLA", ")", "es", "de", "10", "μg", "/", "m3", ")", ".", "Durante", "los", "doce", "años", "que", "estuvo", "trabajando", "se", "le", "había", "realizado", "un", "reconocimiento", "inicial", "y", "dos", "reconocimientos", "periódicos", "inespecíficos", "sin", "controlar", "la", "exposición", "al", "cadmio", "y", "a", "otros", "contaminantes", "químicos", ";", "los", "resultados", "del", "laboratorio", "se", "encontraban", "dentro", "de", "la", "normalidad", "(", "hemograma", "completo", ",", "glucemia", ",", "colesterol", ",", "transaminasas", "hepáticas", ",", "creatinina", "sérica", "y", "el", "estudio", "cito", "-", "químico", "de", "orina", ")", ".", "En", "una", "analítica", "general", "realizada", "por", "su", "médico", "de", "familia", "se", "le", "detecta", "una", "microhematuria", "y", "una", "proteinuria", ".", "Cuando", "su", "médico", "le", "realiza", "la", "historia", "clínica", "detecta", "la", "exposición", "a", "humos", "de", "cadmio", "por", "lo", "que", "es", "remitido", "a", "la", "Unidad", "de", "Toxicología", "de", "nuestro", "hospital", ".", "Al", "ingreso", "el", "paciente", "está", "asintomático", ",", "no", "tiene", "antecedentes", "personales", "ni", "familiares", "nefrológicos", ",", "no", "tiene", "problemas", "de", "obesidad", ",", "ni", "de", "diabetes", "(", "las", "glucemias", "son", "normales", ")", ",", "no", "toma", "ningún", "tipo", "de", "medicación", "de", "forma", "habitual", "y", "la", "presión", "arterial", "es", "de", "105/65", "mm", "/", "Hg", ".", "En", "la", "analítica", "destaca", "una", "proteinuria", "de", "2", "g/24", "h", ",", "microhematuria", "de", "150", "hematíes", "/", "campo", ",", "cadmio", "en", "sangre", "de", "20", "μg", "/", "l", "(", "Valor", "Límite", "Biológico", "[", "VLB", "]", ":", "5μg", "/", "l", ")", "y", "cadmio", "en", "la", "orina", "de", "85", "μg", "/", "g", "de", "creatinina", "(", "VLB", ":", "5", "μg", "/", "g", "creatinina", ")", ".", "Debido", "a", "que", "las", "afectaciones", "renales", "eran", "de", "tipo", "glomerular", ",", "y", "el", "cadmio", "ocasiona", "principalmente", "lesiones", "de", "tipo", "tubular", ",", "se", "le", "recomendó", "un", "estudio", "mediante", "una", "biopsia", "renal", ".", "En", "la", "microscopía", "óptica", "se", "observaron", "cinco", "glomérulos", ",", "uno", "de", "ellos", "totalmente", "esclerosado", ";", "el", "resto", "mostró", "una", "ligera", "hipercelularidad", "segmentaria", ";", "en", "dos", "glomérulos", "se", "detecta", "una", "proliferación", "segmentaria", "extracapilar", "y", "focos", "de", "fibrosis", "intersticial", "con", "atrofia", "tubular", ".", "La", "inmunofluorescencia", "fue", "positiva", "para", "C3", "(", "+", "+", "+", ")", "y", "IgA", "(", "+", "+", ")", "con", "patrón", "mesangial", ".", "El", "diagnóstico", "fue", "de", "una", "glomerulonefritis", "focal", "Ig", "A", "mesangial", "y", "se", "inició", "tratamiento", "con", "enalapril", "10", "mg", "/", "día", ".", "Debido", "a", "las", "altas", "concentraciones", "de", "cadmio", "en", "líquidos", "biológicos", "(", "sangre", "y", "orina", ")", ",", "que", "después", "de", "ocho", "años", "de", "hacer", "cesado", "la", "exposición", "se", "encuentran", "por", "encima", "de", "los", "valores", "límites", "máximos", "permitidos", "en", "España", "en", "trabajadores", "expuestos", "al", "cadmio", ",", "el", "paciente", "fue", "apartado", "de", "su", "trabajo", ";", "además", ",", "se", "le", "consideró", "un", "trabajador", "especialmente", "sensible", "a", "la", "exposición", "a", "nefrotóxicos", "donde", "aconsejamos", "que", "se", "evitase", "su", "exposición", "con", "la", "finalidad", "de", "minimizar", "al", "máximo", "la", "posibilidad", "de", "que", "el", "paciente", "evolucione", "hacía", "una", "enfermedad", "renal", "crónica", ".", "Se", "le", "realizó", "un", "seguimiento", "durante", "8", "años", "(", "los", "valores", "de", "creatinina", "sérica", ",", "filtrado", "glomerular", ",", "proteinuria", "y", "sedimento", "urinario", "vienen", "expresados", "en", "la", "tabla", "1", ")", "y", "los", "repetidos", "controles", "de", "beta2-globulina", "y", "de", "N", "-", "acetilglucosaminidasa", "(", "NAG", ")", "se", "encontraron", "dentro", "de", "la", "normalidad", ".", "En", "el", "momento", "actual", "las", "concentraciones", "de", "cadmio", "en", "sangre", "son", "de", "7", "μg", "/", "l", "(", "VLB", ":", "5", "μg", "/", "l", ")", "y", "el", "cadmio", "en", "orina", "es", "de", "18", "μg", "/", "g", "(", "VLB", ":", "5", "μg", "/", "g", ")", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR", "NO_NORMALIZABLES" ]
cigarrillos is a UNCLEAR, acero is a NORMALIZABLES, cobalto is a NORMALIZABLES, carburo de tungsteno is a NORMALIZABLES, mármol is a NO_NORMALIZABLES, granito is a NO_NORMALIZABLES, plata is a NORMALIZABLES, cadmio is a NORMALIZABLES, cobre is a NORMALIZABLES, zinc is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, colesterol is a NORMALIZABLES, transaminasas is a PROTEINAS, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, C3 is a PROTEINAS, IgA is a PROTEINAS, Ig A is a PROTEINAS, enalapril is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, beta2-globulina is a PROTEINAS, N - acetilglucosaminidasa is a PROTEINAS, NAG is a PROTEINAS, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES	411_task1	Sentence: Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g). Instructions: please typing these entity words according to sentence: cigarrillos, acero, cobalto, carburo de tungsteno, mármol, granito, plata, cadmio, cobre, zinc, cadmio, cadmio, colesterol, transaminasas, creatinina, cadmio, cadmio, cadmio, creatinina, cadmio, C3, IgA, Ig A, enalapril, cadmio, cadmio, creatinina, beta2-globulina, N - acetilglucosaminidasa, NAG, cadmio, cadmio Options: UNCLEAR, NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-PROTEINAS", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g).	[ "Varón", "de", "47", "años", ",", "que", "cesó", "el", "hábito", "tabáquico", "hace", "diez", "años", ",", "fumó", "entre", "10", "-", "20", "cigarrillos", "/", "día", "durante", "15", "años", "y", "fue", "diagnosticado", "hace", "8", "años", "de", "glomerulonefritis", "mesangial", "IgA.", "Había", "estado", "trabajando", "durante", "12", "años", "como", "soldador", "en", "una", "empresa", "de", "fabricación", "de", "discos", "de", "acero", "que", "llevaban", "insertados", "unos", "«", "dientes", "»", "de", "cobalto", "y", "carburo", "de", "tungsteno", "que", "se", "utilizan", "para", "cortar", "mármol", "y", "granito", ".", "El", "soldador", "utilizaba", "un", "sistema", "de", "soldadura", "autógena", "de", "la", "que", "utilizaban", ",", "como", "metal", "de", "aporte", ",", "unas", "varillas", "metálicas", "a", "base", "de", ":", "plata", "(", "39", "%", ")", ",", "cadmio", "(", "25", "%", ")", ",", "cobre", "(", "22", "%", ")", "y", "zinc", "(", "14", "%", ")", ".", "Consumía", "1", "Kg", "/", "semana", ";", "no", "utilizaba", "equipos", "de", "protección", "respiratoria", "y", "su", "lugar", "de", "trabajo", "no", "tenía", "un", "sistema", "de", "extracción", "localizada", "de", "humos", ".", "Las", "concentraciones", "de", "cadmio", "en", "su", "puesto", "de", "trabajo", "fueron", "de", "52", "μg", "/", "m3", "(", "Valor", "Límite", "Ambiental", "(", "VLA", ")", "es", "de", "10", "μg", "/", "m3", ")", ".", "Durante", "los", "doce", "años", "que", "estuvo", "trabajando", "se", "le", "había", "realizado", "un", "reconocimiento", "inicial", "y", "dos", "reconocimientos", "periódicos", "inespecíficos", "sin", "controlar", "la", "exposición", "al", "cadmio", "y", "a", "otros", "contaminantes", "químicos", ";", "los", "resultados", "del", "laboratorio", "se", "encontraban", "dentro", "de", "la", "normalidad", "(", "hemograma", "completo", ",", "glucemia", ",", "colesterol", ",", "transaminasas", "hepáticas", ",", "creatinina", "sérica", "y", "el", "estudio", "cito", "-", "químico", "de", "orina", ")", ".", "En", "una", "analítica", "general", "realizada", "por", "su", "médico", "de", "familia", "se", "le", "detecta", "una", "microhematuria", "y", "una", "proteinuria", ".", "Cuando", "su", "médico", "le", "realiza", "la", "historia", "clínica", "detecta", "la", "exposición", "a", "humos", "de", "cadmio", "por", "lo", "que", "es", "remitido", "a", "la", "Unidad", "de", "Toxicología", "de", "nuestro", "hospital", ".", "Al", "ingreso", "el", "paciente", "está", "asintomático", ",", "no", "tiene", "antecedentes", "personales", "ni", "familiares", "nefrológicos", ",", "no", "tiene", "problemas", "de", "obesidad", ",", "ni", "de", "diabetes", "(", "las", "glucemias", "son", "normales", ")", ",", "no", "toma", "ningún", "tipo", "de", "medicación", "de", "forma", "habitual", "y", "la", "presión", "arterial", "es", "de", "105/65", "mm", "/", "Hg", ".", "En", "la", "analítica", "destaca", "una", "proteinuria", "de", "2", "g/24", "h", ",", "microhematuria", "de", "150", "hematíes", "/", "campo", ",", "cadmio", "en", "sangre", "de", "20", "μg", "/", "l", "(", "Valor", "Límite", "Biológico", "[", "VLB", "]", ":", "5μg", "/", "l", ")", "y", "cadmio", "en", "la", "orina", "de", "85", "μg", "/", "g", "de", "creatinina", "(", "VLB", ":", "5", "μg", "/", "g", "creatinina", ")", ".", "Debido", "a", "que", "las", "afectaciones", "renales", "eran", "de", "tipo", "glomerular", ",", "y", "el", "cadmio", "ocasiona", "principalmente", "lesiones", "de", "tipo", "tubular", ",", "se", "le", "recomendó", "un", "estudio", "mediante", "una", "biopsia", "renal", ".", "En", "la", "microscopía", "óptica", "se", "observaron", "cinco", "glomérulos", ",", "uno", "de", "ellos", "totalmente", "esclerosado", ";", "el", "resto", "mostró", "una", "ligera", "hipercelularidad", "segmentaria", ";", "en", "dos", "glomérulos", "se", "detecta", "una", "proliferación", "segmentaria", "extracapilar", "y", "focos", "de", "fibrosis", "intersticial", "con", "atrofia", "tubular", ".", "La", "inmunofluorescencia", "fue", "positiva", "para", "C3", "(", "+", "+", "+", ")", "y", "IgA", "(", "+", "+", ")", "con", "patrón", "mesangial", ".", "El", "diagnóstico", "fue", "de", "una", "glomerulonefritis", "focal", "Ig", "A", "mesangial", "y", "se", "inició", "tratamiento", "con", "enalapril", "10", "mg", "/", "día", ".", "Debido", "a", "las", "altas", "concentraciones", "de", "cadmio", "en", "líquidos", "biológicos", "(", "sangre", "y", "orina", ")", ",", "que", "después", "de", "ocho", "años", "de", "hacer", "cesado", "la", "exposición", "se", "encuentran", "por", "encima", "de", "los", "valores", "límites", "máximos", "permitidos", "en", "España", "en", "trabajadores", "expuestos", "al", "cadmio", ",", "el", "paciente", "fue", "apartado", "de", "su", "trabajo", ";", "además", ",", "se", "le", "consideró", "un", "trabajador", "especialmente", "sensible", "a", "la", "exposición", "a", "nefrotóxicos", "donde", "aconsejamos", "que", "se", "evitase", "su", "exposición", "con", "la", "finalidad", "de", "minimizar", "al", "máximo", "la", "posibilidad", "de", "que", "el", "paciente", "evolucione", "hacía", "una", "enfermedad", "renal", "crónica", ".", "Se", "le", "realizó", "un", "seguimiento", "durante", "8", "años", "(", "los", "valores", "de", "creatinina", "sérica", ",", "filtrado", "glomerular", ",", "proteinuria", "y", "sedimento", "urinario", "vienen", "expresados", "en", "la", "tabla", "1", ")", "y", "los", "repetidos", "controles", "de", "beta2-globulina", "y", "de", "N", "-", "acetilglucosaminidasa", "(", "NAG", ")", "se", "encontraron", "dentro", "de", "la", "normalidad", ".", "En", "el", "momento", "actual", "las", "concentraciones", "de", "cadmio", "en", "sangre", "son", "de", "7", "μg", "/", "l", "(", "VLB", ":", "5", "μg", "/", "l", ")", "y", "el", "cadmio", "en", "orina", "es", "de", "18", "μg", "/", "g", "(", "VLB", ":", "5", "μg", "/", "g", ")", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR", "NO_NORMALIZABLES" ]
cigarrillos, acero, cobalto, carburo de tungsteno, mármol, granito, plata, cadmio, cobre, zinc, cadmio, cadmio, colesterol, transaminasas, creatinina, cadmio, cadmio, cadmio, creatinina, cadmio, C3, IgA, Ig A, enalapril, cadmio, cadmio, creatinina, beta2-globulina, N - acetilglucosaminidasa, NAG, cadmio, cadmio	411_task2	Sentence: Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-PROTEINAS", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g).	[ "Varón", "de", "47", "años", ",", "que", "cesó", "el", "hábito", "tabáquico", "hace", "diez", "años", ",", "fumó", "entre", "10", "-", "20", "cigarrillos", "/", "día", "durante", "15", "años", "y", "fue", "diagnosticado", "hace", "8", "años", "de", "glomerulonefritis", "mesangial", "IgA.", "Había", "estado", "trabajando", "durante", "12", "años", "como", "soldador", "en", "una", "empresa", "de", "fabricación", "de", "discos", "de", "acero", "que", "llevaban", "insertados", "unos", "«", "dientes", "»", "de", "cobalto", "y", "carburo", "de", "tungsteno", "que", "se", "utilizan", "para", "cortar", "mármol", "y", "granito", ".", "El", "soldador", "utilizaba", "un", "sistema", "de", "soldadura", "autógena", "de", "la", "que", "utilizaban", ",", "como", "metal", "de", "aporte", ",", "unas", "varillas", "metálicas", "a", "base", "de", ":", "plata", "(", "39", "%", ")", ",", "cadmio", "(", "25", "%", ")", ",", "cobre", "(", "22", "%", ")", "y", "zinc", "(", "14", "%", ")", ".", "Consumía", "1", "Kg", "/", "semana", ";", "no", "utilizaba", "equipos", "de", "protección", "respiratoria", "y", "su", "lugar", "de", "trabajo", "no", "tenía", "un", "sistema", "de", "extracción", "localizada", "de", "humos", ".", "Las", "concentraciones", "de", "cadmio", "en", "su", "puesto", "de", "trabajo", "fueron", "de", "52", "μg", "/", "m3", "(", "Valor", "Límite", "Ambiental", "(", "VLA", ")", "es", "de", "10", "μg", "/", "m3", ")", ".", "Durante", "los", "doce", "años", "que", "estuvo", "trabajando", "se", "le", "había", "realizado", "un", "reconocimiento", "inicial", "y", "dos", "reconocimientos", "periódicos", "inespecíficos", "sin", "controlar", "la", "exposición", "al", "cadmio", "y", "a", "otros", "contaminantes", "químicos", ";", "los", "resultados", "del", "laboratorio", "se", "encontraban", "dentro", "de", "la", "normalidad", "(", "hemograma", "completo", ",", "glucemia", ",", "colesterol", ",", "transaminasas", "hepáticas", ",", "creatinina", "sérica", "y", "el", "estudio", "cito", "-", "químico", "de", "orina", ")", ".", "En", "una", "analítica", "general", "realizada", "por", "su", "médico", "de", "familia", "se", "le", "detecta", "una", "microhematuria", "y", "una", "proteinuria", ".", "Cuando", "su", "médico", "le", "realiza", "la", "historia", "clínica", "detecta", "la", "exposición", "a", "humos", "de", "cadmio", "por", "lo", "que", "es", "remitido", "a", "la", "Unidad", "de", "Toxicología", "de", "nuestro", "hospital", ".", "Al", "ingreso", "el", "paciente", "está", "asintomático", ",", "no", "tiene", "antecedentes", "personales", "ni", "familiares", "nefrológicos", ",", "no", "tiene", "problemas", "de", "obesidad", ",", "ni", "de", "diabetes", "(", "las", "glucemias", "son", "normales", ")", ",", "no", "toma", "ningún", "tipo", "de", "medicación", "de", "forma", "habitual", "y", "la", "presión", "arterial", "es", "de", "105/65", "mm", "/", "Hg", ".", "En", "la", "analítica", "destaca", "una", "proteinuria", "de", "2", "g/24", "h", ",", "microhematuria", "de", "150", "hematíes", "/", "campo", ",", "cadmio", "en", "sangre", "de", "20", "μg", "/", "l", "(", "Valor", "Límite", "Biológico", "[", "VLB", "]", ":", "5μg", "/", "l", ")", "y", "cadmio", "en", "la", "orina", "de", "85", "μg", "/", "g", "de", "creatinina", "(", "VLB", ":", "5", "μg", "/", "g", "creatinina", ")", ".", "Debido", "a", "que", "las", "afectaciones", "renales", "eran", "de", "tipo", "glomerular", ",", "y", "el", "cadmio", "ocasiona", "principalmente", "lesiones", "de", "tipo", "tubular", ",", "se", "le", "recomendó", "un", "estudio", "mediante", "una", "biopsia", "renal", ".", "En", "la", "microscopía", "óptica", "se", "observaron", "cinco", "glomérulos", ",", "uno", "de", "ellos", "totalmente", "esclerosado", ";", "el", "resto", "mostró", "una", "ligera", "hipercelularidad", "segmentaria", ";", "en", "dos", "glomérulos", "se", "detecta", "una", "proliferación", "segmentaria", "extracapilar", "y", "focos", "de", "fibrosis", "intersticial", "con", "atrofia", "tubular", ".", "La", "inmunofluorescencia", "fue", "positiva", "para", "C3", "(", "+", "+", "+", ")", "y", "IgA", "(", "+", "+", ")", "con", "patrón", "mesangial", ".", "El", "diagnóstico", "fue", "de", "una", "glomerulonefritis", "focal", "Ig", "A", "mesangial", "y", "se", "inició", "tratamiento", "con", "enalapril", "10", "mg", "/", "día", ".", "Debido", "a", "las", "altas", "concentraciones", "de", "cadmio", "en", "líquidos", "biológicos", "(", "sangre", "y", "orina", ")", ",", "que", "después", "de", "ocho", "años", "de", "hacer", "cesado", "la", "exposición", "se", "encuentran", "por", "encima", "de", "los", "valores", "límites", "máximos", "permitidos", "en", "España", "en", "trabajadores", "expuestos", "al", "cadmio", ",", "el", "paciente", "fue", "apartado", "de", "su", "trabajo", ";", "además", ",", "se", "le", "consideró", "un", "trabajador", "especialmente", "sensible", "a", "la", "exposición", "a", "nefrotóxicos", "donde", "aconsejamos", "que", "se", "evitase", "su", "exposición", "con", "la", "finalidad", "de", "minimizar", "al", "máximo", "la", "posibilidad", "de", "que", "el", "paciente", "evolucione", "hacía", "una", "enfermedad", "renal", "crónica", ".", "Se", "le", "realizó", "un", "seguimiento", "durante", "8", "años", "(", "los", "valores", "de", "creatinina", "sérica", ",", "filtrado", "glomerular", ",", "proteinuria", "y", "sedimento", "urinario", "vienen", "expresados", "en", "la", "tabla", "1", ")", "y", "los", "repetidos", "controles", "de", "beta2-globulina", "y", "de", "N", "-", "acetilglucosaminidasa", "(", "NAG", ")", "se", "encontraron", "dentro", "de", "la", "normalidad", ".", "En", "el", "momento", "actual", "las", "concentraciones", "de", "cadmio", "en", "sangre", "son", "de", "7", "μg", "/", "l", "(", "VLB", ":", "5", "μg", "/", "l", ")", "y", "el", "cadmio", "en", "orina", "es", "de", "18", "μg", "/", "g", "(", "VLB", ":", "5", "μg", "/", "g", ")", ".", "\n\n" ]	[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR", "NO_NORMALIZABLES" ]
therapy is an umlsterm, personality is an umlsterm, therapy is an umlsterm, questionnaire is an umlsterm	Psychotherapeut.00450286.eng.abstr_task0	Sentence: 46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire .	[ "46", "therapy", "non", "-", "completers", "were", "compared", "with", "599", "completers", "regarding", "their", "conspicuous", "personality", "characteristics", ".", "In", "addition", ",", "they", "were", "asked", "to", "give", "their", "personal", "reasons", "for", "breaking", "off", "the", "therapy", "in", "a", "questionnaire", "." ]	[ "umlsterm" ]
therapy is an umlsterm, personality is an umlsterm, therapy is an umlsterm, questionnaire is an umlsterm	Psychotherapeut.00450286.eng.abstr_task1	Sentence: 46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire . Instructions: please typing these entity words according to sentence: therapy, personality, therapy, questionnaire Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire .	[ "46", "therapy", "non", "-", "completers", "were", "compared", "with", "599", "completers", "regarding", "their", "conspicuous", "personality", "characteristics", ".", "In", "addition", ",", "they", "were", "asked", "to", "give", "their", "personal", "reasons", "for", "breaking", "off", "the", "therapy", "in", "a", "questionnaire", "." ]	[ "umlsterm" ]
therapy, personality, therapy, questionnaire	Psychotherapeut.00450286.eng.abstr_task2	Sentence: 46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire .	[ "46", "therapy", "non", "-", "completers", "were", "compared", "with", "599", "completers", "regarding", "their", "conspicuous", "personality", "characteristics", ".", "In", "addition", ",", "they", "were", "asked", "to", "give", "their", "personal", "reasons", "for", "breaking", "off", "the", "therapy", "in", "a", "questionnaire", "." ]	[ "umlsterm" ]
Arbeit is an umlsterm, Techniken is an umlsterm, Kataraktchirurgie is an umlsterm, Astigmatismus is an umlsterm, Visus is an umlsterm	DerOpthalmologe.80950427.ger.abstr_task0	Sentence: Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen .	[ "Hintergrund", ":", "Ziel", "dieser", "Arbeit", "war", "es", ",", "die", "sich", "veraendernden", "Techniken", "der", "Kataraktchirurgie", "der", "letzten", "16", "Jahre", "im", "Hinblick", "auf", "fruehpostoperativen", "Astigmatismus", "und", "Visus", "zu", "vergleichen", "." ]	[ "umlsterm" ]
Arbeit is an umlsterm, Techniken is an umlsterm, Kataraktchirurgie is an umlsterm, Astigmatismus is an umlsterm, Visus is an umlsterm	DerOpthalmologe.80950427.ger.abstr_task1	Sentence: Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen . Instructions: please typing these entity words according to sentence: Arbeit, Techniken, Kataraktchirurgie, Astigmatismus, Visus Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen .	[ "Hintergrund", ":", "Ziel", "dieser", "Arbeit", "war", "es", ",", "die", "sich", "veraendernden", "Techniken", "der", "Kataraktchirurgie", "der", "letzten", "16", "Jahre", "im", "Hinblick", "auf", "fruehpostoperativen", "Astigmatismus", "und", "Visus", "zu", "vergleichen", "." ]	[ "umlsterm" ]
Arbeit, Techniken, Kataraktchirurgie, Astigmatismus, Visus	DerOpthalmologe.80950427.ger.abstr_task2	Sentence: Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen .	[ "Hintergrund", ":", "Ziel", "dieser", "Arbeit", "war", "es", ",", "die", "sich", "veraendernden", "Techniken", "der", "Kataraktchirurgie", "der", "letzten", "16", "Jahre", "im", "Hinblick", "auf", "fruehpostoperativen", "Astigmatismus", "und", "Visus", "zu", "vergleichen", "." ]	[ "umlsterm" ]
knowledge is an umlsterm, eosinophil is an umlsterm, regulation is an umlsterm, eosinophilia is an umlsterm, blood is an umlsterm, role is an umlsterm, cytokines is an umlsterm, chemoattraction is an umlsterm, eosinophils is an umlsterm, cytokines is an umlsterm, release is an umlsterm, reactive oxygen species is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, inflammatory reaction is an umlsterm, tissue is an umlsterm, tissue is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, eosinophils is an umlsterm, eosinophil is an umlsterm, granulocytes is an umlsterm, eosinophil is an umlsterm, atopic dermatitis is an umlsterm, skin diseases is an umlsterm, review is an umlsterm, Evaluation is an umlsterm, role is an umlsterm, eosinophils is an umlsterm, therapeutic is an umlsterm	DerHautarzt.80490176.eng.abstr_task0	Sentence: Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance .	[ "Recent", "in", "vitro", "-", "studies", "have", "substantially", "increased", "our", "knowledge", "of", "eosinophil", "activation", ",", "the", "regulation", "of", "eosinophilia", "in", "the", "peripheral", "blood", "and", "the", "role", "of", "cytokines", "in", "that", "process", ".", "Accordingly", ",", "chemoattraction", "and", "activation", "of", "eosinophils", "by", "cytokines", "results", "in", "the", "local", "release", "of", "reactive", "oxygen", "species", "and", "toxic", "cationic", "granule", "proteins", "followed", "by", "local", "propagation", "of", "the", "inflammatory", "reaction", "and", "tissue", "damage", ".", "This", "extracellular", "tissue", "deposition", "of", "toxic", "granule", "proteins", "as", "an", "expression", "of", "complete", "activation", "of", "eosinophils", ",", "rather", "than", "only", "the", "presence", "of", "intact", "eosinophil", "granulocytes", ",", "is", "crucial", "for", "their", "functional", "effect", "in", "situ", ".", "Semiquantitative", "studies", "of", "local", "eosinophil", "granula", "deposition", "so", "far", "have", "been", "done", "only", "in", "atopic", "dermatitis", "and", "a", "limited", "number", "of", "other", "inflammatory", "skin", "diseases", "as", "summarized", "in", "this", "review", ".", "Evaluation", "of", "the", "pathogenetic", "role", "of", "eosinophils", "may", "be", "of", "potential", "therapeutic", "importance", "." ]	[ "umlsterm" ]
knowledge is an umlsterm, eosinophil is an umlsterm, regulation is an umlsterm, eosinophilia is an umlsterm, blood is an umlsterm, role is an umlsterm, cytokines is an umlsterm, chemoattraction is an umlsterm, eosinophils is an umlsterm, cytokines is an umlsterm, release is an umlsterm, reactive oxygen species is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, inflammatory reaction is an umlsterm, tissue is an umlsterm, tissue is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, eosinophils is an umlsterm, eosinophil is an umlsterm, granulocytes is an umlsterm, eosinophil is an umlsterm, atopic dermatitis is an umlsterm, skin diseases is an umlsterm, review is an umlsterm, Evaluation is an umlsterm, role is an umlsterm, eosinophils is an umlsterm, therapeutic is an umlsterm	DerHautarzt.80490176.eng.abstr_task1	Sentence: Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance . Instructions: please typing these entity words according to sentence: knowledge, eosinophil, regulation, eosinophilia, blood, role, cytokines, chemoattraction, eosinophils, cytokines, release, reactive oxygen species, toxic, granule, proteins, inflammatory reaction, tissue, tissue, toxic, granule, proteins, eosinophils, eosinophil, granulocytes, eosinophil, atopic dermatitis, skin diseases, review, Evaluation, role, eosinophils, therapeutic Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance .	[ "Recent", "in", "vitro", "-", "studies", "have", "substantially", "increased", "our", "knowledge", "of", "eosinophil", "activation", ",", "the", "regulation", "of", "eosinophilia", "in", "the", "peripheral", "blood", "and", "the", "role", "of", "cytokines", "in", "that", "process", ".", "Accordingly", ",", "chemoattraction", "and", "activation", "of", "eosinophils", "by", "cytokines", "results", "in", "the", "local", "release", "of", "reactive", "oxygen", "species", "and", "toxic", "cationic", "granule", "proteins", "followed", "by", "local", "propagation", "of", "the", "inflammatory", "reaction", "and", "tissue", "damage", ".", "This", "extracellular", "tissue", "deposition", "of", "toxic", "granule", "proteins", "as", "an", "expression", "of", "complete", "activation", "of", "eosinophils", ",", "rather", "than", "only", "the", "presence", "of", "intact", "eosinophil", "granulocytes", ",", "is", "crucial", "for", "their", "functional", "effect", "in", "situ", ".", "Semiquantitative", "studies", "of", "local", "eosinophil", "granula", "deposition", "so", "far", "have", "been", "done", "only", "in", "atopic", "dermatitis", "and", "a", "limited", "number", "of", "other", "inflammatory", "skin", "diseases", "as", "summarized", "in", "this", "review", ".", "Evaluation", "of", "the", "pathogenetic", "role", "of", "eosinophils", "may", "be", "of", "potential", "therapeutic", "importance", "." ]	[ "umlsterm" ]
knowledge, eosinophil, regulation, eosinophilia, blood, role, cytokines, chemoattraction, eosinophils, cytokines, release, reactive oxygen species, toxic, granule, proteins, inflammatory reaction, tissue, tissue, toxic, granule, proteins, eosinophils, eosinophil, granulocytes, eosinophil, atopic dermatitis, skin diseases, review, Evaluation, role, eosinophils, therapeutic	DerHautarzt.80490176.eng.abstr_task2	Sentence: Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance .	[ "Recent", "in", "vitro", "-", "studies", "have", "substantially", "increased", "our", "knowledge", "of", "eosinophil", "activation", ",", "the", "regulation", "of", "eosinophilia", "in", "the", "peripheral", "blood", "and", "the", "role", "of", "cytokines", "in", "that", "process", ".", "Accordingly", ",", "chemoattraction", "and", "activation", "of", "eosinophils", "by", "cytokines", "results", "in", "the", "local", "release", "of", "reactive", "oxygen", "species", "and", "toxic", "cationic", "granule", "proteins", "followed", "by", "local", "propagation", "of", "the", "inflammatory", "reaction", "and", "tissue", "damage", ".", "This", "extracellular", "tissue", "deposition", "of", "toxic", "granule", "proteins", "as", "an", "expression", "of", "complete", "activation", "of", "eosinophils", ",", "rather", "than", "only", "the", "presence", "of", "intact", "eosinophil", "granulocytes", ",", "is", "crucial", "for", "their", "functional", "effect", "in", "situ", ".", "Semiquantitative", "studies", "of", "local", "eosinophil", "granula", "deposition", "so", "far", "have", "been", "done", "only", "in", "atopic", "dermatitis", "and", "a", "limited", "number", "of", "other", "inflammatory", "skin", "diseases", "as", "summarized", "in", "this", "review", ".", "Evaluation", "of", "the", "pathogenetic", "role", "of", "eosinophils", "may", "be", "of", "potential", "therapeutic", "importance", "." ]	[ "umlsterm" ]
Foxp3 is a Protein, Foxp3 is a Protein, FKH domain is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, which is a Anaphora, nucleus is a Entity, deltaFKH mutant is a Protein, nucleus is a Entity, deltaFKH mutant is a Protein, nuclear is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, nucleus is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, p65 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, p65 is a Protein, Foxp3 is a Protein, nuclear is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein	4_task0	Sentence: The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Anaphora, Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Anaphora", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.	[ "The", "Carboxyl", "-", "Terminal", "FKH", "Domain", "Is", "Not", "Required", "for", "Suppression", "of", "NF", "-", "kappaB", "Activation", "in", "T", "Cells", "\n", "To", "define", "the", "requirements", "of", "Foxp3", "with", "respect", "to", "inhibition", "of", "NF", "-", "kappaB", "-", "dependent", "transcription", ",", "we", "utilized", "a", "mutant", "of", "Foxp3", "lacking", "the", "FKH", "domain", "(", "Figure", "2A", ")", "[", "16", "]", ",", "similar", "to", "the", "scurfy", "mutant", "Foxp3", "of", "mice", ",", "and", "a", "mutant", "Foxp3", "protein", "from", "a", "patient", "with", "IPEX", "[", "4,11,14,17", "]", ".", "Unlike", "full", "-", "length", "Foxp3", ",", "which", "localizes", "almost", "exclusively", "to", "the", "nucleus", "and", "can", "bind", "in", "a", "sequence", "-", "specific", "manner", "to", "forkhead", "binding", "sites", ",", "the", "deltaFKH", "mutant", "fails", "to", "localize", "to", "the", "nucleus", "and", "thus", "cannot", "interact", "with", "promoter", "elements", "or", "nuclear", "proteins", "[", "16", "]", ".", "Therefore", ",", "we", "utilized", "the", "deltaFKH", "mutant", "to", "determine", "whether", "nuclear", "localization", "(", "or", "other", "function", "associated", "with", "the", "FKH", "domain", ")", "of", "Foxp3", "was", "a", "prerequisite", "for", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "Although", "Foxp3", "interaction", "with", "NF", "-", "kappaB", "presumably", "takes", "place", "in", "the", "nucleus", ",", "it", "may", "also", "be", "possible", "for", "a", "cytoplasmic", "Foxp3", "protein", "to", "bind", "to", "NF", "-", "kappaB", "in", "the", "cytoplasm", "and", "prevent", "localization", "to", "the", "nucleus", "following", "an", "activation", "stimulus", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "of", "deltaFKH", ",", "was", "able", "to", "suppress", "activation", "of", "a", "cotransfected", "NF", "-", "kappaB", "reporter", "vector", "in", "HEK", "293", "T", "cells", "(", "Figure", "2B", ")", ".", "Both", "Foxp3", "and", "deltaFKH", "were", "expressed", "at", "very", "high", "levels", "following", "transfection", "as", "detected", "by", "real", "-", "time", "RT", "-", "PCR", "(", "unpublished", "data", ")", ".", "These", "data", "appear", "to", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", "is", "critically", "important", "for", "Foxp3", "to", "down", "-", "regulate", "NF", "-", "kappaB", "-", "dependent", "transcription", ".", "However", ",", "NF", "-", "kappaB", "activation", "was", "blocked", "to", "a", "similar", "extent", "by", "both", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "2C", ")", "and", "primary", "human", "CD4", "+", "T", "cells", "(", "Figure", "2D", ")", ".", "Western", "blot", "analysis", "of", "NF", "-", "kappaB", "p65", "expression", "demonstrated", "that", "Foxp3", "and", "deltaFKH", "does", "not", "block", "NF", "-", "kappaB", "activation", "at", "the", "level", "of", "p65", "protein", "expression", "(", "Figure", "2E", ")", ".", "These", "results", "are", "very", "interesting", "with", "respect", "to", "Foxp3", "function", ",", "because", "they", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", ",", "and", "possibly", "nuclear", "localization", ",", "are", "dispensable", "for", "Foxp3", "function", "in", "T", "cell", "populations", ".", "Alternative", "interpretations", "may", "include", "the", "possibility", "that", "the", "localization", "of", "deltaFKH", "differ", "between", "epithelial", "cells", "and", "T", "cells", ".", "In", "either", "case", ",", "these", "results", "suggest", "a", "cell", "type", "-", "specific", "mechanism", "of", "action", "for", "this", "Foxp3", "mutant", "." ]	[ "Protein", "Entity", "Anaphora" ]
Foxp3 is a Protein, Foxp3 is a Protein, FKH domain is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, which is a Anaphora, nucleus is a Entity, deltaFKH mutant is a Protein, nucleus is a Entity, deltaFKH mutant is a Protein, nuclear is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, nucleus is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, p65 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, p65 is a Protein, Foxp3 is a Protein, nuclear is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein	4_task1	Sentence: The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant. Instructions: please typing these entity words according to sentence: Foxp3, Foxp3, FKH domain, Foxp3, Foxp3, Foxp3, which, nucleus, deltaFKH mutant, nucleus, deltaFKH mutant, nuclear, Foxp3, Foxp3, Foxp3, nucleus, Foxp3, deltaFKH, Foxp3, deltaFKH, Foxp3, Foxp3, deltaFKH, CD4, p65, Foxp3, deltaFKH, p65, Foxp3, nuclear, Foxp3, deltaFKH, Foxp3 Options: Anaphora, Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Anaphora", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.	[ "The", "Carboxyl", "-", "Terminal", "FKH", "Domain", "Is", "Not", "Required", "for", "Suppression", "of", "NF", "-", "kappaB", "Activation", "in", "T", "Cells", "\n", "To", "define", "the", "requirements", "of", "Foxp3", "with", "respect", "to", "inhibition", "of", "NF", "-", "kappaB", "-", "dependent", "transcription", ",", "we", "utilized", "a", "mutant", "of", "Foxp3", "lacking", "the", "FKH", "domain", "(", "Figure", "2A", ")", "[", "16", "]", ",", "similar", "to", "the", "scurfy", "mutant", "Foxp3", "of", "mice", ",", "and", "a", "mutant", "Foxp3", "protein", "from", "a", "patient", "with", "IPEX", "[", "4,11,14,17", "]", ".", "Unlike", "full", "-", "length", "Foxp3", ",", "which", "localizes", "almost", "exclusively", "to", "the", "nucleus", "and", "can", "bind", "in", "a", "sequence", "-", "specific", "manner", "to", "forkhead", "binding", "sites", ",", "the", "deltaFKH", "mutant", "fails", "to", "localize", "to", "the", "nucleus", "and", "thus", "cannot", "interact", "with", "promoter", "elements", "or", "nuclear", "proteins", "[", "16", "]", ".", "Therefore", ",", "we", "utilized", "the", "deltaFKH", "mutant", "to", "determine", "whether", "nuclear", "localization", "(", "or", "other", "function", "associated", "with", "the", "FKH", "domain", ")", "of", "Foxp3", "was", "a", "prerequisite", "for", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "Although", "Foxp3", "interaction", "with", "NF", "-", "kappaB", "presumably", "takes", "place", "in", "the", "nucleus", ",", "it", "may", "also", "be", "possible", "for", "a", "cytoplasmic", "Foxp3", "protein", "to", "bind", "to", "NF", "-", "kappaB", "in", "the", "cytoplasm", "and", "prevent", "localization", "to", "the", "nucleus", "following", "an", "activation", "stimulus", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "of", "deltaFKH", ",", "was", "able", "to", "suppress", "activation", "of", "a", "cotransfected", "NF", "-", "kappaB", "reporter", "vector", "in", "HEK", "293", "T", "cells", "(", "Figure", "2B", ")", ".", "Both", "Foxp3", "and", "deltaFKH", "were", "expressed", "at", "very", "high", "levels", "following", "transfection", "as", "detected", "by", "real", "-", "time", "RT", "-", "PCR", "(", "unpublished", "data", ")", ".", "These", "data", "appear", "to", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", "is", "critically", "important", "for", "Foxp3", "to", "down", "-", "regulate", "NF", "-", "kappaB", "-", "dependent", "transcription", ".", "However", ",", "NF", "-", "kappaB", "activation", "was", "blocked", "to", "a", "similar", "extent", "by", "both", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "2C", ")", "and", "primary", "human", "CD4", "+", "T", "cells", "(", "Figure", "2D", ")", ".", "Western", "blot", "analysis", "of", "NF", "-", "kappaB", "p65", "expression", "demonstrated", "that", "Foxp3", "and", "deltaFKH", "does", "not", "block", "NF", "-", "kappaB", "activation", "at", "the", "level", "of", "p65", "protein", "expression", "(", "Figure", "2E", ")", ".", "These", "results", "are", "very", "interesting", "with", "respect", "to", "Foxp3", "function", ",", "because", "they", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", ",", "and", "possibly", "nuclear", "localization", ",", "are", "dispensable", "for", "Foxp3", "function", "in", "T", "cell", "populations", ".", "Alternative", "interpretations", "may", "include", "the", "possibility", "that", "the", "localization", "of", "deltaFKH", "differ", "between", "epithelial", "cells", "and", "T", "cells", ".", "In", "either", "case", ",", "these", "results", "suggest", "a", "cell", "type", "-", "specific", "mechanism", "of", "action", "for", "this", "Foxp3", "mutant", "." ]	[ "Protein", "Entity", "Anaphora" ]
Foxp3, Foxp3, FKH domain, Foxp3, Foxp3, Foxp3, which, nucleus, deltaFKH mutant, nucleus, deltaFKH mutant, nuclear, Foxp3, Foxp3, Foxp3, nucleus, Foxp3, deltaFKH, Foxp3, deltaFKH, Foxp3, Foxp3, deltaFKH, CD4, p65, Foxp3, deltaFKH, p65, Foxp3, nuclear, Foxp3, deltaFKH, Foxp3	4_task2	Sentence: The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Anaphora", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]	The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.	[ "The", "Carboxyl", "-", "Terminal", "FKH", "Domain", "Is", "Not", "Required", "for", "Suppression", "of", "NF", "-", "kappaB", "Activation", "in", "T", "Cells", "\n", "To", "define", "the", "requirements", "of", "Foxp3", "with", "respect", "to", "inhibition", "of", "NF", "-", "kappaB", "-", "dependent", "transcription", ",", "we", "utilized", "a", "mutant", "of", "Foxp3", "lacking", "the", "FKH", "domain", "(", "Figure", "2A", ")", "[", "16", "]", ",", "similar", "to", "the", "scurfy", "mutant", "Foxp3", "of", "mice", ",", "and", "a", "mutant", "Foxp3", "protein", "from", "a", "patient", "with", "IPEX", "[", "4,11,14,17", "]", ".", "Unlike", "full", "-", "length", "Foxp3", ",", "which", "localizes", "almost", "exclusively", "to", "the", "nucleus", "and", "can", "bind", "in", "a", "sequence", "-", "specific", "manner", "to", "forkhead", "binding", "sites", ",", "the", "deltaFKH", "mutant", "fails", "to", "localize", "to", "the", "nucleus", "and", "thus", "cannot", "interact", "with", "promoter", "elements", "or", "nuclear", "proteins", "[", "16", "]", ".", "Therefore", ",", "we", "utilized", "the", "deltaFKH", "mutant", "to", "determine", "whether", "nuclear", "localization", "(", "or", "other", "function", "associated", "with", "the", "FKH", "domain", ")", "of", "Foxp3", "was", "a", "prerequisite", "for", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "Although", "Foxp3", "interaction", "with", "NF", "-", "kappaB", "presumably", "takes", "place", "in", "the", "nucleus", ",", "it", "may", "also", "be", "possible", "for", "a", "cytoplasmic", "Foxp3", "protein", "to", "bind", "to", "NF", "-", "kappaB", "in", "the", "cytoplasm", "and", "prevent", "localization", "to", "the", "nucleus", "following", "an", "activation", "stimulus", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "of", "deltaFKH", ",", "was", "able", "to", "suppress", "activation", "of", "a", "cotransfected", "NF", "-", "kappaB", "reporter", "vector", "in", "HEK", "293", "T", "cells", "(", "Figure", "2B", ")", ".", "Both", "Foxp3", "and", "deltaFKH", "were", "expressed", "at", "very", "high", "levels", "following", "transfection", "as", "detected", "by", "real", "-", "time", "RT", "-", "PCR", "(", "unpublished", "data", ")", ".", "These", "data", "appear", "to", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", "is", "critically", "important", "for", "Foxp3", "to", "down", "-", "regulate", "NF", "-", "kappaB", "-", "dependent", "transcription", ".", "However", ",", "NF", "-", "kappaB", "activation", "was", "blocked", "to", "a", "similar", "extent", "by", "both", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "2C", ")", "and", "primary", "human", "CD4", "+", "T", "cells", "(", "Figure", "2D", ")", ".", "Western", "blot", "analysis", "of", "NF", "-", "kappaB", "p65", "expression", "demonstrated", "that", "Foxp3", "and", "deltaFKH", "does", "not", "block", "NF", "-", "kappaB", "activation", "at", "the", "level", "of", "p65", "protein", "expression", "(", "Figure", "2E", ")", ".", "These", "results", "are", "very", "interesting", "with", "respect", "to", "Foxp3", "function", ",", "because", "they", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", ",", "and", "possibly", "nuclear", "localization", ",", "are", "dispensable", "for", "Foxp3", "function", "in", "T", "cell", "populations", ".", "Alternative", "interpretations", "may", "include", "the", "possibility", "that", "the", "localization", "of", "deltaFKH", "differ", "between", "epithelial", "cells", "and", "T", "cells", ".", "In", "either", "case", ",", "these", "results", "suggest", "a", "cell", "type", "-", "specific", "mechanism", "of", "action", "for", "this", "Foxp3", "mutant", "." ]	[ "Protein", "Entity", "Anaphora" ]
vitamin K - dependent carboxylase is a Protein, vitamin K - dependent carboxylase is a Protein, N459 is a Entity, N550 is a Entity, N605 is a Entity, N627 is a Entity, N570 is a Entity, oligosaccharides is a Entity	222_task0	Sentence: Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.	[ "Identification", "of", "the", "N", "-", "linked", "glycosylation", "sites", "of", "vitamin", "K", "-", "dependent", "carboxylase", "and", "effect", "of", "glycosylation", "on", "carboxylase", "function", ".", "\n", "The", "vitamin", "K", "-", "dependent", "carboxylase", "is", "an", "integral", "membrane", "protein", "which", "is", "required", "for", "the", "post", "-", "translational", "modification", "of", "a", "variety", "of", "vitamin", "K", "-", "dependent", "proteins", ".", "Previous", "studies", "have", "suggested", "carboxylase", "is", "a", "glycoprotein", "with", "N", "-", "linked", "glycosylation", "sites", ".", "In", "this", "study", ",", "we", "identify", "the", "N", "-", "glycosylation", "sites", "of", "carboxylase", "by", "mass", "spectrometric", "peptide", "mapping", "analyses", "combined", "with", "site", "-", "directed", "mutagenesis", ".", "Our", "mass", "spectrometric", "results", "show", "that", "the", "N", "-", "linked", "glycosylation", "in", "carboxylase", "occurs", "at", "positions", "N459", ",", "N550", ",", "N605", ",", "and", "N627", ".", "Eliminating", "these", "glycosylation", "sites", "by", "changing", "asparagine", "to", "glutamine", "caused", "the", "mutant", "carboxylase", "to", "migrate", "faster", "on", "SDS", "-", "PAGE", "gels", ",", "adding", "further", "evidence", "that", "these", "sites", "are", "glycosylated", ".", "In", "addition", ",", "the", "mutation", "studies", "identified", "N525", ",", "a", "site", "that", "cannot", "be", "recovered", "by", "mass", "spectroscopy", "analysis", ",", "as", "a", "glycosylation", "site", ".", "Furthermore", ",", "the", "potential", "glycosylation", "site", "at", "N570", "is", "glycosylated", "only", "if", "all", "five", "natural", "glycosylation", "sites", "are", "simultaneously", "mutated", ".", "Removal", "of", "the", "oligosaccharides", "by", "glycosidase", "from", "wild", "-", "type", "carboxylase", "or", "by", "elimination", "of", "the", "functional", "glycosylation", "sites", "by", "site", "-", "directed", "mutagenesis", "did", "not", "affect", "either", "the", "carboxylation", "or", "epoxidation", "activity", "when", "the", "small", "FLEEL", "pentapeptide", "was", "used", "as", "a", "substrate", ",", "suggesting", "that", "N", "-", "linked", "glycosylation", "is", "not", "required", "for", "the", "enzymatic", "function", "of", "carboxylase", ".", "In", "contrast", ",", "when", "site", "N570", "and", "the", "five", "natural", "glycosylation", "sites", "were", "mutated", "simultaneously", ",", "the", "resulting", "carboxylase", "protein", "was", "degraded", ".", "Our", "results", "suggest", "that", "N", "-", "linked", "glycosylation", "is", "not", "essential", "for", "carboxylase", "enzymatic", "activity", "but", "is", "important", "for", "protein", "folding", "and", "stability", ".", "\n" ]	[ "Protein", "Entity" ]
vitamin K - dependent carboxylase is a Protein, vitamin K - dependent carboxylase is a Protein, N459 is a Entity, N550 is a Entity, N605 is a Entity, N627 is a Entity, N570 is a Entity, oligosaccharides is a Entity	222_task1	Sentence: Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. Instructions: please typing these entity words according to sentence: vitamin K - dependent carboxylase, vitamin K - dependent carboxylase, N459, N550, N605, N627, N570, oligosaccharides Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.	[ "Identification", "of", "the", "N", "-", "linked", "glycosylation", "sites", "of", "vitamin", "K", "-", "dependent", "carboxylase", "and", "effect", "of", "glycosylation", "on", "carboxylase", "function", ".", "\n", "The", "vitamin", "K", "-", "dependent", "carboxylase", "is", "an", "integral", "membrane", "protein", "which", "is", "required", "for", "the", "post", "-", "translational", "modification", "of", "a", "variety", "of", "vitamin", "K", "-", "dependent", "proteins", ".", "Previous", "studies", "have", "suggested", "carboxylase", "is", "a", "glycoprotein", "with", "N", "-", "linked", "glycosylation", "sites", ".", "In", "this", "study", ",", "we", "identify", "the", "N", "-", "glycosylation", "sites", "of", "carboxylase", "by", "mass", "spectrometric", "peptide", "mapping", "analyses", "combined", "with", "site", "-", "directed", "mutagenesis", ".", "Our", "mass", "spectrometric", "results", "show", "that", "the", "N", "-", "linked", "glycosylation", "in", "carboxylase", "occurs", "at", "positions", "N459", ",", "N550", ",", "N605", ",", "and", "N627", ".", "Eliminating", "these", "glycosylation", "sites", "by", "changing", "asparagine", "to", "glutamine", "caused", "the", "mutant", "carboxylase", "to", "migrate", "faster", "on", "SDS", "-", "PAGE", "gels", ",", "adding", "further", "evidence", "that", "these", "sites", "are", "glycosylated", ".", "In", "addition", ",", "the", "mutation", "studies", "identified", "N525", ",", "a", "site", "that", "cannot", "be", "recovered", "by", "mass", "spectroscopy", "analysis", ",", "as", "a", "glycosylation", "site", ".", "Furthermore", ",", "the", "potential", "glycosylation", "site", "at", "N570", "is", "glycosylated", "only", "if", "all", "five", "natural", "glycosylation", "sites", "are", "simultaneously", "mutated", ".", "Removal", "of", "the", "oligosaccharides", "by", "glycosidase", "from", "wild", "-", "type", "carboxylase", "or", "by", "elimination", "of", "the", "functional", "glycosylation", "sites", "by", "site", "-", "directed", "mutagenesis", "did", "not", "affect", "either", "the", "carboxylation", "or", "epoxidation", "activity", "when", "the", "small", "FLEEL", "pentapeptide", "was", "used", "as", "a", "substrate", ",", "suggesting", "that", "N", "-", "linked", "glycosylation", "is", "not", "required", "for", "the", "enzymatic", "function", "of", "carboxylase", ".", "In", "contrast", ",", "when", "site", "N570", "and", "the", "five", "natural", "glycosylation", "sites", "were", "mutated", "simultaneously", ",", "the", "resulting", "carboxylase", "protein", "was", "degraded", ".", "Our", "results", "suggest", "that", "N", "-", "linked", "glycosylation", "is", "not", "essential", "for", "carboxylase", "enzymatic", "activity", "but", "is", "important", "for", "protein", "folding", "and", "stability", ".", "\n" ]	[ "Protein", "Entity" ]
vitamin K - dependent carboxylase, vitamin K - dependent carboxylase, N459, N550, N605, N627, N570, oligosaccharides	222_task2	Sentence: Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.	[ "Identification", "of", "the", "N", "-", "linked", "glycosylation", "sites", "of", "vitamin", "K", "-", "dependent", "carboxylase", "and", "effect", "of", "glycosylation", "on", "carboxylase", "function", ".", "\n", "The", "vitamin", "K", "-", "dependent", "carboxylase", "is", "an", "integral", "membrane", "protein", "which", "is", "required", "for", "the", "post", "-", "translational", "modification", "of", "a", "variety", "of", "vitamin", "K", "-", "dependent", "proteins", ".", "Previous", "studies", "have", "suggested", "carboxylase", "is", "a", "glycoprotein", "with", "N", "-", "linked", "glycosylation", "sites", ".", "In", "this", "study", ",", "we", "identify", "the", "N", "-", "glycosylation", "sites", "of", "carboxylase", "by", "mass", "spectrometric", "peptide", "mapping", "analyses", "combined", "with", "site", "-", "directed", "mutagenesis", ".", "Our", "mass", "spectrometric", "results", "show", "that", "the", "N", "-", "linked", "glycosylation", "in", "carboxylase", "occurs", "at", "positions", "N459", ",", "N550", ",", "N605", ",", "and", "N627", ".", "Eliminating", "these", "glycosylation", "sites", "by", "changing", "asparagine", "to", "glutamine", "caused", "the", "mutant", "carboxylase", "to", "migrate", "faster", "on", "SDS", "-", "PAGE", "gels", ",", "adding", "further", "evidence", "that", "these", "sites", "are", "glycosylated", ".", "In", "addition", ",", "the", "mutation", "studies", "identified", "N525", ",", "a", "site", "that", "cannot", "be", "recovered", "by", "mass", "spectroscopy", "analysis", ",", "as", "a", "glycosylation", "site", ".", "Furthermore", ",", "the", "potential", "glycosylation", "site", "at", "N570", "is", "glycosylated", "only", "if", "all", "five", "natural", "glycosylation", "sites", "are", "simultaneously", "mutated", ".", "Removal", "of", "the", "oligosaccharides", "by", "glycosidase", "from", "wild", "-", "type", "carboxylase", "or", "by", "elimination", "of", "the", "functional", "glycosylation", "sites", "by", "site", "-", "directed", "mutagenesis", "did", "not", "affect", "either", "the", "carboxylation", "or", "epoxidation", "activity", "when", "the", "small", "FLEEL", "pentapeptide", "was", "used", "as", "a", "substrate", ",", "suggesting", "that", "N", "-", "linked", "glycosylation", "is", "not", "required", "for", "the", "enzymatic", "function", "of", "carboxylase", ".", "In", "contrast", ",", "when", "site", "N570", "and", "the", "five", "natural", "glycosylation", "sites", "were", "mutated", "simultaneously", ",", "the", "resulting", "carboxylase", "protein", "was", "degraded", ".", "Our", "results", "suggest", "that", "N", "-", "linked", "glycosylation", "is", "not", "essential", "for", "carboxylase", "enzymatic", "activity", "but", "is", "important", "for", "protein", "folding", "and", "stability", ".", "\n" ]	[ "Protein", "Entity" ]
woman is an umlsterm, dyspnea is an umlsterm, tumors is an umlsterm, malignant schwannoma is an umlsterm, diagnosis is an umlsterm, S-100 protein is an umlsterm, tumor is an umlsterm, cells is an umlsterm	DerPathologe.60170222.eng.abstr_task0	Sentence: The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]	The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells .	[ "The", "case", "is", "presented", "of", "a", "51-year", "-", "old", "woman", "with", "increased", "of", "nightly", "dyspnea", ".", "An", "echocardiographic", "examination", "shows", "two", "intracardiac", "tumors", ".", "Histological", "features", "demonstrate", "an", "malignant", "schwannoma", ".", "The", "diagnosis", "was", "verified", "by", "immunohistological", "proof", "of", "S-100", "protein", "in", "tumor", "cells", "." ]	[ "umlsterm" ]
woman is an umlsterm, dyspnea is an umlsterm, tumors is an umlsterm, malignant schwannoma is an umlsterm, diagnosis is an umlsterm, S-100 protein is an umlsterm, tumor is an umlsterm, cells is an umlsterm	DerPathologe.60170222.eng.abstr_task1	Sentence: The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells . Instructions: please typing these entity words according to sentence: woman, dyspnea, tumors, malignant schwannoma, diagnosis, S-100 protein, tumor, cells Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]	The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells .	[ "The", "case", "is", "presented", "of", "a", "51-year", "-", "old", "woman", "with", "increased", "of", "nightly", "dyspnea", ".", "An", "echocardiographic", "examination", "shows", "two", "intracardiac", "tumors", ".", "Histological", "features", "demonstrate", "an", "malignant", "schwannoma", ".", "The", "diagnosis", "was", "verified", "by", "immunohistological", "proof", "of", "S-100", "protein", "in", "tumor", "cells", "." ]	[ "umlsterm" ]
woman, dyspnea, tumors, malignant schwannoma, diagnosis, S-100 protein, tumor, cells	DerPathologe.60170222.eng.abstr_task2	Sentence: The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]	The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells .	[ "The", "case", "is", "presented", "of", "a", "51-year", "-", "old", "woman", "with", "increased", "of", "nightly", "dyspnea", ".", "An", "echocardiographic", "examination", "shows", "two", "intracardiac", "tumors", ".", "Histological", "features", "demonstrate", "an", "malignant", "schwannoma", ".", "The", "diagnosis", "was", "verified", "by", "immunohistological", "proof", "of", "S-100", "protein", "in", "tumor", "cells", "." ]	[ "umlsterm" ]
selenium is a CHEMICAL, adenosine deaminase is a GENE-Y	23536521_task0	Sentence: Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats.	[ "Differential", "effects", "of", "organic", "and", "inorganic", "selenium", "compounds", "on", "adenosine", "deaminase", "activity", "and", "scavenger", "capacity", "in", "cerebral", "cortex", "slices", "of", "young", "rats", "." ]	[ "CHEMICAL", "GENE-Y" ]
selenium is a CHEMICAL, adenosine deaminase is a GENE-Y	23536521_task1	Sentence: Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats. Instructions: please typing these entity words according to sentence: selenium, adenosine deaminase Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats.	[ "Differential", "effects", "of", "organic", "and", "inorganic", "selenium", "compounds", "on", "adenosine", "deaminase", "activity", "and", "scavenger", "capacity", "in", "cerebral", "cortex", "slices", "of", "young", "rats", "." ]	[ "CHEMICAL", "GENE-Y" ]
selenium, adenosine deaminase	23536521_task2	Sentence: Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats.	[ "Differential", "effects", "of", "organic", "and", "inorganic", "selenium", "compounds", "on", "adenosine", "deaminase", "activity", "and", "scavenger", "capacity", "in", "cerebral", "cortex", "slices", "of", "young", "rats", "." ]	[ "CHEMICAL", "GENE-Y" ]
Green tea is a Plant, cancer is a Disease, green tea is a Plant, green tea is a Plant, colorectal polyps is a Disease, cancer is a Disease, green tea is a Plant, lung cancer is a Disease, lung cancer is a Disease, green tea is a Plant	21199169_task0	Sentence: Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant	[ "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O" ]	Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs.	[ "Green", "tea", "is", "now", "recognized", "as", "the", "most", "effective", "cancer", "preventive", "beverage", ".", "In", "one", "study", ",", "10", "Japanese", "-", "size", "cups", "of", "green", "tea", "daily", "supplemented", "with", "tablets", "of", "green", "tea", "extract", "limited", "the", "recurrence", "of", "colorectal", "polyps", "in", "humans", "to", "50", "%", ".", "Thus", ",", "cancer", "patients", "who", "consume", "green", "tea", "and", "take", "anticancer", "drugs", "will", "have", "double", "prevention", ".", "We", "studied", "the", "effects", "of", "combining", "(", "-)-epigallocatechin", "gallate", "(", "EGCG", ")", "and", "anticancer", "drugs", ",", "focusing", "on", "inhibition", "of", "cell", "growth", "and", "induction", "of", "apoptosis", ".", "Numerous", "anticancer", "drugs", ",", "such", "as", "tamoxifen", ",", "COX-2", "inhibitors", ",", "and", "retinoids", "were", "used", "for", "the", "experiments", ",", "and", "the", "combination", "of", "EGCG", "and", "COX-2", "inhibitors", "consistently", "induced", "the", "enhancement", "of", "apoptosis", ".", "To", "study", "the", "mechanism", "of", "the", "enhancement", ",", "we", "paid", "special", "attention", "to", "the", "enhanced", "expressions", "of", "DDIT3", "(", "growth", "arrest", "and", "DNA", "damage", "-", "inducible", "153", ",", "GADD153", ")", ",", "GADD45A", ",", "and", "CDKN1A", "(", "p21", "/", "WAF1", "/", "CIP1", ")", "genes", ",", "based", "on", "our", "previous", "evidence", "that", "a", "combination", "of", "EGCG", "and", "sulindac", "specifically", "induced", "upregulated", "expression", "of", "GADD153", "and", "p21", "genes", "in", "PC-9", "lung", "cancer", "cells", ".", "The", "synergistic", "enhancements", "of", "apoptosis", "and", "GADD153", "gene", "expression", "in", "human", "non", "-", "small", "cell", "lung", "cancer", "cells", "by", "the", "combination", "of", "EGCG", "and", "celecoxib", "were", "mediated", "through", "the", "activation", "of", "the", "MAPK", "signaling", "pathway", ".", "This", "article", "reviews", "the", "synergistic", "enhancement", "of", "apoptosis", ",", "gene", "expression", ",", "and", "anticancer", "effects", "using", "various", "combinations", "of", "EGCG", "and", "anticancer", "drugs", ",", "including", "the", "combination", "of", "(", "-)-epicatechin", "(", "EC", ")", "and", "curcumin", ".", "Based", "on", "the", "evidence", ",", "we", "present", "a", "new", "concept", ":", "green", "tea", "catechins", "as", "synergists", "with", "anticancer", "drugs", "." ]	[ "Disease", "Plant" ]
Green tea is a Plant, cancer is a Disease, green tea is a Plant, green tea is a Plant, colorectal polyps is a Disease, cancer is a Disease, green tea is a Plant, lung cancer is a Disease, lung cancer is a Disease, green tea is a Plant	21199169_task1	Sentence: Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. Instructions: please typing these entity words according to sentence: Green tea, cancer, green tea, green tea, colorectal polyps, cancer, green tea, lung cancer, lung cancer, green tea Options: Disease, Plant	[ "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O" ]	Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs.	[ "Green", "tea", "is", "now", "recognized", "as", "the", "most", "effective", "cancer", "preventive", "beverage", ".", "In", "one", "study", ",", "10", "Japanese", "-", "size", "cups", "of", "green", "tea", "daily", "supplemented", "with", "tablets", "of", "green", "tea", "extract", "limited", "the", "recurrence", "of", "colorectal", "polyps", "in", "humans", "to", "50", "%", ".", "Thus", ",", "cancer", "patients", "who", "consume", "green", "tea", "and", "take", "anticancer", "drugs", "will", "have", "double", "prevention", ".", "We", "studied", "the", "effects", "of", "combining", "(", "-)-epigallocatechin", "gallate", "(", "EGCG", ")", "and", "anticancer", "drugs", ",", "focusing", "on", "inhibition", "of", "cell", "growth", "and", "induction", "of", "apoptosis", ".", "Numerous", "anticancer", "drugs", ",", "such", "as", "tamoxifen", ",", "COX-2", "inhibitors", ",", "and", "retinoids", "were", "used", "for", "the", "experiments", ",", "and", "the", "combination", "of", "EGCG", "and", "COX-2", "inhibitors", "consistently", "induced", "the", "enhancement", "of", "apoptosis", ".", "To", "study", "the", "mechanism", "of", "the", "enhancement", ",", "we", "paid", "special", "attention", "to", "the", "enhanced", "expressions", "of", "DDIT3", "(", "growth", "arrest", "and", "DNA", "damage", "-", "inducible", "153", ",", "GADD153", ")", ",", "GADD45A", ",", "and", "CDKN1A", "(", "p21", "/", "WAF1", "/", "CIP1", ")", "genes", ",", "based", "on", "our", "previous", "evidence", "that", "a", "combination", "of", "EGCG", "and", "sulindac", "specifically", "induced", "upregulated", "expression", "of", "GADD153", "and", "p21", "genes", "in", "PC-9", "lung", "cancer", "cells", ".", "The", "synergistic", "enhancements", "of", "apoptosis", "and", "GADD153", "gene", "expression", "in", "human", "non", "-", "small", "cell", "lung", "cancer", "cells", "by", "the", "combination", "of", "EGCG", "and", "celecoxib", "were", "mediated", "through", "the", "activation", "of", "the", "MAPK", "signaling", "pathway", ".", "This", "article", "reviews", "the", "synergistic", "enhancement", "of", "apoptosis", ",", "gene", "expression", ",", "and", "anticancer", "effects", "using", "various", "combinations", "of", "EGCG", "and", "anticancer", "drugs", ",", "including", "the", "combination", "of", "(", "-)-epicatechin", "(", "EC", ")", "and", "curcumin", ".", "Based", "on", "the", "evidence", ",", "we", "present", "a", "new", "concept", ":", "green", "tea", "catechins", "as", "synergists", "with", "anticancer", "drugs", "." ]	[ "Disease", "Plant" ]
Green tea, cancer, green tea, green tea, colorectal polyps, cancer, green tea, lung cancer, lung cancer, green tea	21199169_task2	Sentence: Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. Instructions: please extract entity words from the input sentence	[ "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O" ]	Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs.	[ "Green", "tea", "is", "now", "recognized", "as", "the", "most", "effective", "cancer", "preventive", "beverage", ".", "In", "one", "study", ",", "10", "Japanese", "-", "size", "cups", "of", "green", "tea", "daily", "supplemented", "with", "tablets", "of", "green", "tea", "extract", "limited", "the", "recurrence", "of", "colorectal", "polyps", "in", "humans", "to", "50", "%", ".", "Thus", ",", "cancer", "patients", "who", "consume", "green", "tea", "and", "take", "anticancer", "drugs", "will", "have", "double", "prevention", ".", "We", "studied", "the", "effects", "of", "combining", "(", "-)-epigallocatechin", "gallate", "(", "EGCG", ")", "and", "anticancer", "drugs", ",", "focusing", "on", "inhibition", "of", "cell", "growth", "and", "induction", "of", "apoptosis", ".", "Numerous", "anticancer", "drugs", ",", "such", "as", "tamoxifen", ",", "COX-2", "inhibitors", ",", "and", "retinoids", "were", "used", "for", "the", "experiments", ",", "and", "the", "combination", "of", "EGCG", "and", "COX-2", "inhibitors", "consistently", "induced", "the", "enhancement", "of", "apoptosis", ".", "To", "study", "the", "mechanism", "of", "the", "enhancement", ",", "we", "paid", "special", "attention", "to", "the", "enhanced", "expressions", "of", "DDIT3", "(", "growth", "arrest", "and", "DNA", "damage", "-", "inducible", "153", ",", "GADD153", ")", ",", "GADD45A", ",", "and", "CDKN1A", "(", "p21", "/", "WAF1", "/", "CIP1", ")", "genes", ",", "based", "on", "our", "previous", "evidence", "that", "a", "combination", "of", "EGCG", "and", "sulindac", "specifically", "induced", "upregulated", "expression", "of", "GADD153", "and", "p21", "genes", "in", "PC-9", "lung", "cancer", "cells", ".", "The", "synergistic", "enhancements", "of", "apoptosis", "and", "GADD153", "gene", "expression", "in", "human", "non", "-", "small", "cell", "lung", "cancer", "cells", "by", "the", "combination", "of", "EGCG", "and", "celecoxib", "were", "mediated", "through", "the", "activation", "of", "the", "MAPK", "signaling", "pathway", ".", "This", "article", "reviews", "the", "synergistic", "enhancement", "of", "apoptosis", ",", "gene", "expression", ",", "and", "anticancer", "effects", "using", "various", "combinations", "of", "EGCG", "and", "anticancer", "drugs", ",", "including", "the", "combination", "of", "(", "-)-epicatechin", "(", "EC", ")", "and", "curcumin", ".", "Based", "on", "the", "evidence", ",", "we", "present", "a", "new", "concept", ":", "green", "tea", "catechins", "as", "synergists", "with", "anticancer", "drugs", "." ]	[ "Disease", "Plant" ]
Females is a Person, high response is a Condition, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved is a Scope	NCT03209687_exc_task0	Sentence: Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Condition	[ "B-Person", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)	[ "Females", "who", "have", "high", "response", "(", "estradiol", "at", "time", "of", "ovulation", "trigger", "is", ">", "5000", "pg", "/", "ml", "or", "more", "than", "15", "oocytes", "are", "retrieved", ")", "\n" ]	[ "Scope", "Temporal", "Reference_point", "Condition", "Value", "Measurement", "Person" ]
Females is a Person, high response is a Condition, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved is a Scope	NCT03209687_exc_task1	Sentence: Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved) Instructions: please typing these entity words according to sentence: Females, high response, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved Options: Scope, Person, Condition	[ "B-Person", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)	[ "Females", "who", "have", "high", "response", "(", "estradiol", "at", "time", "of", "ovulation", "trigger", "is", ">", "5000", "pg", "/", "ml", "or", "more", "than", "15", "oocytes", "are", "retrieved", ")", "\n" ]	[ "Scope", "Temporal", "Reference_point", "Condition", "Value", "Measurement", "Person" ]
Females, high response, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved	NCT03209687_exc_task2	Sentence: Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved) Instructions: please extract entity words from the input sentence	[ "B-Person", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)	[ "Females", "who", "have", "high", "response", "(", "estradiol", "at", "time", "of", "ovulation", "trigger", "is", ">", "5000", "pg", "/", "ml", "or", "more", "than", "15", "oocytes", "are", "retrieved", ")", "\n" ]	[ "Scope", "Temporal", "Reference_point", "Condition", "Value", "Measurement", "Person" ]
alpha - catenin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, plakoglobin is a Gene/protein/RNA	748_task0	Sentence: The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium.	[ "The", "observed", "in", "vivo", "expression", "patterns", "of", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "suggest", "that", "these", "proteins", "are", "directly", "linked", "with", "the", "developmental", "regulation", "of", "cell", "junctions", ",", "as", "cardiac", "cells", "become", "stably", "committed", "and", "phenotypically", "differentiated", "to", "eventually", "form", "a", "mature", "myocardium", "." ]	[ "Gene/protein/RNA" ]
alpha - catenin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, plakoglobin is a Gene/protein/RNA	748_task1	Sentence: The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium. Instructions: please typing these entity words according to sentence: alpha - catenin, beta - catenin, plakoglobin Options: Gene/protein/RNA	[ "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium.	[ "The", "observed", "in", "vivo", "expression", "patterns", "of", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "suggest", "that", "these", "proteins", "are", "directly", "linked", "with", "the", "developmental", "regulation", "of", "cell", "junctions", ",", "as", "cardiac", "cells", "become", "stably", "committed", "and", "phenotypically", "differentiated", "to", "eventually", "form", "a", "mature", "myocardium", "." ]	[ "Gene/protein/RNA" ]
alpha - catenin, beta - catenin, plakoglobin	748_task2	Sentence: The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium.	[ "The", "observed", "in", "vivo", "expression", "patterns", "of", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "suggest", "that", "these", "proteins", "are", "directly", "linked", "with", "the", "developmental", "regulation", "of", "cell", "junctions", ",", "as", "cardiac", "cells", "become", "stably", "committed", "and", "phenotypically", "differentiated", "to", "eventually", "form", "a", "mature", "myocardium", "." ]	[ "Gene/protein/RNA" ]
work is an umlsterm, magnetic resonance imaging is an umlsterm, MRI is an umlsterm, spectroscopy is an umlsterm, MRS is an umlsterm, bone marrow is an umlsterm, methods is an umlsterm, assessment is an umlsterm, normal values is an umlsterm, persons is an umlsterm, patients is an umlsterm, hematological diseases is an umlsterm, therapies is an umlsterm, bone marrow is an umlsterm	DerRadiologe.00400700.eng.abstr_task0	Sentence: Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow .	[ "Purpose", ".", "Methodological", "work", "was", "performed", "in", "the", "field", "of", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "spectroscopy", "(", "MRS", ")", "in", "order", "to", "develop", "suitable", "tools", "for", "non", "-", "invasive", "characterization", "of", "hematopoetic", "bone", "marrow", ".", "The", "methods", "were", "applied", "for", "the", "assessment", "of", "normal", "values", "in", "healthy", "persons", "and", "to", "examine", "patients", "with", "generalized", "hematological", "diseases", "or", "to", "monitor", "effects", "of", "therapies", "influencing", "the", "composition", "of", "bone", "marrow", "." ]	[ "umlsterm" ]
work is an umlsterm, magnetic resonance imaging is an umlsterm, MRI is an umlsterm, spectroscopy is an umlsterm, MRS is an umlsterm, bone marrow is an umlsterm, methods is an umlsterm, assessment is an umlsterm, normal values is an umlsterm, persons is an umlsterm, patients is an umlsterm, hematological diseases is an umlsterm, therapies is an umlsterm, bone marrow is an umlsterm	DerRadiologe.00400700.eng.abstr_task1	Sentence: Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow . Instructions: please typing these entity words according to sentence: work, magnetic resonance imaging, MRI, spectroscopy, MRS, bone marrow, methods, assessment, normal values, persons, patients, hematological diseases, therapies, bone marrow Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow .	[ "Purpose", ".", "Methodological", "work", "was", "performed", "in", "the", "field", "of", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "spectroscopy", "(", "MRS", ")", "in", "order", "to", "develop", "suitable", "tools", "for", "non", "-", "invasive", "characterization", "of", "hematopoetic", "bone", "marrow", ".", "The", "methods", "were", "applied", "for", "the", "assessment", "of", "normal", "values", "in", "healthy", "persons", "and", "to", "examine", "patients", "with", "generalized", "hematological", "diseases", "or", "to", "monitor", "effects", "of", "therapies", "influencing", "the", "composition", "of", "bone", "marrow", "." ]	[ "umlsterm" ]
work, magnetic resonance imaging, MRI, spectroscopy, MRS, bone marrow, methods, assessment, normal values, persons, patients, hematological diseases, therapies, bone marrow	DerRadiologe.00400700.eng.abstr_task2	Sentence: Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow .	[ "Purpose", ".", "Methodological", "work", "was", "performed", "in", "the", "field", "of", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "spectroscopy", "(", "MRS", ")", "in", "order", "to", "develop", "suitable", "tools", "for", "non", "-", "invasive", "characterization", "of", "hematopoetic", "bone", "marrow", ".", "The", "methods", "were", "applied", "for", "the", "assessment", "of", "normal", "values", "in", "healthy", "persons", "and", "to", "examine", "patients", "with", "generalized", "hematological", "diseases", "or", "to", "monitor", "effects", "of", "therapies", "influencing", "the", "composition", "of", "bone", "marrow", "." ]	[ "umlsterm" ]
visual field defects is an umlsterm, antiepileptic drugs is an umlsterm, antiepileptic drugs is an umlsterm, causes is an umlsterm, retinopathy is an umlsterm, chloroquine is an umlsterm, phenothiazine is an umlsterm, visual field is an umlsterm, Visual field defects is an umlsterm, tiagabine is an umlsterm, diazepam is an umlsterm, carbamazepine is an umlsterm, treatment is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, population is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, visual field defects is an umlsterm	DerNervenarzt.90700552.eng.abstr_task0	Sentence: Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O" ]	Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary .	[ "Within", "the", "last", "years", "several", "reports", "concerning", "visual", "field", "defects", ",", "associated", "with", "antiepileptic", "drugs", ",", "have", "been", "published", ".", "In", "addition", "to", "antiepileptic", "drugs", "several", "other", "causes", "(", "e.g", ".", "retinopathy", "or", "chloroquine", ",", "phenothiazine", "etc", ".", ")", "may", "induce", "visual", "field", "disturbances", ".", "Visual", "field", "defects", "have", "been", "observed", "during", "vigabatrine", ",", "tiagabine", ",", "gabapentine", ",", "diazepam", ",", "phenytoine", ",", "and", "carbamazepine", "treatment", ".", "In", "13", "to", "46", "%", "visual", "field", "defects", "are", "reported", "to", "be", "linked", "with", "epilepsies", ".", "In", "addition", "to", "general", "population", "based", "studies", "concerning", "visual", "field", "defects", "and", "prospective", "etiological", "studies", "in", "epilepsies", ",", "preclinical", "studies", "for", "the", "examination", "of", "the", "pathomechanism", "of", "visual", "field", "defects", "are", "necessary", "." ]	[ "umlsterm" ]
visual field defects is an umlsterm, antiepileptic drugs is an umlsterm, antiepileptic drugs is an umlsterm, causes is an umlsterm, retinopathy is an umlsterm, chloroquine is an umlsterm, phenothiazine is an umlsterm, visual field is an umlsterm, Visual field defects is an umlsterm, tiagabine is an umlsterm, diazepam is an umlsterm, carbamazepine is an umlsterm, treatment is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, population is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, visual field defects is an umlsterm	DerNervenarzt.90700552.eng.abstr_task1	Sentence: Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary . Instructions: please typing these entity words according to sentence: visual field defects, antiepileptic drugs, antiepileptic drugs, causes, retinopathy, chloroquine, phenothiazine, visual field, Visual field defects, tiagabine, diazepam, carbamazepine, treatment, visual field defects, epilepsies, population, visual field defects, epilepsies, visual field defects Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O" ]	Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary .	[ "Within", "the", "last", "years", "several", "reports", "concerning", "visual", "field", "defects", ",", "associated", "with", "antiepileptic", "drugs", ",", "have", "been", "published", ".", "In", "addition", "to", "antiepileptic", "drugs", "several", "other", "causes", "(", "e.g", ".", "retinopathy", "or", "chloroquine", ",", "phenothiazine", "etc", ".", ")", "may", "induce", "visual", "field", "disturbances", ".", "Visual", "field", "defects", "have", "been", "observed", "during", "vigabatrine", ",", "tiagabine", ",", "gabapentine", ",", "diazepam", ",", "phenytoine", ",", "and", "carbamazepine", "treatment", ".", "In", "13", "to", "46", "%", "visual", "field", "defects", "are", "reported", "to", "be", "linked", "with", "epilepsies", ".", "In", "addition", "to", "general", "population", "based", "studies", "concerning", "visual", "field", "defects", "and", "prospective", "etiological", "studies", "in", "epilepsies", ",", "preclinical", "studies", "for", "the", "examination", "of", "the", "pathomechanism", "of", "visual", "field", "defects", "are", "necessary", "." ]	[ "umlsterm" ]
visual field defects, antiepileptic drugs, antiepileptic drugs, causes, retinopathy, chloroquine, phenothiazine, visual field, Visual field defects, tiagabine, diazepam, carbamazepine, treatment, visual field defects, epilepsies, population, visual field defects, epilepsies, visual field defects	DerNervenarzt.90700552.eng.abstr_task2	Sentence: Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O" ]	Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary .	[ "Within", "the", "last", "years", "several", "reports", "concerning", "visual", "field", "defects", ",", "associated", "with", "antiepileptic", "drugs", ",", "have", "been", "published", ".", "In", "addition", "to", "antiepileptic", "drugs", "several", "other", "causes", "(", "e.g", ".", "retinopathy", "or", "chloroquine", ",", "phenothiazine", "etc", ".", ")", "may", "induce", "visual", "field", "disturbances", ".", "Visual", "field", "defects", "have", "been", "observed", "during", "vigabatrine", ",", "tiagabine", ",", "gabapentine", ",", "diazepam", ",", "phenytoine", ",", "and", "carbamazepine", "treatment", ".", "In", "13", "to", "46", "%", "visual", "field", "defects", "are", "reported", "to", "be", "linked", "with", "epilepsies", ".", "In", "addition", "to", "general", "population", "based", "studies", "concerning", "visual", "field", "defects", "and", "prospective", "etiological", "studies", "in", "epilepsies", ",", "preclinical", "studies", "for", "the", "examination", "of", "the", "pathomechanism", "of", "visual", "field", "defects", "are", "necessary", "." ]	[ "umlsterm" ]
glycine is a CHEMICAL, glycine decarboxylase is a GENE-Y, serine hydroxymethyltransferase is a GENE-Y	3143355_task0	Sentence: Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O" ]	Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.	[ "Resolution", "and", "characterization", "of", "the", "glycine", "-", "cleavage", "reaction", "in", "pea", "leaf", "mitochondria", ".", "Properties", "of", "the", "forward", "reaction", "catalysed", "by", "glycine", "decarboxylase", "and", "serine", "hydroxymethyltransferase", "." ]	[ "CHEMICAL", "GENE-Y" ]
glycine is a CHEMICAL, glycine decarboxylase is a GENE-Y, serine hydroxymethyltransferase is a GENE-Y	3143355_task1	Sentence: Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase. Instructions: please typing these entity words according to sentence: glycine, glycine decarboxylase, serine hydroxymethyltransferase Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O" ]	Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.	[ "Resolution", "and", "characterization", "of", "the", "glycine", "-", "cleavage", "reaction", "in", "pea", "leaf", "mitochondria", ".", "Properties", "of", "the", "forward", "reaction", "catalysed", "by", "glycine", "decarboxylase", "and", "serine", "hydroxymethyltransferase", "." ]	[ "CHEMICAL", "GENE-Y" ]
glycine, glycine decarboxylase, serine hydroxymethyltransferase	3143355_task2	Sentence: Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O" ]	Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.	[ "Resolution", "and", "characterization", "of", "the", "glycine", "-", "cleavage", "reaction", "in", "pea", "leaf", "mitochondria", ".", "Properties", "of", "the", "forward", "reaction", "catalysed", "by", "glycine", "decarboxylase", "and", "serine", "hydroxymethyltransferase", "." ]	[ "CHEMICAL", "GENE-Y" ]
Glaukompatienten is an umlsterm, Tomographie is an umlsterm, Nervenfaserschicht is an umlsterm, Methoden is an umlsterm, Nervenfaserfotografie is an umlsterm, Gesichtsfeldbefunden is an umlsterm, Augen is an umlsterm, Patienten is an umlsterm, Offenwinkelglaukom is an umlsterm, Glaukomverdacht is an umlsterm, Nervenfaserschichtdicke is an umlsterm, Papillenpol is an umlsterm, Beurteilung is an umlsterm, Nervenfaserschicht is an umlsterm, Gesichtsfeldparametern is an umlsterm, Nervenfaserschicht is an umlsterm, Gesichtsfeldveraenderungen is an umlsterm, Nervenfaserschichtbefunde is an umlsterm, Erweiterung is an umlsterm, Pupille is an umlsterm	DerOpthalmologe.60930520.ger.abstr_task0	Sentence: Beim Glaukompatienten bestehen klinisch eindeutige Zusammenhaenge zwischen morphologischen und funktionellen Veraenderungen . Die neuen Scanning-Laser-Ophthalmoskope zur Tomographie der Papille und Polarimetrie der Nervenfaserschicht sollten gegenueber klinischen Methoden objektivere Daten und damit bessere Korrelationen ermoeglichen . In einer Querschnittsstudie wurden die Ergebnisse der konventionellen Papillen- und Nervenfaserfotografie , die Stereoplanimetrie , der Laser-Scanning-Tomographie ( TopSS und Polarimetrie ( ) Nerve Fiber Analyzer ) mit den Gesichtsfeldbefunden Octopus-Programm G 1 ) korreliert . Es wurden 157 Augen von 157 Patienten mit manifestem Offenwinkelglaukom sowie Glaukomverdacht untersucht . Von den polarimetrischen Parametern korreliert die Modulation der Nervenfaserschichtdicke ( Maximum - Minimum ) am besten mit der mittleren Sensitivitaet ( r2 = 0,23 ) . Von den tomographischen Parametern korrelierte die neuroretinale Randzone am oberen und unteren Papillenpol am besten mit der Verlustvarianz ( LV ) ( r2 = 0,20 ) . Die planimetrischen Papillenparameter sowie die klinische Beurteilung der Nervenfaserschicht korrelierten geringfuegig besser mit den Gesichtsfeldparametern als die Daten der Scanning-Laser-Tomographie oder Polarimetrie . Die Parameter der Nervenfaserschicht sind zwar schwieriger zu erfassen , korrelieren jedoch generell besser mit den diffusen Gesichtsfeldveraenderungen als die Papillenparameter . Die neuen Scanning-Laser-Verfahren verbessern die Korrelationen nicht , ermoeglichen jedoch eine objektive Erfassung der Papillen- und Nervenfaserschichtbefunde ohne Erweiterung der Pupille . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	Beim Glaukompatienten bestehen klinisch eindeutige Zusammenhaenge zwischen morphologischen und funktionellen Veraenderungen . Die neuen Scanning-Laser-Ophthalmoskope zur Tomographie der Papille und Polarimetrie der Nervenfaserschicht sollten gegenueber klinischen Methoden objektivere Daten und damit bessere Korrelationen ermoeglichen . In einer Querschnittsstudie wurden die Ergebnisse der konventionellen Papillen- und Nervenfaserfotografie , die Stereoplanimetrie , der Laser-Scanning-Tomographie ( TopSS und Polarimetrie ( ) Nerve Fiber Analyzer ) mit den Gesichtsfeldbefunden Octopus-Programm G 1 ) korreliert . Es wurden 157 Augen von 157 Patienten mit manifestem Offenwinkelglaukom sowie Glaukomverdacht untersucht . Von den polarimetrischen Parametern korreliert die Modulation der Nervenfaserschichtdicke ( Maximum - Minimum ) am besten mit der mittleren Sensitivitaet ( r2 = 0,23 ) . Von den tomographischen Parametern korrelierte die neuroretinale Randzone am oberen und unteren Papillenpol am besten mit der Verlustvarianz ( LV ) ( r2 = 0,20 ) . Die planimetrischen Papillenparameter sowie die klinische Beurteilung der Nervenfaserschicht korrelierten geringfuegig besser mit den Gesichtsfeldparametern als die Daten der Scanning-Laser-Tomographie oder Polarimetrie . Die Parameter der Nervenfaserschicht sind zwar schwieriger zu erfassen , korrelieren jedoch generell besser mit den diffusen Gesichtsfeldveraenderungen als die Papillenparameter . Die neuen Scanning-Laser-Verfahren verbessern die Korrelationen nicht , ermoeglichen jedoch eine objektive Erfassung der Papillen- und Nervenfaserschichtbefunde ohne Erweiterung der Pupille .	[ "Beim", "Glaukompatienten", "bestehen", "klinisch", "eindeutige", "Zusammenhaenge", "zwischen", "morphologischen", "und", "funktionellen", "Veraenderungen", ".", "Die", "neuen", "Scanning", "-", "Laser", "-", "Ophthalmoskope", "zur", "Tomographie", "der", "Papille", "und", "Polarimetrie", "der", "Nervenfaserschicht", "sollten", "gegenueber", "klinischen", "Methoden", "objektivere", "Daten", "und", "damit", "bessere", "Korrelationen", "ermoeglichen", ".", "In", "einer", "Querschnittsstudie", "wurden", "die", "Ergebnisse", "der", "konventionellen", "Papillen-", "und", "Nervenfaserfotografie", ",", "die", "Stereoplanimetrie", ",", "der", "Laser", "-", "Scanning", "-", "Tomographie", "(", "TopSS", "und", "Polarimetrie", "(", ")", "Nerve", "Fiber", "Analyzer", ")", "mit", "den", "Gesichtsfeldbefunden", "Octopus", "-", "Programm", "G", "1", ")", "korreliert", ".", "Es", "wurden", "157", "Augen", "von", "157", "Patienten", "mit", "manifestem", "Offenwinkelglaukom", "sowie", "Glaukomverdacht", "untersucht", ".", "Von", "den", "polarimetrischen", "Parametern", "korreliert", "die", "Modulation", "der", "Nervenfaserschichtdicke", "(", "Maximum", "-", "Minimum", ")", "am", "besten", "mit", "der", "mittleren", "Sensitivitaet", "(", "r2", "=", "0,23", ")", ".", "Von", "den", "tomographischen", "Parametern", "korrelierte", "die", "neuroretinale", "Randzone", "am", "oberen", "und", "unteren", "Papillenpol", "am", "besten", "mit", "der", "Verlustvarianz", "(", "LV", ")", "(", "r2", "=", "0,20", ")", ".", "Die", "planimetrischen", "Papillenparameter", "sowie", "die", "klinische", "Beurteilung", "der", "Nervenfaserschicht", "korrelierten", "geringfuegig", "besser", "mit", "den", "Gesichtsfeldparametern", "als", "die", "Daten", "der", "Scanning", "-", "Laser", "-", "Tomographie", "oder", "Polarimetrie", ".", "Die", "Parameter", "der", "Nervenfaserschicht", "sind", "zwar", "schwieriger", "zu", "erfassen", ",", "korrelieren", "jedoch", "generell", "besser", "mit", "den", "diffusen", "Gesichtsfeldveraenderungen", "als", "die", "Papillenparameter", ".", "Die", "neuen", "Scanning", "-", "Laser", "-", "Verfahren", "verbessern", "die", "Korrelationen", "nicht", ",", "ermoeglichen", "jedoch", "eine", "objektive", "Erfassung", "der", "Papillen-", "und", "Nervenfaserschichtbefunde", "ohne", "Erweiterung", "der", "Pupille", "." ]	[ "umlsterm" ]

LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, IL4 is a Protein, CD19 is a Protein, LMP1 is a Protein, L32 is a Protein, GAPDH is a Protein, LMP1 is a Protein, pStat6 is a Protein, CD19 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, IL4 is a Protein, LMP1 is a Protein

105_task0

Sentence: Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.

[ "Wild", "-", "Type", "and", "LMP1", "Transgenic", "Lymphoma", "Cells", "Survive", "Independently", "of", "IL4", "/", "Stat6", "Signaling", "in", "Culture", "\n", "(", "A", ")", "Rnase", "protection", "assay", "for", "IL4", "mRNA", "from", "purified", "B", "cells", "(", "CD19", "+", ")", "from", "WT", "and", "LMP1", "transgenic", "splenocytes", ".", "The", "L32", "and", "GAPDH", "housekeeping", "genes", "were", "used", "as", "a", "loading", "control", ".", "Arrow", "indicates", "the", "position", "of", "the", "protected", "probe", ".", "\n", "(", "B", "and", "C", ")", "Immunoblot", "analysis", "of", "WT", "and", "LMP1", "transgenic", "mice", "for", "activated", "pStat6", "in", "(", "B", ")", "purified", "B", "cells", "(", "CD19", "+", ")", "at", "the", "time", "of", "harvest", "or", "in", "(", "C", ")", "whole", "splenocytes", "cultured", "with", "or", "without", "IL4", ".", "(", "B", ")", "Actin", "was", "used", "as", "a", "loading", "control", ",", "and", "the", "white", "line", "indicates", "that", "intervening", "lanes", "have", "been", "spliced", "out", ".", "\n", "(", "D", "and", "E", ")", "MTS", "assay", "of", "(", "D", ")", "WT", "lymphocytes", "and", "(", "E", ")", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "IL4", ",", "a", "neutralizing", "antibody", "to", "IL4", ",", "or", "a", "rat", "IgG", "isotype", "control", "at", "the", "indicated", "concentrations", ".", "Shown", "are", "the", "results", "from", "LMP1", "transgenic", "lymphoma", "3", ".", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "from", "a", "single", "representative", "experiment", "that", "was", "repeated", "twice", "with", "similar", "results", "." ]

[ "Protein" ]

LMP1 is a Protein, IL4 is a Protein, Stat6 is a Protein, IL4 is a Protein, CD19 is a Protein, LMP1 is a Protein, L32 is a Protein, GAPDH is a Protein, LMP1 is a Protein, pStat6 is a Protein, CD19 is a Protein, IL4 is a Protein, LMP1 is a Protein, IL4 is a Protein, IL4 is a Protein, LMP1 is a Protein

105_task1

Sentence: Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results. Instructions: please typing these entity words according to sentence: LMP1, IL4, Stat6, IL4, CD19, LMP1, L32, GAPDH, LMP1, pStat6, CD19, IL4, LMP1, IL4, IL4, LMP1 Options: Protein

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.

[ "Wild", "-", "Type", "and", "LMP1", "Transgenic", "Lymphoma", "Cells", "Survive", "Independently", "of", "IL4", "/", "Stat6", "Signaling", "in", "Culture", "\n", "(", "A", ")", "Rnase", "protection", "assay", "for", "IL4", "mRNA", "from", "purified", "B", "cells", "(", "CD19", "+", ")", "from", "WT", "and", "LMP1", "transgenic", "splenocytes", ".", "The", "L32", "and", "GAPDH", "housekeeping", "genes", "were", "used", "as", "a", "loading", "control", ".", "Arrow", "indicates", "the", "position", "of", "the", "protected", "probe", ".", "\n", "(", "B", "and", "C", ")", "Immunoblot", "analysis", "of", "WT", "and", "LMP1", "transgenic", "mice", "for", "activated", "pStat6", "in", "(", "B", ")", "purified", "B", "cells", "(", "CD19", "+", ")", "at", "the", "time", "of", "harvest", "or", "in", "(", "C", ")", "whole", "splenocytes", "cultured", "with", "or", "without", "IL4", ".", "(", "B", ")", "Actin", "was", "used", "as", "a", "loading", "control", ",", "and", "the", "white", "line", "indicates", "that", "intervening", "lanes", "have", "been", "spliced", "out", ".", "\n", "(", "D", "and", "E", ")", "MTS", "assay", "of", "(", "D", ")", "WT", "lymphocytes", "and", "(", "E", ")", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "IL4", ",", "a", "neutralizing", "antibody", "to", "IL4", ",", "or", "a", "rat", "IgG", "isotype", "control", "at", "the", "indicated", "concentrations", ".", "Shown", "are", "the", "results", "from", "LMP1", "transgenic", "lymphoma", "3", ".", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "from", "a", "single", "representative", "experiment", "that", "was", "repeated", "twice", "with", "similar", "results", "." ]

[ "Protein" ]

LMP1, IL4, Stat6, IL4, CD19, LMP1, L32, GAPDH, LMP1, pStat6, CD19, IL4, LMP1, IL4, IL4, LMP1

105_task2

Sentence: Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Wild-Type and LMP1 Transgenic Lymphoma Cells Survive Independently of IL4/Stat6 Signaling in Culture (A) Rnase protection assay for IL4 mRNA from purified B cells (CD19+) from WT and LMP1 transgenic splenocytes. The L32 and GAPDH housekeeping genes were used as a loading control. Arrow indicates the position of the protected probe. (B and C) Immunoblot analysis of WT and LMP1 transgenic mice for activated pStat6 in (B) purified B cells (CD19+) at the time of harvest or in (C) whole splenocytes cultured with or without IL4. (B) Actin was used as a loading control, and the white line indicates that intervening lanes have been spliced out. (D and E) MTS assay of (D) WT lymphocytes and (E) LMP1 transgenic lymphoma cells cultured with IL4, a neutralizing antibody to IL4, or a rat IgG isotype control at the indicated concentrations. Shown are the results from LMP1 transgenic lymphoma 3. The results are the mean +/- SEM of triplicate samples from a single representative experiment that was repeated twice with similar results.

[ "Wild", "-", "Type", "and", "LMP1", "Transgenic", "Lymphoma", "Cells", "Survive", "Independently", "of", "IL4", "/", "Stat6", "Signaling", "in", "Culture", "\n", "(", "A", ")", "Rnase", "protection", "assay", "for", "IL4", "mRNA", "from", "purified", "B", "cells", "(", "CD19", "+", ")", "from", "WT", "and", "LMP1", "transgenic", "splenocytes", ".", "The", "L32", "and", "GAPDH", "housekeeping", "genes", "were", "used", "as", "a", "loading", "control", ".", "Arrow", "indicates", "the", "position", "of", "the", "protected", "probe", ".", "\n", "(", "B", "and", "C", ")", "Immunoblot", "analysis", "of", "WT", "and", "LMP1", "transgenic", "mice", "for", "activated", "pStat6", "in", "(", "B", ")", "purified", "B", "cells", "(", "CD19", "+", ")", "at", "the", "time", "of", "harvest", "or", "in", "(", "C", ")", "whole", "splenocytes", "cultured", "with", "or", "without", "IL4", ".", "(", "B", ")", "Actin", "was", "used", "as", "a", "loading", "control", ",", "and", "the", "white", "line", "indicates", "that", "intervening", "lanes", "have", "been", "spliced", "out", ".", "\n", "(", "D", "and", "E", ")", "MTS", "assay", "of", "(", "D", ")", "WT", "lymphocytes", "and", "(", "E", ")", "LMP1", "transgenic", "lymphoma", "cells", "cultured", "with", "IL4", ",", "a", "neutralizing", "antibody", "to", "IL4", ",", "or", "a", "rat", "IgG", "isotype", "control", "at", "the", "indicated", "concentrations", ".", "Shown", "are", "the", "results", "from", "LMP1", "transgenic", "lymphoma", "3", ".", "The", "results", "are", "the", "mean", "+", "/-", "SEM", "of", "triplicate", "samples", "from", "a", "single", "representative", "experiment", "that", "was", "repeated", "twice", "with", "similar", "results", "." ]

[ "Protein" ]

squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, vaginal tumor is a DISEASE, vesicovaginal fistula is a ADVERSE, squamous cell carcinoma of the vagina is a DISEASE

example-224_task0

Sentence: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE, DISEASE

[ "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.

[ "Concurrent", "chemoradiation", "for", "locally", "advanced", "squamous", "cell", "carcinoma", "of", "the", "vagina", ":", "case", "series", "and", "literature", "review", ".", " ", "BACKGROUND", ":", "We", "reviewed", "our", "experience", "with", "patients", "with", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "received", "concurrent", "chemoradiation", "therapy", "(", "CCRT", ")", ".", "METHODS", ":", "We", "retrospectively", "analyzed", "six", "patients", "(", "median", "age", ",", "60", "years", ")", "with", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "underwent", "CCRT", "between", "2002", "and", "2005", "at", "the", "University", "of", "the", "Ryukyus", "Hospital", ".", "Two", "patients", "were", "in", "International", "Federation", "of", "Obstetricians", "and", "Gynecologists", "(", "FIGO", ")", "stage", "II", ",", "one", "in", "stage", "III", ",", "and", "three", "in", "stage", "IVA", ".", "All", "patients", "had", "an", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "performance", "status", "of", "2", "or", "less", ".", "Tumor", "size", "ranged", "from", "3.2", "to", "7.7", "cm", ".", "All", "patients", "were", "treated", "with", "true", "pelvic", "external", "-", "beam", "radiotherapy", "(", "EBRT", ")", "at", "50", "Gy", ".", "Then", "two", "of", "the", "six", "patients", "underwent", "intracavitary", "vaginal", "brachy", "-", "therapy", ".", "The", "remaining", "four", "patients", "received", "boost", "EBRT", "with", "shrinking", "fields", ".", "Total", "radiation", "dose", "to", "the", "vaginal", "tumor", "ranged", "from", "60", "to", "66", "Gy", ".", "All", "patients", "received", "two", "or", "three", "concomitant", "cycles", "of", "cisplatin", "during", "EBRT", ".", "RESULTS", ":", "All", "six", "patients", "completed", "their", "scheduled", "CCRT", ",", "and", "achieved", "a", "clinical", "complete", "response", ".", "One", "stage", "II", "patient", "died", "of", "disease", "24", "months", "after", "treatment", ",", "and", "the", "stage", "III", "patient", "had", "local", "failure", "at", "12", "months", ".", "The", "remaining", "four", "patients", "were", "free", "of", "their", "disease", "at", "18", ",", "23", ",", "33", ",", "and", "55", "months", ",", "respectively", ".", "One", "patient", "with", "stage", "IVA", "developed", "a", "vesicovaginal", "fistula", "during", "CCRT", ".", "Nevertheless", ",", "CCRT", "was", "well", "tolerated", "by", "all", "six", "patients", ",", "and", "no", "grade", "3", "or", "4", "late", "toxicity", "was", "observed", ",", "as", "evaluated", "by", "the", "Radiation", "Therapy", "Oncology", "Group", "(", "RTOG", ")", "scoring", "system", ".", "CONCLUSION", ":", "CCRT", "is", "effective", "for", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "and", "should", "be", "considered", "for", "treatment", "in", "patients", "with", "high", "-", "risk", "disease", "having", "good", "performance", "status", "." ]

[ "DISEASE", "ADVERSE" ]

squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, squamous cell carcinoma of the vagina is a DISEASE, vaginal tumor is a DISEASE, vesicovaginal fistula is a ADVERSE, squamous cell carcinoma of the vagina is a DISEASE

example-224_task1

Sentence: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status. Instructions: please typing these entity words according to sentence: squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, vaginal tumor, vesicovaginal fistula, squamous cell carcinoma of the vagina Options: ADVERSE, DISEASE

[ "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.

[ "Concurrent", "chemoradiation", "for", "locally", "advanced", "squamous", "cell", "carcinoma", "of", "the", "vagina", ":", "case", "series", "and", "literature", "review", ".", " ", "BACKGROUND", ":", "We", "reviewed", "our", "experience", "with", "patients", "with", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "received", "concurrent", "chemoradiation", "therapy", "(", "CCRT", ")", ".", "METHODS", ":", "We", "retrospectively", "analyzed", "six", "patients", "(", "median", "age", ",", "60", "years", ")", "with", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "underwent", "CCRT", "between", "2002", "and", "2005", "at", "the", "University", "of", "the", "Ryukyus", "Hospital", ".", "Two", "patients", "were", "in", "International", "Federation", "of", "Obstetricians", "and", "Gynecologists", "(", "FIGO", ")", "stage", "II", ",", "one", "in", "stage", "III", ",", "and", "three", "in", "stage", "IVA", ".", "All", "patients", "had", "an", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "performance", "status", "of", "2", "or", "less", ".", "Tumor", "size", "ranged", "from", "3.2", "to", "7.7", "cm", ".", "All", "patients", "were", "treated", "with", "true", "pelvic", "external", "-", "beam", "radiotherapy", "(", "EBRT", ")", "at", "50", "Gy", ".", "Then", "two", "of", "the", "six", "patients", "underwent", "intracavitary", "vaginal", "brachy", "-", "therapy", ".", "The", "remaining", "four", "patients", "received", "boost", "EBRT", "with", "shrinking", "fields", ".", "Total", "radiation", "dose", "to", "the", "vaginal", "tumor", "ranged", "from", "60", "to", "66", "Gy", ".", "All", "patients", "received", "two", "or", "three", "concomitant", "cycles", "of", "cisplatin", "during", "EBRT", ".", "RESULTS", ":", "All", "six", "patients", "completed", "their", "scheduled", "CCRT", ",", "and", "achieved", "a", "clinical", "complete", "response", ".", "One", "stage", "II", "patient", "died", "of", "disease", "24", "months", "after", "treatment", ",", "and", "the", "stage", "III", "patient", "had", "local", "failure", "at", "12", "months", ".", "The", "remaining", "four", "patients", "were", "free", "of", "their", "disease", "at", "18", ",", "23", ",", "33", ",", "and", "55", "months", ",", "respectively", ".", "One", "patient", "with", "stage", "IVA", "developed", "a", "vesicovaginal", "fistula", "during", "CCRT", ".", "Nevertheless", ",", "CCRT", "was", "well", "tolerated", "by", "all", "six", "patients", ",", "and", "no", "grade", "3", "or", "4", "late", "toxicity", "was", "observed", ",", "as", "evaluated", "by", "the", "Radiation", "Therapy", "Oncology", "Group", "(", "RTOG", ")", "scoring", "system", ".", "CONCLUSION", ":", "CCRT", "is", "effective", "for", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "and", "should", "be", "considered", "for", "treatment", "in", "patients", "with", "high", "-", "risk", "disease", "having", "good", "performance", "status", "." ]

[ "DISEASE", "ADVERSE" ]

squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, squamous cell carcinoma of the vagina, vaginal tumor, vesicovaginal fistula, squamous cell carcinoma of the vagina

example-224_task2

Sentence: Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "I-DISEASE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Concurrent chemoradiation for locally advanced squamous cell carcinoma of the vagina: case series and literature review. BACKGROUND: We reviewed our experience with patients with primary squamous cell carcinoma of the vagina who received concurrent chemoradiation therapy (CCRT). METHODS: We retrospectively analyzed six patients (median age, 60 years) with squamous cell carcinoma of the vagina who underwent CCRT between 2002 and 2005 at the University of the Ryukyus Hospital. Two patients were in International Federation of Obstetricians and Gynecologists (FIGO) stage II, one in stage III, and three in stage IVA. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Tumor size ranged from 3.2 to 7.7 cm. All patients were treated with true pelvic external-beam radiotherapy (EBRT) at 50 Gy. Then two of the six patients underwent intracavitary vaginal brachy-therapy. The remaining four patients received boost EBRT with shrinking fields. Total radiation dose to the vaginal tumor ranged from 60 to 66 Gy. All patients received two or three concomitant cycles of cisplatin during EBRT. RESULTS: All six patients completed their scheduled CCRT, and achieved a clinical complete response. One stage II patient died of disease 24 months after treatment, and the stage III patient had local failure at 12 months. The remaining four patients were free of their disease at 18, 23, 33, and 55 months, respectively. One patient with stage IVA developed a vesicovaginal fistula during CCRT. Nevertheless, CCRT was well tolerated by all six patients, and no grade 3 or 4 late toxicity was observed, as evaluated by the Radiation Therapy Oncology Group (RTOG) scoring system. CONCLUSION: CCRT is effective for primary squamous cell carcinoma of the vagina and should be considered for treatment in patients with high-risk disease having good performance status.

[ "Concurrent", "chemoradiation", "for", "locally", "advanced", "squamous", "cell", "carcinoma", "of", "the", "vagina", ":", "case", "series", "and", "literature", "review", ".", " ", "BACKGROUND", ":", "We", "reviewed", "our", "experience", "with", "patients", "with", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "received", "concurrent", "chemoradiation", "therapy", "(", "CCRT", ")", ".", "METHODS", ":", "We", "retrospectively", "analyzed", "six", "patients", "(", "median", "age", ",", "60", "years", ")", "with", "squamous", "cell", "carcinoma", "of", "the", "vagina", "who", "underwent", "CCRT", "between", "2002", "and", "2005", "at", "the", "University", "of", "the", "Ryukyus", "Hospital", ".", "Two", "patients", "were", "in", "International", "Federation", "of", "Obstetricians", "and", "Gynecologists", "(", "FIGO", ")", "stage", "II", ",", "one", "in", "stage", "III", ",", "and", "three", "in", "stage", "IVA", ".", "All", "patients", "had", "an", "Eastern", "Cooperative", "Oncology", "Group", "(", "ECOG", ")", "performance", "status", "of", "2", "or", "less", ".", "Tumor", "size", "ranged", "from", "3.2", "to", "7.7", "cm", ".", "All", "patients", "were", "treated", "with", "true", "pelvic", "external", "-", "beam", "radiotherapy", "(", "EBRT", ")", "at", "50", "Gy", ".", "Then", "two", "of", "the", "six", "patients", "underwent", "intracavitary", "vaginal", "brachy", "-", "therapy", ".", "The", "remaining", "four", "patients", "received", "boost", "EBRT", "with", "shrinking", "fields", ".", "Total", "radiation", "dose", "to", "the", "vaginal", "tumor", "ranged", "from", "60", "to", "66", "Gy", ".", "All", "patients", "received", "two", "or", "three", "concomitant", "cycles", "of", "cisplatin", "during", "EBRT", ".", "RESULTS", ":", "All", "six", "patients", "completed", "their", "scheduled", "CCRT", ",", "and", "achieved", "a", "clinical", "complete", "response", ".", "One", "stage", "II", "patient", "died", "of", "disease", "24", "months", "after", "treatment", ",", "and", "the", "stage", "III", "patient", "had", "local", "failure", "at", "12", "months", ".", "The", "remaining", "four", "patients", "were", "free", "of", "their", "disease", "at", "18", ",", "23", ",", "33", ",", "and", "55", "months", ",", "respectively", ".", "One", "patient", "with", "stage", "IVA", "developed", "a", "vesicovaginal", "fistula", "during", "CCRT", ".", "Nevertheless", ",", "CCRT", "was", "well", "tolerated", "by", "all", "six", "patients", ",", "and", "no", "grade", "3", "or", "4", "late", "toxicity", "was", "observed", ",", "as", "evaluated", "by", "the", "Radiation", "Therapy", "Oncology", "Group", "(", "RTOG", ")", "scoring", "system", ".", "CONCLUSION", ":", "CCRT", "is", "effective", "for", "primary", "squamous", "cell", "carcinoma", "of", "the", "vagina", "and", "should", "be", "considered", "for", "treatment", "in", "patients", "with", "high", "-", "risk", "disease", "having", "good", "performance", "status", "." ]

[ "DISEASE", "ADVERSE" ]

cochlear implant is an umlsterm, method is an umlsterm, rehabilitation is an umlsterm, deafness is an umlsterm, adults is an umlsterm, children is an umlsterm, speech is an umlsterm, use is an umlsterm, adults is an umlsterm, children is an umlsterm, cochlear implant is an umlsterm, software is an umlsterm, cochlear implants is an umlsterm, patients is an umlsterm, hearing is an umlsterm, evaluation is an umlsterm, deformities is an umlsterm, children is an umlsterm, implantations is an umlsterm, deafness is an umlsterm

HNO.80460012.eng.abstr_task0

Sentence: In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness .

[ "In", "recent", "years", "the", "cochlear", "implant", "has", "become", "an", "established", "method", "for", "rehabilitation", "of", "bilateral", "sensory", "deafness", "in", "adults", "and", "children", ".", "Intracochlear", "multichannel", "stimulation", "with", "sophisticated", "speech", "coding", "strategies", "has", "proved", "to", "be", "reliable", "and", "safe", "enough", "for", "use", "in", "adults", "as", "well", "as", "young", "children", ";", "thus", ",", "a", "few", "cochlear", "implant", "systems", "with", "different", "specifications", "are", "currently", "available", ".", "The", "differences", "in", "their", "hardware", "and", "software", "are", "discussed", ".", "Furthermore", ",", "the", "current", "indications", "for", "cochlear", "implants", "in", "patients", "whose", "hearing", "is", "severely", "impaired", "and", "important", "aspects", "of", "the", "preoperative", "evaluation", "are", "presented", "with", "special", "emphasis", "on", "dificult", "cases", "such", "as", "deformities", ",", "multihandicapped", "subjects", "and", "very", "young", "children", ".", "Our", "results", "after", "12", "years", "of", "experience", "and", "more", "than", "700", "implantations", "suggest", "that", "the", "most", "important", "prognostic", "factor", "is", "the", "duration", "of", "deafness", "." ]

[ "umlsterm" ]

cochlear implant is an umlsterm, method is an umlsterm, rehabilitation is an umlsterm, deafness is an umlsterm, adults is an umlsterm, children is an umlsterm, speech is an umlsterm, use is an umlsterm, adults is an umlsterm, children is an umlsterm, cochlear implant is an umlsterm, software is an umlsterm, cochlear implants is an umlsterm, patients is an umlsterm, hearing is an umlsterm, evaluation is an umlsterm, deformities is an umlsterm, children is an umlsterm, implantations is an umlsterm, deafness is an umlsterm

HNO.80460012.eng.abstr_task1

Sentence: In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness . Instructions: please typing these entity words according to sentence: cochlear implant, method, rehabilitation, deafness, adults, children, speech, use, adults, children, cochlear implant, software, cochlear implants, patients, hearing, evaluation, deformities, children, implantations, deafness Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness .

[ "In", "recent", "years", "the", "cochlear", "implant", "has", "become", "an", "established", "method", "for", "rehabilitation", "of", "bilateral", "sensory", "deafness", "in", "adults", "and", "children", ".", "Intracochlear", "multichannel", "stimulation", "with", "sophisticated", "speech", "coding", "strategies", "has", "proved", "to", "be", "reliable", "and", "safe", "enough", "for", "use", "in", "adults", "as", "well", "as", "young", "children", ";", "thus", ",", "a", "few", "cochlear", "implant", "systems", "with", "different", "specifications", "are", "currently", "available", ".", "The", "differences", "in", "their", "hardware", "and", "software", "are", "discussed", ".", "Furthermore", ",", "the", "current", "indications", "for", "cochlear", "implants", "in", "patients", "whose", "hearing", "is", "severely", "impaired", "and", "important", "aspects", "of", "the", "preoperative", "evaluation", "are", "presented", "with", "special", "emphasis", "on", "dificult", "cases", "such", "as", "deformities", ",", "multihandicapped", "subjects", "and", "very", "young", "children", ".", "Our", "results", "after", "12", "years", "of", "experience", "and", "more", "than", "700", "implantations", "suggest", "that", "the", "most", "important", "prognostic", "factor", "is", "the", "duration", "of", "deafness", "." ]

[ "umlsterm" ]

cochlear implant, method, rehabilitation, deafness, adults, children, speech, use, adults, children, cochlear implant, software, cochlear implants, patients, hearing, evaluation, deformities, children, implantations, deafness

HNO.80460012.eng.abstr_task2

Sentence: In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

In recent years the cochlear implant has become an established method for rehabilitation of bilateral sensory deafness in adults and children . Intracochlear multichannel stimulation with sophisticated speech coding strategies has proved to be reliable and safe enough for use in adults as well as young children ; thus , a few cochlear implant systems with different specifications are currently available . The differences in their hardware and software are discussed . Furthermore , the current indications for cochlear implants in patients whose hearing is severely impaired and important aspects of the preoperative evaluation are presented with special emphasis on dificult cases such as deformities , multihandicapped subjects and very young children . Our results after 12 years of experience and more than 700 implantations suggest that the most important prognostic factor is the duration of deafness .

[ "In", "recent", "years", "the", "cochlear", "implant", "has", "become", "an", "established", "method", "for", "rehabilitation", "of", "bilateral", "sensory", "deafness", "in", "adults", "and", "children", ".", "Intracochlear", "multichannel", "stimulation", "with", "sophisticated", "speech", "coding", "strategies", "has", "proved", "to", "be", "reliable", "and", "safe", "enough", "for", "use", "in", "adults", "as", "well", "as", "young", "children", ";", "thus", ",", "a", "few", "cochlear", "implant", "systems", "with", "different", "specifications", "are", "currently", "available", ".", "The", "differences", "in", "their", "hardware", "and", "software", "are", "discussed", ".", "Furthermore", ",", "the", "current", "indications", "for", "cochlear", "implants", "in", "patients", "whose", "hearing", "is", "severely", "impaired", "and", "important", "aspects", "of", "the", "preoperative", "evaluation", "are", "presented", "with", "special", "emphasis", "on", "dificult", "cases", "such", "as", "deformities", ",", "multihandicapped", "subjects", "and", "very", "young", "children", ".", "Our", "results", "after", "12", "years", "of", "experience", "and", "more", "than", "700", "implantations", "suggest", "that", "the", "most", "important", "prognostic", "factor", "is", "the", "duration", "of", "deafness", "." ]

[ "umlsterm" ]

Verwendung is an umlsterm, Kreuzbandchirurgie is an umlsterm, Transplantatentnahmemorbiditaet is an umlsterm, Zugfestigkeit is an umlsterm, Transplantatintegration is an umlsterm, Transplantatverankerung is an umlsterm, Gelenkspalt is an umlsterm, biologischen Faktoren is an umlsterm, Weichgewebe - Transplantaten is an umlsterm

DerChirurg.00711034.ger.abstr_task0

Sentence: Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation .

[ "Zusammenfassung", ".", "Die", "Verwendung", "von", "Hamstringsehnen", "-", "Transplantaten", "in", "der", "Kreuzbandchirurgie", "hat", "in", "den", "letzten", "Jahren", "wieder", "zunehmend", "an", "Bedeutung", "gewonnen", ".", "Der", "wesentliche", "Vorteil", "der", "Hamstringsehnen", "gegenueber", "dem", "mittleren", "Patellarsehnendrittel", "liegt", "in", "einer", "erheblich", "reduzierten", "Transplantatentnahmemorbiditaet", ",", "kombiniert", "mit", "einer", "sehr", "hohen", "Zugfestigkeit", ".", "Die", "ossaere", "Transplantatintegration", "unterliegt", "jedoch", "spezifischen", "biomechanischen", "und", "biologischen", "Rahmenbedingungen", ".", "Neue", "Entwicklungen", "auf", "dem", "Gebiet", "der", "Transplantatverankerung", "haben", "sich", "darauf", "konzentriert", "die", "initiale", "Verankerungsfestigkeit", "zu", "erhoehen", "und", "das", "Verankerungslevel", "weiter", "in", "Richtung", "Gelenkspalt", "zu", "verschieben", ".", "Es", "wird", "also", "eine", "anatomische", "Verankerung", ",", "moeglichst", "nahe", "dem", "original", "Kreuzbandansatz", "angestrebt", ".", "Ziel", "der", "vorliegenden", "Uebersichtsarbeit", "ist", "es", "neue", "Entwicklungen", "unter", "besonderer", "Beruecksichtigung", "von", "biomechanischen", "und", "biologischen", "Faktoren", "vorzustellen", "und", "zu", "diskutieren", ".", "Spezielles", "Augenmerk", "liegt", "hier", "auf", "der", "Interferenzschrauben", "-", "Verankerung", "von", "Weichgewebe", "-", "Transplantaten", ",", "femoralen", "Transfixationsystemen", "und", "dem", "sog", ".", "Konzept", "der", "Hybridfixation", "." ]

[ "umlsterm" ]

Verwendung is an umlsterm, Kreuzbandchirurgie is an umlsterm, Transplantatentnahmemorbiditaet is an umlsterm, Zugfestigkeit is an umlsterm, Transplantatintegration is an umlsterm, Transplantatverankerung is an umlsterm, Gelenkspalt is an umlsterm, biologischen Faktoren is an umlsterm, Weichgewebe - Transplantaten is an umlsterm

DerChirurg.00711034.ger.abstr_task1

Sentence: Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation . Instructions: please typing these entity words according to sentence: Verwendung, Kreuzbandchirurgie, Transplantatentnahmemorbiditaet, Zugfestigkeit, Transplantatintegration, Transplantatverankerung, Gelenkspalt, biologischen Faktoren, Weichgewebe - Transplantaten Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation .

[ "Zusammenfassung", ".", "Die", "Verwendung", "von", "Hamstringsehnen", "-", "Transplantaten", "in", "der", "Kreuzbandchirurgie", "hat", "in", "den", "letzten", "Jahren", "wieder", "zunehmend", "an", "Bedeutung", "gewonnen", ".", "Der", "wesentliche", "Vorteil", "der", "Hamstringsehnen", "gegenueber", "dem", "mittleren", "Patellarsehnendrittel", "liegt", "in", "einer", "erheblich", "reduzierten", "Transplantatentnahmemorbiditaet", ",", "kombiniert", "mit", "einer", "sehr", "hohen", "Zugfestigkeit", ".", "Die", "ossaere", "Transplantatintegration", "unterliegt", "jedoch", "spezifischen", "biomechanischen", "und", "biologischen", "Rahmenbedingungen", ".", "Neue", "Entwicklungen", "auf", "dem", "Gebiet", "der", "Transplantatverankerung", "haben", "sich", "darauf", "konzentriert", "die", "initiale", "Verankerungsfestigkeit", "zu", "erhoehen", "und", "das", "Verankerungslevel", "weiter", "in", "Richtung", "Gelenkspalt", "zu", "verschieben", ".", "Es", "wird", "also", "eine", "anatomische", "Verankerung", ",", "moeglichst", "nahe", "dem", "original", "Kreuzbandansatz", "angestrebt", ".", "Ziel", "der", "vorliegenden", "Uebersichtsarbeit", "ist", "es", "neue", "Entwicklungen", "unter", "besonderer", "Beruecksichtigung", "von", "biomechanischen", "und", "biologischen", "Faktoren", "vorzustellen", "und", "zu", "diskutieren", ".", "Spezielles", "Augenmerk", "liegt", "hier", "auf", "der", "Interferenzschrauben", "-", "Verankerung", "von", "Weichgewebe", "-", "Transplantaten", ",", "femoralen", "Transfixationsystemen", "und", "dem", "sog", ".", "Konzept", "der", "Hybridfixation", "." ]

[ "umlsterm" ]

Verwendung, Kreuzbandchirurgie, Transplantatentnahmemorbiditaet, Zugfestigkeit, Transplantatintegration, Transplantatverankerung, Gelenkspalt, biologischen Faktoren, Weichgewebe - Transplantaten

DerChirurg.00711034.ger.abstr_task2

Sentence: Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Verwendung von Hamstringsehnen-Transplantaten in der Kreuzbandchirurgie hat in den letzten Jahren wieder zunehmend an Bedeutung gewonnen . Der wesentliche Vorteil der Hamstringsehnen gegenueber dem mittleren Patellarsehnendrittel liegt in einer erheblich reduzierten Transplantatentnahmemorbiditaet , kombiniert mit einer sehr hohen Zugfestigkeit . Die ossaere Transplantatintegration unterliegt jedoch spezifischen biomechanischen und biologischen Rahmenbedingungen . Neue Entwicklungen auf dem Gebiet der Transplantatverankerung haben sich darauf konzentriert die initiale Verankerungsfestigkeit zu erhoehen und das Verankerungslevel weiter in Richtung Gelenkspalt zu verschieben . Es wird also eine anatomische Verankerung , moeglichst nahe dem original Kreuzbandansatz angestrebt . Ziel der vorliegenden Uebersichtsarbeit ist es neue Entwicklungen unter besonderer Beruecksichtigung von biomechanischen und biologischen Faktoren vorzustellen und zu diskutieren . Spezielles Augenmerk liegt hier auf der Interferenzschrauben-Verankerung von Weichgewebe-Transplantaten , femoralen Transfixationsystemen und dem sog . Konzept der Hybridfixation .

[ "Zusammenfassung", ".", "Die", "Verwendung", "von", "Hamstringsehnen", "-", "Transplantaten", "in", "der", "Kreuzbandchirurgie", "hat", "in", "den", "letzten", "Jahren", "wieder", "zunehmend", "an", "Bedeutung", "gewonnen", ".", "Der", "wesentliche", "Vorteil", "der", "Hamstringsehnen", "gegenueber", "dem", "mittleren", "Patellarsehnendrittel", "liegt", "in", "einer", "erheblich", "reduzierten", "Transplantatentnahmemorbiditaet", ",", "kombiniert", "mit", "einer", "sehr", "hohen", "Zugfestigkeit", ".", "Die", "ossaere", "Transplantatintegration", "unterliegt", "jedoch", "spezifischen", "biomechanischen", "und", "biologischen", "Rahmenbedingungen", ".", "Neue", "Entwicklungen", "auf", "dem", "Gebiet", "der", "Transplantatverankerung", "haben", "sich", "darauf", "konzentriert", "die", "initiale", "Verankerungsfestigkeit", "zu", "erhoehen", "und", "das", "Verankerungslevel", "weiter", "in", "Richtung", "Gelenkspalt", "zu", "verschieben", ".", "Es", "wird", "also", "eine", "anatomische", "Verankerung", ",", "moeglichst", "nahe", "dem", "original", "Kreuzbandansatz", "angestrebt", ".", "Ziel", "der", "vorliegenden", "Uebersichtsarbeit", "ist", "es", "neue", "Entwicklungen", "unter", "besonderer", "Beruecksichtigung", "von", "biomechanischen", "und", "biologischen", "Faktoren", "vorzustellen", "und", "zu", "diskutieren", ".", "Spezielles", "Augenmerk", "liegt", "hier", "auf", "der", "Interferenzschrauben", "-", "Verankerung", "von", "Weichgewebe", "-", "Transplantaten", ",", "femoralen", "Transfixationsystemen", "und", "dem", "sog", ".", "Konzept", "der", "Hybridfixation", "." ]

[ "umlsterm" ]

H2O2 is a compound, IL-6 is a protein

DS.d1608_task0

Sentence: Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]

Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels.

[ "Muscular", "oxidative", "stress", "and", "inflammation", "induced", "by", "H2O2", "or", "MS", "were", "assessed", "by", "measurements", "of", "isoprostanes", "and", "IL-6", "levels", "." ]

[ "protein", "compound" ]

H2O2 is a compound, IL-6 is a protein

DS.d1608_task1

Sentence: Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels. Instructions: please typing these entity words according to sentence: H2O2, IL-6 Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]

Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels.

[ "Muscular", "oxidative", "stress", "and", "inflammation", "induced", "by", "H2O2", "or", "MS", "were", "assessed", "by", "measurements", "of", "isoprostanes", "and", "IL-6", "levels", "." ]

[ "protein", "compound" ]

H2O2, IL-6

DS.d1608_task2

Sentence: Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O" ]

Muscular oxidative stress and inflammation induced by H2O2 or MS were assessed by measurements of isoprostanes and IL-6 levels.

[ "Muscular", "oxidative", "stress", "and", "inflammation", "induced", "by", "H2O2", "or", "MS", "were", "assessed", "by", "measurements", "of", "isoprostanes", "and", "IL-6", "levels", "." ]

[ "protein", "compound" ]

complication is an umlsterm, stent is an umlsterm, implantation is an umlsterm, arteries is an umlsterm, complications is an umlsterm, case report is an umlsterm, artery is an umlsterm, old is an umlsterm, graft is an umlsterm, stent - implantation is an umlsterm, vessel is an umlsterm, methods is an umlsterm, pericardial effusion is an umlsterm, patient is an umlsterm, surgical revision is an umlsterm

ZfuerKardiologie.80870233.eng.abstr_task0

Sentence: We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed .

[ "We", "describe", "a", "case", "-", "report", "on", "an", "perforation", "of", "an", "aorto", "-", "coronary", "venous", "bypass", "-", "graft", ",", "a", "complication", "induced", "by", "a", "stent", "implantation", ".", "Perforations", "of", "coronary", "arteries", "are", "rare", ",", "however", ",", "for", "interventional", "cardiologists", "well", "-", "known", "complications", ".", "This", "case", "report", "is", "of", "special", "interest", "(", "1", ")", "because", "the", "perforation", "did", "not", "occur", "in", "a", "coronary", "artery", "but", "rather", "in", "an", "eight", "year", "old", "venous", "bypass", "graft", "and", "(", "2", ")", "because", "the", "perforation", "was", "induced", "by", "a", "stent", "-", "implantation", ".", "In", "addition", ",", "this", "case", "-", "report", "describes", "in", "great", "detail", "the", "management", "of", "vessel", "perforation", ":", "several", "invasive", "methods", "contributed", "to", "minimize", "pericardial", "effusion", "and", "to", "stabilize", "the", "patient", "until", "surgical", "revision", "could", "be", "performed", "." ]

[ "umlsterm" ]

complication is an umlsterm, stent is an umlsterm, implantation is an umlsterm, arteries is an umlsterm, complications is an umlsterm, case report is an umlsterm, artery is an umlsterm, old is an umlsterm, graft is an umlsterm, stent - implantation is an umlsterm, vessel is an umlsterm, methods is an umlsterm, pericardial effusion is an umlsterm, patient is an umlsterm, surgical revision is an umlsterm

ZfuerKardiologie.80870233.eng.abstr_task1

Sentence: We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed . Instructions: please typing these entity words according to sentence: complication, stent, implantation, arteries, complications, case report, artery, old, graft, stent - implantation, vessel, methods, pericardial effusion, patient, surgical revision Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed .

[ "We", "describe", "a", "case", "-", "report", "on", "an", "perforation", "of", "an", "aorto", "-", "coronary", "venous", "bypass", "-", "graft", ",", "a", "complication", "induced", "by", "a", "stent", "implantation", ".", "Perforations", "of", "coronary", "arteries", "are", "rare", ",", "however", ",", "for", "interventional", "cardiologists", "well", "-", "known", "complications", ".", "This", "case", "report", "is", "of", "special", "interest", "(", "1", ")", "because", "the", "perforation", "did", "not", "occur", "in", "a", "coronary", "artery", "but", "rather", "in", "an", "eight", "year", "old", "venous", "bypass", "graft", "and", "(", "2", ")", "because", "the", "perforation", "was", "induced", "by", "a", "stent", "-", "implantation", ".", "In", "addition", ",", "this", "case", "-", "report", "describes", "in", "great", "detail", "the", "management", "of", "vessel", "perforation", ":", "several", "invasive", "methods", "contributed", "to", "minimize", "pericardial", "effusion", "and", "to", "stabilize", "the", "patient", "until", "surgical", "revision", "could", "be", "performed", "." ]

[ "umlsterm" ]

complication, stent, implantation, arteries, complications, case report, artery, old, graft, stent - implantation, vessel, methods, pericardial effusion, patient, surgical revision

ZfuerKardiologie.80870233.eng.abstr_task2

Sentence: We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

We describe a case-report on an perforation of an aorto-coronary venous bypass-graft , a complication induced by a stent implantation . Perforations of coronary arteries are rare , however , for interventional cardiologists well-known complications . This case report is of special interest ( 1 ) because the perforation did not occur in a coronary artery but rather in an eight year old venous bypass graft and ( 2 ) because the perforation was induced by a stent-implantation . In addition , this case-report describes in great detail the management of vessel perforation : several invasive methods contributed to minimize pericardial effusion and to stabilize the patient until surgical revision could be performed .

[ "We", "describe", "a", "case", "-", "report", "on", "an", "perforation", "of", "an", "aorto", "-", "coronary", "venous", "bypass", "-", "graft", ",", "a", "complication", "induced", "by", "a", "stent", "implantation", ".", "Perforations", "of", "coronary", "arteries", "are", "rare", ",", "however", ",", "for", "interventional", "cardiologists", "well", "-", "known", "complications", ".", "This", "case", "report", "is", "of", "special", "interest", "(", "1", ")", "because", "the", "perforation", "did", "not", "occur", "in", "a", "coronary", "artery", "but", "rather", "in", "an", "eight", "year", "old", "venous", "bypass", "graft", "and", "(", "2", ")", "because", "the", "perforation", "was", "induced", "by", "a", "stent", "-", "implantation", ".", "In", "addition", ",", "this", "case", "-", "report", "describes", "in", "great", "detail", "the", "management", "of", "vessel", "perforation", ":", "several", "invasive", "methods", "contributed", "to", "minimize", "pericardial", "effusion", "and", "to", "stabilize", "the", "patient", "until", "surgical", "revision", "could", "be", "performed", "." ]

[ "umlsterm" ]

Italian and US American context sensitivity and Fear of Isolation is a Participant_Condition, differences is a Outcome_Other, chronic is a Outcome_Physical, different Western cultures is a Participant_Condition, Testing Italian ( IT ) and US American ( US ) is a Participant_Condition, adults is a Participant_Age, information more holistically and had a higher chronic level of FOI is a Outcome_Physical, US participants is a Participant_Condition, FOI affected context sensitivity is a Outcome_Mental, this difference is due to different chronic levels of FOI . is a Outcome_Physical

48234_task0

Sentence: West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]

West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI .

[ "West", "vs", ".", "West", "like", "East", "vs", ".", "West", "?", "A", "comparison", "between", "Italian", "and", "US", "American", "context", "sensitivity", "and", "Fear", "of", "Isolation", ".", "Easterners", "tend", "to", "process", "information", "more", "holistically", "than", "Westerners", ".", "Kim", "and", "Markman", "(", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "suggest", "that", "these", "differences", "are", "rooted", "in", "higher", "chronic", "levels", "of", "Fear", "of", "Isolation", "(", "FOI", ")", "for", "those", "cultures", "that", "process", "information", "more", "holistically", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "if", "these", "differences", "and", "their", "suggested", "cause", "could", "be", "found", "with", "two", "different", "Western", "cultures", ".", "Testing", "Italian", "(", "IT", ")", "and", "US", "American", "(", "US", ")", "adults", ",", "we", "found", "that", "IT", "participants", "processed", "information", "more", "holistically", "and", "had", "a", "higher", "chronic", "level", "of", "FOI", "than", "US", "participants", ";", "furthermore", ",", "the", "manipulation", "of", "FOI", "affected", "context", "sensitivity", "more", "for", "IT", "than", "for", "US", "participants", ".", "The", "results", "demonstrate", "that", "IT", "participants", "were", "more", "similar", "to", "previous", "research", "with", "Eastern", "populations", "than", "with", "Western", "populations", "(", "Kim", "and", "Markman", "in", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "and", "indicate", "a", "within", "-", "Western", "culture", "difference", "for", "reasoning", "styles", "and", "support", "the", "hypothesis", "that", "this", "difference", "is", "due", "to", "different", "chronic", "levels", "of", "FOI", "." ]

[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Outcome_Other", "Participant_Age" ]

Italian and US American context sensitivity and Fear of Isolation is a Participant_Condition, differences is a Outcome_Other, chronic is a Outcome_Physical, different Western cultures is a Participant_Condition, Testing Italian ( IT ) and US American ( US ) is a Participant_Condition, adults is a Participant_Age, information more holistically and had a higher chronic level of FOI is a Outcome_Physical, US participants is a Participant_Condition, FOI affected context sensitivity is a Outcome_Mental, this difference is due to different chronic levels of FOI . is a Outcome_Physical

48234_task1

Sentence: West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI . Instructions: please typing these entity words according to sentence: Italian and US American context sensitivity and Fear of Isolation, differences, chronic, different Western cultures, Testing Italian ( IT ) and US American ( US ), adults, information more holistically and had a higher chronic level of FOI, US participants, FOI affected context sensitivity, this difference is due to different chronic levels of FOI . Options: Participant_Condition, Participant_Age, Outcome_Physical, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]

West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI .

[ "West", "vs", ".", "West", "like", "East", "vs", ".", "West", "?", "A", "comparison", "between", "Italian", "and", "US", "American", "context", "sensitivity", "and", "Fear", "of", "Isolation", ".", "Easterners", "tend", "to", "process", "information", "more", "holistically", "than", "Westerners", ".", "Kim", "and", "Markman", "(", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "suggest", "that", "these", "differences", "are", "rooted", "in", "higher", "chronic", "levels", "of", "Fear", "of", "Isolation", "(", "FOI", ")", "for", "those", "cultures", "that", "process", "information", "more", "holistically", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "if", "these", "differences", "and", "their", "suggested", "cause", "could", "be", "found", "with", "two", "different", "Western", "cultures", ".", "Testing", "Italian", "(", "IT", ")", "and", "US", "American", "(", "US", ")", "adults", ",", "we", "found", "that", "IT", "participants", "processed", "information", "more", "holistically", "and", "had", "a", "higher", "chronic", "level", "of", "FOI", "than", "US", "participants", ";", "furthermore", ",", "the", "manipulation", "of", "FOI", "affected", "context", "sensitivity", "more", "for", "IT", "than", "for", "US", "participants", ".", "The", "results", "demonstrate", "that", "IT", "participants", "were", "more", "similar", "to", "previous", "research", "with", "Eastern", "populations", "than", "with", "Western", "populations", "(", "Kim", "and", "Markman", "in", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "and", "indicate", "a", "within", "-", "Western", "culture", "difference", "for", "reasoning", "styles", "and", "support", "the", "hypothesis", "that", "this", "difference", "is", "due", "to", "different", "chronic", "levels", "of", "FOI", "." ]

[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Outcome_Other", "Participant_Age" ]

Italian and US American context sensitivity and Fear of Isolation, differences, chronic, different Western cultures, Testing Italian ( IT ) and US American ( US ), adults, information more holistically and had a higher chronic level of FOI, US participants, FOI affected context sensitivity, this difference is due to different chronic levels of FOI .

48234_task2

Sentence: West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical" ]

West vs. West like East vs. West ? A comparison between Italian and US American context sensitivity and Fear of Isolation . Easterners tend to process information more holistically than Westerners . Kim and Markman ( J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) suggest that these differences are rooted in higher chronic levels of Fear of Isolation ( FOI ) for those cultures that process information more holistically . The goal of this study was to determine if these differences and their suggested cause could be found with two different Western cultures . Testing Italian ( IT ) and US American ( US ) adults , we found that IT participants processed information more holistically and had a higher chronic level of FOI than US participants ; furthermore , the manipulation of FOI affected context sensitivity more for IT than for US participants . The results demonstrate that IT participants were more similar to previous research with Eastern populations than with Western populations ( Kim and Markman in J Exp Soc Psychol 42 ( 3 ) :350-364 , 2006 ) and indicate a within-Western culture difference for reasoning styles and support the hypothesis that this difference is due to different chronic levels of FOI .

[ "West", "vs", ".", "West", "like", "East", "vs", ".", "West", "?", "A", "comparison", "between", "Italian", "and", "US", "American", "context", "sensitivity", "and", "Fear", "of", "Isolation", ".", "Easterners", "tend", "to", "process", "information", "more", "holistically", "than", "Westerners", ".", "Kim", "and", "Markman", "(", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "suggest", "that", "these", "differences", "are", "rooted", "in", "higher", "chronic", "levels", "of", "Fear", "of", "Isolation", "(", "FOI", ")", "for", "those", "cultures", "that", "process", "information", "more", "holistically", ".", "The", "goal", "of", "this", "study", "was", "to", "determine", "if", "these", "differences", "and", "their", "suggested", "cause", "could", "be", "found", "with", "two", "different", "Western", "cultures", ".", "Testing", "Italian", "(", "IT", ")", "and", "US", "American", "(", "US", ")", "adults", ",", "we", "found", "that", "IT", "participants", "processed", "information", "more", "holistically", "and", "had", "a", "higher", "chronic", "level", "of", "FOI", "than", "US", "participants", ";", "furthermore", ",", "the", "manipulation", "of", "FOI", "affected", "context", "sensitivity", "more", "for", "IT", "than", "for", "US", "participants", ".", "The", "results", "demonstrate", "that", "IT", "participants", "were", "more", "similar", "to", "previous", "research", "with", "Eastern", "populations", "than", "with", "Western", "populations", "(", "Kim", "and", "Markman", "in", "J", "Exp", "Soc", "Psychol", "42", "(", "3", ")", ":", "350", "-", "364", ",", "2006", ")", "and", "indicate", "a", "within", "-", "Western", "culture", "difference", "for", "reasoning", "styles", "and", "support", "the", "hypothesis", "that", "this", "difference", "is", "due", "to", "different", "chronic", "levels", "of", "FOI", "." ]

[ "Outcome_Physical", "Participant_Condition", "Outcome_Mental", "Outcome_Other", "Participant_Age" ]

heparin ( dalteparin ) is a Intervention_Pharmacological, extended duration therapy is a Intervention_Pharmacological, venous thromboembolism is a Participant_Condition, cancer is a Participant_Condition, anti - Xa levels is a Outcome_Physical, acute venous thromboembolism is a Participant_Condition, active cancer is a Participant_Condition, oral anticoagulant therapy is a Intervention_Pharmacological, Anti - Xa levels is a Outcome_Physical, bleeding is a Outcome_Adverse-effects, recurrent venous thromboembolism is a Outcome_Physical, 24 patients is a Participant_Sample-size, died is a Outcome_Mortality, mean anti - Xa levels is a Outcome_Physical, accumulation of anti - Xa effect is a Outcome_Physical

22422_task0

Sentence: Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required .

[ "Anti", "-", "Xa", "effect", "of", "a", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "does", "not", "accumulate", "in", "extended", "duration", "therapy", "for", "venous", "thromboembolism", "in", "cancer", "patients", ".", "Many", "patients", "with", "venous", "thromboembolism", "are", "being", "treated", "with", "low", "molecular", "weight", "heparin", "for", "extended", "periods", "of", "time", ".", "It", "is", "not", "certain", "if", "it", "is", "necessary", "to", "assess", "anti", "-", "Xa", "levels", "for", "extended", "treatment", "periods", ".", "This", "study", "is", "a", "prospective", "assessment", "of", "anti", "-", "Xa", "levels", "in", "patients", "on", "long", "-", "term", "therapy", "for", "acute", "venous", "thromboembolism", "who", "have", "active", "cancer", ".", "Consecutive", "consenting", "patients", "from", "one", "center", "in", "a", "multicenter", "trial", "that", "compared", "6", "months", "of", "low", "molecular", "weight", "heparin", "with", "oral", "anticoagulant", "therapy", "were", "treated", "with", "therapeutic", "doses", "of", "dalteparin", "(", "200", "IU", "per", "kilogram", ")", "subcutaneously", "daily", ".", "Anti", "-", "Xa", "levels", "were", "assessed", "at", "the", "end", "of", "weeks", "1", "and", "4,4", "-", "6", "hours", "after", "injection", "of", "dalteparin", ".", "Patients", "were", "followed", "for", "bleeding", "and", "recurrent", "venous", "thromboembolism", ".", "There", "were", "24", "patients", "who", "had", "anti", "-", "Xa", "levels", "measured", "at", "weeks", "1", "and", "4", ".", "Two", "other", "patients", "had", "week", "1", "measurements", "performed", "but", "died", "before", "the", "week", "4", "sample", "was", "collected", "due", "to", "their", "underlying", "cancer", ".", "The", "mean", "anti", "-", "Xa", "levels", "at", "weeks", "1", "and", "4", "were", "1.11", "and", "1.03", "anti", "-", "Xa", "units", "/", "ml", "respectively", "(", "P=0.13", ")", ".", "These", "results", "suggest", "that", "for", "patients", "with", "active", "cancer", "receiving", "extended", "duration", "therapy", "with", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "there", "is", "no", "accumulation", "of", "anti", "-", "Xa", "effect", "over", "the", "first", "month", "of", "therapy", ".", "Monitoring", "of", "anti", "-", "Xa", "levels", "in", "this", "situation", "is", "usually", "not", "required", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Adverse-effects", "Outcome_Mortality" ]

heparin ( dalteparin ) is a Intervention_Pharmacological, extended duration therapy is a Intervention_Pharmacological, venous thromboembolism is a Participant_Condition, cancer is a Participant_Condition, anti - Xa levels is a Outcome_Physical, acute venous thromboembolism is a Participant_Condition, active cancer is a Participant_Condition, oral anticoagulant therapy is a Intervention_Pharmacological, Anti - Xa levels is a Outcome_Physical, bleeding is a Outcome_Adverse-effects, recurrent venous thromboembolism is a Outcome_Physical, 24 patients is a Participant_Sample-size, died is a Outcome_Mortality, mean anti - Xa levels is a Outcome_Physical, accumulation of anti - Xa effect is a Outcome_Physical

22422_task1

Sentence: Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required . Instructions: please typing these entity words according to sentence: heparin ( dalteparin ), extended duration therapy, venous thromboembolism, cancer, anti - Xa levels, acute venous thromboembolism, active cancer, oral anticoagulant therapy, Anti - Xa levels, bleeding, recurrent venous thromboembolism, 24 patients, died, mean anti - Xa levels, accumulation of anti - Xa effect Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required .

[ "Anti", "-", "Xa", "effect", "of", "a", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "does", "not", "accumulate", "in", "extended", "duration", "therapy", "for", "venous", "thromboembolism", "in", "cancer", "patients", ".", "Many", "patients", "with", "venous", "thromboembolism", "are", "being", "treated", "with", "low", "molecular", "weight", "heparin", "for", "extended", "periods", "of", "time", ".", "It", "is", "not", "certain", "if", "it", "is", "necessary", "to", "assess", "anti", "-", "Xa", "levels", "for", "extended", "treatment", "periods", ".", "This", "study", "is", "a", "prospective", "assessment", "of", "anti", "-", "Xa", "levels", "in", "patients", "on", "long", "-", "term", "therapy", "for", "acute", "venous", "thromboembolism", "who", "have", "active", "cancer", ".", "Consecutive", "consenting", "patients", "from", "one", "center", "in", "a", "multicenter", "trial", "that", "compared", "6", "months", "of", "low", "molecular", "weight", "heparin", "with", "oral", "anticoagulant", "therapy", "were", "treated", "with", "therapeutic", "doses", "of", "dalteparin", "(", "200", "IU", "per", "kilogram", ")", "subcutaneously", "daily", ".", "Anti", "-", "Xa", "levels", "were", "assessed", "at", "the", "end", "of", "weeks", "1", "and", "4,4", "-", "6", "hours", "after", "injection", "of", "dalteparin", ".", "Patients", "were", "followed", "for", "bleeding", "and", "recurrent", "venous", "thromboembolism", ".", "There", "were", "24", "patients", "who", "had", "anti", "-", "Xa", "levels", "measured", "at", "weeks", "1", "and", "4", ".", "Two", "other", "patients", "had", "week", "1", "measurements", "performed", "but", "died", "before", "the", "week", "4", "sample", "was", "collected", "due", "to", "their", "underlying", "cancer", ".", "The", "mean", "anti", "-", "Xa", "levels", "at", "weeks", "1", "and", "4", "were", "1.11", "and", "1.03", "anti", "-", "Xa", "units", "/", "ml", "respectively", "(", "P=0.13", ")", ".", "These", "results", "suggest", "that", "for", "patients", "with", "active", "cancer", "receiving", "extended", "duration", "therapy", "with", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "there", "is", "no", "accumulation", "of", "anti", "-", "Xa", "effect", "over", "the", "first", "month", "of", "therapy", ".", "Monitoring", "of", "anti", "-", "Xa", "levels", "in", "this", "situation", "is", "usually", "not", "required", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Adverse-effects", "Outcome_Mortality" ]

heparin ( dalteparin ), extended duration therapy, venous thromboembolism, cancer, anti - Xa levels, acute venous thromboembolism, active cancer, oral anticoagulant therapy, Anti - Xa levels, bleeding, recurrent venous thromboembolism, 24 patients, died, mean anti - Xa levels, accumulation of anti - Xa effect

22422_task2

Sentence: Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anti-Xa effect of a low molecular weight heparin ( dalteparin ) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients . Many patients with venous thromboembolism are being treated with low molecular weight heparin for extended periods of time . It is not certain if it is necessary to assess anti-Xa levels for extended treatment periods . This study is a prospective assessment of anti-Xa levels in patients on long-term therapy for acute venous thromboembolism who have active cancer . Consecutive consenting patients from one center in a multicenter trial that compared 6 months of low molecular weight heparin with oral anticoagulant therapy were treated with therapeutic doses of dalteparin ( 200 IU per kilogram ) subcutaneously daily . Anti-Xa levels were assessed at the end of weeks 1 and 4,4-6 hours after injection of dalteparin . Patients were followed for bleeding and recurrent venous thromboembolism . There were 24 patients who had anti-Xa levels measured at weeks 1 and 4 . Two other patients had week 1 measurements performed but died before the week 4 sample was collected due to their underlying cancer . The mean anti-Xa levels at weeks 1 and 4 were 1.11 and 1.03 anti-Xa units/ml respectively ( P=0.13 ) . These results suggest that for patients with active cancer receiving extended duration therapy with low molecular weight heparin ( dalteparin ) there is no accumulation of anti-Xa effect over the first month of therapy . Monitoring of anti-Xa levels in this situation is usually not required .

[ "Anti", "-", "Xa", "effect", "of", "a", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "does", "not", "accumulate", "in", "extended", "duration", "therapy", "for", "venous", "thromboembolism", "in", "cancer", "patients", ".", "Many", "patients", "with", "venous", "thromboembolism", "are", "being", "treated", "with", "low", "molecular", "weight", "heparin", "for", "extended", "periods", "of", "time", ".", "It", "is", "not", "certain", "if", "it", "is", "necessary", "to", "assess", "anti", "-", "Xa", "levels", "for", "extended", "treatment", "periods", ".", "This", "study", "is", "a", "prospective", "assessment", "of", "anti", "-", "Xa", "levels", "in", "patients", "on", "long", "-", "term", "therapy", "for", "acute", "venous", "thromboembolism", "who", "have", "active", "cancer", ".", "Consecutive", "consenting", "patients", "from", "one", "center", "in", "a", "multicenter", "trial", "that", "compared", "6", "months", "of", "low", "molecular", "weight", "heparin", "with", "oral", "anticoagulant", "therapy", "were", "treated", "with", "therapeutic", "doses", "of", "dalteparin", "(", "200", "IU", "per", "kilogram", ")", "subcutaneously", "daily", ".", "Anti", "-", "Xa", "levels", "were", "assessed", "at", "the", "end", "of", "weeks", "1", "and", "4,4", "-", "6", "hours", "after", "injection", "of", "dalteparin", ".", "Patients", "were", "followed", "for", "bleeding", "and", "recurrent", "venous", "thromboembolism", ".", "There", "were", "24", "patients", "who", "had", "anti", "-", "Xa", "levels", "measured", "at", "weeks", "1", "and", "4", ".", "Two", "other", "patients", "had", "week", "1", "measurements", "performed", "but", "died", "before", "the", "week", "4", "sample", "was", "collected", "due", "to", "their", "underlying", "cancer", ".", "The", "mean", "anti", "-", "Xa", "levels", "at", "weeks", "1", "and", "4", "were", "1.11", "and", "1.03", "anti", "-", "Xa", "units", "/", "ml", "respectively", "(", "P=0.13", ")", ".", "These", "results", "suggest", "that", "for", "patients", "with", "active", "cancer", "receiving", "extended", "duration", "therapy", "with", "low", "molecular", "weight", "heparin", "(", "dalteparin", ")", "there", "is", "no", "accumulation", "of", "anti", "-", "Xa", "effect", "over", "the", "first", "month", "of", "therapy", ".", "Monitoring", "of", "anti", "-", "Xa", "levels", "in", "this", "situation", "is", "usually", "not", "required", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Participant_Sample-size", "Outcome_Adverse-effects", "Outcome_Mortality" ]

paraganglioma is a Cancer, pheochromocytoma is a Cancer, succinate dehydrogenase is a Gene_or_gene_product, Mitochondrial is a Cellular_component, complex II is a Gene_or_gene_product, succinate dehydrogenase is a Gene_or_gene_product, tricarboxylic acid is a Simple_chemical, TCA is a Simple_chemical, mitochondrial is a Cellular_component, succinate dehydrogenase subunit A is a Gene_or_gene_product, SDHA is a Gene_or_gene_product, patients is a Organism, mitochondrial is a Cellular_component, succinate dehydrogenase is a Gene_or_gene_product, SDHB is a Gene_or_gene_product, SDHC is a Gene_or_gene_product, SDHD is a Gene_or_gene_product, patients is a Organism, paraganglioma is a Cancer, pheochromocytoma is a Cancer, cancer is a Cancer, patients is a Organism, paragangliomas is a Cancer, pheochromocytomas is a Cancer, fumarase is a Gene_or_gene_product, TCA is a Simple_chemical, renal is a Cancer, uterine is a Cancer, cutaneous tumors is a Cancer, TCA is a Simple_chemical, mitochondria is a Cellular_component, cancer is a Cancer

70_task0

Sentence: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product

[ "O", "B-Cancer", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "B-Cancer", "O", "O" ]

Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer.

[ "Hereditary", "paraganglioma", "/", "pheochromocytoma", "and", "inherited", "succinate", "dehydrogenase", "deficiency", ".", "\n", "Mitochondrial", "complex", "II", ",", "or", "succinate", "dehydrogenase", ",", "is", "a", "key", "enzymatic", "complex", "involved", "in", "both", "the", "tricarboxylic", "acid", "(", "TCA", ")", "cycle", "and", "oxidative", "phosphorylation", "as", "part", "of", "the", "mitochondrial", "respiratory", "chain", ".", "Germline", "succinate", "dehydrogenase", "subunit", "A", "(", "SDHA", ")", "mutations", "have", "been", "reported", "in", "a", "few", "patients", "with", "a", "classical", "mitochondrial", "neurodegenerative", "disease", ".", "Mutations", "in", "the", "genes", "encoding", "the", "three", "other", "succinate", "dehydrogenase", "subunits", "(", "SDHB", ",", "SDHC", "and", "SDHD", ")", "have", "been", "identified", "in", "patients", "affected", "by", "familial", "or", "'", "apparently", "sporadic", "'", "paraganglioma", "and", "/", "or", "pheochromocytoma", ",", "an", "autosomal", "inherited", "cancer", "-", "susceptibility", "syndrome", ".", "These", "discoveries", "have", "dramatically", "changed", "the", "work", "-", "up", "and", "genetic", "counseling", "of", "patients", "and", "families", "with", "paragangliomas", "and", "/", "or", "pheochromocytomas", ".", "The", "subsequent", "identification", "of", "germline", "mutations", "in", "the", "gene", "encoding", "fumarase", "--", "another", "TCA", "cycle", "enzyme", "--", "in", "a", "new", "hereditary", "form", "of", "susceptibility", "to", "renal", ",", "uterine", "and", "cutaneous", "tumors", "has", "highlighted", "the", "potential", "role", "of", "the", "TCA", "cycle", "and", ",", "more", "generally", ",", "of", "the", "mitochondria", "in", "cancer", ".", "\n" ]

[ "Gene_or_gene_product", "Simple_chemical", "Cancer", "Cellular_component", "Organism" ]

paraganglioma is a Cancer, pheochromocytoma is a Cancer, succinate dehydrogenase is a Gene_or_gene_product, Mitochondrial is a Cellular_component, complex II is a Gene_or_gene_product, succinate dehydrogenase is a Gene_or_gene_product, tricarboxylic acid is a Simple_chemical, TCA is a Simple_chemical, mitochondrial is a Cellular_component, succinate dehydrogenase subunit A is a Gene_or_gene_product, SDHA is a Gene_or_gene_product, patients is a Organism, mitochondrial is a Cellular_component, succinate dehydrogenase is a Gene_or_gene_product, SDHB is a Gene_or_gene_product, SDHC is a Gene_or_gene_product, SDHD is a Gene_or_gene_product, patients is a Organism, paraganglioma is a Cancer, pheochromocytoma is a Cancer, cancer is a Cancer, patients is a Organism, paragangliomas is a Cancer, pheochromocytomas is a Cancer, fumarase is a Gene_or_gene_product, TCA is a Simple_chemical, renal is a Cancer, uterine is a Cancer, cutaneous tumors is a Cancer, TCA is a Simple_chemical, mitochondria is a Cellular_component, cancer is a Cancer

70_task1

Sentence: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer. Instructions: please typing these entity words according to sentence: paraganglioma, pheochromocytoma, succinate dehydrogenase, Mitochondrial, complex II, succinate dehydrogenase, tricarboxylic acid, TCA, mitochondrial, succinate dehydrogenase subunit A, SDHA, patients, mitochondrial, succinate dehydrogenase, SDHB, SDHC, SDHD, patients, paraganglioma, pheochromocytoma, cancer, patients, paragangliomas, pheochromocytomas, fumarase, TCA, renal, uterine, cutaneous tumors, TCA, mitochondria, cancer Options: Cellular_component, Organism, Simple_chemical, Cancer, Gene_or_gene_product

[ "O", "B-Cancer", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "B-Cancer", "O", "O" ]

Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer.

[ "Hereditary", "paraganglioma", "/", "pheochromocytoma", "and", "inherited", "succinate", "dehydrogenase", "deficiency", ".", "\n", "Mitochondrial", "complex", "II", ",", "or", "succinate", "dehydrogenase", ",", "is", "a", "key", "enzymatic", "complex", "involved", "in", "both", "the", "tricarboxylic", "acid", "(", "TCA", ")", "cycle", "and", "oxidative", "phosphorylation", "as", "part", "of", "the", "mitochondrial", "respiratory", "chain", ".", "Germline", "succinate", "dehydrogenase", "subunit", "A", "(", "SDHA", ")", "mutations", "have", "been", "reported", "in", "a", "few", "patients", "with", "a", "classical", "mitochondrial", "neurodegenerative", "disease", ".", "Mutations", "in", "the", "genes", "encoding", "the", "three", "other", "succinate", "dehydrogenase", "subunits", "(", "SDHB", ",", "SDHC", "and", "SDHD", ")", "have", "been", "identified", "in", "patients", "affected", "by", "familial", "or", "'", "apparently", "sporadic", "'", "paraganglioma", "and", "/", "or", "pheochromocytoma", ",", "an", "autosomal", "inherited", "cancer", "-", "susceptibility", "syndrome", ".", "These", "discoveries", "have", "dramatically", "changed", "the", "work", "-", "up", "and", "genetic", "counseling", "of", "patients", "and", "families", "with", "paragangliomas", "and", "/", "or", "pheochromocytomas", ".", "The", "subsequent", "identification", "of", "germline", "mutations", "in", "the", "gene", "encoding", "fumarase", "--", "another", "TCA", "cycle", "enzyme", "--", "in", "a", "new", "hereditary", "form", "of", "susceptibility", "to", "renal", ",", "uterine", "and", "cutaneous", "tumors", "has", "highlighted", "the", "potential", "role", "of", "the", "TCA", "cycle", "and", ",", "more", "generally", ",", "of", "the", "mitochondria", "in", "cancer", ".", "\n" ]

[ "Gene_or_gene_product", "Simple_chemical", "Cancer", "Cellular_component", "Organism" ]

paraganglioma, pheochromocytoma, succinate dehydrogenase, Mitochondrial, complex II, succinate dehydrogenase, tricarboxylic acid, TCA, mitochondrial, succinate dehydrogenase subunit A, SDHA, patients, mitochondrial, succinate dehydrogenase, SDHB, SDHC, SDHD, patients, paraganglioma, pheochromocytoma, cancer, patients, paragangliomas, pheochromocytomas, fumarase, TCA, renal, uterine, cutaneous tumors, TCA, mitochondria, cancer

70_task2

Sentence: Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer. Instructions: please extract entity words from the input sentence

[ "O", "B-Cancer", "O", "B-Cancer", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "B-Cancer", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "B-Cancer", "O", "B-Cancer", "I-Cancer", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "B-Cancer", "O", "O" ]

Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Mitochondrial complex II, or succinate dehydrogenase, is a key enzymatic complex involved in both the tricarboxylic acid (TCA) cycle and oxidative phosphorylation as part of the mitochondrial respiratory chain. Germline succinate dehydrogenase subunit A (SDHA) mutations have been reported in a few patients with a classical mitochondrial neurodegenerative disease. Mutations in the genes encoding the three other succinate dehydrogenase subunits (SDHB, SDHC and SDHD) have been identified in patients affected by familial or 'apparently sporadic' paraganglioma and/or pheochromocytoma, an autosomal inherited cancer-susceptibility syndrome. These discoveries have dramatically changed the work-up and genetic counseling of patients and families with paragangliomas and/or pheochromocytomas. The subsequent identification of germline mutations in the gene encoding fumarase--another TCA cycle enzyme--in a new hereditary form of susceptibility to renal, uterine and cutaneous tumors has highlighted the potential role of the TCA cycle and, more generally, of the mitochondria in cancer.

[ "Hereditary", "paraganglioma", "/", "pheochromocytoma", "and", "inherited", "succinate", "dehydrogenase", "deficiency", ".", "\n", "Mitochondrial", "complex", "II", ",", "or", "succinate", "dehydrogenase", ",", "is", "a", "key", "enzymatic", "complex", "involved", "in", "both", "the", "tricarboxylic", "acid", "(", "TCA", ")", "cycle", "and", "oxidative", "phosphorylation", "as", "part", "of", "the", "mitochondrial", "respiratory", "chain", ".", "Germline", "succinate", "dehydrogenase", "subunit", "A", "(", "SDHA", ")", "mutations", "have", "been", "reported", "in", "a", "few", "patients", "with", "a", "classical", "mitochondrial", "neurodegenerative", "disease", ".", "Mutations", "in", "the", "genes", "encoding", "the", "three", "other", "succinate", "dehydrogenase", "subunits", "(", "SDHB", ",", "SDHC", "and", "SDHD", ")", "have", "been", "identified", "in", "patients", "affected", "by", "familial", "or", "'", "apparently", "sporadic", "'", "paraganglioma", "and", "/", "or", "pheochromocytoma", ",", "an", "autosomal", "inherited", "cancer", "-", "susceptibility", "syndrome", ".", "These", "discoveries", "have", "dramatically", "changed", "the", "work", "-", "up", "and", "genetic", "counseling", "of", "patients", "and", "families", "with", "paragangliomas", "and", "/", "or", "pheochromocytomas", ".", "The", "subsequent", "identification", "of", "germline", "mutations", "in", "the", "gene", "encoding", "fumarase", "--", "another", "TCA", "cycle", "enzyme", "--", "in", "a", "new", "hereditary", "form", "of", "susceptibility", "to", "renal", ",", "uterine", "and", "cutaneous", "tumors", "has", "highlighted", "the", "potential", "role", "of", "the", "TCA", "cycle", "and", ",", "more", "generally", ",", "of", "the", "mitochondria", "in", "cancer", ".", "\n" ]

[ "Gene_or_gene_product", "Simple_chemical", "Cancer", "Cellular_component", "Organism" ]

Cholinesterase is a GENE-N, carboxylesterase is a GENE-N, azinphos - methyl is a CHEMICAL, chlorpyrifos is a CHEMICAL

23291050_task0

Sentence: Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O" ]

Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.

[ "Cholinesterase", "and", "carboxylesterase", "inhibition", "in", "Planorbarius", "corneus", "exposed", "to", "binary", "mixtures", "of", "azinphos", "-", "methyl", "and", "chlorpyrifos", "." ]

[ "GENE-N", "CHEMICAL" ]

Cholinesterase is a GENE-N, carboxylesterase is a GENE-N, azinphos - methyl is a CHEMICAL, chlorpyrifos is a CHEMICAL

23291050_task1

Sentence: Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos. Instructions: please typing these entity words according to sentence: Cholinesterase, carboxylesterase, azinphos - methyl, chlorpyrifos Options: GENE-N, CHEMICAL

[ "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O" ]

Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.

[ "Cholinesterase", "and", "carboxylesterase", "inhibition", "in", "Planorbarius", "corneus", "exposed", "to", "binary", "mixtures", "of", "azinphos", "-", "methyl", "and", "chlorpyrifos", "." ]

[ "GENE-N", "CHEMICAL" ]

Cholinesterase, carboxylesterase, azinphos - methyl, chlorpyrifos

23291050_task2

Sentence: Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos. Instructions: please extract entity words from the input sentence

[ "B-GENE-N", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O" ]

Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.

[ "Cholinesterase", "and", "carboxylesterase", "inhibition", "in", "Planorbarius", "corneus", "exposed", "to", "binary", "mixtures", "of", "azinphos", "-", "methyl", "and", "chlorpyrifos", "." ]

[ "GENE-N", "CHEMICAL" ]

Angiopoietin-1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Tissue, Src is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Angiopoietin 1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, blood vessels is a Multi-tissue_structure, VEGF is a Gene_or_gene_product, plasma is a Organism_substance, Ang1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, endothelial is a Tissue, Ang1 is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, mDia is a Gene_or_gene_product, RhoA is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Cell

38_task0

Sentence: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, Gene_or_gene_product, Organism_substance, Multi-tissue_structure, Cell

[ "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability.

[ "Angiopoietin-1", "prevents", "VEGF", "-", "induced", "endothelial", "permeability", "by", "sequestering", "Src", "through", "mDia", ".", "\n\n", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "and", "Angiopoietin", "1", "(", "Ang1", ")", "are", "both", "potent", "proangiogenic", "factors", ",", "but", ",", "whereas", "VEGF", "causes", "vascular", "permeability", ",", "Ang1", "stabilizes", "blood", "vessels", "and", "protects", "them", "from", "VEGF", "-", "induced", "plasma", "leakage", ".", "The", "antivascular", "permeability", "mechanisms", "deployed", "by", "Ang1", "are", "still", "undefined", ".", "Here", ",", "we", "demonstrate", "that", "Ang1", "halts", "the", "ability", "of", "VEGF", "to", "induce", "the", "phosphorylation", "-", "dependent", "redistribution", "of", "the", "adhesion", "molecule", "VE", "-", "cadherin", ",", "thereby", "rescuing", "the", "endothelial", "barrier", "function", ".", "Ang1", "inhibits", "the", "activation", "of", "Src", "by", "VEGF", ",", "the", "most", "upstream", "component", "of", "the", "pathway", "linking", "VEGF", "receptors", "to", "VE", "-", "cadherin", "internalization", ".", "Indeed", ",", "Ang1", "promotes", "the", "activation", "of", "mDia", "through", "RhoA", ",", "resulting", "in", "the", "association", "of", "mDia", "with", "Src", ".", "This", "ultimately", "deprives", "VEGF", "receptors", "of", "an", "essential", "molecule", "required", "for", "promoting", "the", "disruption", "of", "endothelial", "cell", "-", "cell", "contacts", "and", "paracellular", "permeability", ".", "\n" ]

[ "Gene_or_gene_product", "Multi-tissue_structure", "Cell", "Tissue", "Organism_substance" ]

Angiopoietin-1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Tissue, Src is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Vascular endothelial growth factor is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Angiopoietin 1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, blood vessels is a Multi-tissue_structure, VEGF is a Gene_or_gene_product, plasma is a Organism_substance, Ang1 is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, endothelial is a Tissue, Ang1 is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, VE - cadherin is a Gene_or_gene_product, Ang1 is a Gene_or_gene_product, mDia is a Gene_or_gene_product, RhoA is a Gene_or_gene_product, mDia is a Gene_or_gene_product, Src is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial is a Cell

38_task1

Sentence: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability. Instructions: please typing these entity words according to sentence: Angiopoietin-1, VEGF, endothelial, Src, mDia, Vascular endothelial growth factor, VEGF, Angiopoietin 1, Ang1, VEGF, Ang1, blood vessels, VEGF, plasma, Ang1, Ang1, VEGF, VE - cadherin, endothelial, Ang1, Src, VEGF, VEGF, VE - cadherin, Ang1, mDia, RhoA, mDia, Src, VEGF, endothelial Options: Tissue, Gene_or_gene_product, Organism_substance, Multi-tissue_structure, Cell

[ "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability.

[ "Angiopoietin-1", "prevents", "VEGF", "-", "induced", "endothelial", "permeability", "by", "sequestering", "Src", "through", "mDia", ".", "\n\n", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "and", "Angiopoietin", "1", "(", "Ang1", ")", "are", "both", "potent", "proangiogenic", "factors", ",", "but", ",", "whereas", "VEGF", "causes", "vascular", "permeability", ",", "Ang1", "stabilizes", "blood", "vessels", "and", "protects", "them", "from", "VEGF", "-", "induced", "plasma", "leakage", ".", "The", "antivascular", "permeability", "mechanisms", "deployed", "by", "Ang1", "are", "still", "undefined", ".", "Here", ",", "we", "demonstrate", "that", "Ang1", "halts", "the", "ability", "of", "VEGF", "to", "induce", "the", "phosphorylation", "-", "dependent", "redistribution", "of", "the", "adhesion", "molecule", "VE", "-", "cadherin", ",", "thereby", "rescuing", "the", "endothelial", "barrier", "function", ".", "Ang1", "inhibits", "the", "activation", "of", "Src", "by", "VEGF", ",", "the", "most", "upstream", "component", "of", "the", "pathway", "linking", "VEGF", "receptors", "to", "VE", "-", "cadherin", "internalization", ".", "Indeed", ",", "Ang1", "promotes", "the", "activation", "of", "mDia", "through", "RhoA", ",", "resulting", "in", "the", "association", "of", "mDia", "with", "Src", ".", "This", "ultimately", "deprives", "VEGF", "receptors", "of", "an", "essential", "molecule", "required", "for", "promoting", "the", "disruption", "of", "endothelial", "cell", "-", "cell", "contacts", "and", "paracellular", "permeability", ".", "\n" ]

[ "Gene_or_gene_product", "Multi-tissue_structure", "Cell", "Tissue", "Organism_substance" ]

Angiopoietin-1, VEGF, endothelial, Src, mDia, Vascular endothelial growth factor, VEGF, Angiopoietin 1, Ang1, VEGF, Ang1, blood vessels, VEGF, plasma, Ang1, Ang1, VEGF, VE - cadherin, endothelial, Ang1, Src, VEGF, VEGF, VE - cadherin, Ang1, mDia, RhoA, mDia, Src, VEGF, endothelial

38_task2

Sentence: Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability. Instructions: please extract entity words from the input sentence

[ "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Organism_substance", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Tissue", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Vascular endothelial growth factor (VEGF) and Angiopoietin 1 (Ang1) are both potent proangiogenic factors, but, whereas VEGF causes vascular permeability, Ang1 stabilizes blood vessels and protects them from VEGF-induced plasma leakage. The antivascular permeability mechanisms deployed by Ang1 are still undefined. Here, we demonstrate that Ang1 halts the ability of VEGF to induce the phosphorylation-dependent redistribution of the adhesion molecule VE-cadherin, thereby rescuing the endothelial barrier function. Ang1 inhibits the activation of Src by VEGF, the most upstream component of the pathway linking VEGF receptors to VE-cadherin internalization. Indeed, Ang1 promotes the activation of mDia through RhoA, resulting in the association of mDia with Src. This ultimately deprives VEGF receptors of an essential molecule required for promoting the disruption of endothelial cell-cell contacts and paracellular permeability.

[ "Angiopoietin-1", "prevents", "VEGF", "-", "induced", "endothelial", "permeability", "by", "sequestering", "Src", "through", "mDia", ".", "\n\n", "Vascular", "endothelial", "growth", "factor", "(", "VEGF", ")", "and", "Angiopoietin", "1", "(", "Ang1", ")", "are", "both", "potent", "proangiogenic", "factors", ",", "but", ",", "whereas", "VEGF", "causes", "vascular", "permeability", ",", "Ang1", "stabilizes", "blood", "vessels", "and", "protects", "them", "from", "VEGF", "-", "induced", "plasma", "leakage", ".", "The", "antivascular", "permeability", "mechanisms", "deployed", "by", "Ang1", "are", "still", "undefined", ".", "Here", ",", "we", "demonstrate", "that", "Ang1", "halts", "the", "ability", "of", "VEGF", "to", "induce", "the", "phosphorylation", "-", "dependent", "redistribution", "of", "the", "adhesion", "molecule", "VE", "-", "cadherin", ",", "thereby", "rescuing", "the", "endothelial", "barrier", "function", ".", "Ang1", "inhibits", "the", "activation", "of", "Src", "by", "VEGF", ",", "the", "most", "upstream", "component", "of", "the", "pathway", "linking", "VEGF", "receptors", "to", "VE", "-", "cadherin", "internalization", ".", "Indeed", ",", "Ang1", "promotes", "the", "activation", "of", "mDia", "through", "RhoA", ",", "resulting", "in", "the", "association", "of", "mDia", "with", "Src", ".", "This", "ultimately", "deprives", "VEGF", "receptors", "of", "an", "essential", "molecule", "required", "for", "promoting", "the", "disruption", "of", "endothelial", "cell", "-", "cell", "contacts", "and", "paracellular", "permeability", ".", "\n" ]

[ "Gene_or_gene_product", "Multi-tissue_structure", "Cell", "Tissue", "Organism_substance" ]

chemotherapy is a Intervention_Physical, doxorubicin is a Intervention_Pharmacological, lomustine is a Intervention_Pharmacological, DC is a Intervention_Pharmacological, cyclophosphamide and 5-FU ( CF ) is a Intervention_Pharmacological, tolerated is a Outcome_Other, levels of myelosuppression is a Outcome_Physical, objective partial response rate is a Outcome_Other, Objective stabilization is a Outcome_Physical, subjective response rate ( partial plus complete ) is a Outcome_Other, response rates is a Outcome_Other, survival is a Outcome_Mortality

77043_task0

Sentence: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Physical, Outcome_Mortality, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .

[ "Randomized", "trial", "of", "combination", "chemotherapy", "in", "hormone", "-", "resistant", "metastatic", "prostate", "carcinoma", ".", "A", "prospective", "randomized", "study", "was", "conducted", "in", "51", "patients", "with", "stage", "D", "hormone", "-", "resistant", "prostatic", "carcinoma", ",", "comparing", "a", "combination", "of", "doxorubicin", "and", "lomustine", "(", "DC", ")", "with", "cyclophosphamide", "and", "5-FU", "(", "CF", ")", ".", "Patients", "were", "assessed", "objectively", "(", "employing", "National", "Prostate", "Cancer", "Project", "criteria", ")", "and", "subjectively", "(", "using", "a", "numerical", "scoring", "scheme", ")", ".", "Each", "regimen", "was", "well", "tolerated", "with", "acceptable", "levels", "of", "myelosuppression", ".", "The", "objective", "partial", "response", "rate", "was", "57", "%", "for", "DC", "and", "8", "%", "for", "CF", ".", "Objective", "stabilization", "occurred", ",", "respectively", ",", "in", "14", "%", "and", "44", "%", "of", "the", "patients", ".", "Similarly", ",", "DC", "demonstrated", "a", "significantly", "superior", "subjective", "response", "rate", "(", "partial", "plus", "complete", ")", "of", "82", "%", ",", "compared", "to", "48", "%", "for", "CF", ".", "Patients", "with", "poor", "initial", "performance", "status", "or", "liver", "involvement", "had", "significantly", "lower", "response", "rates", "and", "reduced", "survival", ".", "Overall", ",", "there", "was", "no", "significant", "difference", "in", "survival", "between", "the", "two", "arms", ",", "reflecting", "the", "similarity", "between", "DC", "and", "CF", "in", "total", "objective", "response", "rate", "(", "partial", "response", "plus", "stable", "disease", ")", ".", "DC", "provided", "superior", "palliation", "and", "was", "well", "tolerated", "by", "an", "essentially", "geriatric", "population", "." ]

[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Physical", "Outcome_Mortality" ]

chemotherapy is a Intervention_Physical, doxorubicin is a Intervention_Pharmacological, lomustine is a Intervention_Pharmacological, DC is a Intervention_Pharmacological, cyclophosphamide and 5-FU ( CF ) is a Intervention_Pharmacological, tolerated is a Outcome_Other, levels of myelosuppression is a Outcome_Physical, objective partial response rate is a Outcome_Other, Objective stabilization is a Outcome_Physical, subjective response rate ( partial plus complete ) is a Outcome_Other, response rates is a Outcome_Other, survival is a Outcome_Mortality

77043_task1

Sentence: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population . Instructions: please typing these entity words according to sentence: chemotherapy, doxorubicin, lomustine, DC, cyclophosphamide and 5-FU ( CF ), tolerated, levels of myelosuppression, objective partial response rate, Objective stabilization, subjective response rate ( partial plus complete ), response rates, survival Options: Intervention_Pharmacological, Intervention_Physical, Outcome_Mortality, Outcome_Physical, Outcome_Other

[ "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .

[ "Randomized", "trial", "of", "combination", "chemotherapy", "in", "hormone", "-", "resistant", "metastatic", "prostate", "carcinoma", ".", "A", "prospective", "randomized", "study", "was", "conducted", "in", "51", "patients", "with", "stage", "D", "hormone", "-", "resistant", "prostatic", "carcinoma", ",", "comparing", "a", "combination", "of", "doxorubicin", "and", "lomustine", "(", "DC", ")", "with", "cyclophosphamide", "and", "5-FU", "(", "CF", ")", ".", "Patients", "were", "assessed", "objectively", "(", "employing", "National", "Prostate", "Cancer", "Project", "criteria", ")", "and", "subjectively", "(", "using", "a", "numerical", "scoring", "scheme", ")", ".", "Each", "regimen", "was", "well", "tolerated", "with", "acceptable", "levels", "of", "myelosuppression", ".", "The", "objective", "partial", "response", "rate", "was", "57", "%", "for", "DC", "and", "8", "%", "for", "CF", ".", "Objective", "stabilization", "occurred", ",", "respectively", ",", "in", "14", "%", "and", "44", "%", "of", "the", "patients", ".", "Similarly", ",", "DC", "demonstrated", "a", "significantly", "superior", "subjective", "response", "rate", "(", "partial", "plus", "complete", ")", "of", "82", "%", ",", "compared", "to", "48", "%", "for", "CF", ".", "Patients", "with", "poor", "initial", "performance", "status", "or", "liver", "involvement", "had", "significantly", "lower", "response", "rates", "and", "reduced", "survival", ".", "Overall", ",", "there", "was", "no", "significant", "difference", "in", "survival", "between", "the", "two", "arms", ",", "reflecting", "the", "similarity", "between", "DC", "and", "CF", "in", "total", "objective", "response", "rate", "(", "partial", "response", "plus", "stable", "disease", ")", ".", "DC", "provided", "superior", "palliation", "and", "was", "well", "tolerated", "by", "an", "essentially", "geriatric", "population", "." ]

[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Physical", "Outcome_Mortality" ]

chemotherapy, doxorubicin, lomustine, DC, cyclophosphamide and 5-FU ( CF ), tolerated, levels of myelosuppression, objective partial response rate, Objective stabilization, subjective response rate ( partial plus complete ), response rates, survival

77043_task2

Sentence: Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma . A prospective randomized study was conducted in 51 patients with stage D hormone-resistant prostatic carcinoma , comparing a combination of doxorubicin and lomustine ( DC ) with cyclophosphamide and 5-FU ( CF ) . Patients were assessed objectively ( employing National Prostate Cancer Project criteria ) and subjectively ( using a numerical scoring scheme ) . Each regimen was well tolerated with acceptable levels of myelosuppression . The objective partial response rate was 57 % for DC and 8 % for CF . Objective stabilization occurred , respectively , in 14 % and 44 % of the patients . Similarly , DC demonstrated a significantly superior subjective response rate ( partial plus complete ) of 82 % , compared to 48 % for CF . Patients with poor initial performance status or liver involvement had significantly lower response rates and reduced survival . Overall , there was no significant difference in survival between the two arms , reflecting the similarity between DC and CF in total objective response rate ( partial response plus stable disease ) . DC provided superior palliation and was well tolerated by an essentially geriatric population .

[ "Randomized", "trial", "of", "combination", "chemotherapy", "in", "hormone", "-", "resistant", "metastatic", "prostate", "carcinoma", ".", "A", "prospective", "randomized", "study", "was", "conducted", "in", "51", "patients", "with", "stage", "D", "hormone", "-", "resistant", "prostatic", "carcinoma", ",", "comparing", "a", "combination", "of", "doxorubicin", "and", "lomustine", "(", "DC", ")", "with", "cyclophosphamide", "and", "5-FU", "(", "CF", ")", ".", "Patients", "were", "assessed", "objectively", "(", "employing", "National", "Prostate", "Cancer", "Project", "criteria", ")", "and", "subjectively", "(", "using", "a", "numerical", "scoring", "scheme", ")", ".", "Each", "regimen", "was", "well", "tolerated", "with", "acceptable", "levels", "of", "myelosuppression", ".", "The", "objective", "partial", "response", "rate", "was", "57", "%", "for", "DC", "and", "8", "%", "for", "CF", ".", "Objective", "stabilization", "occurred", ",", "respectively", ",", "in", "14", "%", "and", "44", "%", "of", "the", "patients", ".", "Similarly", ",", "DC", "demonstrated", "a", "significantly", "superior", "subjective", "response", "rate", "(", "partial", "plus", "complete", ")", "of", "82", "%", ",", "compared", "to", "48", "%", "for", "CF", ".", "Patients", "with", "poor", "initial", "performance", "status", "or", "liver", "involvement", "had", "significantly", "lower", "response", "rates", "and", "reduced", "survival", ".", "Overall", ",", "there", "was", "no", "significant", "difference", "in", "survival", "between", "the", "two", "arms", ",", "reflecting", "the", "similarity", "between", "DC", "and", "CF", "in", "total", "objective", "response", "rate", "(", "partial", "response", "plus", "stable", "disease", ")", ".", "DC", "provided", "superior", "palliation", "and", "was", "well", "tolerated", "by", "an", "essentially", "geriatric", "population", "." ]

[ "Outcome_Other", "Intervention_Pharmacological", "Outcome_Physical", "Intervention_Physical", "Outcome_Mortality" ]

paper is an umlsterm, period is an umlsterm, turnover is an umlsterm, human is an umlsterm, cartilages is an umlsterm, in vitro is an umlsterm, method is an umlsterm, relative is an umlsterm, human is an umlsterm, cartilages is an umlsterm, osteoarthritis is an umlsterm, rheumatoid arthritis is an umlsterm, cartilages is an umlsterm, cartilages is an umlsterm, turnover is an umlsterm, cartilages is an umlsterm, cells is an umlsterm, proteolytic enzymes is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, collagen is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, in vitro is an umlsterm, extracellular matrix is an umlsterm, human is an umlsterm, cartilages is an umlsterm, Aceclofenac is an umlsterm, Tenidap is an umlsterm, Tolmetin is an umlsterm, Piroxicam is an umlsterm, Tiaprofenic Acid is an umlsterm, Aspirin is an umlsterm, Naproxen is an umlsterm, Ibuprofen is an umlsterm, Indomethacin is an umlsterm, NSAID is an umlsterm, inhibition is an umlsterm, IL1 is an umlsterm, growth factor is an umlsterm, NSAIDs is an umlsterm, IL1 is an umlsterm, release is an umlsterm, chondrocyte is an umlsterm, toxic effects is an umlsterm, cartilage is an umlsterm, metabolism is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, Aceclofenac is an umlsterm, long - term treatment is an umlsterm, in vitro is an umlsterm, human is an umlsterm, cartilage is an umlsterm

ZfuerRheumatologie.90580125.eng.abstr_task0

Sentence: The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo .

[ "The", "present", "paper", "presents", "data", "obtained", "over", "a", "12", "year", "period", ",", "on", "the", "matrix", "synthesis", "and", "turnover", "in", "some", "650", "arthritic", "and", "180", "non", "-", "arthritic", "(", "N", ")", "human", "cartilages", "using", "a", "standardised", "in", "vitro", "method", ".", "When", "the", "relative", "metabolic", "(", "synthetic", "/", "repair", "activity", ")", "of", "these", "human", "cartilages", "was", "compared", ",", "it", "was", "demonstrated", "that", "in", "osteoarthritis", "(", "OA", ")", "and", "rheumatoid", "arthritis", "(", "RA", ")", "cartilages", "synthetic", "activity", "was", "diminished", "by", "approximately", "50", "%", "as", "compared", "with", "N", "cartilages", ".", "However", ",", "the", "turnover", "rate", "of", "matrix", "was", "not", "significantly", "different", "between", "Non", "-", "arthritic", "and", "OA", ",", "but", "was", "very", "substantially", "increased", "in", "RA", "cartilages", "compatible", "with", "the", "activity", "of", "inflammatory", "cells", "and", "proteolytic", "enzymes", "released", "from", "pannus", ".", "The", "action", "of", "13", "NSAIDs", "was", "compared", "in", "terms", "of", "their", "effect", "on", "cartilage", "GAG", "synthesis", ".", "3", "of", "these", "NSAIDs", "were", "also", "studied", "in", "terms", "of", "their", "effect", "on", "cartilage", "collagen", "synthesis", ".", "Consideration", "of", "the", "results", "in", "this", "study", "and", "from", "published", "material", ",", "led", "to", "the", "suggestion", "that", "NSAIDs", "may", "be", "divided", "into", "3", "categories", "in", "respect", "of", "their", "in", "vitro", "action", "on", "the", "extracellular", "matrix", "of", "human", "arthritic", "cartilages", ":", "1", ".", "Those", "such", "as", "Aceclofenac", ",", "Tenidap", "and", "Tolmetin", "which", "can", "stimulate", "matrix", "synthesis", "2", ".", "Those", "such", "as", "Piroxicam", ",", "Tiaprofenic", "Acid", "and", "Aspirin", "which", "appear", "to", "be", "without", "significant", "effect", "on", "matrix", "synthesis", "and", ",", "3", ".", "Those", "like", "Naproxen", ",", "Ibuprofen", ",", "Indomethacin", ",", "Nimezulide", "which", "significantly", "inhibit", "matrix", "synthesis", ".", "It", "is", "suggested", "that", "the", "stimulatory", "action", "of", "group", "1", "NSAID", "is", "due", "to", "inhibition", "of", "locally", "produced", "IL1", "and", "consequent", "expression", "of", "growth", "factor", "activity", ".", "Other", "NSAIDs", "may", "also", "inhibit", "IL1", "synthesis", "or", "release", ",", "but", "probably", "do", "not", "have", "a", "beneficial", "effect", "on", "chondrocyte", "synthetic", "activity", "as", "they", "have", "toxic", "effects", "on", "cartilage", "metabolism", ".", "These", "experiments", "led", "to", "the", "suggestion", "that", "NSAIDs", "such", "as", "Aceclofenac", "would", "be", "appropriate", "for", "long", "-", "term", "treatment", "of", "arthritic", "conditions", "provided", "that", "one", "is", "prepared", "to", "extrapolate", "between", "in", "vitro", "experiments", "on", "human", "cartilage", "and", "what", "may", "be", "happening", "in", "vivo", "." ]

[ "umlsterm" ]

paper is an umlsterm, period is an umlsterm, turnover is an umlsterm, human is an umlsterm, cartilages is an umlsterm, in vitro is an umlsterm, method is an umlsterm, relative is an umlsterm, human is an umlsterm, cartilages is an umlsterm, osteoarthritis is an umlsterm, rheumatoid arthritis is an umlsterm, cartilages is an umlsterm, cartilages is an umlsterm, turnover is an umlsterm, cartilages is an umlsterm, cells is an umlsterm, proteolytic enzymes is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, NSAIDs is an umlsterm, cartilage is an umlsterm, collagen is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, in vitro is an umlsterm, extracellular matrix is an umlsterm, human is an umlsterm, cartilages is an umlsterm, Aceclofenac is an umlsterm, Tenidap is an umlsterm, Tolmetin is an umlsterm, Piroxicam is an umlsterm, Tiaprofenic Acid is an umlsterm, Aspirin is an umlsterm, Naproxen is an umlsterm, Ibuprofen is an umlsterm, Indomethacin is an umlsterm, NSAID is an umlsterm, inhibition is an umlsterm, IL1 is an umlsterm, growth factor is an umlsterm, NSAIDs is an umlsterm, IL1 is an umlsterm, release is an umlsterm, chondrocyte is an umlsterm, toxic effects is an umlsterm, cartilage is an umlsterm, metabolism is an umlsterm, suggestion is an umlsterm, NSAIDs is an umlsterm, Aceclofenac is an umlsterm, long - term treatment is an umlsterm, in vitro is an umlsterm, human is an umlsterm, cartilage is an umlsterm

ZfuerRheumatologie.90580125.eng.abstr_task1

Sentence: The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo . Instructions: please typing these entity words according to sentence: paper, period, turnover, human, cartilages, in vitro, method, relative, human, cartilages, osteoarthritis, rheumatoid arthritis, cartilages, cartilages, turnover, cartilages, cells, proteolytic enzymes, NSAIDs, cartilage, NSAIDs, cartilage, collagen, suggestion, NSAIDs, in vitro, extracellular matrix, human, cartilages, Aceclofenac, Tenidap, Tolmetin, Piroxicam, Tiaprofenic Acid, Aspirin, Naproxen, Ibuprofen, Indomethacin, NSAID, inhibition, IL1, growth factor, NSAIDs, IL1, release, chondrocyte, toxic effects, cartilage, metabolism, suggestion, NSAIDs, Aceclofenac, long - term treatment, in vitro, human, cartilage Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo .

[ "The", "present", "paper", "presents", "data", "obtained", "over", "a", "12", "year", "period", ",", "on", "the", "matrix", "synthesis", "and", "turnover", "in", "some", "650", "arthritic", "and", "180", "non", "-", "arthritic", "(", "N", ")", "human", "cartilages", "using", "a", "standardised", "in", "vitro", "method", ".", "When", "the", "relative", "metabolic", "(", "synthetic", "/", "repair", "activity", ")", "of", "these", "human", "cartilages", "was", "compared", ",", "it", "was", "demonstrated", "that", "in", "osteoarthritis", "(", "OA", ")", "and", "rheumatoid", "arthritis", "(", "RA", ")", "cartilages", "synthetic", "activity", "was", "diminished", "by", "approximately", "50", "%", "as", "compared", "with", "N", "cartilages", ".", "However", ",", "the", "turnover", "rate", "of", "matrix", "was", "not", "significantly", "different", "between", "Non", "-", "arthritic", "and", "OA", ",", "but", "was", "very", "substantially", "increased", "in", "RA", "cartilages", "compatible", "with", "the", "activity", "of", "inflammatory", "cells", "and", "proteolytic", "enzymes", "released", "from", "pannus", ".", "The", "action", "of", "13", "NSAIDs", "was", "compared", "in", "terms", "of", "their", "effect", "on", "cartilage", "GAG", "synthesis", ".", "3", "of", "these", "NSAIDs", "were", "also", "studied", "in", "terms", "of", "their", "effect", "on", "cartilage", "collagen", "synthesis", ".", "Consideration", "of", "the", "results", "in", "this", "study", "and", "from", "published", "material", ",", "led", "to", "the", "suggestion", "that", "NSAIDs", "may", "be", "divided", "into", "3", "categories", "in", "respect", "of", "their", "in", "vitro", "action", "on", "the", "extracellular", "matrix", "of", "human", "arthritic", "cartilages", ":", "1", ".", "Those", "such", "as", "Aceclofenac", ",", "Tenidap", "and", "Tolmetin", "which", "can", "stimulate", "matrix", "synthesis", "2", ".", "Those", "such", "as", "Piroxicam", ",", "Tiaprofenic", "Acid", "and", "Aspirin", "which", "appear", "to", "be", "without", "significant", "effect", "on", "matrix", "synthesis", "and", ",", "3", ".", "Those", "like", "Naproxen", ",", "Ibuprofen", ",", "Indomethacin", ",", "Nimezulide", "which", "significantly", "inhibit", "matrix", "synthesis", ".", "It", "is", "suggested", "that", "the", "stimulatory", "action", "of", "group", "1", "NSAID", "is", "due", "to", "inhibition", "of", "locally", "produced", "IL1", "and", "consequent", "expression", "of", "growth", "factor", "activity", ".", "Other", "NSAIDs", "may", "also", "inhibit", "IL1", "synthesis", "or", "release", ",", "but", "probably", "do", "not", "have", "a", "beneficial", "effect", "on", "chondrocyte", "synthetic", "activity", "as", "they", "have", "toxic", "effects", "on", "cartilage", "metabolism", ".", "These", "experiments", "led", "to", "the", "suggestion", "that", "NSAIDs", "such", "as", "Aceclofenac", "would", "be", "appropriate", "for", "long", "-", "term", "treatment", "of", "arthritic", "conditions", "provided", "that", "one", "is", "prepared", "to", "extrapolate", "between", "in", "vitro", "experiments", "on", "human", "cartilage", "and", "what", "may", "be", "happening", "in", "vivo", "." ]

[ "umlsterm" ]

paper, period, turnover, human, cartilages, in vitro, method, relative, human, cartilages, osteoarthritis, rheumatoid arthritis, cartilages, cartilages, turnover, cartilages, cells, proteolytic enzymes, NSAIDs, cartilage, NSAIDs, cartilage, collagen, suggestion, NSAIDs, in vitro, extracellular matrix, human, cartilages, Aceclofenac, Tenidap, Tolmetin, Piroxicam, Tiaprofenic Acid, Aspirin, Naproxen, Ibuprofen, Indomethacin, NSAID, inhibition, IL1, growth factor, NSAIDs, IL1, release, chondrocyte, toxic effects, cartilage, metabolism, suggestion, NSAIDs, Aceclofenac, long - term treatment, in vitro, human, cartilage

ZfuerRheumatologie.90580125.eng.abstr_task2

Sentence: The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O" ]

The present paper presents data obtained over a 12 year period , on the matrix synthesis and turnover in some 650 arthritic and 180 non-arthritic ( N ) human cartilages using a standardised in vitro method . When the relative metabolic ( synthetic/repair activity ) of these human cartilages was compared , it was demonstrated that in osteoarthritis ( OA ) and rheumatoid arthritis ( RA ) cartilages synthetic activity was diminished by approximately 50% as compared with N cartilages . However , the turnover rate of matrix was not significantly different between Non-arthritic and OA , but was very substantially increased in RA cartilages compatible with the activity of inflammatory cells and proteolytic enzymes released from pannus . The action of 13 NSAIDs was compared in terms of their effect on cartilage GAG synthesis . 3 of these NSAIDs were also studied in terms of their effect on cartilage collagen synthesis . Consideration of the results in this study and from published material , led to the suggestion that NSAIDs may be divided into 3 categories in respect of their in vitro action on the extracellular matrix of human arthritic cartilages : 1. Those such as Aceclofenac , Tenidap and Tolmetin which can stimulate matrix synthesis 2. Those such as Piroxicam , Tiaprofenic Acid and Aspirin which appear to be without significant effect on matrix synthesis and , 3. Those like Naproxen , Ibuprofen , Indomethacin , Nimezulide which significantly inhibit matrix synthesis . It is suggested that the stimulatory action of group 1 NSAID is due to inhibition of locally produced IL1 and consequent expression of growth factor activity . Other NSAIDs may also inhibit IL1 synthesis or release , but probably do not have a beneficial effect on chondrocyte synthetic activity as they have toxic effects on cartilage metabolism . These experiments led to the suggestion that NSAIDs such as Aceclofenac would be appropriate for long-term treatment of arthritic conditions provided that one is prepared to extrapolate between in vitro experiments on human cartilage and what may be happening in vivo .

[ "The", "present", "paper", "presents", "data", "obtained", "over", "a", "12", "year", "period", ",", "on", "the", "matrix", "synthesis", "and", "turnover", "in", "some", "650", "arthritic", "and", "180", "non", "-", "arthritic", "(", "N", ")", "human", "cartilages", "using", "a", "standardised", "in", "vitro", "method", ".", "When", "the", "relative", "metabolic", "(", "synthetic", "/", "repair", "activity", ")", "of", "these", "human", "cartilages", "was", "compared", ",", "it", "was", "demonstrated", "that", "in", "osteoarthritis", "(", "OA", ")", "and", "rheumatoid", "arthritis", "(", "RA", ")", "cartilages", "synthetic", "activity", "was", "diminished", "by", "approximately", "50", "%", "as", "compared", "with", "N", "cartilages", ".", "However", ",", "the", "turnover", "rate", "of", "matrix", "was", "not", "significantly", "different", "between", "Non", "-", "arthritic", "and", "OA", ",", "but", "was", "very", "substantially", "increased", "in", "RA", "cartilages", "compatible", "with", "the", "activity", "of", "inflammatory", "cells", "and", "proteolytic", "enzymes", "released", "from", "pannus", ".", "The", "action", "of", "13", "NSAIDs", "was", "compared", "in", "terms", "of", "their", "effect", "on", "cartilage", "GAG", "synthesis", ".", "3", "of", "these", "NSAIDs", "were", "also", "studied", "in", "terms", "of", "their", "effect", "on", "cartilage", "collagen", "synthesis", ".", "Consideration", "of", "the", "results", "in", "this", "study", "and", "from", "published", "material", ",", "led", "to", "the", "suggestion", "that", "NSAIDs", "may", "be", "divided", "into", "3", "categories", "in", "respect", "of", "their", "in", "vitro", "action", "on", "the", "extracellular", "matrix", "of", "human", "arthritic", "cartilages", ":", "1", ".", "Those", "such", "as", "Aceclofenac", ",", "Tenidap", "and", "Tolmetin", "which", "can", "stimulate", "matrix", "synthesis", "2", ".", "Those", "such", "as", "Piroxicam", ",", "Tiaprofenic", "Acid", "and", "Aspirin", "which", "appear", "to", "be", "without", "significant", "effect", "on", "matrix", "synthesis", "and", ",", "3", ".", "Those", "like", "Naproxen", ",", "Ibuprofen", ",", "Indomethacin", ",", "Nimezulide", "which", "significantly", "inhibit", "matrix", "synthesis", ".", "It", "is", "suggested", "that", "the", "stimulatory", "action", "of", "group", "1", "NSAID", "is", "due", "to", "inhibition", "of", "locally", "produced", "IL1", "and", "consequent", "expression", "of", "growth", "factor", "activity", ".", "Other", "NSAIDs", "may", "also", "inhibit", "IL1", "synthesis", "or", "release", ",", "but", "probably", "do", "not", "have", "a", "beneficial", "effect", "on", "chondrocyte", "synthetic", "activity", "as", "they", "have", "toxic", "effects", "on", "cartilage", "metabolism", ".", "These", "experiments", "led", "to", "the", "suggestion", "that", "NSAIDs", "such", "as", "Aceclofenac", "would", "be", "appropriate", "for", "long", "-", "term", "treatment", "of", "arthritic", "conditions", "provided", "that", "one", "is", "prepared", "to", "extrapolate", "between", "in", "vitro", "experiments", "on", "human", "cartilage", "and", "what", "may", "be", "happening", "in", "vivo", "." ]

[ "umlsterm" ]

CIITA is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, class II major histocompatibility complex gene is a Entity, N - terminal region is a Entity, reporter gene is a Entity, DNA binding domain is a Entity, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, CIITA is a Protein, TBP is a Protein, TBP is a Protein, TBP is a Protein, TAFII250 is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, acidic activation domains is a Entity, CIITA is a Protein, VP16 is a Protein, CIITA is a Protein, CIITA is a Protein, VP16 is a Protein

302_task0

Sentence: Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.

[ "Transactivation", "by", "CIITA", ",", "the", "type", "II", "bare", "lymphocyte", "syndrome", "-", "associated", "factor", ",", "requires", "participation", "of", "multiple", "regions", "of", "the", "TATA", "box", "binding", "protein", ".", "\n", "CIITA", "is", "a", "positive", "regulator", "of", "class", "II", "major", "histocompatibility", "complex", "gene", "transcription", "that", "has", "been", "found", "to", "be", "defective", "in", "one", "of", "the", "five", "complementation", "groups", "of", "class", "II", "major", "histocompatibility", "complex", "-", "negative", "cell", "lines", ".", "Its", "N", "-", "terminal", "region", "is", "capable", "of", "activating", "transcription", "from", "a", "reporter", "gene", "when", "fused", "to", "a", "DNA", "binding", "domain", ".", "We", "have", "investigated", "the", "mechanism", "of", "transactivation", "mediated", "by", "the", "CIITA", "activation", "domain", "by", "studying", "its", "role", "in", "the", "process", "of", "transcription", "initiation", "and", "elongation", ".", "Specifically", "the", "altered", "specificity", "TBP", "(", "TATA", "box", "binding", "protein", ")", "assay", "has", "been", "used", "to", "analyze", "the", "response", "of", "the", "CIITA", "activation", "domain", "to", "mutations", "in", "TBP", "known", "to", "disrupt", "its", "interaction", "with", "its", "associated", "general", "factors", ".", "Transactivation", "by", "CIITA", "was", "extremely", "sensitive", "to", "a", "mutation", "in", "TBP", "that", "in", "yeast", "is", "known", "to", "abolish", "VP16-mediated", "transcription", "but", "leaves", "basal", "transcription", "unaffected", ".", "A", "TBP", "mutant", "defective", "in", "interaction", "with", "TBP", "-", "associated", "factor", "TAFII250", "also", "failed", "to", "mediate", "transactivation", "through", "the", "CIITA", "activation", "domain", ".", "Certain", "interactions", "between", "TBP", "and", "general", "factors", "that", "are", "specifically", "required", "for", "acidic", "activation", "domains", "were", "also", "required", "for", "CIITA", "-", "mediated", "transactivation", "to", "reach", "its", "full", "potential", ".", "Finally", ",", "like", "VP16", ",", "CIITA", "was", "able", "to", "stimulate", "elongation", "of", "transcription", ".", "Overall", "the", "mechanism", "of", "transactivation", "by", "the", "human", "B", "-", "cell", "-", "specific", "CIITA", "is", "very", "similar", "to", "that", "mediated", "by", "the", "herpes", "virus", "transactivator", "VP16", "in", "the", "ways", "that", "have", "been", "tested", ".", "\n" ]

[ "Entity", "Protein" ]

CIITA is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, class II major histocompatibility complex gene is a Entity, N - terminal region is a Entity, reporter gene is a Entity, DNA binding domain is a Entity, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, TATA box binding protein is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, CIITA is a Protein, TBP is a Protein, TBP is a Protein, TBP is a Protein, TAFII250 is a Protein, CIITA is a Protein, activation domain is a Entity, TBP is a Protein, acidic activation domains is a Entity, CIITA is a Protein, VP16 is a Protein, CIITA is a Protein, CIITA is a Protein, VP16 is a Protein

302_task1

Sentence: Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested. Instructions: please typing these entity words according to sentence: CIITA, TATA box binding protein, CIITA, class II major histocompatibility complex gene, N - terminal region, reporter gene, DNA binding domain, CIITA, activation domain, TBP, TATA box binding protein, CIITA, activation domain, TBP, CIITA, TBP, TBP, TBP, TAFII250, CIITA, activation domain, TBP, acidic activation domains, CIITA, VP16, CIITA, CIITA, VP16 Options: Entity, Protein

[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.

[ "Transactivation", "by", "CIITA", ",", "the", "type", "II", "bare", "lymphocyte", "syndrome", "-", "associated", "factor", ",", "requires", "participation", "of", "multiple", "regions", "of", "the", "TATA", "box", "binding", "protein", ".", "\n", "CIITA", "is", "a", "positive", "regulator", "of", "class", "II", "major", "histocompatibility", "complex", "gene", "transcription", "that", "has", "been", "found", "to", "be", "defective", "in", "one", "of", "the", "five", "complementation", "groups", "of", "class", "II", "major", "histocompatibility", "complex", "-", "negative", "cell", "lines", ".", "Its", "N", "-", "terminal", "region", "is", "capable", "of", "activating", "transcription", "from", "a", "reporter", "gene", "when", "fused", "to", "a", "DNA", "binding", "domain", ".", "We", "have", "investigated", "the", "mechanism", "of", "transactivation", "mediated", "by", "the", "CIITA", "activation", "domain", "by", "studying", "its", "role", "in", "the", "process", "of", "transcription", "initiation", "and", "elongation", ".", "Specifically", "the", "altered", "specificity", "TBP", "(", "TATA", "box", "binding", "protein", ")", "assay", "has", "been", "used", "to", "analyze", "the", "response", "of", "the", "CIITA", "activation", "domain", "to", "mutations", "in", "TBP", "known", "to", "disrupt", "its", "interaction", "with", "its", "associated", "general", "factors", ".", "Transactivation", "by", "CIITA", "was", "extremely", "sensitive", "to", "a", "mutation", "in", "TBP", "that", "in", "yeast", "is", "known", "to", "abolish", "VP16-mediated", "transcription", "but", "leaves", "basal", "transcription", "unaffected", ".", "A", "TBP", "mutant", "defective", "in", "interaction", "with", "TBP", "-", "associated", "factor", "TAFII250", "also", "failed", "to", "mediate", "transactivation", "through", "the", "CIITA", "activation", "domain", ".", "Certain", "interactions", "between", "TBP", "and", "general", "factors", "that", "are", "specifically", "required", "for", "acidic", "activation", "domains", "were", "also", "required", "for", "CIITA", "-", "mediated", "transactivation", "to", "reach", "its", "full", "potential", ".", "Finally", ",", "like", "VP16", ",", "CIITA", "was", "able", "to", "stimulate", "elongation", "of", "transcription", ".", "Overall", "the", "mechanism", "of", "transactivation", "by", "the", "human", "B", "-", "cell", "-", "specific", "CIITA", "is", "very", "similar", "to", "that", "mediated", "by", "the", "herpes", "virus", "transactivator", "VP16", "in", "the", "ways", "that", "have", "been", "tested", ".", "\n" ]

[ "Entity", "Protein" ]

CIITA, TATA box binding protein, CIITA, class II major histocompatibility complex gene, N - terminal region, reporter gene, DNA binding domain, CIITA, activation domain, TBP, TATA box binding protein, CIITA, activation domain, TBP, CIITA, TBP, TBP, TBP, TAFII250, CIITA, activation domain, TBP, acidic activation domains, CIITA, VP16, CIITA, CIITA, VP16

302_task2

Sentence: Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "B-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines. Its N-terminal region is capable of activating transcription from a reporter gene when fused to a DNA binding domain. We have investigated the mechanism of transactivation mediated by the CIITA activation domain by studying its role in the process of transcription initiation and elongation. Specifically the altered specificity TBP (TATA box binding protein) assay has been used to analyze the response of the CIITA activation domain to mutations in TBP known to disrupt its interaction with its associated general factors. Transactivation by CIITA was extremely sensitive to a mutation in TBP that in yeast is known to abolish VP16-mediated transcription but leaves basal transcription unaffected. A TBP mutant defective in interaction with TBP-associated factor TAFII250 also failed to mediate transactivation through the CIITA activation domain. Certain interactions between TBP and general factors that are specifically required for acidic activation domains were also required for CIITA-mediated transactivation to reach its full potential. Finally, like VP16, CIITA was able to stimulate elongation of transcription. Overall the mechanism of transactivation by the human B-cell-specific CIITA is very similar to that mediated by the herpes virus transactivator VP16 in the ways that have been tested.

[ "Transactivation", "by", "CIITA", ",", "the", "type", "II", "bare", "lymphocyte", "syndrome", "-", "associated", "factor", ",", "requires", "participation", "of", "multiple", "regions", "of", "the", "TATA", "box", "binding", "protein", ".", "\n", "CIITA", "is", "a", "positive", "regulator", "of", "class", "II", "major", "histocompatibility", "complex", "gene", "transcription", "that", "has", "been", "found", "to", "be", "defective", "in", "one", "of", "the", "five", "complementation", "groups", "of", "class", "II", "major", "histocompatibility", "complex", "-", "negative", "cell", "lines", ".", "Its", "N", "-", "terminal", "region", "is", "capable", "of", "activating", "transcription", "from", "a", "reporter", "gene", "when", "fused", "to", "a", "DNA", "binding", "domain", ".", "We", "have", "investigated", "the", "mechanism", "of", "transactivation", "mediated", "by", "the", "CIITA", "activation", "domain", "by", "studying", "its", "role", "in", "the", "process", "of", "transcription", "initiation", "and", "elongation", ".", "Specifically", "the", "altered", "specificity", "TBP", "(", "TATA", "box", "binding", "protein", ")", "assay", "has", "been", "used", "to", "analyze", "the", "response", "of", "the", "CIITA", "activation", "domain", "to", "mutations", "in", "TBP", "known", "to", "disrupt", "its", "interaction", "with", "its", "associated", "general", "factors", ".", "Transactivation", "by", "CIITA", "was", "extremely", "sensitive", "to", "a", "mutation", "in", "TBP", "that", "in", "yeast", "is", "known", "to", "abolish", "VP16-mediated", "transcription", "but", "leaves", "basal", "transcription", "unaffected", ".", "A", "TBP", "mutant", "defective", "in", "interaction", "with", "TBP", "-", "associated", "factor", "TAFII250", "also", "failed", "to", "mediate", "transactivation", "through", "the", "CIITA", "activation", "domain", ".", "Certain", "interactions", "between", "TBP", "and", "general", "factors", "that", "are", "specifically", "required", "for", "acidic", "activation", "domains", "were", "also", "required", "for", "CIITA", "-", "mediated", "transactivation", "to", "reach", "its", "full", "potential", ".", "Finally", ",", "like", "VP16", ",", "CIITA", "was", "able", "to", "stimulate", "elongation", "of", "transcription", ".", "Overall", "the", "mechanism", "of", "transactivation", "by", "the", "human", "B", "-", "cell", "-", "specific", "CIITA", "is", "very", "similar", "to", "that", "mediated", "by", "the", "herpes", "virus", "transactivator", "VP16", "in", "the", "ways", "that", "have", "been", "tested", ".", "\n" ]

[ "Entity", "Protein" ]

V3 loop is a Entity, peptides is a Entity, V3 region is a Entity, V3-BH10 is a Entity, 42 amino acids is a Entity, loop structure is a Entity, CD4 is a Protein, V3 loop is a Entity, V3-BH10 is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, chromatin is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, V3-BH10 is a Entity, IL-2 is a Protein, IL-2 receptors is a Entity, tyrosyl is a Entity, p120 is a Protein, p98 is a Protein, p96 is a Protein, p54 is a Protein, p38 is a Protein, IL-2 is a Protein, V3-BH10 is a Entity, c - fos is a Protein, c - myc is a Protein, V3 loop is a Entity, gp120 is a Protein, IL-2 is a Protein

679_task0

Sentence: V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth.

[ "V3", "loop", "of", "human", "immunodeficiency", "virus", "type", "1", "suppresses", "interleukin", "2-induced", "T", "cell", "growth", "[", "published", "erratum", "appears", "in", "AIDS", "Res", "Hum", "Retroviruses", "1997", "May", "1;13(7):633", "]", "\n", "We", "tested", "the", "effect", "of", "three", "linear", "or", "two", "loop", "peptides", "derived", "from", "the", "V3", "region", "of", "the", "HTLV", "-", "III", "BH10", "clone", "or", "the", "SF2", "strain", "of", "human", "immunodeficiency", "virus", "type", "1", "on", "IL-2-driven", "T", "cell", "proliferation", ".", "V3-BH10", ",", "which", "consists", "of", "42", "amino", "acids", "and", "has", "a", "loop", "structure", ",", "suppressed", "IL-2-driven", "proliferation", "of", "all", "IL-2-dependent", "cells", "[", "Kit225", ",", "ED-40515(+", ")", ",", "KT-3", ",", "7-day", "PHA", "-", "blasts", ",", "and", "fresh", "peripheral", "blood", "mononuclear", "cells", "]", "tested", ",", "whereas", "it", "did", "not", "suppress", "the", "cell", "growth", "of", "IL-2-independent", "cell", "lines", "(", "Hut102", ",", "Molt-4", ",", "and", "Jurkat", ")", ".", "This", "suppressive", "effect", "was", "also", "seen", "in", "IL-2-driven", "cell", "growth", "of", "CD8-positive", "lymphocytes", "purified", "from", "7-day", "PHA", "-", "blasts", ",", "indicating", "that", "CD4", "molecules", "were", "not", "required", "for", "the", "suppression", ".", "The", "treatment", "with", "anti", "-", "V3", "loop", "monoclonal", "antibody", "(", "902", "antibody", ")", "completely", "abolished", "the", "suppressive", "effect", "of", "V3-BH10", ".", "In", "addition", ",", "V3-BH10", "generated", "the", "arrest", "of", "Kit225", "cells", "and", "also", "purified", "CD8-positive", "lymphocytes", "in", "G1", "phase", "in", "the", "presence", "of", "IL-2", ".", "Neither", "chromatin", "condensation", "nor", "DNA", "fragmentation", "was", "detected", "in", "Kit225", "cells", "cultured", "with", "V3-BH10", "and", "IL-2", ".", "V3-BH10", "neither", "blocked", "radiolabeled", "IL-2", "binding", "to", "IL-2", "receptors", "nor", "affected", "tyrosyl", "phosphorylation", "of", "several", "cellular", "proteins", "(", "p120", ",", "p98", ",", "p96", ",", "p54", ",", "and", "p38", ")", ",", "which", "is", "immediately", "induced", "by", "IL-2", "stimulation", ".", "However", ",", "V3-BH10", "enhanced", "IL-2-induced", "mRNA", "expression", "of", "c", "-", "fos", "but", "not", "c", "-", "myc", "or", "junB.", "Thus", ",", "the", "binding", "of", "V3", "loop", "of", "gp120", "to", "the", "cell", "surface", "molecule(s", ")", "appears", "to", "affect", "intracellular", "IL-2", "signaling", ",", "which", "leads", "to", "the", "suppression", "of", "IL-2-induced", "T", "cell", "growth", ".", "\n" ]

[ "Entity", "Protein" ]

V3 loop is a Entity, peptides is a Entity, V3 region is a Entity, V3-BH10 is a Entity, 42 amino acids is a Entity, loop structure is a Entity, CD4 is a Protein, V3 loop is a Entity, V3-BH10 is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, chromatin is a Entity, V3-BH10 is a Entity, IL-2 is a Protein, V3-BH10 is a Entity, IL-2 is a Protein, IL-2 receptors is a Entity, tyrosyl is a Entity, p120 is a Protein, p98 is a Protein, p96 is a Protein, p54 is a Protein, p38 is a Protein, IL-2 is a Protein, V3-BH10 is a Entity, c - fos is a Protein, c - myc is a Protein, V3 loop is a Entity, gp120 is a Protein, IL-2 is a Protein

679_task1

Sentence: V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth. Instructions: please typing these entity words according to sentence: V3 loop, peptides, V3 region, V3-BH10, 42 amino acids, loop structure, CD4, V3 loop, V3-BH10, V3-BH10, IL-2, chromatin, V3-BH10, IL-2, V3-BH10, IL-2, IL-2 receptors, tyrosyl, p120, p98, p96, p54, p38, IL-2, V3-BH10, c - fos, c - myc, V3 loop, gp120, IL-2 Options: Entity, Protein

[ "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth.

[ "V3", "loop", "of", "human", "immunodeficiency", "virus", "type", "1", "suppresses", "interleukin", "2-induced", "T", "cell", "growth", "[", "published", "erratum", "appears", "in", "AIDS", "Res", "Hum", "Retroviruses", "1997", "May", "1;13(7):633", "]", "\n", "We", "tested", "the", "effect", "of", "three", "linear", "or", "two", "loop", "peptides", "derived", "from", "the", "V3", "region", "of", "the", "HTLV", "-", "III", "BH10", "clone", "or", "the", "SF2", "strain", "of", "human", "immunodeficiency", "virus", "type", "1", "on", "IL-2-driven", "T", "cell", "proliferation", ".", "V3-BH10", ",", "which", "consists", "of", "42", "amino", "acids", "and", "has", "a", "loop", "structure", ",", "suppressed", "IL-2-driven", "proliferation", "of", "all", "IL-2-dependent", "cells", "[", "Kit225", ",", "ED-40515(+", ")", ",", "KT-3", ",", "7-day", "PHA", "-", "blasts", ",", "and", "fresh", "peripheral", "blood", "mononuclear", "cells", "]", "tested", ",", "whereas", "it", "did", "not", "suppress", "the", "cell", "growth", "of", "IL-2-independent", "cell", "lines", "(", "Hut102", ",", "Molt-4", ",", "and", "Jurkat", ")", ".", "This", "suppressive", "effect", "was", "also", "seen", "in", "IL-2-driven", "cell", "growth", "of", "CD8-positive", "lymphocytes", "purified", "from", "7-day", "PHA", "-", "blasts", ",", "indicating", "that", "CD4", "molecules", "were", "not", "required", "for", "the", "suppression", ".", "The", "treatment", "with", "anti", "-", "V3", "loop", "monoclonal", "antibody", "(", "902", "antibody", ")", "completely", "abolished", "the", "suppressive", "effect", "of", "V3-BH10", ".", "In", "addition", ",", "V3-BH10", "generated", "the", "arrest", "of", "Kit225", "cells", "and", "also", "purified", "CD8-positive", "lymphocytes", "in", "G1", "phase", "in", "the", "presence", "of", "IL-2", ".", "Neither", "chromatin", "condensation", "nor", "DNA", "fragmentation", "was", "detected", "in", "Kit225", "cells", "cultured", "with", "V3-BH10", "and", "IL-2", ".", "V3-BH10", "neither", "blocked", "radiolabeled", "IL-2", "binding", "to", "IL-2", "receptors", "nor", "affected", "tyrosyl", "phosphorylation", "of", "several", "cellular", "proteins", "(", "p120", ",", "p98", ",", "p96", ",", "p54", ",", "and", "p38", ")", ",", "which", "is", "immediately", "induced", "by", "IL-2", "stimulation", ".", "However", ",", "V3-BH10", "enhanced", "IL-2-induced", "mRNA", "expression", "of", "c", "-", "fos", "but", "not", "c", "-", "myc", "or", "junB.", "Thus", ",", "the", "binding", "of", "V3", "loop", "of", "gp120", "to", "the", "cell", "surface", "molecule(s", ")", "appears", "to", "affect", "intracellular", "IL-2", "signaling", ",", "which", "leads", "to", "the", "suppression", "of", "IL-2-induced", "T", "cell", "growth", ".", "\n" ]

[ "Entity", "Protein" ]

V3 loop, peptides, V3 region, V3-BH10, 42 amino acids, loop structure, CD4, V3 loop, V3-BH10, V3-BH10, IL-2, chromatin, V3-BH10, IL-2, V3-BH10, IL-2, IL-2 receptors, tyrosyl, p120, p98, p96, p54, p38, IL-2, V3-BH10, c - fos, c - myc, V3 loop, gp120, IL-2

679_task2

Sentence: V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth. Instructions: please extract entity words from the input sentence

[ "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Protein", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth [published erratum appears in AIDS Res Hum Retroviruses 1997 May 1;13(7):633] We tested the effect of three linear or two loop peptides derived from the V3 region of the HTLV-III BH10 clone or the SF2 strain of human immunodeficiency virus type 1 on IL-2-driven T cell proliferation. V3-BH10, which consists of 42 amino acids and has a loop structure, suppressed IL-2-driven proliferation of all IL-2-dependent cells [Kit225, ED-40515(+), KT-3, 7-day PHA-blasts, and fresh peripheral blood mononuclear cells] tested, whereas it did not suppress the cell growth of IL-2-independent cell lines (Hut102, Molt-4, and Jurkat). This suppressive effect was also seen in IL-2-driven cell growth of CD8-positive lymphocytes purified from 7-day PHA-blasts, indicating that CD4 molecules were not required for the suppression. The treatment with anti-V3 loop monoclonal antibody (902 antibody) completely abolished the suppressive effect of V3-BH10. In addition, V3-BH10 generated the arrest of Kit225 cells and also purified CD8-positive lymphocytes in G1 phase in the presence of IL-2. Neither chromatin condensation nor DNA fragmentation was detected in Kit225 cells cultured with V3-BH10 and IL-2. V3-BH10 neither blocked radiolabeled IL-2 binding to IL-2 receptors nor affected tyrosyl phosphorylation of several cellular proteins (p120, p98, p96, p54, and p38), which is immediately induced by IL-2 stimulation. However, V3-BH10 enhanced IL-2-induced mRNA expression of c-fos but not c-myc or junB. Thus, the binding of V3 loop of gp120 to the cell surface molecule(s) appears to affect intracellular IL-2 signaling, which leads to the suppression of IL-2-induced T cell growth.

[ "V3", "loop", "of", "human", "immunodeficiency", "virus", "type", "1", "suppresses", "interleukin", "2-induced", "T", "cell", "growth", "[", "published", "erratum", "appears", "in", "AIDS", "Res", "Hum", "Retroviruses", "1997", "May", "1;13(7):633", "]", "\n", "We", "tested", "the", "effect", "of", "three", "linear", "or", "two", "loop", "peptides", "derived", "from", "the", "V3", "region", "of", "the", "HTLV", "-", "III", "BH10", "clone", "or", "the", "SF2", "strain", "of", "human", "immunodeficiency", "virus", "type", "1", "on", "IL-2-driven", "T", "cell", "proliferation", ".", "V3-BH10", ",", "which", "consists", "of", "42", "amino", "acids", "and", "has", "a", "loop", "structure", ",", "suppressed", "IL-2-driven", "proliferation", "of", "all", "IL-2-dependent", "cells", "[", "Kit225", ",", "ED-40515(+", ")", ",", "KT-3", ",", "7-day", "PHA", "-", "blasts", ",", "and", "fresh", "peripheral", "blood", "mononuclear", "cells", "]", "tested", ",", "whereas", "it", "did", "not", "suppress", "the", "cell", "growth", "of", "IL-2-independent", "cell", "lines", "(", "Hut102", ",", "Molt-4", ",", "and", "Jurkat", ")", ".", "This", "suppressive", "effect", "was", "also", "seen", "in", "IL-2-driven", "cell", "growth", "of", "CD8-positive", "lymphocytes", "purified", "from", "7-day", "PHA", "-", "blasts", ",", "indicating", "that", "CD4", "molecules", "were", "not", "required", "for", "the", "suppression", ".", "The", "treatment", "with", "anti", "-", "V3", "loop", "monoclonal", "antibody", "(", "902", "antibody", ")", "completely", "abolished", "the", "suppressive", "effect", "of", "V3-BH10", ".", "In", "addition", ",", "V3-BH10", "generated", "the", "arrest", "of", "Kit225", "cells", "and", "also", "purified", "CD8-positive", "lymphocytes", "in", "G1", "phase", "in", "the", "presence", "of", "IL-2", ".", "Neither", "chromatin", "condensation", "nor", "DNA", "fragmentation", "was", "detected", "in", "Kit225", "cells", "cultured", "with", "V3-BH10", "and", "IL-2", ".", "V3-BH10", "neither", "blocked", "radiolabeled", "IL-2", "binding", "to", "IL-2", "receptors", "nor", "affected", "tyrosyl", "phosphorylation", "of", "several", "cellular", "proteins", "(", "p120", ",", "p98", ",", "p96", ",", "p54", ",", "and", "p38", ")", ",", "which", "is", "immediately", "induced", "by", "IL-2", "stimulation", ".", "However", ",", "V3-BH10", "enhanced", "IL-2-induced", "mRNA", "expression", "of", "c", "-", "fos", "but", "not", "c", "-", "myc", "or", "junB.", "Thus", ",", "the", "binding", "of", "V3", "loop", "of", "gp120", "to", "the", "cell", "surface", "molecule(s", ")", "appears", "to", "affect", "intracellular", "IL-2", "signaling", ",", "which", "leads", "to", "the", "suppression", "of", "IL-2-induced", "T", "cell", "growth", ".", "\n" ]

[ "Entity", "Protein" ]

urokinase is a Intervention_Pharmacological, A multicentre trial ( 10 centres ) of urokinase ( UK ) is a Intervention_Pharmacological, patients with acute severe pulmonary embolism ( PE ) . is a Participant_Condition, two doses of UK is a Intervention_Pharmacological, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin is a Intervention_Pharmacological, degree of early revascularization is a Outcome_Physical, thrombolytic treatment is a Intervention_Pharmacological, died is a Outcome_Mortality, Miller angiographic index is a Outcome_Physical, significant degree of resolution is a Outcome_Physical, Minor and major bleeding problems is a Outcome_Adverse-effects

76212_task0

Sentence: The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "The", "UKEP", "study", ":", "multicentre", "clinical", "trial", "on", "two", "local", "regimens", "of", "urokinase", "in", "massive", "pulmonary", "embolism", ".", "The", "UKEP", "Study", "Research", "Group", ".", "A", "multicentre", "trial", "(", "10", "centres", ")", "of", "urokinase", "(", "UK", ")", "was", "performed", "in", "patients", "with", "acute", "severe", "pulmonary", "embolism", "(", "PE", ")", ".", "The", "aim", "of", "this", "trial", "was", ",", "to", "compare", "the", "efficacy", "of", "two", "doses", "of", "UK", "administered", "via", "a", "catheter", "in", "the", "pulmonary", "artery", ":", "2000", "IU", "kg-1", "h-1", "for", "24", "hours", "(", "UK", "2000", ")", "in", "conjunction", "with", "heparin", "versus", "4400", "IU", "kg-1", "h-1", "UK", "alone", "for", "12", "hours", "(", "UK", "4400", ")", "followed", "by", "heparin", ".", "PE", "was", "less", "than", "5", "days", "old", "and", "the", "clinical", "diagnosis", "was", "confirmed", "by", "pulmonary", "angiograms", "demonstrating", "a", "vascular", "obstruction", "of", "more", "than", "30", "%", "(", "Miller", "'", "s", "index", "greater", "than", "11", ")", ".", "The", "efficacy", "of", "treatment", "was", "evaluated", "by", "the", "degree", "of", "early", "revascularization", "(", "pulmonary", "angiograms", "were", "performed", "30", "to", "48", "hours", "after", "initiation", "of", "thrombolytic", "treatment", "and", "analysed", "blindly", "by", "four", "independent", "vascular", "radiologists", ")", ".", "133", "patients", "were", "included", "in", "this", "trial", ":", "two", "patients", "died", "before", "treatment", "and", "two", "were", "excluded", "retrospectively", ",", "leaving", "129", "patients", "for", "final", "analysis", "(", "67", ":", "UK", "2000", "+", "heparin", ";", "62", ":", "UK", "4400", ")", ".", "The", "two", "groups", "had", "similar", "pretreatment", "clinical", ",", "haemodynamic", "and", "angiographic", "characteristics", ":", "the", "Miller", "angiographic", "index", "of", "severity", "averaged", "22.6", "+", "/-", "3.7", "for", "patients", "in", "the", "UK", "2000", "group", ",", "and", "22.6", "+", "/-", "3.4", "for", "patients", "in", "the", "UK", "4400", "group", "(", "average", "filling", "defect", "of", "66", "%", "on", "pulmonary", "angiograms", ")", ".", "There", "was", "a", "similar", "and", "significant", "degree", "of", "resolution", "in", "the", "two", "groups", ":", "26", "%", "and", "20", "%", ",", "respectively", ".", "Minor", "and", "major", "bleeding", "problems", "were", "observed", "with", "equal", "frequency", "in", "the", "two", "groups", "(", "24", "%", "and", "29", "%", ",", "respectively", ")", ".", "These", "bleeding", "complications", "were", "severe", "in", "only", "4.5", "%", "and", "3", "%", ",", "respectively", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Mortality" ]

urokinase is a Intervention_Pharmacological, A multicentre trial ( 10 centres ) of urokinase ( UK ) is a Intervention_Pharmacological, patients with acute severe pulmonary embolism ( PE ) . is a Participant_Condition, two doses of UK is a Intervention_Pharmacological, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin is a Intervention_Pharmacological, degree of early revascularization is a Outcome_Physical, thrombolytic treatment is a Intervention_Pharmacological, died is a Outcome_Mortality, Miller angiographic index is a Outcome_Physical, significant degree of resolution is a Outcome_Physical, Minor and major bleeding problems is a Outcome_Adverse-effects

76212_task1

Sentence: The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please typing these entity words according to sentence: urokinase, A multicentre trial ( 10 centres ) of urokinase ( UK ), patients with acute severe pulmonary embolism ( PE ) ., two doses of UK, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin, degree of early revascularization, thrombolytic treatment, died, Miller angiographic index, significant degree of resolution, Minor and major bleeding problems Options: Intervention_Pharmacological, Outcome_Adverse-effects, Participant_Condition, Outcome_Mortality, Outcome_Physical

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "The", "UKEP", "study", ":", "multicentre", "clinical", "trial", "on", "two", "local", "regimens", "of", "urokinase", "in", "massive", "pulmonary", "embolism", ".", "The", "UKEP", "Study", "Research", "Group", ".", "A", "multicentre", "trial", "(", "10", "centres", ")", "of", "urokinase", "(", "UK", ")", "was", "performed", "in", "patients", "with", "acute", "severe", "pulmonary", "embolism", "(", "PE", ")", ".", "The", "aim", "of", "this", "trial", "was", ",", "to", "compare", "the", "efficacy", "of", "two", "doses", "of", "UK", "administered", "via", "a", "catheter", "in", "the", "pulmonary", "artery", ":", "2000", "IU", "kg-1", "h-1", "for", "24", "hours", "(", "UK", "2000", ")", "in", "conjunction", "with", "heparin", "versus", "4400", "IU", "kg-1", "h-1", "UK", "alone", "for", "12", "hours", "(", "UK", "4400", ")", "followed", "by", "heparin", ".", "PE", "was", "less", "than", "5", "days", "old", "and", "the", "clinical", "diagnosis", "was", "confirmed", "by", "pulmonary", "angiograms", "demonstrating", "a", "vascular", "obstruction", "of", "more", "than", "30", "%", "(", "Miller", "'", "s", "index", "greater", "than", "11", ")", ".", "The", "efficacy", "of", "treatment", "was", "evaluated", "by", "the", "degree", "of", "early", "revascularization", "(", "pulmonary", "angiograms", "were", "performed", "30", "to", "48", "hours", "after", "initiation", "of", "thrombolytic", "treatment", "and", "analysed", "blindly", "by", "four", "independent", "vascular", "radiologists", ")", ".", "133", "patients", "were", "included", "in", "this", "trial", ":", "two", "patients", "died", "before", "treatment", "and", "two", "were", "excluded", "retrospectively", ",", "leaving", "129", "patients", "for", "final", "analysis", "(", "67", ":", "UK", "2000", "+", "heparin", ";", "62", ":", "UK", "4400", ")", ".", "The", "two", "groups", "had", "similar", "pretreatment", "clinical", ",", "haemodynamic", "and", "angiographic", "characteristics", ":", "the", "Miller", "angiographic", "index", "of", "severity", "averaged", "22.6", "+", "/-", "3.7", "for", "patients", "in", "the", "UK", "2000", "group", ",", "and", "22.6", "+", "/-", "3.4", "for", "patients", "in", "the", "UK", "4400", "group", "(", "average", "filling", "defect", "of", "66", "%", "on", "pulmonary", "angiograms", ")", ".", "There", "was", "a", "similar", "and", "significant", "degree", "of", "resolution", "in", "the", "two", "groups", ":", "26", "%", "and", "20", "%", ",", "respectively", ".", "Minor", "and", "major", "bleeding", "problems", "were", "observed", "with", "equal", "frequency", "in", "the", "two", "groups", "(", "24", "%", "and", "29", "%", ",", "respectively", ")", ".", "These", "bleeding", "complications", "were", "severe", "in", "only", "4.5", "%", "and", "3", "%", ",", "respectively", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Mortality" ]

urokinase, A multicentre trial ( 10 centres ) of urokinase ( UK ), patients with acute severe pulmonary embolism ( PE ) ., two doses of UK, a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin, degree of early revascularization, thrombolytic treatment, died, Miller angiographic index, significant degree of resolution, Minor and major bleeding problems

76212_task2

Sentence: The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS ) Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The UKEP study : multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism . The UKEP Study Research Group . A multicentre trial ( 10 centres ) of urokinase ( UK ) was performed in patients with acute severe pulmonary embolism ( PE ) . The aim of this trial was , to compare the efficacy of two doses of UK administered via a catheter in the pulmonary artery : 2000 IU kg-1 h-1 for 24 hours ( UK 2000 ) in conjunction with heparin versus 4400 IU kg-1 h-1 UK alone for 12 hours ( UK 4400 ) followed by heparin . PE was less than 5 days old and the clinical diagnosis was confirmed by pulmonary angiograms demonstrating a vascular obstruction of more than 30 % ( Miller 's index greater than 11 ) . The efficacy of treatment was evaluated by the degree of early revascularization ( pulmonary angiograms were performed 30 to 48 hours after initiation of thrombolytic treatment and analysed blindly by four independent vascular radiologists ) . 133 patients were included in this trial : two patients died before treatment and two were excluded retrospectively , leaving 129 patients for final analysis ( 67 : UK 2000 + heparin ; 62 : UK 4400 ) . The two groups had similar pretreatment clinical , haemodynamic and angiographic characteristics : the Miller angiographic index of severity averaged 22.6 +/- 3.7 for patients in the UK 2000 group , and 22.6 +/- 3.4 for patients in the UK 4400 group ( average filling defect of 66 % on pulmonary angiograms ) . There was a similar and significant degree of resolution in the two groups : 26 % and 20 % , respectively . Minor and major bleeding problems were observed with equal frequency in the two groups ( 24 % and 29 % , respectively ) . These bleeding complications were severe in only 4.5 % and 3 % , respectively . ( ABSTRACT TRUNCATED AT 250 WORDS )

[ "The", "UKEP", "study", ":", "multicentre", "clinical", "trial", "on", "two", "local", "regimens", "of", "urokinase", "in", "massive", "pulmonary", "embolism", ".", "The", "UKEP", "Study", "Research", "Group", ".", "A", "multicentre", "trial", "(", "10", "centres", ")", "of", "urokinase", "(", "UK", ")", "was", "performed", "in", "patients", "with", "acute", "severe", "pulmonary", "embolism", "(", "PE", ")", ".", "The", "aim", "of", "this", "trial", "was", ",", "to", "compare", "the", "efficacy", "of", "two", "doses", "of", "UK", "administered", "via", "a", "catheter", "in", "the", "pulmonary", "artery", ":", "2000", "IU", "kg-1", "h-1", "for", "24", "hours", "(", "UK", "2000", ")", "in", "conjunction", "with", "heparin", "versus", "4400", "IU", "kg-1", "h-1", "UK", "alone", "for", "12", "hours", "(", "UK", "4400", ")", "followed", "by", "heparin", ".", "PE", "was", "less", "than", "5", "days", "old", "and", "the", "clinical", "diagnosis", "was", "confirmed", "by", "pulmonary", "angiograms", "demonstrating", "a", "vascular", "obstruction", "of", "more", "than", "30", "%", "(", "Miller", "'", "s", "index", "greater", "than", "11", ")", ".", "The", "efficacy", "of", "treatment", "was", "evaluated", "by", "the", "degree", "of", "early", "revascularization", "(", "pulmonary", "angiograms", "were", "performed", "30", "to", "48", "hours", "after", "initiation", "of", "thrombolytic", "treatment", "and", "analysed", "blindly", "by", "four", "independent", "vascular", "radiologists", ")", ".", "133", "patients", "were", "included", "in", "this", "trial", ":", "two", "patients", "died", "before", "treatment", "and", "two", "were", "excluded", "retrospectively", ",", "leaving", "129", "patients", "for", "final", "analysis", "(", "67", ":", "UK", "2000", "+", "heparin", ";", "62", ":", "UK", "4400", ")", ".", "The", "two", "groups", "had", "similar", "pretreatment", "clinical", ",", "haemodynamic", "and", "angiographic", "characteristics", ":", "the", "Miller", "angiographic", "index", "of", "severity", "averaged", "22.6", "+", "/-", "3.7", "for", "patients", "in", "the", "UK", "2000", "group", ",", "and", "22.6", "+", "/-", "3.4", "for", "patients", "in", "the", "UK", "4400", "group", "(", "average", "filling", "defect", "of", "66", "%", "on", "pulmonary", "angiograms", ")", ".", "There", "was", "a", "similar", "and", "significant", "degree", "of", "resolution", "in", "the", "two", "groups", ":", "26", "%", "and", "20", "%", ",", "respectively", ".", "Minor", "and", "major", "bleeding", "problems", "were", "observed", "with", "equal", "frequency", "in", "the", "two", "groups", "(", "24", "%", "and", "29", "%", ",", "respectively", ")", ".", "These", "bleeding", "complications", "were", "severe", "in", "only", "4.5", "%", "and", "3", "%", ",", "respectively", ".", "(", "ABSTRACT", "TRUNCATED", "AT", "250", "WORDS", ")" ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Outcome_Mortality" ]

Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, CD4 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein

212_task0

Sentence: Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].

[ "Foxp3", "Suppresses", "HIV-1", "Gene", "Expression", "in", "Part", "through", "Blocking", "Activation", "of", "NF", "-", "kappaB", "\n", "If", "Foxp3", "functions", "as", "a", "repressor", "of", "NF", "-", "kappaB", "-", "dependent", "gene", "expression", ",", "then", "we", "hypothesized", "that", "Foxp3", "overexpression", "could", "selectively", "down", "-", "regulate", "transcription", "from", "promoters", "previously", "shown", "to", "be", "responsive", "to", "NF", "-", "kappaB.", "To", "address", "this", "question", ",", "we", "examined", "the", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", ",", "which", "contains", "two", "tandem", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", "located", "between", "positions", "-102", "and", "-81", "with", "respect", "to", "the", "transcription", "initiation", "site", "[", "21", "]", ".", "NF", "-", "kappaB", "plays", "a", "crucial", "role", "in", "regulating", "gene", "expression", "directed", "from", "the", "HIV-1", "LTR", "in", "CD4", "+", "T", "cells", "[", "21", "]", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "deltaFKH", ",", "in", "HEK", "293", "T", "cells", "was", "able", "to", "inhibit", "basal", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3A", ")", ",", "similar", "to", "what", "was", "previously", "demonstrated", "with", "the", "synthetic", "NF", "-", "kappaB", "reporter", "vector", "(", "Figure", "2B", ")", ".", "Furthermore", ",", "HIV-1", "LTR", "activation", "was", "suppressed", "by", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "3B", ")", ".", "To", "demonstrate", "that", "Foxp3-mediated", "HIV-1", "LTR", "repression", "was", "associated", "with", "interactions", "with", "NF", "-", "kappaB", "bound", "to", "the", "HIV-1", "LTR", ",", "we", "compared", "basal", "activation", "of", "the", "HIV-1", "LTR", "or", "an", "identical", "HIV-1", "LTR", "lacking", "the", "NF", "-", "kappaB", "sites", "located", "between", "-102", "and", "-81", "(", "HIV-1", "delta", "-", "kappaB", "LTR", ")", "(", "Figure", "3C", ")", ".", "This", "mutant", "HIV-1", "LTR", "construct", "exhibited", "reduced", "levels", "of", "transcription", "compared", "to", "the", "parental", "HIV-1", "LTR", "in", "purified", "healthy", "donor", "CD4", "+", "T", "cells", "(", "unpublished", "data", ")", ".", "However", ",", "directly", "comparing", "the", "effect", "of", "Foxp3", "overexpression", "on", "the", "activation", "of", "these", "two", "viral", "promoters", "demonstrated", "that", "Foxp3", "was", "more", "capable", "of", "suppressing", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3D", ")", "compared", "to", "the", "mutated", "HIV-1", "LTR", "(", "Figure", "3E", ")", ".", "These", "results", "suggest", "that", "Foxp3", "down", "-", "regulation", "of", "HIV-1", "LTR", "activation", "was", "mediated", "at", "least", "in", "part", "by", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", ".", "Residual", "levels", "of", "inhibition", "of", "the", "HIV-1", "delta", "-", "kappaB", "LTR", "by", "Foxp3", "may", "be", "due", "to", "NF", "-", "AT", "binding", "sites", "located", "upstream", "of", "the", "NF", "-", "kappaB", "sites", "within", "the", "HIV-1", "LTR", "[", "22,23", "]", "." ]

[ "Protein" ]

Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, CD4 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein

212_task1

Sentence: Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23]. Instructions: please typing these entity words according to sentence: Foxp3, Foxp3, Foxp3, CD4, Foxp3, deltaFKH, Foxp3, deltaFKH, CD4, Foxp3, Foxp3, Foxp3, Foxp3 Options: Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].

[ "Foxp3", "Suppresses", "HIV-1", "Gene", "Expression", "in", "Part", "through", "Blocking", "Activation", "of", "NF", "-", "kappaB", "\n", "If", "Foxp3", "functions", "as", "a", "repressor", "of", "NF", "-", "kappaB", "-", "dependent", "gene", "expression", ",", "then", "we", "hypothesized", "that", "Foxp3", "overexpression", "could", "selectively", "down", "-", "regulate", "transcription", "from", "promoters", "previously", "shown", "to", "be", "responsive", "to", "NF", "-", "kappaB.", "To", "address", "this", "question", ",", "we", "examined", "the", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", ",", "which", "contains", "two", "tandem", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", "located", "between", "positions", "-102", "and", "-81", "with", "respect", "to", "the", "transcription", "initiation", "site", "[", "21", "]", ".", "NF", "-", "kappaB", "plays", "a", "crucial", "role", "in", "regulating", "gene", "expression", "directed", "from", "the", "HIV-1", "LTR", "in", "CD4", "+", "T", "cells", "[", "21", "]", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "deltaFKH", ",", "in", "HEK", "293", "T", "cells", "was", "able", "to", "inhibit", "basal", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3A", ")", ",", "similar", "to", "what", "was", "previously", "demonstrated", "with", "the", "synthetic", "NF", "-", "kappaB", "reporter", "vector", "(", "Figure", "2B", ")", ".", "Furthermore", ",", "HIV-1", "LTR", "activation", "was", "suppressed", "by", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "3B", ")", ".", "To", "demonstrate", "that", "Foxp3-mediated", "HIV-1", "LTR", "repression", "was", "associated", "with", "interactions", "with", "NF", "-", "kappaB", "bound", "to", "the", "HIV-1", "LTR", ",", "we", "compared", "basal", "activation", "of", "the", "HIV-1", "LTR", "or", "an", "identical", "HIV-1", "LTR", "lacking", "the", "NF", "-", "kappaB", "sites", "located", "between", "-102", "and", "-81", "(", "HIV-1", "delta", "-", "kappaB", "LTR", ")", "(", "Figure", "3C", ")", ".", "This", "mutant", "HIV-1", "LTR", "construct", "exhibited", "reduced", "levels", "of", "transcription", "compared", "to", "the", "parental", "HIV-1", "LTR", "in", "purified", "healthy", "donor", "CD4", "+", "T", "cells", "(", "unpublished", "data", ")", ".", "However", ",", "directly", "comparing", "the", "effect", "of", "Foxp3", "overexpression", "on", "the", "activation", "of", "these", "two", "viral", "promoters", "demonstrated", "that", "Foxp3", "was", "more", "capable", "of", "suppressing", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3D", ")", "compared", "to", "the", "mutated", "HIV-1", "LTR", "(", "Figure", "3E", ")", ".", "These", "results", "suggest", "that", "Foxp3", "down", "-", "regulation", "of", "HIV-1", "LTR", "activation", "was", "mediated", "at", "least", "in", "part", "by", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", ".", "Residual", "levels", "of", "inhibition", "of", "the", "HIV-1", "delta", "-", "kappaB", "LTR", "by", "Foxp3", "may", "be", "due", "to", "NF", "-", "AT", "binding", "sites", "located", "upstream", "of", "the", "NF", "-", "kappaB", "sites", "within", "the", "HIV-1", "LTR", "[", "22,23", "]", "." ]

[ "Protein" ]

Foxp3, Foxp3, Foxp3, CD4, Foxp3, deltaFKH, Foxp3, deltaFKH, CD4, Foxp3, Foxp3, Foxp3, Foxp3

212_task2

Sentence: Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23]. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Foxp3 Suppresses HIV-1 Gene Expression in Part through Blocking Activation of NF-kappaB If Foxp3 functions as a repressor of NF-kappaB-dependent gene expression, then we hypothesized that Foxp3 overexpression could selectively down-regulate transcription from promoters previously shown to be responsive to NF-kappaB. To address this question, we examined the transcriptional activation of the HIV-1 LTR, which contains two tandem cis-acting NF-kappaB binding sites located between positions -102 and -81 with respect to the transcription initiation site [21]. NF-kappaB plays a crucial role in regulating gene expression directed from the HIV-1 LTR in CD4+ T cells [21]. Overexpression of full-length Foxp3, but not deltaFKH, in HEK 293T cells was able to inhibit basal activation of the HIV-1 LTR (Figure 3A), similar to what was previously demonstrated with the synthetic NF-kappaB reporter vector (Figure 2B). Furthermore, HIV-1 LTR activation was suppressed by full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 3B). To demonstrate that Foxp3-mediated HIV-1 LTR repression was associated with interactions with NF-kappaB bound to the HIV-1 LTR, we compared basal activation of the HIV-1 LTR or an identical HIV-1 LTR lacking the NF-kappaB sites located between -102 and -81 (HIV-1 delta-kappaB LTR) (Figure 3C). This mutant HIV-1 LTR construct exhibited reduced levels of transcription compared to the parental HIV-1 LTR in purified healthy donor CD4+ T cells (unpublished data). However, directly comparing the effect of Foxp3 overexpression on the activation of these two viral promoters demonstrated that Foxp3 was more capable of suppressing transcriptional activation of the HIV-1 LTR (Figure 3D) compared to the mutated HIV-1 LTR (Figure 3E). These results suggest that Foxp3 down-regulation of HIV-1 LTR activation was mediated at least in part by cis-acting NF-kappaB binding sites. Residual levels of inhibition of the HIV-1 delta-kappaB LTR by Foxp3 may be due to NF-AT binding sites located upstream of the NF-kappaB sites within the HIV-1 LTR [22,23].

[ "Foxp3", "Suppresses", "HIV-1", "Gene", "Expression", "in", "Part", "through", "Blocking", "Activation", "of", "NF", "-", "kappaB", "\n", "If", "Foxp3", "functions", "as", "a", "repressor", "of", "NF", "-", "kappaB", "-", "dependent", "gene", "expression", ",", "then", "we", "hypothesized", "that", "Foxp3", "overexpression", "could", "selectively", "down", "-", "regulate", "transcription", "from", "promoters", "previously", "shown", "to", "be", "responsive", "to", "NF", "-", "kappaB.", "To", "address", "this", "question", ",", "we", "examined", "the", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", ",", "which", "contains", "two", "tandem", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", "located", "between", "positions", "-102", "and", "-81", "with", "respect", "to", "the", "transcription", "initiation", "site", "[", "21", "]", ".", "NF", "-", "kappaB", "plays", "a", "crucial", "role", "in", "regulating", "gene", "expression", "directed", "from", "the", "HIV-1", "LTR", "in", "CD4", "+", "T", "cells", "[", "21", "]", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "deltaFKH", ",", "in", "HEK", "293", "T", "cells", "was", "able", "to", "inhibit", "basal", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3A", ")", ",", "similar", "to", "what", "was", "previously", "demonstrated", "with", "the", "synthetic", "NF", "-", "kappaB", "reporter", "vector", "(", "Figure", "2B", ")", ".", "Furthermore", ",", "HIV-1", "LTR", "activation", "was", "suppressed", "by", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "3B", ")", ".", "To", "demonstrate", "that", "Foxp3-mediated", "HIV-1", "LTR", "repression", "was", "associated", "with", "interactions", "with", "NF", "-", "kappaB", "bound", "to", "the", "HIV-1", "LTR", ",", "we", "compared", "basal", "activation", "of", "the", "HIV-1", "LTR", "or", "an", "identical", "HIV-1", "LTR", "lacking", "the", "NF", "-", "kappaB", "sites", "located", "between", "-102", "and", "-81", "(", "HIV-1", "delta", "-", "kappaB", "LTR", ")", "(", "Figure", "3C", ")", ".", "This", "mutant", "HIV-1", "LTR", "construct", "exhibited", "reduced", "levels", "of", "transcription", "compared", "to", "the", "parental", "HIV-1", "LTR", "in", "purified", "healthy", "donor", "CD4", "+", "T", "cells", "(", "unpublished", "data", ")", ".", "However", ",", "directly", "comparing", "the", "effect", "of", "Foxp3", "overexpression", "on", "the", "activation", "of", "these", "two", "viral", "promoters", "demonstrated", "that", "Foxp3", "was", "more", "capable", "of", "suppressing", "transcriptional", "activation", "of", "the", "HIV-1", "LTR", "(", "Figure", "3D", ")", "compared", "to", "the", "mutated", "HIV-1", "LTR", "(", "Figure", "3E", ")", ".", "These", "results", "suggest", "that", "Foxp3", "down", "-", "regulation", "of", "HIV-1", "LTR", "activation", "was", "mediated", "at", "least", "in", "part", "by", "cis", "-", "acting", "NF", "-", "kappaB", "binding", "sites", ".", "Residual", "levels", "of", "inhibition", "of", "the", "HIV-1", "delta", "-", "kappaB", "LTR", "by", "Foxp3", "may", "be", "due", "to", "NF", "-", "AT", "binding", "sites", "located", "upstream", "of", "the", "NF", "-", "kappaB", "sites", "within", "the", "HIV-1", "LTR", "[", "22,23", "]", "." ]

[ "Protein" ]

posterior is an umlsterm, orbit is an umlsterm, optic nerve is an umlsterm, artery is an umlsterm, vein is an umlsterm, ocular muscles is an umlsterm, nerves is an umlsterm, surgical is an umlsterm, transmaxillary is an umlsterm, procedures is an umlsterm, injury is an umlsterm, non - tumor is an umlsterm, case report is an umlsterm, hemangioma is an umlsterm, mobilization is an umlsterm, optic nerve is an umlsterm, sphenoid sinus is an umlsterm, lamina is an umlsterm, sphenoid sinus is an umlsterm, skull base is an umlsterm, rectus muscle is an umlsterm, tumor is an umlsterm, hemangioma is an umlsterm, toto is an umlsterm, control is an umlsterm, Surgery is an umlsterm, technique is an umlsterm, procedure is an umlsterm, minor is an umlsterm, risk is an umlsterm, hands is an umlsterm, treatment is an umlsterm

HNO.90470192.eng.abstr_task0

Sentence: The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions .

[ "The", "posterior", "orbit", "contain", "'s", "a", "number", "of", "important", "and", "vulnerable", "structures", ",", "including", "the", "optic", "nerve", ",", "the", "opthalmic", "artery", "and", "vein", ",", "the", "ocular", "muscles", "and", "their", "motor", "nerves", ".", "Because", "of", "their", "close", "relation", "to", "the", "ocular", "bult", ",", "surgical", "access", "to", "this", "region", "is", "very", "difficult", ".", "Transfrontal", ",", "transfrontalethmoidal", "and", "transmaxillary", "procedures", "have", "the", "disadvantage", "of", "possible", "injury", "to", "a", "number", "of", "non", "-", "tumor", "affected", "structures", ".", "The", "endonasal", "microsurgical", "transethmoid", "access", "is", "described", "here", "along", "with", "a", "case", "report", "of", "a", "2x1", "cm", "intraconal", "hemangioma", ".", "Ethmoidectomy", "was", "performed", "after", "septal", "mobilization", ".", "The", "optic", "nerve", "was", "identified", "in", "the", "wall", "of", "the", "sphenoid", "sinus", ".", "The", "lamina", "papyracea", "was", "resected", "between", "the", "sphenoid", "sinus", "wall", ",", "skull", "base", "and", "ethmoid", ".", "The", "medial", "rectus", "muscle", "was", "mobilized", "after", "slitting", "open", "the", "periorbita", "to", "expose", "tumor", ".", "The", "hemangioma", "was", "then", "removed", "in", "toto", "under", "microscopic", "control", ".", "Surgery", "in", "the", "retrobulbar", "region", "could", "be", "performed", "gently", "and", "under", "microscopic", "magnification", "with", "this", "technique", ".", "The", "procedure", "used", "has", "a", "minor", "risk", "in", "the", "hands", "of", "an", "experienced", "nasalsurgeon", "and", "opens", "up", "new", "possibilities", "for", "the", "treatment", "of", "retroorbital", "lesions", "." ]

[ "umlsterm" ]

posterior is an umlsterm, orbit is an umlsterm, optic nerve is an umlsterm, artery is an umlsterm, vein is an umlsterm, ocular muscles is an umlsterm, nerves is an umlsterm, surgical is an umlsterm, transmaxillary is an umlsterm, procedures is an umlsterm, injury is an umlsterm, non - tumor is an umlsterm, case report is an umlsterm, hemangioma is an umlsterm, mobilization is an umlsterm, optic nerve is an umlsterm, sphenoid sinus is an umlsterm, lamina is an umlsterm, sphenoid sinus is an umlsterm, skull base is an umlsterm, rectus muscle is an umlsterm, tumor is an umlsterm, hemangioma is an umlsterm, toto is an umlsterm, control is an umlsterm, Surgery is an umlsterm, technique is an umlsterm, procedure is an umlsterm, minor is an umlsterm, risk is an umlsterm, hands is an umlsterm, treatment is an umlsterm

HNO.90470192.eng.abstr_task1

Sentence: The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions . Instructions: please typing these entity words according to sentence: posterior, orbit, optic nerve, artery, vein, ocular muscles, nerves, surgical, transmaxillary, procedures, injury, non - tumor, case report, hemangioma, mobilization, optic nerve, sphenoid sinus, lamina, sphenoid sinus, skull base, rectus muscle, tumor, hemangioma, toto, control, Surgery, technique, procedure, minor, risk, hands, treatment Options: umlsterm

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions .

[ "The", "posterior", "orbit", "contain", "'s", "a", "number", "of", "important", "and", "vulnerable", "structures", ",", "including", "the", "optic", "nerve", ",", "the", "opthalmic", "artery", "and", "vein", ",", "the", "ocular", "muscles", "and", "their", "motor", "nerves", ".", "Because", "of", "their", "close", "relation", "to", "the", "ocular", "bult", ",", "surgical", "access", "to", "this", "region", "is", "very", "difficult", ".", "Transfrontal", ",", "transfrontalethmoidal", "and", "transmaxillary", "procedures", "have", "the", "disadvantage", "of", "possible", "injury", "to", "a", "number", "of", "non", "-", "tumor", "affected", "structures", ".", "The", "endonasal", "microsurgical", "transethmoid", "access", "is", "described", "here", "along", "with", "a", "case", "report", "of", "a", "2x1", "cm", "intraconal", "hemangioma", ".", "Ethmoidectomy", "was", "performed", "after", "septal", "mobilization", ".", "The", "optic", "nerve", "was", "identified", "in", "the", "wall", "of", "the", "sphenoid", "sinus", ".", "The", "lamina", "papyracea", "was", "resected", "between", "the", "sphenoid", "sinus", "wall", ",", "skull", "base", "and", "ethmoid", ".", "The", "medial", "rectus", "muscle", "was", "mobilized", "after", "slitting", "open", "the", "periorbita", "to", "expose", "tumor", ".", "The", "hemangioma", "was", "then", "removed", "in", "toto", "under", "microscopic", "control", ".", "Surgery", "in", "the", "retrobulbar", "region", "could", "be", "performed", "gently", "and", "under", "microscopic", "magnification", "with", "this", "technique", ".", "The", "procedure", "used", "has", "a", "minor", "risk", "in", "the", "hands", "of", "an", "experienced", "nasalsurgeon", "and", "opens", "up", "new", "possibilities", "for", "the", "treatment", "of", "retroorbital", "lesions", "." ]

[ "umlsterm" ]

posterior, orbit, optic nerve, artery, vein, ocular muscles, nerves, surgical, transmaxillary, procedures, injury, non - tumor, case report, hemangioma, mobilization, optic nerve, sphenoid sinus, lamina, sphenoid sinus, skull base, rectus muscle, tumor, hemangioma, toto, control, Surgery, technique, procedure, minor, risk, hands, treatment

HNO.90470192.eng.abstr_task2

Sentence: The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

The posterior orbit contain's a number of important and vulnerable structures , including the optic nerve , the opthalmic artery and vein , the ocular muscles and their motor nerves . Because of their close relation to the ocular bult , surgical access to this region is very difficult . Transfrontal , transfrontalethmoidal and transmaxillary procedures have the disadvantage of possible injury to a number of non-tumor affected structures . The endonasal microsurgical transethmoid access is described here along with a case report of a 2x1 cm intraconal hemangioma . Ethmoidectomy was performed after septal mobilization . The optic nerve was identified in the wall of the sphenoid sinus . The lamina papyracea was resected between the sphenoid sinus wall , skull base and ethmoid . The medial rectus muscle was mobilized after slitting open the periorbita to expose tumor . The hemangioma was then removed in toto under microscopic control . Surgery in the retrobulbar region could be performed gently and under microscopic magnification with this technique . The procedure used has a minor risk in the hands of an experienced nasalsurgeon and opens up new possibilities for the treatment of retroorbital lesions .

[ "The", "posterior", "orbit", "contain", "'s", "a", "number", "of", "important", "and", "vulnerable", "structures", ",", "including", "the", "optic", "nerve", ",", "the", "opthalmic", "artery", "and", "vein", ",", "the", "ocular", "muscles", "and", "their", "motor", "nerves", ".", "Because", "of", "their", "close", "relation", "to", "the", "ocular", "bult", ",", "surgical", "access", "to", "this", "region", "is", "very", "difficult", ".", "Transfrontal", ",", "transfrontalethmoidal", "and", "transmaxillary", "procedures", "have", "the", "disadvantage", "of", "possible", "injury", "to", "a", "number", "of", "non", "-", "tumor", "affected", "structures", ".", "The", "endonasal", "microsurgical", "transethmoid", "access", "is", "described", "here", "along", "with", "a", "case", "report", "of", "a", "2x1", "cm", "intraconal", "hemangioma", ".", "Ethmoidectomy", "was", "performed", "after", "septal", "mobilization", ".", "The", "optic", "nerve", "was", "identified", "in", "the", "wall", "of", "the", "sphenoid", "sinus", ".", "The", "lamina", "papyracea", "was", "resected", "between", "the", "sphenoid", "sinus", "wall", ",", "skull", "base", "and", "ethmoid", ".", "The", "medial", "rectus", "muscle", "was", "mobilized", "after", "slitting", "open", "the", "periorbita", "to", "expose", "tumor", ".", "The", "hemangioma", "was", "then", "removed", "in", "toto", "under", "microscopic", "control", ".", "Surgery", "in", "the", "retrobulbar", "region", "could", "be", "performed", "gently", "and", "under", "microscopic", "magnification", "with", "this", "technique", ".", "The", "procedure", "used", "has", "a", "minor", "risk", "in", "the", "hands", "of", "an", "experienced", "nasalsurgeon", "and", "opens", "up", "new", "possibilities", "for", "the", "treatment", "of", "retroorbital", "lesions", "." ]

[ "umlsterm" ]

Dokumentation is an umlsterm, Femur is an umlsterm, zementfreien is an umlsterm, robotergestuetzte is an umlsterm, Verwendung is an umlsterm, artefaktunterdrueckenden is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Technologie is an umlsterm, Robotersystemen is an umlsterm, Technik is an umlsterm

DerChirurg.80690973.ger.abstr_task0

Sentence: Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen .

[ "Zusammenfassung", ".", "Von", "14", "humanen", "Femura", "wurden", "anhand", "von", "CT", "-", "Daten", "dreidimensionale", "Rekonstruktionen", "durchgefuehrt", ".", "An", "jedem", "Praeparat", "erfolgte", "die", "digitale", "Dokumentation", "des", "Centrum", "-", "Collum", "-", "Diaphysen", "(", "CCD", "und", "Antetorsionswinkels", "(", "AT", ")", ".", ")", "-", "Mit", "Hilfe", "eines", "speziellen", "Operationsplanungsprogramms", "wurde", "fuer", "jeden", "Femur", "eine", "virtuelle", "Operationsplanung", "fuer", "die", "Implantation", "einer", "zementfreien", "Hueftendoprothese", "durchgefuehrt", ".", "Die", "so", "ermittelten", "Endoprothesen", "wurden", "-", "nach", "randomisierter", "Zuweisung", "von", "je", "7", "Femura", "zu", "den", "Gruppen", "standardisiert", "manuelle", "bzw", ".", "robotergestuetzte", "Implantation", "-", "eingebracht", ".", "Anschliessend", "wurden", "alle", "Praeparate", "wiederum", "computertomographisch", "erfasst", "und", "unter", "Verwendung", "eines", "artefaktunterdrueckenden", "Algorithmus", "dreidimensional", "rekonstruiert", ".", "Die", "praeoperativ", "dokumentierten", "Parameter", "wurden", "anschliessend", "erneut", "ermittelt", ".", "Der", "Mittelwert", "der", "CCD", "-", "Winkel", "betrug", "praeoperativ", "in", "der", "manuellen", "Gruppe", "126,7", "Grad", "(", "SD", "=", "4,0", ")", "und", "in", "der", "Robotergruppe", "127,8", "Grad", "(", "SD", "=", "4,3", ")", ".", "Postoperativ", "aenderte", "er", "sich", "in", "der", "1", ".", "Gruppe", "im", "Mittel", "auf", "131,9", "Grad", "(", "SD", "=", "0,8", ")", "und", "in", "der", "2", ".", "Gruppe", "auf", "133,2", "Grad", "(", "SD", "=", "1,9", ")", ".", "Signifikante", "Unterschiede", "ergaben", "sich", "beim", "AT", "-", "Winkel", ".", "Dieser", "betrug", "in", "der", "manuellen", "Gruppe", "praeoperativ", "31,3", "Grad", "(", "SD", "=", "8,8", ")", "und", "lag", "postoperativ", "lediglich", "noch", "bei", "20,5", "Grad", "(", "SD", "=", "9,5", ")", ".", "In", "der", "Robotergruppe", "lag", "dieser", "Winkel", "vor", "der", "Implantation", "bei", "30,9", "Grad", "(", "SD", "=", "8,0", ")", "und", "nach", "der", "Implantation", "bei", "31,3", "Grad", "(", "SD", "=", "8,7", ")", ".", "Die", "Betragsdifferenz", "zwischen", "prae-", "und", "postoperativem", "AT", "-", "Winkel", "betrug", "in", "der", "manuellen", "Gruppe", "10,8", "Grad", "(", "SD", "=", "6,4", ")", "und", "in", "der", "Robotergruppe", "0,4", "Grad", "(", "SD", "=", "0,9", ";", "p", "=", "0,01", ")", ".", "Fazit", ":", "Mit", "der", "verwendeten", "Technologie", "ist", "eine", "weitaus", "exaktere", "Berechnung", "moeglich", "als", "mit", "den", "bisherigen", ",", "allein", "auf", "Roentgenbildern", "basierenden", "Operationsplanungen", ".", "Die", "virtuelle", "Operationsplanung", "laesst", "sich", "mit", "Hilfe", "von", "Robotersystemen", "mit", "hoher", "Praezision", "umsetzen", ".", "Die", "verwendete", "Technik", "scheint", "in", "der", "Lage", "zu", "sein", ",", "eine", "Verbesserung", "in", "der", "Prozess-", "und", "Ergebnisqualitaet", "mit", "sich", "zu", "bringen", "." ]

[ "umlsterm" ]

Dokumentation is an umlsterm, Femur is an umlsterm, zementfreien is an umlsterm, robotergestuetzte is an umlsterm, Verwendung is an umlsterm, artefaktunterdrueckenden is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Robotergruppe is an umlsterm, Technologie is an umlsterm, Robotersystemen is an umlsterm, Technik is an umlsterm

DerChirurg.80690973.ger.abstr_task1

Sentence: Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen . Instructions: please typing these entity words according to sentence: Dokumentation, Femur, zementfreien, robotergestuetzte, Verwendung, artefaktunterdrueckenden, Robotergruppe, Robotergruppe, Robotergruppe, Technologie, Robotersystemen, Technik Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen .

[ "Zusammenfassung", ".", "Von", "14", "humanen", "Femura", "wurden", "anhand", "von", "CT", "-", "Daten", "dreidimensionale", "Rekonstruktionen", "durchgefuehrt", ".", "An", "jedem", "Praeparat", "erfolgte", "die", "digitale", "Dokumentation", "des", "Centrum", "-", "Collum", "-", "Diaphysen", "(", "CCD", "und", "Antetorsionswinkels", "(", "AT", ")", ".", ")", "-", "Mit", "Hilfe", "eines", "speziellen", "Operationsplanungsprogramms", "wurde", "fuer", "jeden", "Femur", "eine", "virtuelle", "Operationsplanung", "fuer", "die", "Implantation", "einer", "zementfreien", "Hueftendoprothese", "durchgefuehrt", ".", "Die", "so", "ermittelten", "Endoprothesen", "wurden", "-", "nach", "randomisierter", "Zuweisung", "von", "je", "7", "Femura", "zu", "den", "Gruppen", "standardisiert", "manuelle", "bzw", ".", "robotergestuetzte", "Implantation", "-", "eingebracht", ".", "Anschliessend", "wurden", "alle", "Praeparate", "wiederum", "computertomographisch", "erfasst", "und", "unter", "Verwendung", "eines", "artefaktunterdrueckenden", "Algorithmus", "dreidimensional", "rekonstruiert", ".", "Die", "praeoperativ", "dokumentierten", "Parameter", "wurden", "anschliessend", "erneut", "ermittelt", ".", "Der", "Mittelwert", "der", "CCD", "-", "Winkel", "betrug", "praeoperativ", "in", "der", "manuellen", "Gruppe", "126,7", "Grad", "(", "SD", "=", "4,0", ")", "und", "in", "der", "Robotergruppe", "127,8", "Grad", "(", "SD", "=", "4,3", ")", ".", "Postoperativ", "aenderte", "er", "sich", "in", "der", "1", ".", "Gruppe", "im", "Mittel", "auf", "131,9", "Grad", "(", "SD", "=", "0,8", ")", "und", "in", "der", "2", ".", "Gruppe", "auf", "133,2", "Grad", "(", "SD", "=", "1,9", ")", ".", "Signifikante", "Unterschiede", "ergaben", "sich", "beim", "AT", "-", "Winkel", ".", "Dieser", "betrug", "in", "der", "manuellen", "Gruppe", "praeoperativ", "31,3", "Grad", "(", "SD", "=", "8,8", ")", "und", "lag", "postoperativ", "lediglich", "noch", "bei", "20,5", "Grad", "(", "SD", "=", "9,5", ")", ".", "In", "der", "Robotergruppe", "lag", "dieser", "Winkel", "vor", "der", "Implantation", "bei", "30,9", "Grad", "(", "SD", "=", "8,0", ")", "und", "nach", "der", "Implantation", "bei", "31,3", "Grad", "(", "SD", "=", "8,7", ")", ".", "Die", "Betragsdifferenz", "zwischen", "prae-", "und", "postoperativem", "AT", "-", "Winkel", "betrug", "in", "der", "manuellen", "Gruppe", "10,8", "Grad", "(", "SD", "=", "6,4", ")", "und", "in", "der", "Robotergruppe", "0,4", "Grad", "(", "SD", "=", "0,9", ";", "p", "=", "0,01", ")", ".", "Fazit", ":", "Mit", "der", "verwendeten", "Technologie", "ist", "eine", "weitaus", "exaktere", "Berechnung", "moeglich", "als", "mit", "den", "bisherigen", ",", "allein", "auf", "Roentgenbildern", "basierenden", "Operationsplanungen", ".", "Die", "virtuelle", "Operationsplanung", "laesst", "sich", "mit", "Hilfe", "von", "Robotersystemen", "mit", "hoher", "Praezision", "umsetzen", ".", "Die", "verwendete", "Technik", "scheint", "in", "der", "Lage", "zu", "sein", ",", "eine", "Verbesserung", "in", "der", "Prozess-", "und", "Ergebnisqualitaet", "mit", "sich", "zu", "bringen", "." ]

[ "umlsterm" ]

Dokumentation, Femur, zementfreien, robotergestuetzte, Verwendung, artefaktunterdrueckenden, Robotergruppe, Robotergruppe, Robotergruppe, Technologie, Robotersystemen, Technik

DerChirurg.80690973.ger.abstr_task2

Sentence: Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Von 14 humanen Femura wurden anhand von CT-Daten dreidimensionale Rekonstruktionen durchgefuehrt . An jedem Praeparat erfolgte die digitale Dokumentation des Centrum-Collum-Diaphysen ( CCD und Antetorsionswinkels ( AT ) . ) - Mit Hilfe eines speziellen Operationsplanungsprogramms wurde fuer jeden Femur eine virtuelle Operationsplanung fuer die Implantation einer zementfreien Hueftendoprothese durchgefuehrt . Die so ermittelten Endoprothesen wurden - nach randomisierter Zuweisung von je 7 Femura zu den Gruppen standardisiert manuelle bzw. robotergestuetzte Implantation - eingebracht . Anschliessend wurden alle Praeparate wiederum computertomographisch erfasst und unter Verwendung eines artefaktunterdrueckenden Algorithmus dreidimensional rekonstruiert . Die praeoperativ dokumentierten Parameter wurden anschliessend erneut ermittelt . Der Mittelwert der CCD-Winkel betrug praeoperativ in der manuellen Gruppe 126,7 Grad ( SD = 4,0 ) und in der Robotergruppe 127,8 Grad ( SD = 4,3 ) . Postoperativ aenderte er sich in der 1. Gruppe im Mittel auf 131,9 Grad ( SD = 0,8 ) und in der 2. Gruppe auf 133,2 Grad ( SD = 1,9 ) . Signifikante Unterschiede ergaben sich beim AT-Winkel . Dieser betrug in der manuellen Gruppe praeoperativ 31,3 Grad ( SD = 8,8 ) und lag postoperativ lediglich noch bei 20,5 Grad ( SD = 9,5 ) . In der Robotergruppe lag dieser Winkel vor der Implantation bei 30,9 Grad ( SD = 8,0 ) und nach der Implantation bei 31,3 Grad ( SD = 8,7 ) . Die Betragsdifferenz zwischen prae- und postoperativem AT-Winkel betrug in der manuellen Gruppe 10,8 Grad ( SD = 6,4 ) und in der Robotergruppe 0,4 Grad ( SD = 0,9 ; p = 0,01 ) . Fazit : Mit der verwendeten Technologie ist eine weitaus exaktere Berechnung moeglich als mit den bisherigen , allein auf Roentgenbildern basierenden Operationsplanungen . Die virtuelle Operationsplanung laesst sich mit Hilfe von Robotersystemen mit hoher Praezision umsetzen . Die verwendete Technik scheint in der Lage zu sein , eine Verbesserung in der Prozess- und Ergebnisqualitaet mit sich zu bringen .

[ "Zusammenfassung", ".", "Von", "14", "humanen", "Femura", "wurden", "anhand", "von", "CT", "-", "Daten", "dreidimensionale", "Rekonstruktionen", "durchgefuehrt", ".", "An", "jedem", "Praeparat", "erfolgte", "die", "digitale", "Dokumentation", "des", "Centrum", "-", "Collum", "-", "Diaphysen", "(", "CCD", "und", "Antetorsionswinkels", "(", "AT", ")", ".", ")", "-", "Mit", "Hilfe", "eines", "speziellen", "Operationsplanungsprogramms", "wurde", "fuer", "jeden", "Femur", "eine", "virtuelle", "Operationsplanung", "fuer", "die", "Implantation", "einer", "zementfreien", "Hueftendoprothese", "durchgefuehrt", ".", "Die", "so", "ermittelten", "Endoprothesen", "wurden", "-", "nach", "randomisierter", "Zuweisung", "von", "je", "7", "Femura", "zu", "den", "Gruppen", "standardisiert", "manuelle", "bzw", ".", "robotergestuetzte", "Implantation", "-", "eingebracht", ".", "Anschliessend", "wurden", "alle", "Praeparate", "wiederum", "computertomographisch", "erfasst", "und", "unter", "Verwendung", "eines", "artefaktunterdrueckenden", "Algorithmus", "dreidimensional", "rekonstruiert", ".", "Die", "praeoperativ", "dokumentierten", "Parameter", "wurden", "anschliessend", "erneut", "ermittelt", ".", "Der", "Mittelwert", "der", "CCD", "-", "Winkel", "betrug", "praeoperativ", "in", "der", "manuellen", "Gruppe", "126,7", "Grad", "(", "SD", "=", "4,0", ")", "und", "in", "der", "Robotergruppe", "127,8", "Grad", "(", "SD", "=", "4,3", ")", ".", "Postoperativ", "aenderte", "er", "sich", "in", "der", "1", ".", "Gruppe", "im", "Mittel", "auf", "131,9", "Grad", "(", "SD", "=", "0,8", ")", "und", "in", "der", "2", ".", "Gruppe", "auf", "133,2", "Grad", "(", "SD", "=", "1,9", ")", ".", "Signifikante", "Unterschiede", "ergaben", "sich", "beim", "AT", "-", "Winkel", ".", "Dieser", "betrug", "in", "der", "manuellen", "Gruppe", "praeoperativ", "31,3", "Grad", "(", "SD", "=", "8,8", ")", "und", "lag", "postoperativ", "lediglich", "noch", "bei", "20,5", "Grad", "(", "SD", "=", "9,5", ")", ".", "In", "der", "Robotergruppe", "lag", "dieser", "Winkel", "vor", "der", "Implantation", "bei", "30,9", "Grad", "(", "SD", "=", "8,0", ")", "und", "nach", "der", "Implantation", "bei", "31,3", "Grad", "(", "SD", "=", "8,7", ")", ".", "Die", "Betragsdifferenz", "zwischen", "prae-", "und", "postoperativem", "AT", "-", "Winkel", "betrug", "in", "der", "manuellen", "Gruppe", "10,8", "Grad", "(", "SD", "=", "6,4", ")", "und", "in", "der", "Robotergruppe", "0,4", "Grad", "(", "SD", "=", "0,9", ";", "p", "=", "0,01", ")", ".", "Fazit", ":", "Mit", "der", "verwendeten", "Technologie", "ist", "eine", "weitaus", "exaktere", "Berechnung", "moeglich", "als", "mit", "den", "bisherigen", ",", "allein", "auf", "Roentgenbildern", "basierenden", "Operationsplanungen", ".", "Die", "virtuelle", "Operationsplanung", "laesst", "sich", "mit", "Hilfe", "von", "Robotersystemen", "mit", "hoher", "Praezision", "umsetzen", ".", "Die", "verwendete", "Technik", "scheint", "in", "der", "Lage", "zu", "sein", ",", "eine", "Verbesserung", "in", "der", "Prozess-", "und", "Ergebnisqualitaet", "mit", "sich", "zu", "bringen", "." ]

[ "umlsterm" ]

cigarrillos is a UNCLEAR, acero is a NORMALIZABLES, cobalto is a NORMALIZABLES, carburo de tungsteno is a NORMALIZABLES, mármol is a NO_NORMALIZABLES, granito is a NO_NORMALIZABLES, plata is a NORMALIZABLES, cadmio is a NORMALIZABLES, cobre is a NORMALIZABLES, zinc is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, colesterol is a NORMALIZABLES, transaminasas is a PROTEINAS, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, C3 is a PROTEINAS, IgA is a PROTEINAS, Ig A is a PROTEINAS, enalapril is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, beta2-globulina is a PROTEINAS, N - acetilglucosaminidasa is a PROTEINAS, NAG is a PROTEINAS, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES

411_task0

Sentence: Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: UNCLEAR, NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-PROTEINAS", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g).

[ "Varón", "de", "47", "años", ",", "que", "cesó", "el", "hábito", "tabáquico", "hace", "diez", "años", ",", "fumó", "entre", "10", "-", "20", "cigarrillos", "/", "día", "durante", "15", "años", "y", "fue", "diagnosticado", "hace", "8", "años", "de", "glomerulonefritis", "mesangial", "IgA.", "Había", "estado", "trabajando", "durante", "12", "años", "como", "soldador", "en", "una", "empresa", "de", "fabricación", "de", "discos", "de", "acero", "que", "llevaban", "insertados", "unos", "«", "dientes", "»", "de", "cobalto", "y", "carburo", "de", "tungsteno", "que", "se", "utilizan", "para", "cortar", "mármol", "y", "granito", ".", "El", "soldador", "utilizaba", "un", "sistema", "de", "soldadura", "autógena", "de", "la", "que", "utilizaban", ",", "como", "metal", "de", "aporte", ",", "unas", "varillas", "metálicas", "a", "base", "de", ":", "plata", "(", "39", "%", ")", ",", "cadmio", "(", "25", "%", ")", ",", "cobre", "(", "22", "%", ")", "y", "zinc", "(", "14", "%", ")", ".", "Consumía", "1", "Kg", "/", "semana", ";", "no", "utilizaba", "equipos", "de", "protección", "respiratoria", "y", "su", "lugar", "de", "trabajo", "no", "tenía", "un", "sistema", "de", "extracción", "localizada", "de", "humos", ".", "Las", "concentraciones", "de", "cadmio", "en", "su", "puesto", "de", "trabajo", "fueron", "de", "52", "μg", "/", "m3", "(", "Valor", "Límite", "Ambiental", "(", "VLA", ")", "es", "de", "10", "μg", "/", "m3", ")", ".", "Durante", "los", "doce", "años", "que", "estuvo", "trabajando", "se", "le", "había", "realizado", "un", "reconocimiento", "inicial", "y", "dos", "reconocimientos", "periódicos", "inespecíficos", "sin", "controlar", "la", "exposición", "al", "cadmio", "y", "a", "otros", "contaminantes", "químicos", ";", "los", "resultados", "del", "laboratorio", "se", "encontraban", "dentro", "de", "la", "normalidad", "(", "hemograma", "completo", ",", "glucemia", ",", "colesterol", ",", "transaminasas", "hepáticas", ",", "creatinina", "sérica", "y", "el", "estudio", "cito", "-", "químico", "de", "orina", ")", ".", "En", "una", "analítica", "general", "realizada", "por", "su", "médico", "de", "familia", "se", "le", "detecta", "una", "microhematuria", "y", "una", "proteinuria", ".", "Cuando", "su", "médico", "le", "realiza", "la", "historia", "clínica", "detecta", "la", "exposición", "a", "humos", "de", "cadmio", "por", "lo", "que", "es", "remitido", "a", "la", "Unidad", "de", "Toxicología", "de", "nuestro", "hospital", ".", "Al", "ingreso", "el", "paciente", "está", "asintomático", ",", "no", "tiene", "antecedentes", "personales", "ni", "familiares", "nefrológicos", ",", "no", "tiene", "problemas", "de", "obesidad", ",", "ni", "de", "diabetes", "(", "las", "glucemias", "son", "normales", ")", ",", "no", "toma", "ningún", "tipo", "de", "medicación", "de", "forma", "habitual", "y", "la", "presión", "arterial", "es", "de", "105/65", "mm", "/", "Hg", ".", "En", "la", "analítica", "destaca", "una", "proteinuria", "de", "2", "g/24", "h", ",", "microhematuria", "de", "150", "hematíes", "/", "campo", ",", "cadmio", "en", "sangre", "de", "20", "μg", "/", "l", "(", "Valor", "Límite", "Biológico", "[", "VLB", "]", ":", "5μg", "/", "l", ")", "y", "cadmio", "en", "la", "orina", "de", "85", "μg", "/", "g", "de", "creatinina", "(", "VLB", ":", "5", "μg", "/", "g", "creatinina", ")", ".", "Debido", "a", "que", "las", "afectaciones", "renales", "eran", "de", "tipo", "glomerular", ",", "y", "el", "cadmio", "ocasiona", "principalmente", "lesiones", "de", "tipo", "tubular", ",", "se", "le", "recomendó", "un", "estudio", "mediante", "una", "biopsia", "renal", ".", "En", "la", "microscopía", "óptica", "se", "observaron", "cinco", "glomérulos", ",", "uno", "de", "ellos", "totalmente", "esclerosado", ";", "el", "resto", "mostró", "una", "ligera", "hipercelularidad", "segmentaria", ";", "en", "dos", "glomérulos", "se", "detecta", "una", "proliferación", "segmentaria", "extracapilar", "y", "focos", "de", "fibrosis", "intersticial", "con", "atrofia", "tubular", ".", "La", "inmunofluorescencia", "fue", "positiva", "para", "C3", "(", "+", "+", "+", ")", "y", "IgA", "(", "+", "+", ")", "con", "patrón", "mesangial", ".", "El", "diagnóstico", "fue", "de", "una", "glomerulonefritis", "focal", "Ig", "A", "mesangial", "y", "se", "inició", "tratamiento", "con", "enalapril", "10", "mg", "/", "día", ".", "Debido", "a", "las", "altas", "concentraciones", "de", "cadmio", "en", "líquidos", "biológicos", "(", "sangre", "y", "orina", ")", ",", "que", "después", "de", "ocho", "años", "de", "hacer", "cesado", "la", "exposición", "se", "encuentran", "por", "encima", "de", "los", "valores", "límites", "máximos", "permitidos", "en", "España", "en", "trabajadores", "expuestos", "al", "cadmio", ",", "el", "paciente", "fue", "apartado", "de", "su", "trabajo", ";", "además", ",", "se", "le", "consideró", "un", "trabajador", "especialmente", "sensible", "a", "la", "exposición", "a", "nefrotóxicos", "donde", "aconsejamos", "que", "se", "evitase", "su", "exposición", "con", "la", "finalidad", "de", "minimizar", "al", "máximo", "la", "posibilidad", "de", "que", "el", "paciente", "evolucione", "hacía", "una", "enfermedad", "renal", "crónica", ".", "Se", "le", "realizó", "un", "seguimiento", "durante", "8", "años", "(", "los", "valores", "de", "creatinina", "sérica", ",", "filtrado", "glomerular", ",", "proteinuria", "y", "sedimento", "urinario", "vienen", "expresados", "en", "la", "tabla", "1", ")", "y", "los", "repetidos", "controles", "de", "beta2-globulina", "y", "de", "N", "-", "acetilglucosaminidasa", "(", "NAG", ")", "se", "encontraron", "dentro", "de", "la", "normalidad", ".", "En", "el", "momento", "actual", "las", "concentraciones", "de", "cadmio", "en", "sangre", "son", "de", "7", "μg", "/", "l", "(", "VLB", ":", "5", "μg", "/", "l", ")", "y", "el", "cadmio", "en", "orina", "es", "de", "18", "μg", "/", "g", "(", "VLB", ":", "5", "μg", "/", "g", ")", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR", "NO_NORMALIZABLES" ]

cigarrillos is a UNCLEAR, acero is a NORMALIZABLES, cobalto is a NORMALIZABLES, carburo de tungsteno is a NORMALIZABLES, mármol is a NO_NORMALIZABLES, granito is a NO_NORMALIZABLES, plata is a NORMALIZABLES, cadmio is a NORMALIZABLES, cobre is a NORMALIZABLES, zinc is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, colesterol is a NORMALIZABLES, transaminasas is a PROTEINAS, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, cadmio is a NORMALIZABLES, C3 is a PROTEINAS, IgA is a PROTEINAS, Ig A is a PROTEINAS, enalapril is a NORMALIZABLES, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES, creatinina is a NORMALIZABLES, beta2-globulina is a PROTEINAS, N - acetilglucosaminidasa is a PROTEINAS, NAG is a PROTEINAS, cadmio is a NORMALIZABLES, cadmio is a NORMALIZABLES

411_task1

Sentence: Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g). Instructions: please typing these entity words according to sentence: cigarrillos, acero, cobalto, carburo de tungsteno, mármol, granito, plata, cadmio, cobre, zinc, cadmio, cadmio, colesterol, transaminasas, creatinina, cadmio, cadmio, cadmio, creatinina, cadmio, C3, IgA, Ig A, enalapril, cadmio, cadmio, creatinina, beta2-globulina, N - acetilglucosaminidasa, NAG, cadmio, cadmio Options: UNCLEAR, NORMALIZABLES, PROTEINAS, NO_NORMALIZABLES

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-PROTEINAS", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g).

[ "Varón", "de", "47", "años", ",", "que", "cesó", "el", "hábito", "tabáquico", "hace", "diez", "años", ",", "fumó", "entre", "10", "-", "20", "cigarrillos", "/", "día", "durante", "15", "años", "y", "fue", "diagnosticado", "hace", "8", "años", "de", "glomerulonefritis", "mesangial", "IgA.", "Había", "estado", "trabajando", "durante", "12", "años", "como", "soldador", "en", "una", "empresa", "de", "fabricación", "de", "discos", "de", "acero", "que", "llevaban", "insertados", "unos", "«", "dientes", "»", "de", "cobalto", "y", "carburo", "de", "tungsteno", "que", "se", "utilizan", "para", "cortar", "mármol", "y", "granito", ".", "El", "soldador", "utilizaba", "un", "sistema", "de", "soldadura", "autógena", "de", "la", "que", "utilizaban", ",", "como", "metal", "de", "aporte", ",", "unas", "varillas", "metálicas", "a", "base", "de", ":", "plata", "(", "39", "%", ")", ",", "cadmio", "(", "25", "%", ")", ",", "cobre", "(", "22", "%", ")", "y", "zinc", "(", "14", "%", ")", ".", "Consumía", "1", "Kg", "/", "semana", ";", "no", "utilizaba", "equipos", "de", "protección", "respiratoria", "y", "su", "lugar", "de", "trabajo", "no", "tenía", "un", "sistema", "de", "extracción", "localizada", "de", "humos", ".", "Las", "concentraciones", "de", "cadmio", "en", "su", "puesto", "de", "trabajo", "fueron", "de", "52", "μg", "/", "m3", "(", "Valor", "Límite", "Ambiental", "(", "VLA", ")", "es", "de", "10", "μg", "/", "m3", ")", ".", "Durante", "los", "doce", "años", "que", "estuvo", "trabajando", "se", "le", "había", "realizado", "un", "reconocimiento", "inicial", "y", "dos", "reconocimientos", "periódicos", "inespecíficos", "sin", "controlar", "la", "exposición", "al", "cadmio", "y", "a", "otros", "contaminantes", "químicos", ";", "los", "resultados", "del", "laboratorio", "se", "encontraban", "dentro", "de", "la", "normalidad", "(", "hemograma", "completo", ",", "glucemia", ",", "colesterol", ",", "transaminasas", "hepáticas", ",", "creatinina", "sérica", "y", "el", "estudio", "cito", "-", "químico", "de", "orina", ")", ".", "En", "una", "analítica", "general", "realizada", "por", "su", "médico", "de", "familia", "se", "le", "detecta", "una", "microhematuria", "y", "una", "proteinuria", ".", "Cuando", "su", "médico", "le", "realiza", "la", "historia", "clínica", "detecta", "la", "exposición", "a", "humos", "de", "cadmio", "por", "lo", "que", "es", "remitido", "a", "la", "Unidad", "de", "Toxicología", "de", "nuestro", "hospital", ".", "Al", "ingreso", "el", "paciente", "está", "asintomático", ",", "no", "tiene", "antecedentes", "personales", "ni", "familiares", "nefrológicos", ",", "no", "tiene", "problemas", "de", "obesidad", ",", "ni", "de", "diabetes", "(", "las", "glucemias", "son", "normales", ")", ",", "no", "toma", "ningún", "tipo", "de", "medicación", "de", "forma", "habitual", "y", "la", "presión", "arterial", "es", "de", "105/65", "mm", "/", "Hg", ".", "En", "la", "analítica", "destaca", "una", "proteinuria", "de", "2", "g/24", "h", ",", "microhematuria", "de", "150", "hematíes", "/", "campo", ",", "cadmio", "en", "sangre", "de", "20", "μg", "/", "l", "(", "Valor", "Límite", "Biológico", "[", "VLB", "]", ":", "5μg", "/", "l", ")", "y", "cadmio", "en", "la", "orina", "de", "85", "μg", "/", "g", "de", "creatinina", "(", "VLB", ":", "5", "μg", "/", "g", "creatinina", ")", ".", "Debido", "a", "que", "las", "afectaciones", "renales", "eran", "de", "tipo", "glomerular", ",", "y", "el", "cadmio", "ocasiona", "principalmente", "lesiones", "de", "tipo", "tubular", ",", "se", "le", "recomendó", "un", "estudio", "mediante", "una", "biopsia", "renal", ".", "En", "la", "microscopía", "óptica", "se", "observaron", "cinco", "glomérulos", ",", "uno", "de", "ellos", "totalmente", "esclerosado", ";", "el", "resto", "mostró", "una", "ligera", "hipercelularidad", "segmentaria", ";", "en", "dos", "glomérulos", "se", "detecta", "una", "proliferación", "segmentaria", "extracapilar", "y", "focos", "de", "fibrosis", "intersticial", "con", "atrofia", "tubular", ".", "La", "inmunofluorescencia", "fue", "positiva", "para", "C3", "(", "+", "+", "+", ")", "y", "IgA", "(", "+", "+", ")", "con", "patrón", "mesangial", ".", "El", "diagnóstico", "fue", "de", "una", "glomerulonefritis", "focal", "Ig", "A", "mesangial", "y", "se", "inició", "tratamiento", "con", "enalapril", "10", "mg", "/", "día", ".", "Debido", "a", "las", "altas", "concentraciones", "de", "cadmio", "en", "líquidos", "biológicos", "(", "sangre", "y", "orina", ")", ",", "que", "después", "de", "ocho", "años", "de", "hacer", "cesado", "la", "exposición", "se", "encuentran", "por", "encima", "de", "los", "valores", "límites", "máximos", "permitidos", "en", "España", "en", "trabajadores", "expuestos", "al", "cadmio", ",", "el", "paciente", "fue", "apartado", "de", "su", "trabajo", ";", "además", ",", "se", "le", "consideró", "un", "trabajador", "especialmente", "sensible", "a", "la", "exposición", "a", "nefrotóxicos", "donde", "aconsejamos", "que", "se", "evitase", "su", "exposición", "con", "la", "finalidad", "de", "minimizar", "al", "máximo", "la", "posibilidad", "de", "que", "el", "paciente", "evolucione", "hacía", "una", "enfermedad", "renal", "crónica", ".", "Se", "le", "realizó", "un", "seguimiento", "durante", "8", "años", "(", "los", "valores", "de", "creatinina", "sérica", ",", "filtrado", "glomerular", ",", "proteinuria", "y", "sedimento", "urinario", "vienen", "expresados", "en", "la", "tabla", "1", ")", "y", "los", "repetidos", "controles", "de", "beta2-globulina", "y", "de", "N", "-", "acetilglucosaminidasa", "(", "NAG", ")", "se", "encontraron", "dentro", "de", "la", "normalidad", ".", "En", "el", "momento", "actual", "las", "concentraciones", "de", "cadmio", "en", "sangre", "son", "de", "7", "μg", "/", "l", "(", "VLB", ":", "5", "μg", "/", "l", ")", "y", "el", "cadmio", "en", "orina", "es", "de", "18", "μg", "/", "g", "(", "VLB", ":", "5", "μg", "/", "g", ")", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR", "NO_NORMALIZABLES" ]

cigarrillos, acero, cobalto, carburo de tungsteno, mármol, granito, plata, cadmio, cobre, zinc, cadmio, cadmio, colesterol, transaminasas, creatinina, cadmio, cadmio, cadmio, creatinina, cadmio, C3, IgA, Ig A, enalapril, cadmio, cadmio, creatinina, beta2-globulina, N - acetilglucosaminidasa, NAG, cadmio, cadmio

411_task2

Sentence: Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-UNCLEAR", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-NORMALIZABLES", "I-NORMALIZABLES", "I-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NO_NORMALIZABLES", "O", "B-NO_NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "B-PROTEINAS", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 47 años, que cesó el hábito tabáquico hace diez años, fumó entre 10-20 cigarrillos/día durante 15 años y fue diagnosticado hace 8 años de glomerulonefritis mesangial IgA. Había estado trabajando durante 12 años como soldador en una empresa de fabricación de discos de acero que llevaban insertados unos «dientes» de cobalto y carburo de tungsteno que se utilizan para cortar mármol y granito. El soldador utilizaba un sistema de soldadura autógena de la que utilizaban, como metal de aporte, unas varillas metálicas a base de: plata (39%), cadmio (25%), cobre (22%) y zinc (14%). Consumía 1 Kg/semana; no utilizaba equipos de protección respiratoria y su lugar de trabajo no tenía un sistema de extracción localizada de humos. Las concentraciones de cadmio en su puesto de trabajo fueron de 52 μg/m3 (Valor Límite Ambiental (VLA) es de 10 μg/m3). Durante los doce años que estuvo trabajando se le había realizado un reconocimiento inicial y dos reconocimientos periódicos inespecíficos sin controlar la exposición al cadmio y a otros contaminantes químicos; los resultados del laboratorio se encontraban dentro de la normalidad (hemograma completo, glucemia, colesterol, transaminasas hepáticas, creatinina sérica y el estudio cito-químico de orina). En una analítica general realizada por su médico de familia se le detecta una microhematuria y una proteinuria. Cuando su médico le realiza la historia clínica detecta la exposición a humos de cadmio por lo que es remitido a la Unidad de Toxicología de nuestro hospital. Al ingreso el paciente está asintomático, no tiene antecedentes personales ni familiares nefrológicos, no tiene problemas de obesidad, ni de diabetes (las glucemias son normales), no toma ningún tipo de medicación de forma habitual y la presión arterial es de 105/65 mm/Hg. En la analítica destaca una proteinuria de 2 g/24 h, microhematuria de 150 hematíes/campo, cadmio en sangre de 20 μg/l (Valor Límite Biológico [VLB]: 5μg/l) y cadmio en la orina de 85 μg/g de creatinina (VLB: 5 μg/g creatinina). Debido a que las afectaciones renales eran de tipo glomerular, y el cadmio ocasiona principalmente lesiones de tipo tubular, se le recomendó un estudio mediante una biopsia renal. En la microscopía óptica se observaron cinco glomérulos, uno de ellos totalmente esclerosado; el resto mostró una ligera hipercelularidad segmentaria; en dos glomérulos se detecta una proliferación segmentaria extracapilar y focos de fibrosis intersticial con atrofia tubular. La inmunofluorescencia fue positiva para C3 (+++) y IgA (++) con patrón mesangial. El diagnóstico fue de una glomerulonefritis focal Ig A mesangial y se inició tratamiento con enalapril 10 mg/día. Debido a las altas concentraciones de cadmio en líquidos biológicos (sangre y orina), que después de ocho años de hacer cesado la exposición se encuentran por encima de los valores límites máximos permitidos en España en trabajadores expuestos al cadmio, el paciente fue apartado de su trabajo; además, se le consideró un trabajador especialmente sensible a la exposición a nefrotóxicos donde aconsejamos que se evitase su exposición con la finalidad de minimizar al máximo la posibilidad de que el paciente evolucione hacía una enfermedad renal crónica. Se le realizó un seguimiento durante 8 años (los valores de creatinina sérica, filtrado glomerular, proteinuria y sedimento urinario vienen expresados en la tabla 1) y los repetidos controles de beta2-globulina y de N-acetilglucosaminidasa (NAG) se encontraron dentro de la normalidad. En el momento actual las concentraciones de cadmio en sangre son de 7 μg/l (VLB: 5 μg/l) y el cadmio en orina es de 18 μg/g (VLB: 5 μg/g).

[ "Varón", "de", "47", "años", ",", "que", "cesó", "el", "hábito", "tabáquico", "hace", "diez", "años", ",", "fumó", "entre", "10", "-", "20", "cigarrillos", "/", "día", "durante", "15", "años", "y", "fue", "diagnosticado", "hace", "8", "años", "de", "glomerulonefritis", "mesangial", "IgA.", "Había", "estado", "trabajando", "durante", "12", "años", "como", "soldador", "en", "una", "empresa", "de", "fabricación", "de", "discos", "de", "acero", "que", "llevaban", "insertados", "unos", "«", "dientes", "»", "de", "cobalto", "y", "carburo", "de", "tungsteno", "que", "se", "utilizan", "para", "cortar", "mármol", "y", "granito", ".", "El", "soldador", "utilizaba", "un", "sistema", "de", "soldadura", "autógena", "de", "la", "que", "utilizaban", ",", "como", "metal", "de", "aporte", ",", "unas", "varillas", "metálicas", "a", "base", "de", ":", "plata", "(", "39", "%", ")", ",", "cadmio", "(", "25", "%", ")", ",", "cobre", "(", "22", "%", ")", "y", "zinc", "(", "14", "%", ")", ".", "Consumía", "1", "Kg", "/", "semana", ";", "no", "utilizaba", "equipos", "de", "protección", "respiratoria", "y", "su", "lugar", "de", "trabajo", "no", "tenía", "un", "sistema", "de", "extracción", "localizada", "de", "humos", ".", "Las", "concentraciones", "de", "cadmio", "en", "su", "puesto", "de", "trabajo", "fueron", "de", "52", "μg", "/", "m3", "(", "Valor", "Límite", "Ambiental", "(", "VLA", ")", "es", "de", "10", "μg", "/", "m3", ")", ".", "Durante", "los", "doce", "años", "que", "estuvo", "trabajando", "se", "le", "había", "realizado", "un", "reconocimiento", "inicial", "y", "dos", "reconocimientos", "periódicos", "inespecíficos", "sin", "controlar", "la", "exposición", "al", "cadmio", "y", "a", "otros", "contaminantes", "químicos", ";", "los", "resultados", "del", "laboratorio", "se", "encontraban", "dentro", "de", "la", "normalidad", "(", "hemograma", "completo", ",", "glucemia", ",", "colesterol", ",", "transaminasas", "hepáticas", ",", "creatinina", "sérica", "y", "el", "estudio", "cito", "-", "químico", "de", "orina", ")", ".", "En", "una", "analítica", "general", "realizada", "por", "su", "médico", "de", "familia", "se", "le", "detecta", "una", "microhematuria", "y", "una", "proteinuria", ".", "Cuando", "su", "médico", "le", "realiza", "la", "historia", "clínica", "detecta", "la", "exposición", "a", "humos", "de", "cadmio", "por", "lo", "que", "es", "remitido", "a", "la", "Unidad", "de", "Toxicología", "de", "nuestro", "hospital", ".", "Al", "ingreso", "el", "paciente", "está", "asintomático", ",", "no", "tiene", "antecedentes", "personales", "ni", "familiares", "nefrológicos", ",", "no", "tiene", "problemas", "de", "obesidad", ",", "ni", "de", "diabetes", "(", "las", "glucemias", "son", "normales", ")", ",", "no", "toma", "ningún", "tipo", "de", "medicación", "de", "forma", "habitual", "y", "la", "presión", "arterial", "es", "de", "105/65", "mm", "/", "Hg", ".", "En", "la", "analítica", "destaca", "una", "proteinuria", "de", "2", "g/24", "h", ",", "microhematuria", "de", "150", "hematíes", "/", "campo", ",", "cadmio", "en", "sangre", "de", "20", "μg", "/", "l", "(", "Valor", "Límite", "Biológico", "[", "VLB", "]", ":", "5μg", "/", "l", ")", "y", "cadmio", "en", "la", "orina", "de", "85", "μg", "/", "g", "de", "creatinina", "(", "VLB", ":", "5", "μg", "/", "g", "creatinina", ")", ".", "Debido", "a", "que", "las", "afectaciones", "renales", "eran", "de", "tipo", "glomerular", ",", "y", "el", "cadmio", "ocasiona", "principalmente", "lesiones", "de", "tipo", "tubular", ",", "se", "le", "recomendó", "un", "estudio", "mediante", "una", "biopsia", "renal", ".", "En", "la", "microscopía", "óptica", "se", "observaron", "cinco", "glomérulos", ",", "uno", "de", "ellos", "totalmente", "esclerosado", ";", "el", "resto", "mostró", "una", "ligera", "hipercelularidad", "segmentaria", ";", "en", "dos", "glomérulos", "se", "detecta", "una", "proliferación", "segmentaria", "extracapilar", "y", "focos", "de", "fibrosis", "intersticial", "con", "atrofia", "tubular", ".", "La", "inmunofluorescencia", "fue", "positiva", "para", "C3", "(", "+", "+", "+", ")", "y", "IgA", "(", "+", "+", ")", "con", "patrón", "mesangial", ".", "El", "diagnóstico", "fue", "de", "una", "glomerulonefritis", "focal", "Ig", "A", "mesangial", "y", "se", "inició", "tratamiento", "con", "enalapril", "10", "mg", "/", "día", ".", "Debido", "a", "las", "altas", "concentraciones", "de", "cadmio", "en", "líquidos", "biológicos", "(", "sangre", "y", "orina", ")", ",", "que", "después", "de", "ocho", "años", "de", "hacer", "cesado", "la", "exposición", "se", "encuentran", "por", "encima", "de", "los", "valores", "límites", "máximos", "permitidos", "en", "España", "en", "trabajadores", "expuestos", "al", "cadmio", ",", "el", "paciente", "fue", "apartado", "de", "su", "trabajo", ";", "además", ",", "se", "le", "consideró", "un", "trabajador", "especialmente", "sensible", "a", "la", "exposición", "a", "nefrotóxicos", "donde", "aconsejamos", "que", "se", "evitase", "su", "exposición", "con", "la", "finalidad", "de", "minimizar", "al", "máximo", "la", "posibilidad", "de", "que", "el", "paciente", "evolucione", "hacía", "una", "enfermedad", "renal", "crónica", ".", "Se", "le", "realizó", "un", "seguimiento", "durante", "8", "años", "(", "los", "valores", "de", "creatinina", "sérica", ",", "filtrado", "glomerular", ",", "proteinuria", "y", "sedimento", "urinario", "vienen", "expresados", "en", "la", "tabla", "1", ")", "y", "los", "repetidos", "controles", "de", "beta2-globulina", "y", "de", "N", "-", "acetilglucosaminidasa", "(", "NAG", ")", "se", "encontraron", "dentro", "de", "la", "normalidad", ".", "En", "el", "momento", "actual", "las", "concentraciones", "de", "cadmio", "en", "sangre", "son", "de", "7", "μg", "/", "l", "(", "VLB", ":", "5", "μg", "/", "l", ")", "y", "el", "cadmio", "en", "orina", "es", "de", "18", "μg", "/", "g", "(", "VLB", ":", "5", "μg", "/", "g", ")", ".", "\n\n" ]

[ "PROTEINAS", "NORMALIZABLES", "UNCLEAR", "NO_NORMALIZABLES" ]

therapy is an umlsterm, personality is an umlsterm, therapy is an umlsterm, questionnaire is an umlsterm

Psychotherapeut.00450286.eng.abstr_task0

Sentence: 46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire .

[ "46", "therapy", "non", "-", "completers", "were", "compared", "with", "599", "completers", "regarding", "their", "conspicuous", "personality", "characteristics", ".", "In", "addition", ",", "they", "were", "asked", "to", "give", "their", "personal", "reasons", "for", "breaking", "off", "the", "therapy", "in", "a", "questionnaire", "." ]

[ "umlsterm" ]

therapy is an umlsterm, personality is an umlsterm, therapy is an umlsterm, questionnaire is an umlsterm

Psychotherapeut.00450286.eng.abstr_task1

Sentence: 46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire . Instructions: please typing these entity words according to sentence: therapy, personality, therapy, questionnaire Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire .

[ "46", "therapy", "non", "-", "completers", "were", "compared", "with", "599", "completers", "regarding", "their", "conspicuous", "personality", "characteristics", ".", "In", "addition", ",", "they", "were", "asked", "to", "give", "their", "personal", "reasons", "for", "breaking", "off", "the", "therapy", "in", "a", "questionnaire", "." ]

[ "umlsterm" ]

therapy, personality, therapy, questionnaire

Psychotherapeut.00450286.eng.abstr_task2

Sentence: 46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

46 therapy non-completers were compared with 599 completers regarding their conspicuous personality characteristics . In addition , they were asked to give their personal reasons for breaking off the therapy in a questionnaire .

[ "46", "therapy", "non", "-", "completers", "were", "compared", "with", "599", "completers", "regarding", "their", "conspicuous", "personality", "characteristics", ".", "In", "addition", ",", "they", "were", "asked", "to", "give", "their", "personal", "reasons", "for", "breaking", "off", "the", "therapy", "in", "a", "questionnaire", "." ]

[ "umlsterm" ]

Arbeit is an umlsterm, Techniken is an umlsterm, Kataraktchirurgie is an umlsterm, Astigmatismus is an umlsterm, Visus is an umlsterm

DerOpthalmologe.80950427.ger.abstr_task0

Sentence: Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen .

[ "Hintergrund", ":", "Ziel", "dieser", "Arbeit", "war", "es", ",", "die", "sich", "veraendernden", "Techniken", "der", "Kataraktchirurgie", "der", "letzten", "16", "Jahre", "im", "Hinblick", "auf", "fruehpostoperativen", "Astigmatismus", "und", "Visus", "zu", "vergleichen", "." ]

[ "umlsterm" ]

Arbeit is an umlsterm, Techniken is an umlsterm, Kataraktchirurgie is an umlsterm, Astigmatismus is an umlsterm, Visus is an umlsterm

DerOpthalmologe.80950427.ger.abstr_task1

Sentence: Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen . Instructions: please typing these entity words according to sentence: Arbeit, Techniken, Kataraktchirurgie, Astigmatismus, Visus Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen .

[ "Hintergrund", ":", "Ziel", "dieser", "Arbeit", "war", "es", ",", "die", "sich", "veraendernden", "Techniken", "der", "Kataraktchirurgie", "der", "letzten", "16", "Jahre", "im", "Hinblick", "auf", "fruehpostoperativen", "Astigmatismus", "und", "Visus", "zu", "vergleichen", "." ]

[ "umlsterm" ]

Arbeit, Techniken, Kataraktchirurgie, Astigmatismus, Visus

DerOpthalmologe.80950427.ger.abstr_task2

Sentence: Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

Hintergrund : Ziel dieser Arbeit war es , die sich veraendernden Techniken der Kataraktchirurgie der letzten 16 Jahre im Hinblick auf fruehpostoperativen Astigmatismus und Visus zu vergleichen .

[ "Hintergrund", ":", "Ziel", "dieser", "Arbeit", "war", "es", ",", "die", "sich", "veraendernden", "Techniken", "der", "Kataraktchirurgie", "der", "letzten", "16", "Jahre", "im", "Hinblick", "auf", "fruehpostoperativen", "Astigmatismus", "und", "Visus", "zu", "vergleichen", "." ]

[ "umlsterm" ]

knowledge is an umlsterm, eosinophil is an umlsterm, regulation is an umlsterm, eosinophilia is an umlsterm, blood is an umlsterm, role is an umlsterm, cytokines is an umlsterm, chemoattraction is an umlsterm, eosinophils is an umlsterm, cytokines is an umlsterm, release is an umlsterm, reactive oxygen species is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, inflammatory reaction is an umlsterm, tissue is an umlsterm, tissue is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, eosinophils is an umlsterm, eosinophil is an umlsterm, granulocytes is an umlsterm, eosinophil is an umlsterm, atopic dermatitis is an umlsterm, skin diseases is an umlsterm, review is an umlsterm, Evaluation is an umlsterm, role is an umlsterm, eosinophils is an umlsterm, therapeutic is an umlsterm

DerHautarzt.80490176.eng.abstr_task0

Sentence: Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance .

[ "Recent", "in", "vitro", "-", "studies", "have", "substantially", "increased", "our", "knowledge", "of", "eosinophil", "activation", ",", "the", "regulation", "of", "eosinophilia", "in", "the", "peripheral", "blood", "and", "the", "role", "of", "cytokines", "in", "that", "process", ".", "Accordingly", ",", "chemoattraction", "and", "activation", "of", "eosinophils", "by", "cytokines", "results", "in", "the", "local", "release", "of", "reactive", "oxygen", "species", "and", "toxic", "cationic", "granule", "proteins", "followed", "by", "local", "propagation", "of", "the", "inflammatory", "reaction", "and", "tissue", "damage", ".", "This", "extracellular", "tissue", "deposition", "of", "toxic", "granule", "proteins", "as", "an", "expression", "of", "complete", "activation", "of", "eosinophils", ",", "rather", "than", "only", "the", "presence", "of", "intact", "eosinophil", "granulocytes", ",", "is", "crucial", "for", "their", "functional", "effect", "in", "situ", ".", "Semiquantitative", "studies", "of", "local", "eosinophil", "granula", "deposition", "so", "far", "have", "been", "done", "only", "in", "atopic", "dermatitis", "and", "a", "limited", "number", "of", "other", "inflammatory", "skin", "diseases", "as", "summarized", "in", "this", "review", ".", "Evaluation", "of", "the", "pathogenetic", "role", "of", "eosinophils", "may", "be", "of", "potential", "therapeutic", "importance", "." ]

[ "umlsterm" ]

knowledge is an umlsterm, eosinophil is an umlsterm, regulation is an umlsterm, eosinophilia is an umlsterm, blood is an umlsterm, role is an umlsterm, cytokines is an umlsterm, chemoattraction is an umlsterm, eosinophils is an umlsterm, cytokines is an umlsterm, release is an umlsterm, reactive oxygen species is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, inflammatory reaction is an umlsterm, tissue is an umlsterm, tissue is an umlsterm, toxic is an umlsterm, granule is an umlsterm, proteins is an umlsterm, eosinophils is an umlsterm, eosinophil is an umlsterm, granulocytes is an umlsterm, eosinophil is an umlsterm, atopic dermatitis is an umlsterm, skin diseases is an umlsterm, review is an umlsterm, Evaluation is an umlsterm, role is an umlsterm, eosinophils is an umlsterm, therapeutic is an umlsterm

DerHautarzt.80490176.eng.abstr_task1

Sentence: Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance . Instructions: please typing these entity words according to sentence: knowledge, eosinophil, regulation, eosinophilia, blood, role, cytokines, chemoattraction, eosinophils, cytokines, release, reactive oxygen species, toxic, granule, proteins, inflammatory reaction, tissue, tissue, toxic, granule, proteins, eosinophils, eosinophil, granulocytes, eosinophil, atopic dermatitis, skin diseases, review, Evaluation, role, eosinophils, therapeutic Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance .

[ "Recent", "in", "vitro", "-", "studies", "have", "substantially", "increased", "our", "knowledge", "of", "eosinophil", "activation", ",", "the", "regulation", "of", "eosinophilia", "in", "the", "peripheral", "blood", "and", "the", "role", "of", "cytokines", "in", "that", "process", ".", "Accordingly", ",", "chemoattraction", "and", "activation", "of", "eosinophils", "by", "cytokines", "results", "in", "the", "local", "release", "of", "reactive", "oxygen", "species", "and", "toxic", "cationic", "granule", "proteins", "followed", "by", "local", "propagation", "of", "the", "inflammatory", "reaction", "and", "tissue", "damage", ".", "This", "extracellular", "tissue", "deposition", "of", "toxic", "granule", "proteins", "as", "an", "expression", "of", "complete", "activation", "of", "eosinophils", ",", "rather", "than", "only", "the", "presence", "of", "intact", "eosinophil", "granulocytes", ",", "is", "crucial", "for", "their", "functional", "effect", "in", "situ", ".", "Semiquantitative", "studies", "of", "local", "eosinophil", "granula", "deposition", "so", "far", "have", "been", "done", "only", "in", "atopic", "dermatitis", "and", "a", "limited", "number", "of", "other", "inflammatory", "skin", "diseases", "as", "summarized", "in", "this", "review", ".", "Evaluation", "of", "the", "pathogenetic", "role", "of", "eosinophils", "may", "be", "of", "potential", "therapeutic", "importance", "." ]

[ "umlsterm" ]

knowledge, eosinophil, regulation, eosinophilia, blood, role, cytokines, chemoattraction, eosinophils, cytokines, release, reactive oxygen species, toxic, granule, proteins, inflammatory reaction, tissue, tissue, toxic, granule, proteins, eosinophils, eosinophil, granulocytes, eosinophil, atopic dermatitis, skin diseases, review, Evaluation, role, eosinophils, therapeutic

DerHautarzt.80490176.eng.abstr_task2

Sentence: Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Recent in vitro-studies have substantially increased our knowledge of eosinophil activation , the regulation of eosinophilia in the peripheral blood and the role of cytokines in that process . Accordingly , chemoattraction and activation of eosinophils by cytokines results in the local release of reactive oxygen species and toxic cationic granule proteins followed by local propagation of the inflammatory reaction and tissue damage . This extracellular tissue deposition of toxic granule proteins as an expression of complete activation of eosinophils , rather than only the presence of intact eosinophil granulocytes , is crucial for their functional effect in situ . Semiquantitative studies of local eosinophil granula deposition so far have been done only in atopic dermatitis and a limited number of other inflammatory skin diseases as summarized in this review . Evaluation of the pathogenetic role of eosinophils may be of potential therapeutic importance .

[ "Recent", "in", "vitro", "-", "studies", "have", "substantially", "increased", "our", "knowledge", "of", "eosinophil", "activation", ",", "the", "regulation", "of", "eosinophilia", "in", "the", "peripheral", "blood", "and", "the", "role", "of", "cytokines", "in", "that", "process", ".", "Accordingly", ",", "chemoattraction", "and", "activation", "of", "eosinophils", "by", "cytokines", "results", "in", "the", "local", "release", "of", "reactive", "oxygen", "species", "and", "toxic", "cationic", "granule", "proteins", "followed", "by", "local", "propagation", "of", "the", "inflammatory", "reaction", "and", "tissue", "damage", ".", "This", "extracellular", "tissue", "deposition", "of", "toxic", "granule", "proteins", "as", "an", "expression", "of", "complete", "activation", "of", "eosinophils", ",", "rather", "than", "only", "the", "presence", "of", "intact", "eosinophil", "granulocytes", ",", "is", "crucial", "for", "their", "functional", "effect", "in", "situ", ".", "Semiquantitative", "studies", "of", "local", "eosinophil", "granula", "deposition", "so", "far", "have", "been", "done", "only", "in", "atopic", "dermatitis", "and", "a", "limited", "number", "of", "other", "inflammatory", "skin", "diseases", "as", "summarized", "in", "this", "review", ".", "Evaluation", "of", "the", "pathogenetic", "role", "of", "eosinophils", "may", "be", "of", "potential", "therapeutic", "importance", "." ]

[ "umlsterm" ]

Foxp3 is a Protein, Foxp3 is a Protein, FKH domain is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, which is a Anaphora, nucleus is a Entity, deltaFKH mutant is a Protein, nucleus is a Entity, deltaFKH mutant is a Protein, nuclear is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, nucleus is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, p65 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, p65 is a Protein, Foxp3 is a Protein, nuclear is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein

4_task0

Sentence: The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Anaphora, Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Anaphora", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.

[ "The", "Carboxyl", "-", "Terminal", "FKH", "Domain", "Is", "Not", "Required", "for", "Suppression", "of", "NF", "-", "kappaB", "Activation", "in", "T", "Cells", "\n", "To", "define", "the", "requirements", "of", "Foxp3", "with", "respect", "to", "inhibition", "of", "NF", "-", "kappaB", "-", "dependent", "transcription", ",", "we", "utilized", "a", "mutant", "of", "Foxp3", "lacking", "the", "FKH", "domain", "(", "Figure", "2A", ")", "[", "16", "]", ",", "similar", "to", "the", "scurfy", "mutant", "Foxp3", "of", "mice", ",", "and", "a", "mutant", "Foxp3", "protein", "from", "a", "patient", "with", "IPEX", "[", "4,11,14,17", "]", ".", "Unlike", "full", "-", "length", "Foxp3", ",", "which", "localizes", "almost", "exclusively", "to", "the", "nucleus", "and", "can", "bind", "in", "a", "sequence", "-", "specific", "manner", "to", "forkhead", "binding", "sites", ",", "the", "deltaFKH", "mutant", "fails", "to", "localize", "to", "the", "nucleus", "and", "thus", "cannot", "interact", "with", "promoter", "elements", "or", "nuclear", "proteins", "[", "16", "]", ".", "Therefore", ",", "we", "utilized", "the", "deltaFKH", "mutant", "to", "determine", "whether", "nuclear", "localization", "(", "or", "other", "function", "associated", "with", "the", "FKH", "domain", ")", "of", "Foxp3", "was", "a", "prerequisite", "for", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "Although", "Foxp3", "interaction", "with", "NF", "-", "kappaB", "presumably", "takes", "place", "in", "the", "nucleus", ",", "it", "may", "also", "be", "possible", "for", "a", "cytoplasmic", "Foxp3", "protein", "to", "bind", "to", "NF", "-", "kappaB", "in", "the", "cytoplasm", "and", "prevent", "localization", "to", "the", "nucleus", "following", "an", "activation", "stimulus", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "of", "deltaFKH", ",", "was", "able", "to", "suppress", "activation", "of", "a", "cotransfected", "NF", "-", "kappaB", "reporter", "vector", "in", "HEK", "293", "T", "cells", "(", "Figure", "2B", ")", ".", "Both", "Foxp3", "and", "deltaFKH", "were", "expressed", "at", "very", "high", "levels", "following", "transfection", "as", "detected", "by", "real", "-", "time", "RT", "-", "PCR", "(", "unpublished", "data", ")", ".", "These", "data", "appear", "to", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", "is", "critically", "important", "for", "Foxp3", "to", "down", "-", "regulate", "NF", "-", "kappaB", "-", "dependent", "transcription", ".", "However", ",", "NF", "-", "kappaB", "activation", "was", "blocked", "to", "a", "similar", "extent", "by", "both", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "2C", ")", "and", "primary", "human", "CD4", "+", "T", "cells", "(", "Figure", "2D", ")", ".", "Western", "blot", "analysis", "of", "NF", "-", "kappaB", "p65", "expression", "demonstrated", "that", "Foxp3", "and", "deltaFKH", "does", "not", "block", "NF", "-", "kappaB", "activation", "at", "the", "level", "of", "p65", "protein", "expression", "(", "Figure", "2E", ")", ".", "These", "results", "are", "very", "interesting", "with", "respect", "to", "Foxp3", "function", ",", "because", "they", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", ",", "and", "possibly", "nuclear", "localization", ",", "are", "dispensable", "for", "Foxp3", "function", "in", "T", "cell", "populations", ".", "Alternative", "interpretations", "may", "include", "the", "possibility", "that", "the", "localization", "of", "deltaFKH", "differ", "between", "epithelial", "cells", "and", "T", "cells", ".", "In", "either", "case", ",", "these", "results", "suggest", "a", "cell", "type", "-", "specific", "mechanism", "of", "action", "for", "this", "Foxp3", "mutant", "." ]

[ "Protein", "Entity", "Anaphora" ]

Foxp3 is a Protein, Foxp3 is a Protein, FKH domain is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, which is a Anaphora, nucleus is a Entity, deltaFKH mutant is a Protein, nucleus is a Entity, deltaFKH mutant is a Protein, nuclear is a Entity, Foxp3 is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, nucleus is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, CD4 is a Protein, p65 is a Protein, Foxp3 is a Protein, deltaFKH is a Protein, p65 is a Protein, Foxp3 is a Protein, nuclear is a Entity, Foxp3 is a Protein, deltaFKH is a Protein, Foxp3 is a Protein

4_task1

Sentence: The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant. Instructions: please typing these entity words according to sentence: Foxp3, Foxp3, FKH domain, Foxp3, Foxp3, Foxp3, which, nucleus, deltaFKH mutant, nucleus, deltaFKH mutant, nuclear, Foxp3, Foxp3, Foxp3, nucleus, Foxp3, deltaFKH, Foxp3, deltaFKH, Foxp3, Foxp3, deltaFKH, CD4, p65, Foxp3, deltaFKH, p65, Foxp3, nuclear, Foxp3, deltaFKH, Foxp3 Options: Anaphora, Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Anaphora", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.

[ "The", "Carboxyl", "-", "Terminal", "FKH", "Domain", "Is", "Not", "Required", "for", "Suppression", "of", "NF", "-", "kappaB", "Activation", "in", "T", "Cells", "\n", "To", "define", "the", "requirements", "of", "Foxp3", "with", "respect", "to", "inhibition", "of", "NF", "-", "kappaB", "-", "dependent", "transcription", ",", "we", "utilized", "a", "mutant", "of", "Foxp3", "lacking", "the", "FKH", "domain", "(", "Figure", "2A", ")", "[", "16", "]", ",", "similar", "to", "the", "scurfy", "mutant", "Foxp3", "of", "mice", ",", "and", "a", "mutant", "Foxp3", "protein", "from", "a", "patient", "with", "IPEX", "[", "4,11,14,17", "]", ".", "Unlike", "full", "-", "length", "Foxp3", ",", "which", "localizes", "almost", "exclusively", "to", "the", "nucleus", "and", "can", "bind", "in", "a", "sequence", "-", "specific", "manner", "to", "forkhead", "binding", "sites", ",", "the", "deltaFKH", "mutant", "fails", "to", "localize", "to", "the", "nucleus", "and", "thus", "cannot", "interact", "with", "promoter", "elements", "or", "nuclear", "proteins", "[", "16", "]", ".", "Therefore", ",", "we", "utilized", "the", "deltaFKH", "mutant", "to", "determine", "whether", "nuclear", "localization", "(", "or", "other", "function", "associated", "with", "the", "FKH", "domain", ")", "of", "Foxp3", "was", "a", "prerequisite", "for", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "Although", "Foxp3", "interaction", "with", "NF", "-", "kappaB", "presumably", "takes", "place", "in", "the", "nucleus", ",", "it", "may", "also", "be", "possible", "for", "a", "cytoplasmic", "Foxp3", "protein", "to", "bind", "to", "NF", "-", "kappaB", "in", "the", "cytoplasm", "and", "prevent", "localization", "to", "the", "nucleus", "following", "an", "activation", "stimulus", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "of", "deltaFKH", ",", "was", "able", "to", "suppress", "activation", "of", "a", "cotransfected", "NF", "-", "kappaB", "reporter", "vector", "in", "HEK", "293", "T", "cells", "(", "Figure", "2B", ")", ".", "Both", "Foxp3", "and", "deltaFKH", "were", "expressed", "at", "very", "high", "levels", "following", "transfection", "as", "detected", "by", "real", "-", "time", "RT", "-", "PCR", "(", "unpublished", "data", ")", ".", "These", "data", "appear", "to", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", "is", "critically", "important", "for", "Foxp3", "to", "down", "-", "regulate", "NF", "-", "kappaB", "-", "dependent", "transcription", ".", "However", ",", "NF", "-", "kappaB", "activation", "was", "blocked", "to", "a", "similar", "extent", "by", "both", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "2C", ")", "and", "primary", "human", "CD4", "+", "T", "cells", "(", "Figure", "2D", ")", ".", "Western", "blot", "analysis", "of", "NF", "-", "kappaB", "p65", "expression", "demonstrated", "that", "Foxp3", "and", "deltaFKH", "does", "not", "block", "NF", "-", "kappaB", "activation", "at", "the", "level", "of", "p65", "protein", "expression", "(", "Figure", "2E", ")", ".", "These", "results", "are", "very", "interesting", "with", "respect", "to", "Foxp3", "function", ",", "because", "they", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", ",", "and", "possibly", "nuclear", "localization", ",", "are", "dispensable", "for", "Foxp3", "function", "in", "T", "cell", "populations", ".", "Alternative", "interpretations", "may", "include", "the", "possibility", "that", "the", "localization", "of", "deltaFKH", "differ", "between", "epithelial", "cells", "and", "T", "cells", ".", "In", "either", "case", ",", "these", "results", "suggest", "a", "cell", "type", "-", "specific", "mechanism", "of", "action", "for", "this", "Foxp3", "mutant", "." ]

[ "Protein", "Entity", "Anaphora" ]

Foxp3, Foxp3, FKH domain, Foxp3, Foxp3, Foxp3, which, nucleus, deltaFKH mutant, nucleus, deltaFKH mutant, nuclear, Foxp3, Foxp3, Foxp3, nucleus, Foxp3, deltaFKH, Foxp3, deltaFKH, Foxp3, Foxp3, deltaFKH, CD4, p65, Foxp3, deltaFKH, p65, Foxp3, nuclear, Foxp3, deltaFKH, Foxp3

4_task2

Sentence: The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Anaphora", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O" ]

The Carboxyl-Terminal FKH Domain Is Not Required for Suppression of NF-kappaB Activation in T Cells To define the requirements of Foxp3 with respect to inhibition of NF-kappaB-dependent transcription, we utilized a mutant of Foxp3 lacking the FKH domain (Figure 2A) [16], similar to the scurfy mutant Foxp3 of mice, and a mutant Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike full-length Foxp3, which localizes almost exclusively to the nucleus and can bind in a sequence-specific manner to forkhead binding sites, the deltaFKH mutant fails to localize to the nucleus and thus cannot interact with promoter elements or nuclear proteins [16]. Therefore, we utilized the deltaFKH mutant to determine whether nuclear localization (or other function associated with the FKH domain) of Foxp3 was a prerequisite for inhibition of NF-kappaB activation. Although Foxp3 interaction with NF-kappaB presumably takes place in the nucleus, it may also be possible for a cytoplasmic Foxp3 protein to bind to NF-kappaB in the cytoplasm and prevent localization to the nucleus following an activation stimulus. Overexpression of full-length Foxp3, but not of deltaFKH, was able to suppress activation of a cotransfected NF-kappaB reporter vector in HEK 293T cells (Figure 2B). Both Foxp3 and deltaFKH were expressed at very high levels following transfection as detected by real-time RT-PCR (unpublished data). These data appear to suggest that the carboxyl-terminal FKH domain is critically important for Foxp3 to down-regulate NF-kappaB-dependent transcription. However, NF-kappaB activation was blocked to a similar extent by both full-length Foxp3 and deltaFKH in Jurkat T cells (Figure 2C) and primary human CD4+ T cells (Figure 2D). Western blot analysis of NF-kappaB p65 expression demonstrated that Foxp3 and deltaFKH does not block NF-kappaB activation at the level of p65 protein expression (Figure 2E). These results are very interesting with respect to Foxp3 function, because they suggest that the carboxyl-terminal FKH domain, and possibly nuclear localization, are dispensable for Foxp3 function in T cell populations. Alternative interpretations may include the possibility that the localization of deltaFKH differ between epithelial cells and T cells. In either case, these results suggest a cell type-specific mechanism of action for this Foxp3 mutant.

[ "The", "Carboxyl", "-", "Terminal", "FKH", "Domain", "Is", "Not", "Required", "for", "Suppression", "of", "NF", "-", "kappaB", "Activation", "in", "T", "Cells", "\n", "To", "define", "the", "requirements", "of", "Foxp3", "with", "respect", "to", "inhibition", "of", "NF", "-", "kappaB", "-", "dependent", "transcription", ",", "we", "utilized", "a", "mutant", "of", "Foxp3", "lacking", "the", "FKH", "domain", "(", "Figure", "2A", ")", "[", "16", "]", ",", "similar", "to", "the", "scurfy", "mutant", "Foxp3", "of", "mice", ",", "and", "a", "mutant", "Foxp3", "protein", "from", "a", "patient", "with", "IPEX", "[", "4,11,14,17", "]", ".", "Unlike", "full", "-", "length", "Foxp3", ",", "which", "localizes", "almost", "exclusively", "to", "the", "nucleus", "and", "can", "bind", "in", "a", "sequence", "-", "specific", "manner", "to", "forkhead", "binding", "sites", ",", "the", "deltaFKH", "mutant", "fails", "to", "localize", "to", "the", "nucleus", "and", "thus", "cannot", "interact", "with", "promoter", "elements", "or", "nuclear", "proteins", "[", "16", "]", ".", "Therefore", ",", "we", "utilized", "the", "deltaFKH", "mutant", "to", "determine", "whether", "nuclear", "localization", "(", "or", "other", "function", "associated", "with", "the", "FKH", "domain", ")", "of", "Foxp3", "was", "a", "prerequisite", "for", "inhibition", "of", "NF", "-", "kappaB", "activation", ".", "Although", "Foxp3", "interaction", "with", "NF", "-", "kappaB", "presumably", "takes", "place", "in", "the", "nucleus", ",", "it", "may", "also", "be", "possible", "for", "a", "cytoplasmic", "Foxp3", "protein", "to", "bind", "to", "NF", "-", "kappaB", "in", "the", "cytoplasm", "and", "prevent", "localization", "to", "the", "nucleus", "following", "an", "activation", "stimulus", ".", "Overexpression", "of", "full", "-", "length", "Foxp3", ",", "but", "not", "of", "deltaFKH", ",", "was", "able", "to", "suppress", "activation", "of", "a", "cotransfected", "NF", "-", "kappaB", "reporter", "vector", "in", "HEK", "293", "T", "cells", "(", "Figure", "2B", ")", ".", "Both", "Foxp3", "and", "deltaFKH", "were", "expressed", "at", "very", "high", "levels", "following", "transfection", "as", "detected", "by", "real", "-", "time", "RT", "-", "PCR", "(", "unpublished", "data", ")", ".", "These", "data", "appear", "to", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", "is", "critically", "important", "for", "Foxp3", "to", "down", "-", "regulate", "NF", "-", "kappaB", "-", "dependent", "transcription", ".", "However", ",", "NF", "-", "kappaB", "activation", "was", "blocked", "to", "a", "similar", "extent", "by", "both", "full", "-", "length", "Foxp3", "and", "deltaFKH", "in", "Jurkat", "T", "cells", "(", "Figure", "2C", ")", "and", "primary", "human", "CD4", "+", "T", "cells", "(", "Figure", "2D", ")", ".", "Western", "blot", "analysis", "of", "NF", "-", "kappaB", "p65", "expression", "demonstrated", "that", "Foxp3", "and", "deltaFKH", "does", "not", "block", "NF", "-", "kappaB", "activation", "at", "the", "level", "of", "p65", "protein", "expression", "(", "Figure", "2E", ")", ".", "These", "results", "are", "very", "interesting", "with", "respect", "to", "Foxp3", "function", ",", "because", "they", "suggest", "that", "the", "carboxyl", "-", "terminal", "FKH", "domain", ",", "and", "possibly", "nuclear", "localization", ",", "are", "dispensable", "for", "Foxp3", "function", "in", "T", "cell", "populations", ".", "Alternative", "interpretations", "may", "include", "the", "possibility", "that", "the", "localization", "of", "deltaFKH", "differ", "between", "epithelial", "cells", "and", "T", "cells", ".", "In", "either", "case", ",", "these", "results", "suggest", "a", "cell", "type", "-", "specific", "mechanism", "of", "action", "for", "this", "Foxp3", "mutant", "." ]

[ "Protein", "Entity", "Anaphora" ]

vitamin K - dependent carboxylase is a Protein, vitamin K - dependent carboxylase is a Protein, N459 is a Entity, N550 is a Entity, N605 is a Entity, N627 is a Entity, N570 is a Entity, oligosaccharides is a Entity

222_task0

Sentence: Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.

[ "Identification", "of", "the", "N", "-", "linked", "glycosylation", "sites", "of", "vitamin", "K", "-", "dependent", "carboxylase", "and", "effect", "of", "glycosylation", "on", "carboxylase", "function", ".", "\n", "The", "vitamin", "K", "-", "dependent", "carboxylase", "is", "an", "integral", "membrane", "protein", "which", "is", "required", "for", "the", "post", "-", "translational", "modification", "of", "a", "variety", "of", "vitamin", "K", "-", "dependent", "proteins", ".", "Previous", "studies", "have", "suggested", "carboxylase", "is", "a", "glycoprotein", "with", "N", "-", "linked", "glycosylation", "sites", ".", "In", "this", "study", ",", "we", "identify", "the", "N", "-", "glycosylation", "sites", "of", "carboxylase", "by", "mass", "spectrometric", "peptide", "mapping", "analyses", "combined", "with", "site", "-", "directed", "mutagenesis", ".", "Our", "mass", "spectrometric", "results", "show", "that", "the", "N", "-", "linked", "glycosylation", "in", "carboxylase", "occurs", "at", "positions", "N459", ",", "N550", ",", "N605", ",", "and", "N627", ".", "Eliminating", "these", "glycosylation", "sites", "by", "changing", "asparagine", "to", "glutamine", "caused", "the", "mutant", "carboxylase", "to", "migrate", "faster", "on", "SDS", "-", "PAGE", "gels", ",", "adding", "further", "evidence", "that", "these", "sites", "are", "glycosylated", ".", "In", "addition", ",", "the", "mutation", "studies", "identified", "N525", ",", "a", "site", "that", "cannot", "be", "recovered", "by", "mass", "spectroscopy", "analysis", ",", "as", "a", "glycosylation", "site", ".", "Furthermore", ",", "the", "potential", "glycosylation", "site", "at", "N570", "is", "glycosylated", "only", "if", "all", "five", "natural", "glycosylation", "sites", "are", "simultaneously", "mutated", ".", "Removal", "of", "the", "oligosaccharides", "by", "glycosidase", "from", "wild", "-", "type", "carboxylase", "or", "by", "elimination", "of", "the", "functional", "glycosylation", "sites", "by", "site", "-", "directed", "mutagenesis", "did", "not", "affect", "either", "the", "carboxylation", "or", "epoxidation", "activity", "when", "the", "small", "FLEEL", "pentapeptide", "was", "used", "as", "a", "substrate", ",", "suggesting", "that", "N", "-", "linked", "glycosylation", "is", "not", "required", "for", "the", "enzymatic", "function", "of", "carboxylase", ".", "In", "contrast", ",", "when", "site", "N570", "and", "the", "five", "natural", "glycosylation", "sites", "were", "mutated", "simultaneously", ",", "the", "resulting", "carboxylase", "protein", "was", "degraded", ".", "Our", "results", "suggest", "that", "N", "-", "linked", "glycosylation", "is", "not", "essential", "for", "carboxylase", "enzymatic", "activity", "but", "is", "important", "for", "protein", "folding", "and", "stability", ".", "\n" ]

[ "Protein", "Entity" ]

vitamin K - dependent carboxylase is a Protein, vitamin K - dependent carboxylase is a Protein, N459 is a Entity, N550 is a Entity, N605 is a Entity, N627 is a Entity, N570 is a Entity, oligosaccharides is a Entity

222_task1

Sentence: Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. Instructions: please typing these entity words according to sentence: vitamin K - dependent carboxylase, vitamin K - dependent carboxylase, N459, N550, N605, N627, N570, oligosaccharides Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.

[ "Identification", "of", "the", "N", "-", "linked", "glycosylation", "sites", "of", "vitamin", "K", "-", "dependent", "carboxylase", "and", "effect", "of", "glycosylation", "on", "carboxylase", "function", ".", "\n", "The", "vitamin", "K", "-", "dependent", "carboxylase", "is", "an", "integral", "membrane", "protein", "which", "is", "required", "for", "the", "post", "-", "translational", "modification", "of", "a", "variety", "of", "vitamin", "K", "-", "dependent", "proteins", ".", "Previous", "studies", "have", "suggested", "carboxylase", "is", "a", "glycoprotein", "with", "N", "-", "linked", "glycosylation", "sites", ".", "In", "this", "study", ",", "we", "identify", "the", "N", "-", "glycosylation", "sites", "of", "carboxylase", "by", "mass", "spectrometric", "peptide", "mapping", "analyses", "combined", "with", "site", "-", "directed", "mutagenesis", ".", "Our", "mass", "spectrometric", "results", "show", "that", "the", "N", "-", "linked", "glycosylation", "in", "carboxylase", "occurs", "at", "positions", "N459", ",", "N550", ",", "N605", ",", "and", "N627", ".", "Eliminating", "these", "glycosylation", "sites", "by", "changing", "asparagine", "to", "glutamine", "caused", "the", "mutant", "carboxylase", "to", "migrate", "faster", "on", "SDS", "-", "PAGE", "gels", ",", "adding", "further", "evidence", "that", "these", "sites", "are", "glycosylated", ".", "In", "addition", ",", "the", "mutation", "studies", "identified", "N525", ",", "a", "site", "that", "cannot", "be", "recovered", "by", "mass", "spectroscopy", "analysis", ",", "as", "a", "glycosylation", "site", ".", "Furthermore", ",", "the", "potential", "glycosylation", "site", "at", "N570", "is", "glycosylated", "only", "if", "all", "five", "natural", "glycosylation", "sites", "are", "simultaneously", "mutated", ".", "Removal", "of", "the", "oligosaccharides", "by", "glycosidase", "from", "wild", "-", "type", "carboxylase", "or", "by", "elimination", "of", "the", "functional", "glycosylation", "sites", "by", "site", "-", "directed", "mutagenesis", "did", "not", "affect", "either", "the", "carboxylation", "or", "epoxidation", "activity", "when", "the", "small", "FLEEL", "pentapeptide", "was", "used", "as", "a", "substrate", ",", "suggesting", "that", "N", "-", "linked", "glycosylation", "is", "not", "required", "for", "the", "enzymatic", "function", "of", "carboxylase", ".", "In", "contrast", ",", "when", "site", "N570", "and", "the", "five", "natural", "glycosylation", "sites", "were", "mutated", "simultaneously", ",", "the", "resulting", "carboxylase", "protein", "was", "degraded", ".", "Our", "results", "suggest", "that", "N", "-", "linked", "glycosylation", "is", "not", "essential", "for", "carboxylase", "enzymatic", "activity", "but", "is", "important", "for", "protein", "folding", "and", "stability", ".", "\n" ]

[ "Protein", "Entity" ]

vitamin K - dependent carboxylase, vitamin K - dependent carboxylase, N459, N550, N605, N627, N570, oligosaccharides

222_task2

Sentence: Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Identification of the N-linked glycosylation sites of vitamin K-dependent carboxylase and effect of glycosylation on carboxylase function. The vitamin K-dependent carboxylase is an integral membrane protein which is required for the post-translational modification of a variety of vitamin K-dependent proteins. Previous studies have suggested carboxylase is a glycoprotein with N-linked glycosylation sites. In this study, we identify the N-glycosylation sites of carboxylase by mass spectrometric peptide mapping analyses combined with site-directed mutagenesis. Our mass spectrometric results show that the N-linked glycosylation in carboxylase occurs at positions N459, N550, N605, and N627. Eliminating these glycosylation sites by changing asparagine to glutamine caused the mutant carboxylase to migrate faster on SDS-PAGE gels, adding further evidence that these sites are glycosylated. In addition, the mutation studies identified N525, a site that cannot be recovered by mass spectroscopy analysis, as a glycosylation site. Furthermore, the potential glycosylation site at N570 is glycosylated only if all five natural glycosylation sites are simultaneously mutated. Removal of the oligosaccharides by glycosidase from wild-type carboxylase or by elimination of the functional glycosylation sites by site-directed mutagenesis did not affect either the carboxylation or epoxidation activity when the small FLEEL pentapeptide was used as a substrate, suggesting that N-linked glycosylation is not required for the enzymatic function of carboxylase. In contrast, when site N570 and the five natural glycosylation sites were mutated simultaneously, the resulting carboxylase protein was degraded. Our results suggest that N-linked glycosylation is not essential for carboxylase enzymatic activity but is important for protein folding and stability.

[ "Identification", "of", "the", "N", "-", "linked", "glycosylation", "sites", "of", "vitamin", "K", "-", "dependent", "carboxylase", "and", "effect", "of", "glycosylation", "on", "carboxylase", "function", ".", "\n", "The", "vitamin", "K", "-", "dependent", "carboxylase", "is", "an", "integral", "membrane", "protein", "which", "is", "required", "for", "the", "post", "-", "translational", "modification", "of", "a", "variety", "of", "vitamin", "K", "-", "dependent", "proteins", ".", "Previous", "studies", "have", "suggested", "carboxylase", "is", "a", "glycoprotein", "with", "N", "-", "linked", "glycosylation", "sites", ".", "In", "this", "study", ",", "we", "identify", "the", "N", "-", "glycosylation", "sites", "of", "carboxylase", "by", "mass", "spectrometric", "peptide", "mapping", "analyses", "combined", "with", "site", "-", "directed", "mutagenesis", ".", "Our", "mass", "spectrometric", "results", "show", "that", "the", "N", "-", "linked", "glycosylation", "in", "carboxylase", "occurs", "at", "positions", "N459", ",", "N550", ",", "N605", ",", "and", "N627", ".", "Eliminating", "these", "glycosylation", "sites", "by", "changing", "asparagine", "to", "glutamine", "caused", "the", "mutant", "carboxylase", "to", "migrate", "faster", "on", "SDS", "-", "PAGE", "gels", ",", "adding", "further", "evidence", "that", "these", "sites", "are", "glycosylated", ".", "In", "addition", ",", "the", "mutation", "studies", "identified", "N525", ",", "a", "site", "that", "cannot", "be", "recovered", "by", "mass", "spectroscopy", "analysis", ",", "as", "a", "glycosylation", "site", ".", "Furthermore", ",", "the", "potential", "glycosylation", "site", "at", "N570", "is", "glycosylated", "only", "if", "all", "five", "natural", "glycosylation", "sites", "are", "simultaneously", "mutated", ".", "Removal", "of", "the", "oligosaccharides", "by", "glycosidase", "from", "wild", "-", "type", "carboxylase", "or", "by", "elimination", "of", "the", "functional", "glycosylation", "sites", "by", "site", "-", "directed", "mutagenesis", "did", "not", "affect", "either", "the", "carboxylation", "or", "epoxidation", "activity", "when", "the", "small", "FLEEL", "pentapeptide", "was", "used", "as", "a", "substrate", ",", "suggesting", "that", "N", "-", "linked", "glycosylation", "is", "not", "required", "for", "the", "enzymatic", "function", "of", "carboxylase", ".", "In", "contrast", ",", "when", "site", "N570", "and", "the", "five", "natural", "glycosylation", "sites", "were", "mutated", "simultaneously", ",", "the", "resulting", "carboxylase", "protein", "was", "degraded", ".", "Our", "results", "suggest", "that", "N", "-", "linked", "glycosylation", "is", "not", "essential", "for", "carboxylase", "enzymatic", "activity", "but", "is", "important", "for", "protein", "folding", "and", "stability", ".", "\n" ]

[ "Protein", "Entity" ]

woman is an umlsterm, dyspnea is an umlsterm, tumors is an umlsterm, malignant schwannoma is an umlsterm, diagnosis is an umlsterm, S-100 protein is an umlsterm, tumor is an umlsterm, cells is an umlsterm

DerPathologe.60170222.eng.abstr_task0

Sentence: The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]

The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells .

[ "The", "case", "is", "presented", "of", "a", "51-year", "-", "old", "woman", "with", "increased", "of", "nightly", "dyspnea", ".", "An", "echocardiographic", "examination", "shows", "two", "intracardiac", "tumors", ".", "Histological", "features", "demonstrate", "an", "malignant", "schwannoma", ".", "The", "diagnosis", "was", "verified", "by", "immunohistological", "proof", "of", "S-100", "protein", "in", "tumor", "cells", "." ]

[ "umlsterm" ]

woman is an umlsterm, dyspnea is an umlsterm, tumors is an umlsterm, malignant schwannoma is an umlsterm, diagnosis is an umlsterm, S-100 protein is an umlsterm, tumor is an umlsterm, cells is an umlsterm

DerPathologe.60170222.eng.abstr_task1

Sentence: The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells . Instructions: please typing these entity words according to sentence: woman, dyspnea, tumors, malignant schwannoma, diagnosis, S-100 protein, tumor, cells Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]

The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells .

[ "The", "case", "is", "presented", "of", "a", "51-year", "-", "old", "woman", "with", "increased", "of", "nightly", "dyspnea", ".", "An", "echocardiographic", "examination", "shows", "two", "intracardiac", "tumors", ".", "Histological", "features", "demonstrate", "an", "malignant", "schwannoma", ".", "The", "diagnosis", "was", "verified", "by", "immunohistological", "proof", "of", "S-100", "protein", "in", "tumor", "cells", "." ]

[ "umlsterm" ]

woman, dyspnea, tumors, malignant schwannoma, diagnosis, S-100 protein, tumor, cells

DerPathologe.60170222.eng.abstr_task2

Sentence: The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O" ]

The case is presented of a 51-year-old woman with increased of nightly dyspnea . An echocardiographic examination shows two intracardiac tumors . Histological features demonstrate an malignant schwannoma . The diagnosis was verified by immunohistological proof of S-100 protein in tumor cells .

[ "The", "case", "is", "presented", "of", "a", "51-year", "-", "old", "woman", "with", "increased", "of", "nightly", "dyspnea", ".", "An", "echocardiographic", "examination", "shows", "two", "intracardiac", "tumors", ".", "Histological", "features", "demonstrate", "an", "malignant", "schwannoma", ".", "The", "diagnosis", "was", "verified", "by", "immunohistological", "proof", "of", "S-100", "protein", "in", "tumor", "cells", "." ]

[ "umlsterm" ]

selenium is a CHEMICAL, adenosine deaminase is a GENE-Y

23536521_task0

Sentence: Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats.

[ "Differential", "effects", "of", "organic", "and", "inorganic", "selenium", "compounds", "on", "adenosine", "deaminase", "activity", "and", "scavenger", "capacity", "in", "cerebral", "cortex", "slices", "of", "young", "rats", "." ]

[ "CHEMICAL", "GENE-Y" ]

selenium is a CHEMICAL, adenosine deaminase is a GENE-Y

23536521_task1

Sentence: Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats. Instructions: please typing these entity words according to sentence: selenium, adenosine deaminase Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats.

[ "Differential", "effects", "of", "organic", "and", "inorganic", "selenium", "compounds", "on", "adenosine", "deaminase", "activity", "and", "scavenger", "capacity", "in", "cerebral", "cortex", "slices", "of", "young", "rats", "." ]

[ "CHEMICAL", "GENE-Y" ]

selenium, adenosine deaminase

23536521_task2

Sentence: Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats.

[ "Differential", "effects", "of", "organic", "and", "inorganic", "selenium", "compounds", "on", "adenosine", "deaminase", "activity", "and", "scavenger", "capacity", "in", "cerebral", "cortex", "slices", "of", "young", "rats", "." ]

[ "CHEMICAL", "GENE-Y" ]

Green tea is a Plant, cancer is a Disease, green tea is a Plant, green tea is a Plant, colorectal polyps is a Disease, cancer is a Disease, green tea is a Plant, lung cancer is a Disease, lung cancer is a Disease, green tea is a Plant

21199169_task0

Sentence: Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant

[ "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O" ]

Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs.

[ "Green", "tea", "is", "now", "recognized", "as", "the", "most", "effective", "cancer", "preventive", "beverage", ".", "In", "one", "study", ",", "10", "Japanese", "-", "size", "cups", "of", "green", "tea", "daily", "supplemented", "with", "tablets", "of", "green", "tea", "extract", "limited", "the", "recurrence", "of", "colorectal", "polyps", "in", "humans", "to", "50", "%", ".", "Thus", ",", "cancer", "patients", "who", "consume", "green", "tea", "and", "take", "anticancer", "drugs", "will", "have", "double", "prevention", ".", "We", "studied", "the", "effects", "of", "combining", "(", "-)-epigallocatechin", "gallate", "(", "EGCG", ")", "and", "anticancer", "drugs", ",", "focusing", "on", "inhibition", "of", "cell", "growth", "and", "induction", "of", "apoptosis", ".", "Numerous", "anticancer", "drugs", ",", "such", "as", "tamoxifen", ",", "COX-2", "inhibitors", ",", "and", "retinoids", "were", "used", "for", "the", "experiments", ",", "and", "the", "combination", "of", "EGCG", "and", "COX-2", "inhibitors", "consistently", "induced", "the", "enhancement", "of", "apoptosis", ".", "To", "study", "the", "mechanism", "of", "the", "enhancement", ",", "we", "paid", "special", "attention", "to", "the", "enhanced", "expressions", "of", "DDIT3", "(", "growth", "arrest", "and", "DNA", "damage", "-", "inducible", "153", ",", "GADD153", ")", ",", "GADD45A", ",", "and", "CDKN1A", "(", "p21", "/", "WAF1", "/", "CIP1", ")", "genes", ",", "based", "on", "our", "previous", "evidence", "that", "a", "combination", "of", "EGCG", "and", "sulindac", "specifically", "induced", "upregulated", "expression", "of", "GADD153", "and", "p21", "genes", "in", "PC-9", "lung", "cancer", "cells", ".", "The", "synergistic", "enhancements", "of", "apoptosis", "and", "GADD153", "gene", "expression", "in", "human", "non", "-", "small", "cell", "lung", "cancer", "cells", "by", "the", "combination", "of", "EGCG", "and", "celecoxib", "were", "mediated", "through", "the", "activation", "of", "the", "MAPK", "signaling", "pathway", ".", "This", "article", "reviews", "the", "synergistic", "enhancement", "of", "apoptosis", ",", "gene", "expression", ",", "and", "anticancer", "effects", "using", "various", "combinations", "of", "EGCG", "and", "anticancer", "drugs", ",", "including", "the", "combination", "of", "(", "-)-epicatechin", "(", "EC", ")", "and", "curcumin", ".", "Based", "on", "the", "evidence", ",", "we", "present", "a", "new", "concept", ":", "green", "tea", "catechins", "as", "synergists", "with", "anticancer", "drugs", "." ]

[ "Disease", "Plant" ]

Green tea is a Plant, cancer is a Disease, green tea is a Plant, green tea is a Plant, colorectal polyps is a Disease, cancer is a Disease, green tea is a Plant, lung cancer is a Disease, lung cancer is a Disease, green tea is a Plant

21199169_task1

Sentence: Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. Instructions: please typing these entity words according to sentence: Green tea, cancer, green tea, green tea, colorectal polyps, cancer, green tea, lung cancer, lung cancer, green tea Options: Disease, Plant

[ "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O" ]

Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs.

[ "Green", "tea", "is", "now", "recognized", "as", "the", "most", "effective", "cancer", "preventive", "beverage", ".", "In", "one", "study", ",", "10", "Japanese", "-", "size", "cups", "of", "green", "tea", "daily", "supplemented", "with", "tablets", "of", "green", "tea", "extract", "limited", "the", "recurrence", "of", "colorectal", "polyps", "in", "humans", "to", "50", "%", ".", "Thus", ",", "cancer", "patients", "who", "consume", "green", "tea", "and", "take", "anticancer", "drugs", "will", "have", "double", "prevention", ".", "We", "studied", "the", "effects", "of", "combining", "(", "-)-epigallocatechin", "gallate", "(", "EGCG", ")", "and", "anticancer", "drugs", ",", "focusing", "on", "inhibition", "of", "cell", "growth", "and", "induction", "of", "apoptosis", ".", "Numerous", "anticancer", "drugs", ",", "such", "as", "tamoxifen", ",", "COX-2", "inhibitors", ",", "and", "retinoids", "were", "used", "for", "the", "experiments", ",", "and", "the", "combination", "of", "EGCG", "and", "COX-2", "inhibitors", "consistently", "induced", "the", "enhancement", "of", "apoptosis", ".", "To", "study", "the", "mechanism", "of", "the", "enhancement", ",", "we", "paid", "special", "attention", "to", "the", "enhanced", "expressions", "of", "DDIT3", "(", "growth", "arrest", "and", "DNA", "damage", "-", "inducible", "153", ",", "GADD153", ")", ",", "GADD45A", ",", "and", "CDKN1A", "(", "p21", "/", "WAF1", "/", "CIP1", ")", "genes", ",", "based", "on", "our", "previous", "evidence", "that", "a", "combination", "of", "EGCG", "and", "sulindac", "specifically", "induced", "upregulated", "expression", "of", "GADD153", "and", "p21", "genes", "in", "PC-9", "lung", "cancer", "cells", ".", "The", "synergistic", "enhancements", "of", "apoptosis", "and", "GADD153", "gene", "expression", "in", "human", "non", "-", "small", "cell", "lung", "cancer", "cells", "by", "the", "combination", "of", "EGCG", "and", "celecoxib", "were", "mediated", "through", "the", "activation", "of", "the", "MAPK", "signaling", "pathway", ".", "This", "article", "reviews", "the", "synergistic", "enhancement", "of", "apoptosis", ",", "gene", "expression", ",", "and", "anticancer", "effects", "using", "various", "combinations", "of", "EGCG", "and", "anticancer", "drugs", ",", "including", "the", "combination", "of", "(", "-)-epicatechin", "(", "EC", ")", "and", "curcumin", ".", "Based", "on", "the", "evidence", ",", "we", "present", "a", "new", "concept", ":", "green", "tea", "catechins", "as", "synergists", "with", "anticancer", "drugs", "." ]

[ "Disease", "Plant" ]

Green tea, cancer, green tea, green tea, colorectal polyps, cancer, green tea, lung cancer, lung cancer, green tea

21199169_task2

Sentence: Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs. Instructions: please extract entity words from the input sentence

[ "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "I-Plant", "O", "O", "O", "O", "O", "O", "O" ]

Green tea is now recognized as the most effective cancer preventive beverage. In one study, 10 Japanese-size cups of green tea daily supplemented with tablets of green tea extract limited the recurrence of colorectal polyps in humans to 50%. Thus, cancer patients who consume green tea and take anticancer drugs will have double prevention. We studied the effects of combining (-)-epigallocatechin gallate (EGCG) and anticancer drugs, focusing on inhibition of cell growth and induction of apoptosis. Numerous anticancer drugs, such as tamoxifen, COX-2 inhibitors, and retinoids were used for the experiments, and the combination of EGCG and COX-2 inhibitors consistently induced the enhancement of apoptosis. To study the mechanism of the enhancement, we paid special attention to the enhanced expressions of DDIT3 (growth arrest and DNA damage-inducible 153, GADD153), GADD45A, and CDKN1A (p21/WAF1/CIP1) genes, based on our previous evidence that a combination of EGCG and sulindac specifically induced upregulated expression of GADD153 and p21 genes in PC-9 lung cancer cells. The synergistic enhancements of apoptosis and GADD153 gene expression in human non-small cell lung cancer cells by the combination of EGCG and celecoxib were mediated through the activation of the MAPK signaling pathway. This article reviews the synergistic enhancement of apoptosis, gene expression, and anticancer effects using various combinations of EGCG and anticancer drugs, including the combination of (-)-epicatechin (EC) and curcumin. Based on the evidence, we present a new concept: green tea catechins as synergists with anticancer drugs.

[ "Green", "tea", "is", "now", "recognized", "as", "the", "most", "effective", "cancer", "preventive", "beverage", ".", "In", "one", "study", ",", "10", "Japanese", "-", "size", "cups", "of", "green", "tea", "daily", "supplemented", "with", "tablets", "of", "green", "tea", "extract", "limited", "the", "recurrence", "of", "colorectal", "polyps", "in", "humans", "to", "50", "%", ".", "Thus", ",", "cancer", "patients", "who", "consume", "green", "tea", "and", "take", "anticancer", "drugs", "will", "have", "double", "prevention", ".", "We", "studied", "the", "effects", "of", "combining", "(", "-)-epigallocatechin", "gallate", "(", "EGCG", ")", "and", "anticancer", "drugs", ",", "focusing", "on", "inhibition", "of", "cell", "growth", "and", "induction", "of", "apoptosis", ".", "Numerous", "anticancer", "drugs", ",", "such", "as", "tamoxifen", ",", "COX-2", "inhibitors", ",", "and", "retinoids", "were", "used", "for", "the", "experiments", ",", "and", "the", "combination", "of", "EGCG", "and", "COX-2", "inhibitors", "consistently", "induced", "the", "enhancement", "of", "apoptosis", ".", "To", "study", "the", "mechanism", "of", "the", "enhancement", ",", "we", "paid", "special", "attention", "to", "the", "enhanced", "expressions", "of", "DDIT3", "(", "growth", "arrest", "and", "DNA", "damage", "-", "inducible", "153", ",", "GADD153", ")", ",", "GADD45A", ",", "and", "CDKN1A", "(", "p21", "/", "WAF1", "/", "CIP1", ")", "genes", ",", "based", "on", "our", "previous", "evidence", "that", "a", "combination", "of", "EGCG", "and", "sulindac", "specifically", "induced", "upregulated", "expression", "of", "GADD153", "and", "p21", "genes", "in", "PC-9", "lung", "cancer", "cells", ".", "The", "synergistic", "enhancements", "of", "apoptosis", "and", "GADD153", "gene", "expression", "in", "human", "non", "-", "small", "cell", "lung", "cancer", "cells", "by", "the", "combination", "of", "EGCG", "and", "celecoxib", "were", "mediated", "through", "the", "activation", "of", "the", "MAPK", "signaling", "pathway", ".", "This", "article", "reviews", "the", "synergistic", "enhancement", "of", "apoptosis", ",", "gene", "expression", ",", "and", "anticancer", "effects", "using", "various", "combinations", "of", "EGCG", "and", "anticancer", "drugs", ",", "including", "the", "combination", "of", "(", "-)-epicatechin", "(", "EC", ")", "and", "curcumin", ".", "Based", "on", "the", "evidence", ",", "we", "present", "a", "new", "concept", ":", "green", "tea", "catechins", "as", "synergists", "with", "anticancer", "drugs", "." ]

[ "Disease", "Plant" ]

Females is a Person, high response is a Condition, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved is a Scope

NCT03209687_exc_task0

Sentence: Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved) Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Condition

[ "B-Person", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)

[ "Females", "who", "have", "high", "response", "(", "estradiol", "at", "time", "of", "ovulation", "trigger", "is", ">", "5000", "pg", "/", "ml", "or", "more", "than", "15", "oocytes", "are", "retrieved", ")", "\n" ]

[ "Scope", "Temporal", "Reference_point", "Condition", "Value", "Measurement", "Person" ]

Females is a Person, high response is a Condition, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved is a Scope

NCT03209687_exc_task1

Sentence: Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved) Instructions: please typing these entity words according to sentence: Females, high response, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved Options: Scope, Person, Condition

[ "B-Person", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)

[ "Females", "who", "have", "high", "response", "(", "estradiol", "at", "time", "of", "ovulation", "trigger", "is", ">", "5000", "pg", "/", "ml", "or", "more", "than", "15", "oocytes", "are", "retrieved", ")", "\n" ]

[ "Scope", "Temporal", "Reference_point", "Condition", "Value", "Measurement", "Person" ]

Females, high response, estradiol at time of ovulation trigger is > 5000 pg / ml or more than 15 oocytes are retrieved

NCT03209687_exc_task2

Sentence: Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved) Instructions: please extract entity words from the input sentence

[ "B-Person", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Females who have high response (estradiol at time of ovulation trigger is > 5000 pg/ml or more than 15 oocytes are retrieved)

[ "Females", "who", "have", "high", "response", "(", "estradiol", "at", "time", "of", "ovulation", "trigger", "is", ">", "5000", "pg", "/", "ml", "or", "more", "than", "15", "oocytes", "are", "retrieved", ")", "\n" ]

[ "Scope", "Temporal", "Reference_point", "Condition", "Value", "Measurement", "Person" ]

alpha - catenin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, plakoglobin is a Gene/protein/RNA

748_task0

Sentence: The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium.

[ "The", "observed", "in", "vivo", "expression", "patterns", "of", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "suggest", "that", "these", "proteins", "are", "directly", "linked", "with", "the", "developmental", "regulation", "of", "cell", "junctions", ",", "as", "cardiac", "cells", "become", "stably", "committed", "and", "phenotypically", "differentiated", "to", "eventually", "form", "a", "mature", "myocardium", "." ]

[ "Gene/protein/RNA" ]

alpha - catenin is a Gene/protein/RNA, beta - catenin is a Gene/protein/RNA, plakoglobin is a Gene/protein/RNA

748_task1

Sentence: The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium. Instructions: please typing these entity words according to sentence: alpha - catenin, beta - catenin, plakoglobin Options: Gene/protein/RNA

[ "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium.

[ "The", "observed", "in", "vivo", "expression", "patterns", "of", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "suggest", "that", "these", "proteins", "are", "directly", "linked", "with", "the", "developmental", "regulation", "of", "cell", "junctions", ",", "as", "cardiac", "cells", "become", "stably", "committed", "and", "phenotypically", "differentiated", "to", "eventually", "form", "a", "mature", "myocardium", "." ]

[ "Gene/protein/RNA" ]

alpha - catenin, beta - catenin, plakoglobin

748_task2

Sentence: The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "B-Gene/protein/RNA", "I-Gene/protein/RNA", "I-Gene/protein/RNA", "O", "O", "B-Gene/protein/RNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The observed in vivo expression patterns of alpha-catenin, beta-catenin, and plakoglobin suggest that these proteins are directly linked with the developmental regulation of cell junctions, as cardiac cells become stably committed and phenotypically differentiated to eventually form a mature myocardium.

[ "The", "observed", "in", "vivo", "expression", "patterns", "of", "alpha", "-", "catenin", ",", "beta", "-", "catenin", ",", "and", "plakoglobin", "suggest", "that", "these", "proteins", "are", "directly", "linked", "with", "the", "developmental", "regulation", "of", "cell", "junctions", ",", "as", "cardiac", "cells", "become", "stably", "committed", "and", "phenotypically", "differentiated", "to", "eventually", "form", "a", "mature", "myocardium", "." ]

[ "Gene/protein/RNA" ]

work is an umlsterm, magnetic resonance imaging is an umlsterm, MRI is an umlsterm, spectroscopy is an umlsterm, MRS is an umlsterm, bone marrow is an umlsterm, methods is an umlsterm, assessment is an umlsterm, normal values is an umlsterm, persons is an umlsterm, patients is an umlsterm, hematological diseases is an umlsterm, therapies is an umlsterm, bone marrow is an umlsterm

DerRadiologe.00400700.eng.abstr_task0

Sentence: Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow .

[ "Purpose", ".", "Methodological", "work", "was", "performed", "in", "the", "field", "of", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "spectroscopy", "(", "MRS", ")", "in", "order", "to", "develop", "suitable", "tools", "for", "non", "-", "invasive", "characterization", "of", "hematopoetic", "bone", "marrow", ".", "The", "methods", "were", "applied", "for", "the", "assessment", "of", "normal", "values", "in", "healthy", "persons", "and", "to", "examine", "patients", "with", "generalized", "hematological", "diseases", "or", "to", "monitor", "effects", "of", "therapies", "influencing", "the", "composition", "of", "bone", "marrow", "." ]

[ "umlsterm" ]

work is an umlsterm, magnetic resonance imaging is an umlsterm, MRI is an umlsterm, spectroscopy is an umlsterm, MRS is an umlsterm, bone marrow is an umlsterm, methods is an umlsterm, assessment is an umlsterm, normal values is an umlsterm, persons is an umlsterm, patients is an umlsterm, hematological diseases is an umlsterm, therapies is an umlsterm, bone marrow is an umlsterm

DerRadiologe.00400700.eng.abstr_task1

Sentence: Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow . Instructions: please typing these entity words according to sentence: work, magnetic resonance imaging, MRI, spectroscopy, MRS, bone marrow, methods, assessment, normal values, persons, patients, hematological diseases, therapies, bone marrow Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow .

[ "Purpose", ".", "Methodological", "work", "was", "performed", "in", "the", "field", "of", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "spectroscopy", "(", "MRS", ")", "in", "order", "to", "develop", "suitable", "tools", "for", "non", "-", "invasive", "characterization", "of", "hematopoetic", "bone", "marrow", ".", "The", "methods", "were", "applied", "for", "the", "assessment", "of", "normal", "values", "in", "healthy", "persons", "and", "to", "examine", "patients", "with", "generalized", "hematological", "diseases", "or", "to", "monitor", "effects", "of", "therapies", "influencing", "the", "composition", "of", "bone", "marrow", "." ]

[ "umlsterm" ]

work, magnetic resonance imaging, MRI, spectroscopy, MRS, bone marrow, methods, assessment, normal values, persons, patients, hematological diseases, therapies, bone marrow

DerRadiologe.00400700.eng.abstr_task2

Sentence: Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Purpose . Methodological work was performed in the field of magnetic resonance imaging ( MRI ) and spectroscopy ( MRS ) in order to develop suitable tools for non-invasive characterization of hematopoetic bone marrow . The methods were applied for the assessment of normal values in healthy persons and to examine patients with generalized hematological diseases or to monitor effects of therapies influencing the composition of bone marrow .

[ "Purpose", ".", "Methodological", "work", "was", "performed", "in", "the", "field", "of", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "spectroscopy", "(", "MRS", ")", "in", "order", "to", "develop", "suitable", "tools", "for", "non", "-", "invasive", "characterization", "of", "hematopoetic", "bone", "marrow", ".", "The", "methods", "were", "applied", "for", "the", "assessment", "of", "normal", "values", "in", "healthy", "persons", "and", "to", "examine", "patients", "with", "generalized", "hematological", "diseases", "or", "to", "monitor", "effects", "of", "therapies", "influencing", "the", "composition", "of", "bone", "marrow", "." ]

[ "umlsterm" ]

visual field defects is an umlsterm, antiepileptic drugs is an umlsterm, antiepileptic drugs is an umlsterm, causes is an umlsterm, retinopathy is an umlsterm, chloroquine is an umlsterm, phenothiazine is an umlsterm, visual field is an umlsterm, Visual field defects is an umlsterm, tiagabine is an umlsterm, diazepam is an umlsterm, carbamazepine is an umlsterm, treatment is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, population is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, visual field defects is an umlsterm

DerNervenarzt.90700552.eng.abstr_task0

Sentence: Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O" ]

Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary .

[ "Within", "the", "last", "years", "several", "reports", "concerning", "visual", "field", "defects", ",", "associated", "with", "antiepileptic", "drugs", ",", "have", "been", "published", ".", "In", "addition", "to", "antiepileptic", "drugs", "several", "other", "causes", "(", "e.g", ".", "retinopathy", "or", "chloroquine", ",", "phenothiazine", "etc", ".", ")", "may", "induce", "visual", "field", "disturbances", ".", "Visual", "field", "defects", "have", "been", "observed", "during", "vigabatrine", ",", "tiagabine", ",", "gabapentine", ",", "diazepam", ",", "phenytoine", ",", "and", "carbamazepine", "treatment", ".", "In", "13", "to", "46", "%", "visual", "field", "defects", "are", "reported", "to", "be", "linked", "with", "epilepsies", ".", "In", "addition", "to", "general", "population", "based", "studies", "concerning", "visual", "field", "defects", "and", "prospective", "etiological", "studies", "in", "epilepsies", ",", "preclinical", "studies", "for", "the", "examination", "of", "the", "pathomechanism", "of", "visual", "field", "defects", "are", "necessary", "." ]

[ "umlsterm" ]

visual field defects is an umlsterm, antiepileptic drugs is an umlsterm, antiepileptic drugs is an umlsterm, causes is an umlsterm, retinopathy is an umlsterm, chloroquine is an umlsterm, phenothiazine is an umlsterm, visual field is an umlsterm, Visual field defects is an umlsterm, tiagabine is an umlsterm, diazepam is an umlsterm, carbamazepine is an umlsterm, treatment is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, population is an umlsterm, visual field defects is an umlsterm, epilepsies is an umlsterm, visual field defects is an umlsterm

DerNervenarzt.90700552.eng.abstr_task1

Sentence: Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary . Instructions: please typing these entity words according to sentence: visual field defects, antiepileptic drugs, antiepileptic drugs, causes, retinopathy, chloroquine, phenothiazine, visual field, Visual field defects, tiagabine, diazepam, carbamazepine, treatment, visual field defects, epilepsies, population, visual field defects, epilepsies, visual field defects Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O" ]

Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary .

[ "Within", "the", "last", "years", "several", "reports", "concerning", "visual", "field", "defects", ",", "associated", "with", "antiepileptic", "drugs", ",", "have", "been", "published", ".", "In", "addition", "to", "antiepileptic", "drugs", "several", "other", "causes", "(", "e.g", ".", "retinopathy", "or", "chloroquine", ",", "phenothiazine", "etc", ".", ")", "may", "induce", "visual", "field", "disturbances", ".", "Visual", "field", "defects", "have", "been", "observed", "during", "vigabatrine", ",", "tiagabine", ",", "gabapentine", ",", "diazepam", ",", "phenytoine", ",", "and", "carbamazepine", "treatment", ".", "In", "13", "to", "46", "%", "visual", "field", "defects", "are", "reported", "to", "be", "linked", "with", "epilepsies", ".", "In", "addition", "to", "general", "population", "based", "studies", "concerning", "visual", "field", "defects", "and", "prospective", "etiological", "studies", "in", "epilepsies", ",", "preclinical", "studies", "for", "the", "examination", "of", "the", "pathomechanism", "of", "visual", "field", "defects", "are", "necessary", "." ]

[ "umlsterm" ]

visual field defects, antiepileptic drugs, antiepileptic drugs, causes, retinopathy, chloroquine, phenothiazine, visual field, Visual field defects, tiagabine, diazepam, carbamazepine, treatment, visual field defects, epilepsies, population, visual field defects, epilepsies, visual field defects

DerNervenarzt.90700552.eng.abstr_task2

Sentence: Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O" ]

Within the last years several reports concerning visual field defects , associated with antiepileptic drugs , have been published . In addition to antiepileptic drugs several other causes ( e.g. retinopathy or chloroquine , phenothiazine etc. ) may induce visual field disturbances . Visual field defects have been observed during vigabatrine , tiagabine , gabapentine , diazepam , phenytoine , and carbamazepine treatment . In 13 to 46% visual field defects are reported to be linked with epilepsies . In addition to general population based studies concerning visual field defects and prospective etiological studies in epilepsies , preclinical studies for the examination of the pathomechanism of visual field defects are necessary .

[ "Within", "the", "last", "years", "several", "reports", "concerning", "visual", "field", "defects", ",", "associated", "with", "antiepileptic", "drugs", ",", "have", "been", "published", ".", "In", "addition", "to", "antiepileptic", "drugs", "several", "other", "causes", "(", "e.g", ".", "retinopathy", "or", "chloroquine", ",", "phenothiazine", "etc", ".", ")", "may", "induce", "visual", "field", "disturbances", ".", "Visual", "field", "defects", "have", "been", "observed", "during", "vigabatrine", ",", "tiagabine", ",", "gabapentine", ",", "diazepam", ",", "phenytoine", ",", "and", "carbamazepine", "treatment", ".", "In", "13", "to", "46", "%", "visual", "field", "defects", "are", "reported", "to", "be", "linked", "with", "epilepsies", ".", "In", "addition", "to", "general", "population", "based", "studies", "concerning", "visual", "field", "defects", "and", "prospective", "etiological", "studies", "in", "epilepsies", ",", "preclinical", "studies", "for", "the", "examination", "of", "the", "pathomechanism", "of", "visual", "field", "defects", "are", "necessary", "." ]

[ "umlsterm" ]

glycine is a CHEMICAL, glycine decarboxylase is a GENE-Y, serine hydroxymethyltransferase is a GENE-Y

3143355_task0

Sentence: Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O" ]

Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.

[ "Resolution", "and", "characterization", "of", "the", "glycine", "-", "cleavage", "reaction", "in", "pea", "leaf", "mitochondria", ".", "Properties", "of", "the", "forward", "reaction", "catalysed", "by", "glycine", "decarboxylase", "and", "serine", "hydroxymethyltransferase", "." ]

[ "CHEMICAL", "GENE-Y" ]

glycine is a CHEMICAL, glycine decarboxylase is a GENE-Y, serine hydroxymethyltransferase is a GENE-Y

3143355_task1

Sentence: Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase. Instructions: please typing these entity words according to sentence: glycine, glycine decarboxylase, serine hydroxymethyltransferase Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O" ]

Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.

[ "Resolution", "and", "characterization", "of", "the", "glycine", "-", "cleavage", "reaction", "in", "pea", "leaf", "mitochondria", ".", "Properties", "of", "the", "forward", "reaction", "catalysed", "by", "glycine", "decarboxylase", "and", "serine", "hydroxymethyltransferase", "." ]

[ "CHEMICAL", "GENE-Y" ]

glycine, glycine decarboxylase, serine hydroxymethyltransferase

3143355_task2

Sentence: Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "O" ]

Resolution and characterization of the glycine-cleavage reaction in pea leaf mitochondria. Properties of the forward reaction catalysed by glycine decarboxylase and serine hydroxymethyltransferase.

[ "Resolution", "and", "characterization", "of", "the", "glycine", "-", "cleavage", "reaction", "in", "pea", "leaf", "mitochondria", ".", "Properties", "of", "the", "forward", "reaction", "catalysed", "by", "glycine", "decarboxylase", "and", "serine", "hydroxymethyltransferase", "." ]

[ "CHEMICAL", "GENE-Y" ]

Glaukompatienten is an umlsterm, Tomographie is an umlsterm, Nervenfaserschicht is an umlsterm, Methoden is an umlsterm, Nervenfaserfotografie is an umlsterm, Gesichtsfeldbefunden is an umlsterm, Augen is an umlsterm, Patienten is an umlsterm, Offenwinkelglaukom is an umlsterm, Glaukomverdacht is an umlsterm, Nervenfaserschichtdicke is an umlsterm, Papillenpol is an umlsterm, Beurteilung is an umlsterm, Nervenfaserschicht is an umlsterm, Gesichtsfeldparametern is an umlsterm, Nervenfaserschicht is an umlsterm, Gesichtsfeldveraenderungen is an umlsterm, Nervenfaserschichtbefunde is an umlsterm, Erweiterung is an umlsterm, Pupille is an umlsterm

DerOpthalmologe.60930520.ger.abstr_task0

Sentence: Beim Glaukompatienten bestehen klinisch eindeutige Zusammenhaenge zwischen morphologischen und funktionellen Veraenderungen . Die neuen Scanning-Laser-Ophthalmoskope zur Tomographie der Papille und Polarimetrie der Nervenfaserschicht sollten gegenueber klinischen Methoden objektivere Daten und damit bessere Korrelationen ermoeglichen . In einer Querschnittsstudie wurden die Ergebnisse der konventionellen Papillen- und Nervenfaserfotografie , die Stereoplanimetrie , der Laser-Scanning-Tomographie ( TopSS und Polarimetrie ( ) Nerve Fiber Analyzer ) mit den Gesichtsfeldbefunden Octopus-Programm G 1 ) korreliert . Es wurden 157 Augen von 157 Patienten mit manifestem Offenwinkelglaukom sowie Glaukomverdacht untersucht . Von den polarimetrischen Parametern korreliert die Modulation der Nervenfaserschichtdicke ( Maximum - Minimum ) am besten mit der mittleren Sensitivitaet ( r2 = 0,23 ) . Von den tomographischen Parametern korrelierte die neuroretinale Randzone am oberen und unteren Papillenpol am besten mit der Verlustvarianz ( LV ) ( r2 = 0,20 ) . Die planimetrischen Papillenparameter sowie die klinische Beurteilung der Nervenfaserschicht korrelierten geringfuegig besser mit den Gesichtsfeldparametern als die Daten der Scanning-Laser-Tomographie oder Polarimetrie . Die Parameter der Nervenfaserschicht sind zwar schwieriger zu erfassen , korrelieren jedoch generell besser mit den diffusen Gesichtsfeldveraenderungen als die Papillenparameter . Die neuen Scanning-Laser-Verfahren verbessern die Korrelationen nicht , ermoeglichen jedoch eine objektive Erfassung der Papillen- und Nervenfaserschichtbefunde ohne Erweiterung der Pupille . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

Beim Glaukompatienten bestehen klinisch eindeutige Zusammenhaenge zwischen morphologischen und funktionellen Veraenderungen . Die neuen Scanning-Laser-Ophthalmoskope zur Tomographie der Papille und Polarimetrie der Nervenfaserschicht sollten gegenueber klinischen Methoden objektivere Daten und damit bessere Korrelationen ermoeglichen . In einer Querschnittsstudie wurden die Ergebnisse der konventionellen Papillen- und Nervenfaserfotografie , die Stereoplanimetrie , der Laser-Scanning-Tomographie ( TopSS und Polarimetrie ( ) Nerve Fiber Analyzer ) mit den Gesichtsfeldbefunden Octopus-Programm G 1 ) korreliert . Es wurden 157 Augen von 157 Patienten mit manifestem Offenwinkelglaukom sowie Glaukomverdacht untersucht . Von den polarimetrischen Parametern korreliert die Modulation der Nervenfaserschichtdicke ( Maximum - Minimum ) am besten mit der mittleren Sensitivitaet ( r2 = 0,23 ) . Von den tomographischen Parametern korrelierte die neuroretinale Randzone am oberen und unteren Papillenpol am besten mit der Verlustvarianz ( LV ) ( r2 = 0,20 ) . Die planimetrischen Papillenparameter sowie die klinische Beurteilung der Nervenfaserschicht korrelierten geringfuegig besser mit den Gesichtsfeldparametern als die Daten der Scanning-Laser-Tomographie oder Polarimetrie . Die Parameter der Nervenfaserschicht sind zwar schwieriger zu erfassen , korrelieren jedoch generell besser mit den diffusen Gesichtsfeldveraenderungen als die Papillenparameter . Die neuen Scanning-Laser-Verfahren verbessern die Korrelationen nicht , ermoeglichen jedoch eine objektive Erfassung der Papillen- und Nervenfaserschichtbefunde ohne Erweiterung der Pupille .

[ "Beim", "Glaukompatienten", "bestehen", "klinisch", "eindeutige", "Zusammenhaenge", "zwischen", "morphologischen", "und", "funktionellen", "Veraenderungen", ".", "Die", "neuen", "Scanning", "-", "Laser", "-", "Ophthalmoskope", "zur", "Tomographie", "der", "Papille", "und", "Polarimetrie", "der", "Nervenfaserschicht", "sollten", "gegenueber", "klinischen", "Methoden", "objektivere", "Daten", "und", "damit", "bessere", "Korrelationen", "ermoeglichen", ".", "In", "einer", "Querschnittsstudie", "wurden", "die", "Ergebnisse", "der", "konventionellen", "Papillen-", "und", "Nervenfaserfotografie", ",", "die", "Stereoplanimetrie", ",", "der", "Laser", "-", "Scanning", "-", "Tomographie", "(", "TopSS", "und", "Polarimetrie", "(", ")", "Nerve", "Fiber", "Analyzer", ")", "mit", "den", "Gesichtsfeldbefunden", "Octopus", "-", "Programm", "G", "1", ")", "korreliert", ".", "Es", "wurden", "157", "Augen", "von", "157", "Patienten", "mit", "manifestem", "Offenwinkelglaukom", "sowie", "Glaukomverdacht", "untersucht", ".", "Von", "den", "polarimetrischen", "Parametern", "korreliert", "die", "Modulation", "der", "Nervenfaserschichtdicke", "(", "Maximum", "-", "Minimum", ")", "am", "besten", "mit", "der", "mittleren", "Sensitivitaet", "(", "r2", "=", "0,23", ")", ".", "Von", "den", "tomographischen", "Parametern", "korrelierte", "die", "neuroretinale", "Randzone", "am", "oberen", "und", "unteren", "Papillenpol", "am", "besten", "mit", "der", "Verlustvarianz", "(", "LV", ")", "(", "r2", "=", "0,20", ")", ".", "Die", "planimetrischen", "Papillenparameter", "sowie", "die", "klinische", "Beurteilung", "der", "Nervenfaserschicht", "korrelierten", "geringfuegig", "besser", "mit", "den", "Gesichtsfeldparametern", "als", "die", "Daten", "der", "Scanning", "-", "Laser", "-", "Tomographie", "oder", "Polarimetrie", ".", "Die", "Parameter", "der", "Nervenfaserschicht", "sind", "zwar", "schwieriger", "zu", "erfassen", ",", "korrelieren", "jedoch", "generell", "besser", "mit", "den", "diffusen", "Gesichtsfeldveraenderungen", "als", "die", "Papillenparameter", ".", "Die", "neuen", "Scanning", "-", "Laser", "-", "Verfahren", "verbessern", "die", "Korrelationen", "nicht", ",", "ermoeglichen", "jedoch", "eine", "objektive", "Erfassung", "der", "Papillen-", "und", "Nervenfaserschichtbefunde", "ohne", "Erweiterung", "der", "Pupille", "." ]

[ "umlsterm" ]